US20230250080A1 - Enzyme inhibitors - Google Patents
Enzyme inhibitors Download PDFInfo
- Publication number
- US20230250080A1 US20230250080A1 US18/126,646 US202318126646A US2023250080A1 US 20230250080 A1 US20230250080 A1 US 20230250080A1 US 202318126646 A US202318126646 A US 202318126646A US 2023250080 A1 US2023250080 A1 US 2023250080A1
- Authority
- US
- United States
- Prior art keywords
- methyl
- fluoro
- pyrazole
- carboxamide
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002532 enzyme inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 296
- 239000000203 mixture Substances 0.000 claims abstract description 269
- 238000000034 method Methods 0.000 claims abstract description 76
- 108090000113 Plasma Kallikrein Proteins 0.000 claims abstract description 59
- 102000003827 Plasma Kallikrein Human genes 0.000 claims abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 176
- 125000000217 alkyl group Chemical group 0.000 claims description 164
- 229910052799 carbon Inorganic materials 0.000 claims description 149
- 125000003545 alkoxy group Chemical group 0.000 claims description 115
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 112
- 125000005843 halogen group Chemical group 0.000 claims description 111
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims description 97
- 125000003118 aryl group Chemical group 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 72
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 71
- 125000001072 heteroaryl group Chemical group 0.000 claims description 71
- 229910052757 nitrogen Inorganic materials 0.000 claims description 71
- 125000001424 substituent group Chemical group 0.000 claims description 63
- 239000012453 solvate Substances 0.000 claims description 51
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 50
- 125000004432 carbon atom Chemical group C* 0.000 claims description 49
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 44
- 208000028185 Angioedema Diseases 0.000 claims description 43
- 125000002947 alkylene group Chemical group 0.000 claims description 42
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 37
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 34
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 34
- 102100035792 Kininogen-1 Human genes 0.000 claims description 33
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 33
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 29
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 29
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 29
- 101800004538 Bradykinin Proteins 0.000 claims description 27
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 27
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 27
- 125000002950 monocyclic group Chemical group 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 23
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 23
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 22
- 125000006413 ring segment Chemical group 0.000 claims description 21
- 125000003003 spiro group Chemical group 0.000 claims description 21
- 229910052717 sulfur Inorganic materials 0.000 claims description 21
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004193 piperazinyl group Chemical group 0.000 claims description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 14
- LLEAECOPGZWWOJ-UHFFFAOYSA-N C1(=C(C=CC(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC2=C(CCN(C2)C)C=C1)COC)N1C=C(N=N1)C)OC)F Chemical compound C1(=C(C=CC(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC2=C(CCN(C2)C)C=C1)COC)N1C=C(N=N1)C)OC)F LLEAECOPGZWWOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000002430 hydrocarbons Chemical group 0.000 claims description 12
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 11
- VBCAXHWPXUYZDS-UHFFFAOYSA-N CC(N1CC2=C(C1)C=C(CN1N=C(C(=C1)C(=O)NCC1=C(F)C(OC)=CC=C1N1C=C(N=N1)C)COC)C=C2)C Chemical compound CC(N1CC2=C(C1)C=C(CN1N=C(C(=C1)C(=O)NCC1=C(F)C(OC)=CC=C1N1C=C(N=N1)C)COC)C=C2)C VBCAXHWPXUYZDS-UHFFFAOYSA-N 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000003852 triazoles Chemical class 0.000 claims description 11
- VFDSRJFCGHJWBD-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 VFDSRJFCGHJWBD-UHFFFAOYSA-N 0.000 claims description 10
- JSFXRSPFXCVKBY-UHFFFAOYSA-N N-[[6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 JSFXRSPFXCVKBY-UHFFFAOYSA-N 0.000 claims description 10
- DIQWJGILAGPFHT-UHFFFAOYSA-N 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CCN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 DIQWJGILAGPFHT-UHFFFAOYSA-N 0.000 claims description 9
- GMFXYGPPRKEYBH-UHFFFAOYSA-N 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CCN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 GMFXYGPPRKEYBH-UHFFFAOYSA-N 0.000 claims description 9
- FXJLRLVYNJWUBM-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(C)C)COC)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(C)C)COC)F)OC FXJLRLVYNJWUBM-UHFFFAOYSA-N 0.000 claims description 9
- JFGAIOSAWGTJCK-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C(C)C)COC)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C(C)C)COC)F)OC JFGAIOSAWGTJCK-UHFFFAOYSA-N 0.000 claims description 9
- BFMQGBTWPZEDFG-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(C=C4)C6(CC6)CN(C5)C Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(C=C4)C6(CC6)CN(C5)C BFMQGBTWPZEDFG-UHFFFAOYSA-N 0.000 claims description 9
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 9
- QETUJLNTHBUGNT-UHFFFAOYSA-N N-[[2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4Cl)=O)=C3)=CC=C2CC1 QETUJLNTHBUGNT-UHFFFAOYSA-N 0.000 claims description 9
- SZIMMYXTRPVACP-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(N=C1)=NN1C(C(CNC(C1=CN(CC2=CC=C(CCN(C)C3)C3=C2)N=C1COC)=O)=C1F)=CC=C1OC SZIMMYXTRPVACP-UHFFFAOYSA-N 0.000 claims description 9
- BNWIWFJZMBUBFZ-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(C)C4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 BNWIWFJZMBUBFZ-UHFFFAOYSA-N 0.000 claims description 9
- IFAGTPYLDZYVOR-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 IFAGTPYLDZYVOR-UHFFFAOYSA-N 0.000 claims description 9
- BYDLNBVQNFBIKS-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 BYDLNBVQNFBIKS-UHFFFAOYSA-N 0.000 claims description 9
- DUGJECXUZZTYAR-UHFFFAOYSA-N N-[[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)CC)COC)F)OC DUGJECXUZZTYAR-UHFFFAOYSA-N 0.000 claims description 9
- GGDFZEFTTXBCKQ-UHFFFAOYSA-N N-[[6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CCN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 GGDFZEFTTXBCKQ-UHFFFAOYSA-N 0.000 claims description 9
- GLZSOIYYAWZBEJ-UHFFFAOYSA-N N-[[6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 GLZSOIYYAWZBEJ-UHFFFAOYSA-N 0.000 claims description 9
- XCVARTNQAFLOMD-UHFFFAOYSA-N N-[[6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 XCVARTNQAFLOMD-UHFFFAOYSA-N 0.000 claims description 9
- JFEQNYUSVBTUGQ-UHFFFAOYSA-N N-[[6-[4-(difluoromethyl)triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C(F)F)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 JFEQNYUSVBTUGQ-UHFFFAOYSA-N 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 201000011190 diabetic macular edema Diseases 0.000 claims description 9
- BZALKRSTHRLVJK-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C)COC)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C)COC)F)OC BZALKRSTHRLVJK-UHFFFAOYSA-N 0.000 claims description 8
- NFYHGGHMDNEBTH-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C)COC)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C)COC)F)OC NFYHGGHMDNEBTH-UHFFFAOYSA-N 0.000 claims description 8
- ORUWMRFIIQNYKD-UHFFFAOYSA-N C(#N)C=1C=NN(C=1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(C)C)COC)F)OC Chemical compound C(#N)C=1C=NN(C=1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(C)C)COC)F)OC ORUWMRFIIQNYKD-UHFFFAOYSA-N 0.000 claims description 8
- MPLQKVKDXCJZAJ-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CNC(=O)C1=CC(=CN=C1)CC1=CC=C2CCN(CC2=C1)C)N1C=C(N=N1)C)F Chemical compound C1(=C(OC)C=CC(=C1CNC(=O)C1=CC(=CN=C1)CC1=CC=C2CCN(CC2=C1)C)N1C=C(N=N1)C)F MPLQKVKDXCJZAJ-UHFFFAOYSA-N 0.000 claims description 8
- RJHMHGJYXWHODK-UHFFFAOYSA-N CC(C)N1CCC2=C(C1)C=CC(=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)F Chemical compound CC(C)N1CCC2=C(C1)C=CC(=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)F RJHMHGJYXWHODK-UHFFFAOYSA-N 0.000 claims description 8
- JAEGJBCKXFFKGJ-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)F)CC4=CC5=C(CN(CC5)C)N=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)F)CC4=CC5=C(CN(CC5)C)N=C4 JAEGJBCKXFFKGJ-UHFFFAOYSA-N 0.000 claims description 8
- HTNULYLWWMKYDA-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)F)CC4=NN5CCN(CC5=C4)C Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)F)CC4=NN5CCN(CC5=C4)C HTNULYLWWMKYDA-UHFFFAOYSA-N 0.000 claims description 8
- GCEVTWZOFJHQKI-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(CC5)C(C)C)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(CC5)C(C)C)C=C4 GCEVTWZOFJHQKI-UHFFFAOYSA-N 0.000 claims description 8
- OOCYGNFEBHFQMF-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=N3)CC4=CC5=C(CCN(C5)C)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=N3)CC4=CC5=C(CCN(C5)C)C=C4 OOCYGNFEBHFQMF-UHFFFAOYSA-N 0.000 claims description 8
- JHYYWEPNBPPOKM-UHFFFAOYSA-N CCN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F Chemical compound CCN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F JHYYWEPNBPPOKM-UHFFFAOYSA-N 0.000 claims description 8
- PBYLBJBIIHFKDS-UHFFFAOYSA-N CCN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)F Chemical compound CCN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)F PBYLBJBIIHFKDS-UHFFFAOYSA-N 0.000 claims description 8
- HODOQGQAHUZRPG-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(2-propan-2-yl-1,3-dihydroisoindol-5-yl)methyl]triazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3N=NC(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 HODOQGQAHUZRPG-UHFFFAOYSA-N 0.000 claims description 8
- YXCDOFZNPYSMNT-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC(C=C(CN(C)CC3)C3=C3)=C3F)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 YXCDOFZNPYSMNT-UHFFFAOYSA-N 0.000 claims description 8
- RWHNJLPWKZZVKE-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-(spiro[2,3-dihydro-1H-isoquinoline-4,1'-cyclopropane]-7-ylmethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(C4(CC4)CNC4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 RWHNJLPWKZZVKE-UHFFFAOYSA-N 0.000 claims description 8
- AVTQRESSHPXOFP-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(C)CC4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 AVTQRESSHPXOFP-UHFFFAOYSA-N 0.000 claims description 8
- OFTLPMAMUNHPAG-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 OFTLPMAMUNHPAG-UHFFFAOYSA-N 0.000 claims description 8
- SWEVXEGJTMEQED-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 SWEVXEGJTMEQED-UHFFFAOYSA-N 0.000 claims description 8
- KEVLYGRRRQDXKC-UHFFFAOYSA-N N-[[6-[4-(difluoromethyl)triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C(F)F)=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CC1 KEVLYGRRRQDXKC-UHFFFAOYSA-N 0.000 claims description 8
- YIQFPUUXIZGCMT-UHFFFAOYSA-N O(C1=C(F)C(CNC(=O)C2=CN(C(=O)C=C2)CC2=CC3=C(CCN(C3)C)C=C2)=C(N2C=C(N=N2)C)C=C1)C Chemical compound O(C1=C(F)C(CNC(=O)C2=CN(C(=O)C=C2)CC2=CC3=C(CCN(C3)C)C=C2)=C(N2C=C(N=N2)C)C=C1)C YIQFPUUXIZGCMT-UHFFFAOYSA-N 0.000 claims description 8
- LLEAECOPGZWWOJ-BMSJAHLVSA-N [2H]C([2H])([2H])N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 Chemical compound [2H]C([2H])([2H])N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 LLEAECOPGZWWOJ-BMSJAHLVSA-N 0.000 claims description 8
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- 239000004215 Carbon black (E152) Substances 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 229930195733 hydrocarbon Natural products 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003053 piperidines Chemical class 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 235000010290 biphenyl Nutrition 0.000 claims description 4
- 239000004305 biphenyl Substances 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 4
- 230000007823 neuropathy Effects 0.000 claims description 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims description 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 3
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 230000000740 bleeding effect Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 230000036543 hypotension Effects 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 150000003235 pyrrolidines Chemical class 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- 230000004304 visual acuity Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000000177 1,2,3-triazoles Chemical class 0.000 claims 1
- 150000001537 azepanes Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 238
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 236
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 218
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 150
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 141
- 235000019439 ethyl acetate Nutrition 0.000 description 119
- 239000000243 solution Substances 0.000 description 102
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 84
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 82
- 238000003818 flash chromatography Methods 0.000 description 77
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 70
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 description 65
- 239000012267 brine Substances 0.000 description 62
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- 239000007787 solid Substances 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 58
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 41
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- 239000012044 organic layer Substances 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000007832 Na2SO4 Substances 0.000 description 28
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 28
- 229910052938 sodium sulfate Inorganic materials 0.000 description 28
- 239000010410 layer Substances 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 26
- 230000003993 interaction Effects 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 24
- YUHZIUAREWNXJT-UHFFFAOYSA-N (2-fluoropyridin-3-yl)boronic acid Chemical class OB(O)C1=CC=CN=C1F YUHZIUAREWNXJT-UHFFFAOYSA-N 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 20
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 20
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 20
- 238000010586 diagram Methods 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000003112 inhibitor Substances 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 16
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 239000007789 gas Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 14
- 239000012279 sodium borohydride Substances 0.000 description 14
- 229910000033 sodium borohydride Inorganic materials 0.000 description 14
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 12
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000012458 free base Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- LAZNVVQUAVDZIC-UHFFFAOYSA-N FC1=C(C(=CC=C1OC)N1N=CN=C1)CN Chemical compound FC1=C(C(=CC=C1OC)N1N=CN=C1)CN LAZNVVQUAVDZIC-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 229940009550 c1 esterase inhibitor Drugs 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102100027637 Plasma protease C1 inhibitor Human genes 0.000 description 9
- 108050007539 Plasma protease C1 inhibitor Proteins 0.000 description 9
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 235000011167 hydrochloric acid Nutrition 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- GTLGOKCDUKJDFE-UHFFFAOYSA-N 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CCN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 GTLGOKCDUKJDFE-UHFFFAOYSA-N 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 8
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 8
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 7
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- ZBNZAJFNDPPMDT-UHFFFAOYSA-N imidazole-4-carboxamide Natural products NC(=O)C1=CNC=N1 ZBNZAJFNDPPMDT-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 6
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 6
- 102100038297 Kallikrein-1 Human genes 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 229940126155 plasma kallikrein inhibitor Drugs 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000010189 synthetic method Methods 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- 230000008728 vascular permeability Effects 0.000 description 6
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 5
- XMRIUQZQXHSNDH-UHFFFAOYSA-N 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(CC4)C5CCC5)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 XMRIUQZQXHSNDH-UHFFFAOYSA-N 0.000 description 5
- LJJTVRKFYWTKEB-UHFFFAOYSA-N 2-cyclopropyl-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3)C(C3CC3)=N2)=O)=C2F)=CC=C2OC)N=N1 LJJTVRKFYWTKEB-UHFFFAOYSA-N 0.000 description 5
- ITIPCOSCZLZSPO-UHFFFAOYSA-N C1C2=C(C(N(C1)C)O)C=C(CN1N=C(C(C(=O)NCC3=C(C(OC)=CC=C3N3C=C(N=N3)C)F)=C1)COC)C=C2 Chemical compound C1C2=C(C(N(C1)C)O)C=C(CN1N=C(C(C(=O)NCC3=C(C(OC)=CC=C3N3C=C(N=N3)C)F)=C1)COC)C=C2 ITIPCOSCZLZSPO-UHFFFAOYSA-N 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 5
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 5
- 102000002397 Kinins Human genes 0.000 description 5
- 108010093008 Kinins Proteins 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- AOEWRWPZOYEHDO-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=NN(CCN(C)C4)C4=C3)N=C2C(F)(F)F)=O)=C2F)=CC=C2OC)N=N1 AOEWRWPZOYEHDO-UHFFFAOYSA-N 0.000 description 5
- WLWFNESSYRBMGA-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=NC(CCN(C)C4)=C4C=C3)N=C2C(F)(F)F)=O)=C2F)=CC=C2OC)N=N1 WLWFNESSYRBMGA-UHFFFAOYSA-N 0.000 description 5
- SIYSLWZZSYALNO-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3)C(COC)=N2)=O)=C2F)=CC=C2OC)N=N1 SIYSLWZZSYALNO-UHFFFAOYSA-N 0.000 description 5
- VCCIRXQQWCSIPA-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-2-(methoxymethyl)-1-[(2-propan-2-yl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3C(COC)=NC(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 VCCIRXQQWCSIPA-UHFFFAOYSA-N 0.000 description 5
- RNJWQQQVPTUWMX-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3)C(C)=N2)=O)=C2F)=CC=C2OC)N=N1 RNJWQQQVPTUWMX-UHFFFAOYSA-N 0.000 description 5
- DXPHFQTWOYPJBH-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4=O)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 DXPHFQTWOYPJBH-UHFFFAOYSA-N 0.000 description 5
- QGVSETSYGVGJFH-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(7-propan-2-yl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N(CC1)CC2=C1C=C(CN1N=C(COC)C(C(NCC(C(N3N=NC(C)=C3)=CC=C3OC)=C3F)=O)=C1)C=N2 QGVSETSYGVGJFH-UHFFFAOYSA-N 0.000 description 5
- VZDWZUNUWKQPGQ-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=NC=NN1C(C(CNC(C1=CN(CC2=CC=C(CCN(C)C3)C3=C2)N=C1COC)=O)=C1F)=CC=C1OC VZDWZUNUWKQPGQ-UHFFFAOYSA-N 0.000 description 5
- XIWORBXRSOPQIU-UHFFFAOYSA-N N-[[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C1CC1)COC)F)OC XIWORBXRSOPQIU-UHFFFAOYSA-N 0.000 description 5
- GTQFHHSWSXFPHL-UHFFFAOYSA-N N-[[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)CC)COC)F)OC GTQFHHSWSXFPHL-UHFFFAOYSA-N 0.000 description 5
- ZMNZVGIMJPIAMH-UHFFFAOYSA-N N-[[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CCC(N=C1)=NN1C(C(CNC(C1=CN(CC2=CC=C(CCN(C)C3)C3=C2)N=C1COC)=O)=C1F)=CC=C1OC ZMNZVGIMJPIAMH-UHFFFAOYSA-N 0.000 description 5
- ZNDXJXVBGIFOAU-UHFFFAOYSA-N N-[[6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 ZNDXJXVBGIFOAU-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 5
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002207 retinal effect Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- RQGBOZOCQAFKEN-UHFFFAOYSA-N (6-amino-2-fluoro-3-methoxyphenyl)methanol Chemical compound NC1=CC=C(C(=C1CO)F)OC RQGBOZOCQAFKEN-UHFFFAOYSA-N 0.000 description 4
- PPBOPFJMGXYQKJ-UHFFFAOYSA-N 1-(1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-9-ylmethyl)-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN4C5CCC4)C5=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 PPBOPFJMGXYQKJ-UHFFFAOYSA-N 0.000 description 4
- YVSDHMVQYIDVLC-UHFFFAOYSA-N 1-(3,4-dihydro-1H-isochromen-7-ylmethyl)-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC(COCC4)=C4C=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 YVSDHMVQYIDVLC-UHFFFAOYSA-N 0.000 description 4
- PTGZQVSMGINBBW-UHFFFAOYSA-N 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CCN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 PTGZQVSMGINBBW-UHFFFAOYSA-N 0.000 description 4
- ZDKJNWKQAAGNGE-UHFFFAOYSA-N 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(C)CC4(F)F)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 ZDKJNWKQAAGNGE-UHFFFAOYSA-N 0.000 description 4
- RIFYBYPOGWYRDG-UHFFFAOYSA-N 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(C(CN(C)C4)(F)F)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 RIFYBYPOGWYRDG-UHFFFAOYSA-N 0.000 description 4
- MULIJFMSCBKFHB-UHFFFAOYSA-N 3-(difluoromethyl)-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3)N=C2C(F)F)=O)=C2F)=CC=C2OC)N=N1 MULIJFMSCBKFHB-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WZJNSFNKLZCJOY-UHFFFAOYSA-N C1(=C(C=CC(=C1CN1C(=O)C2=C(C1=O)C=CC=C2)N1C=NC=N1)OC)F Chemical compound C1(=C(C=CC(=C1CN1C(=O)C2=C(C1=O)C=CC=C2)N1C=NC=N1)OC)F WZJNSFNKLZCJOY-UHFFFAOYSA-N 0.000 description 4
- ABQVIOQKHUJUSU-UHFFFAOYSA-N C1(F)=C(CCl)C(N2C=NC=N2)=CC=C1OC Chemical compound C1(F)=C(CCl)C(N2C=NC=N2)=CC=C1OC ABQVIOQKHUJUSU-UHFFFAOYSA-N 0.000 description 4
- WBXCYJFUPOYNOR-UHFFFAOYSA-N CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 Chemical compound CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 WBXCYJFUPOYNOR-UHFFFAOYSA-N 0.000 description 4
- ZBUKMTTWLCWCBN-UHFFFAOYSA-N CC(C)N1CCC2=C(C1)C=C(C=C2)CN3C=C(C=N3)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F Chemical compound CC(C)N1CCC2=C(C1)C=C(C=C2)CN3C=C(C=N3)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F ZBUKMTTWLCWCBN-UHFFFAOYSA-N 0.000 description 4
- MQIZCQUBKRAXRJ-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C(C)C)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C(C)C)C=C4 MQIZCQUBKRAXRJ-UHFFFAOYSA-N 0.000 description 4
- WPOPGLBEIZOPEQ-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C6CC6)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C6CC6)C=C4 WPOPGLBEIZOPEQ-UHFFFAOYSA-N 0.000 description 4
- 125000006519 CCH3 Chemical group 0.000 description 4
- CVDALTLCOOEWHK-UHFFFAOYSA-N CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC=N5 Chemical compound CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC=N5 CVDALTLCOOEWHK-UHFFFAOYSA-N 0.000 description 4
- HAHIAVSEBBMYOG-UHFFFAOYSA-N CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C=N3)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F Chemical compound CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C=N3)C(=O)NCC4=C(C=CC(=C4F)OC)N5C=NC(=N5)C(F)(F)F HAHIAVSEBBMYOG-UHFFFAOYSA-N 0.000 description 4
- KGSVHNBLOMKQQJ-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)F)CC4=CC5=C(CCN(C5)C6CC6)C=C4 Chemical compound COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)F)CC4=CC5=C(CCN(C5)C6CC6)C=C4 KGSVHNBLOMKQQJ-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- CNPLWPSZYAHDDP-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3)N=C2)=O)=C2F)=CC=C2OC)N=N1 CNPLWPSZYAHDDP-UHFFFAOYSA-N 0.000 description 4
- VLCXTMQFJDLLME-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC(F)=C(CN(C)CC4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 VLCXTMQFJDLLME-UHFFFAOYSA-N 0.000 description 4
- PJIKUXXJUHTXIN-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CCN(C)C4)C4=C3F)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 PJIKUXXJUHTXIN-UHFFFAOYSA-N 0.000 description 4
- UWPLVECDRMFMNK-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC(CCN(C)CC4)=C4C=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 UWPLVECDRMFMNK-UHFFFAOYSA-N 0.000 description 4
- UBSRYGOWEWDVGY-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC(CCN(C)C4)=C4N=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 UBSRYGOWEWDVGY-UHFFFAOYSA-N 0.000 description 4
- VEHQBDALDQKYBB-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 VEHQBDALDQKYBB-UHFFFAOYSA-N 0.000 description 4
- NBLCMZKABACNAG-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)N=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 NBLCMZKABACNAG-UHFFFAOYSA-N 0.000 description 4
- AKZFGPGNZWZZNR-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-[3-(trifluoromethyl)pyrazol-1-yl]phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)(F)F)C=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 AKZFGPGNZWZZNR-UHFFFAOYSA-N 0.000 description 4
- YAHRASPYCBRSAH-UHFFFAOYSA-N N-[[6-(3,5-dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=NC(C)=NN1C(C(CNC(C1=CN(CC2=CC=C(CCN(C)C3)C3=C2)N=C1COC)=O)=C1F)=CC=C1OC YAHRASPYCBRSAH-UHFFFAOYSA-N 0.000 description 4
- KRQGYKHNVYSPEC-UHFFFAOYSA-N O(C)C1=C(F)C(CNC(=O)C2=CN(CC3=CC4=C(CCN(CC4)C)C=C3)N=C2COC)=C(N2C=NC(C(F)(F)F)=N2)C=C1 Chemical compound O(C)C1=C(F)C(CNC(=O)C2=CN(CC3=CC4=C(CCN(CC4)C)C=C3)N=C2COC)=C(N2C=NC(C(F)(F)F)=N2)C=C1 KRQGYKHNVYSPEC-UHFFFAOYSA-N 0.000 description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229910000085 borane Inorganic materials 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 150000003840 hydrochlorides Chemical class 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 4
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 4
- 235000010378 sodium ascorbate Nutrition 0.000 description 4
- 229960005055 sodium ascorbate Drugs 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- JBYHSSAVUBIJMK-UHFFFAOYSA-N 1,4-oxathiane Chemical compound C1CSCCO1 JBYHSSAVUBIJMK-UHFFFAOYSA-N 0.000 description 3
- MHFWKJQTWIXXPA-UHFFFAOYSA-N 1-(3,4-dihydro-1H-isochromen-6-ylmethyl)-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC(CCOC4)=C4C=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 MHFWKJQTWIXXPA-UHFFFAOYSA-N 0.000 description 3
- JMLHJJAPLCPJPY-UHFFFAOYSA-N 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(CC4)C5CC5)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 JMLHJJAPLCPJPY-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- OXURLUSRPAOPDN-UHFFFAOYSA-N 2-cyclopropyl-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(2-propan-2-yl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3C(C4CC4)=NC(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1 OXURLUSRPAOPDN-UHFFFAOYSA-N 0.000 description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 3
- OHSNHYUOEKAHAT-UHFFFAOYSA-N 3-(methoxymethyl)-1-[(2-pyrrolidin-1-ylpyrimidin-5-yl)methyl]pyrazole-4-carboxylic acid Chemical compound COCC1=NN(C=C1C(=O)O)CC=1C=NC(=NC=1)N1CCCC1 OHSNHYUOEKAHAT-UHFFFAOYSA-N 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- PEVQRTFXLKLVOP-UHFFFAOYSA-N BrC1=CC=C(C(=C1C(=O)OCC)F)OC Chemical compound BrC1=CC=C(C(=C1C(=O)OCC)F)OC PEVQRTFXLKLVOP-UHFFFAOYSA-N 0.000 description 3
- HKWFMJHFSOKSBG-UHFFFAOYSA-N BrC1=CC=C2CCN(CC2=C1F)C(=O)OC(C)(C)C Chemical compound BrC1=CC=C2CCN(CC2=C1F)C(=O)OC(C)(C)C HKWFMJHFSOKSBG-UHFFFAOYSA-N 0.000 description 3
- JFGMKDZPSHUQSX-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C1CC1)COC)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CNC(=O)C=1C(=NN(C=1)CC=1C=C2CCN(CC2=CC=1)C1CC1)COC)F)OC JFGMKDZPSHUQSX-UHFFFAOYSA-N 0.000 description 3
- VIJCWHFVDYPQBU-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1=CC=C(C(=C1C(=O)OCC)F)OC Chemical compound C(C)(C)(C)OC(=O)NC1=CC=C(C(=C1C(=O)OCC)F)OC VIJCWHFVDYPQBU-UHFFFAOYSA-N 0.000 description 3
- JWQPKPCQSCRAJV-UHFFFAOYSA-N C1(=C(C=CC(=C1C(=O)OCC)N1C=C(N=N1)C(F)F)OC)F Chemical compound C1(=C(C=CC(=C1C(=O)OCC)N1C=C(N=N1)C(F)F)OC)F JWQPKPCQSCRAJV-UHFFFAOYSA-N 0.000 description 3
- IEQNCSKIXZIVTC-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CBr)N1C=C(C)N=N1)F Chemical compound C1(=C(OC)C=CC(=C1CBr)N1C=C(C)N=N1)F IEQNCSKIXZIVTC-UHFFFAOYSA-N 0.000 description 3
- OSCCVNZIWWGFGB-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CO)N1C=NC(C)=N1)F Chemical compound C1(=C(OC)C=CC(=C1CO)N1C=NC(C)=N1)F OSCCVNZIWWGFGB-UHFFFAOYSA-N 0.000 description 3
- IYMCCYDJUDMQMB-UHFFFAOYSA-N C1(F)=C(C(=O)OCC)C(N2C=C(N=N2)CO)=CC=C1OC Chemical compound C1(F)=C(C(=O)OCC)C(N2C=C(N=N2)CO)=CC=C1OC IYMCCYDJUDMQMB-UHFFFAOYSA-N 0.000 description 3
- PBELTUBFDJNAIU-UHFFFAOYSA-N C1(F)=C(CN2C(=O)C3=CC=CC=C3C2=O)C(N2C=C(N=N2)C(F)F)=CC=C1OC Chemical compound C1(F)=C(CN2C(=O)C3=CC=CC=C3C2=O)C(N2C=C(N=N2)C(F)F)=CC=C1OC PBELTUBFDJNAIU-UHFFFAOYSA-N 0.000 description 3
- YXZOICQJNMDZSR-UHFFFAOYSA-N C1=2CN(CC1=CC(CN1C=C(N=N1)C(=O)OC)=CC=2)C(C)C Chemical compound C1=2CN(CC1=CC(CN1C=C(N=N1)C(=O)OC)=CC=2)C(C)C YXZOICQJNMDZSR-UHFFFAOYSA-N 0.000 description 3
- AXNBCULUPRPOQU-UHFFFAOYSA-N C1=CC=CC=C1CN1CCC2=C(C1(C)C)C=C(C(=O)OC)C=C2 Chemical compound C1=CC=CC=C1CN1CCC2=C(C1(C)C)C=C(C(=O)OC)C=C2 AXNBCULUPRPOQU-UHFFFAOYSA-N 0.000 description 3
- SQZRGCQQFYDNGU-UHFFFAOYSA-N C1C2(CN(CC3=C2C=CC(=C3)C(=O)OC)C(=O)OC(C)(C)C)C1 Chemical compound C1C2(CN(CC3=C2C=CC(=C3)C(=O)OC)C(=O)OC(C)(C)C)C1 SQZRGCQQFYDNGU-UHFFFAOYSA-N 0.000 description 3
- DVNIPBQTZGOBII-UHFFFAOYSA-N C1N(C(C2=CC(C(=O)OC)=CC=C2C1)(C)C)C(=O)OC(C)(C)C Chemical compound C1N(C(C2=CC(C(=O)OC)=CC=C2C1)(C)C)C(=O)OC(C)(C)C DVNIPBQTZGOBII-UHFFFAOYSA-N 0.000 description 3
- ULEPAMROVFDXAG-UHFFFAOYSA-N C1N2C(C3=C(C1)C=CC(=C3)C(=O)OC)CCC2=O Chemical compound C1N2C(C3=C(C1)C=CC(=C3)C(=O)OC)CCC2=O ULEPAMROVFDXAG-UHFFFAOYSA-N 0.000 description 3
- XMWUGBUAEVTZCZ-UHFFFAOYSA-N CC1(CN(CC2=CC(=CC=C12)C(=O)OC)C(=O)OC(C)(C)C)C Chemical compound CC1(CN(CC2=CC(=CC=C12)C(=O)OC)C(=O)OC(C)(C)C)C XMWUGBUAEVTZCZ-UHFFFAOYSA-N 0.000 description 3
- LGPWREOFNACAGJ-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CN.Cl Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CN.Cl LGPWREOFNACAGJ-UHFFFAOYSA-N 0.000 description 3
- NRQNHFAGJIETAS-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CN3C(=O)C4=CC=CC=C4C3=O Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CN3C(=O)C4=CC=CC=C4C3=O NRQNHFAGJIETAS-UHFFFAOYSA-N 0.000 description 3
- FEVGVADNPDUGFL-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)(F)F)CC4=NC5=C(CCN(C5)C)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3C(F)(F)F)CC4=NC5=C(CCN(C5)C)C=C4 FEVGVADNPDUGFL-UHFFFAOYSA-N 0.000 description 3
- IXEHTNPZBCUOFD-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(C=C4)C(CNC5)(C)C Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(C=C4)C(CNC5)(C)C IXEHTNPZBCUOFD-UHFFFAOYSA-N 0.000 description 3
- SQBPURNBOIXTKG-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CN(CC5)CC(F)F)N=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CN(CC5)CC(F)F)N=C4 SQBPURNBOIXTKG-UHFFFAOYSA-N 0.000 description 3
- HNSRDAYUFZIDDP-UHFFFAOYSA-N CN1C(C2=CC=C(C=C2C1(C)C)C(=O)OC)=O Chemical compound CN1C(C2=CC=C(C=C2C1(C)C)C(=O)OC)=O HNSRDAYUFZIDDP-UHFFFAOYSA-N 0.000 description 3
- RZCMVKQLUTVATH-UHFFFAOYSA-N COC(=O)C=1C=C2CCOCC2=CC=1 Chemical compound COC(=O)C=1C=C2CCOCC2=CC=1 RZCMVKQLUTVATH-UHFFFAOYSA-N 0.000 description 3
- HYNZYOUEVWWVCB-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)(F)F)CC4=CC5=C(CCN(C5)C6CC6)C=C4 Chemical compound COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)(F)F)CC4=CC5=C(CCN(C5)C6CC6)C=C4 HYNZYOUEVWWVCB-UHFFFAOYSA-N 0.000 description 3
- MSCXOHHWMINANY-UHFFFAOYSA-N ClCC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C Chemical compound ClCC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C MSCXOHHWMINANY-UHFFFAOYSA-N 0.000 description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 3
- RMMZYLYICGIXRQ-UHFFFAOYSA-N FC1=C(C(=CC=C1OC)N1N=CN=C1)CO Chemical compound FC1=C(C(=CC=C1OC)N1N=CN=C1)CO RMMZYLYICGIXRQ-UHFFFAOYSA-N 0.000 description 3
- HSUPSUSDFMXUFH-UHFFFAOYSA-N FC1=CC(=C2CCN(CC2=C1)C(=O)OC(C)(C)C)C=O Chemical compound FC1=CC(=C2CCN(CC2=C1)C(=O)OC(C)(C)C)C=O HSUPSUSDFMXUFH-UHFFFAOYSA-N 0.000 description 3
- PISWUFIPAGGOKY-UHFFFAOYSA-N FC=1C=C2CCN(CC2=CC=1C(=O)OC)C(=O)OC(C)(C)C Chemical compound FC=1C=C2CCN(CC2=CC=1C(=O)OC)C(=O)OC(C)(C)C PISWUFIPAGGOKY-UHFFFAOYSA-N 0.000 description 3
- 108010080865 Factor XII Proteins 0.000 description 3
- 102000000429 Factor XII Human genes 0.000 description 3
- 108010071241 Factor XIIa Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 3
- KPQPQQGCFVPOAL-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(5-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(C)CC4)C4=C3F)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 KPQPQQGCFVPOAL-UHFFFAOYSA-N 0.000 description 3
- NMZJRKNLJLTTEW-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1(C)N(C)CCC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)C=C12 NMZJRKNLJLTTEW-UHFFFAOYSA-N 0.000 description 3
- KHDBJZLGQAZZAM-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1(C)C2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)C=C2CN(C)C1 KHDBJZLGQAZZAM-UHFFFAOYSA-N 0.000 description 3
- KZNQQLKAZWNULP-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC(C=C3CCN4C)=CC=C3C4=O)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 KZNQQLKAZWNULP-UHFFFAOYSA-N 0.000 description 3
- YVHWBMPIOKYJQX-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(5-methyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=NN(CCN(C)C4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 YVHWBMPIOKYJQX-UHFFFAOYSA-N 0.000 description 3
- OCQWMDXZHRUZNC-UHFFFAOYSA-N N-[[3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C(F)F)N=C4)=CC=C4Cl)=C4F)=O)=C3)=CC=C2CC1 OCQWMDXZHRUZNC-UHFFFAOYSA-N 0.000 description 3
- BBFFMWYKHNTMEK-UHFFFAOYSA-N N1(CCC2=C(C1)N=C(C=C2)C(=O)OC)C(=O)OC(C)(C)C Chemical compound N1(CCC2=C(C1)N=C(C=C2)C(=O)OC)C(=O)OC(C)(C)C BBFFMWYKHNTMEK-UHFFFAOYSA-N 0.000 description 3
- KJUFIJQQPRDULK-UHFFFAOYSA-N NC1=CC=C(C(=C1C(=O)OCC)F)OC Chemical compound NC1=CC=C(C(=C1C(=O)OCC)F)OC KJUFIJQQPRDULK-UHFFFAOYSA-N 0.000 description 3
- OIQHWUBJCRWXLM-UHFFFAOYSA-N OCC=1N=CC2=C(N=1)CN(CC2)C(=O)OC(C)(C)C Chemical compound OCC=1N=CC2=C(N=1)CN(CC2)C(=O)OC(C)(C)C OIQHWUBJCRWXLM-UHFFFAOYSA-N 0.000 description 3
- 235000019502 Orange oil Nutrition 0.000 description 3
- 102100034869 Plasma kallikrein Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- WXIONIWNXBAHRU-UHFFFAOYSA-N [dimethylamino(triazolo[4,5-b]pyridin-3-yloxy)methylidene]-dimethylazanium Chemical compound C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 WXIONIWNXBAHRU-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 208000005707 acquired angioedema Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 150000001409 amidines Chemical group 0.000 description 3
- 230000036783 anaphylactic response Effects 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 108010011867 ecallantide Proteins 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 3
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 3
- 239000010502 orange oil Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 239000003001 serine protease inhibitor Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- HDUUVDAIWUCSKP-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-6,7-dihydro-4h-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC2=C1SC(CO)=N2 HDUUVDAIWUCSKP-UHFFFAOYSA-N 0.000 description 3
- SPKVDLFDICLOLM-UHFFFAOYSA-N tert-butyl 7-bromospiro[1,3-dihydroisoquinoline-4,1'-cyclopropane]-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2=CC(Br)=CC=C2C21CC2 SPKVDLFDICLOLM-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- JRHPOFJADXHYBR-YUMQZZPRSA-N (1s,2s)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@H]1CCCC[C@@H]1NC JRHPOFJADXHYBR-YUMQZZPRSA-N 0.000 description 2
- VXINMSIFEZGYLI-UHFFFAOYSA-N (2-fluoro-6-iodo-3-methoxyphenyl)methanol Chemical compound COc1ccc(I)c(CO)c1F VXINMSIFEZGYLI-UHFFFAOYSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- ZHHXDLJOWWSXGC-UHFFFAOYSA-N 1-(7-bromospiro[1,3-dihydroisoquinoline-4,1'-cyclopropane]-2-yl)-2,2,2-trifluoroethanone Chemical compound BrC1=CC=C2C3(CN(CC2=C1)C(C(F)(F)F)=O)CC3 ZHHXDLJOWWSXGC-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- HDNYQHTVSZSJAA-UHFFFAOYSA-N 1-[(4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC(C=NC3=C4CCN(C)C3)=C4Cl)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 HDNYQHTVSZSJAA-UHFFFAOYSA-N 0.000 description 2
- HFDKBGVQWDMCTC-UHFFFAOYSA-N 1-[(5-chloro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(CN(C)CC4)C4=C3Cl)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 HFDKBGVQWDMCTC-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- KYGYMWCDUUDEKQ-UHFFFAOYSA-N 1-[2-(4-bromophenyl)ethyl]pyrrolidine-2,5-dione Chemical compound C1=CC(Br)=CC=C1CCN1C(=O)CCC1=O KYGYMWCDUUDEKQ-UHFFFAOYSA-N 0.000 description 2
- ISPVARWUAHYARB-UHFFFAOYSA-N 1-[2-(bromomethyl)-3-fluoro-4-methoxyphenyl]tetrazole Chemical compound COC1=C(F)C(CBr)=C(C=C1)N1C=NN=N1 ISPVARWUAHYARB-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- ZROILLPDIUNLSE-UHFFFAOYSA-N 1-phenyl-1h-pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1C1=CC=CC=C1 ZROILLPDIUNLSE-UHFFFAOYSA-N 0.000 description 2
- 238000004791 1D NOESY Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- FJTVKPMZVAZMAM-UHFFFAOYSA-M 2-benzyl-7-bromo-1-methyl-3,4-dihydroisoquinolin-2-ium bromide Chemical compound [Br-].C(C1=CC=CC=C1)[N+]1=C(C2=CC(=CC=C2CC1)Br)C FJTVKPMZVAZMAM-UHFFFAOYSA-M 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- OXCBSLIMQWCMHP-UHFFFAOYSA-N 3,4-dihydro-1H-isochromen-6-ylmethanol Chemical compound C1OCCC2=CC(CO)=CC=C21 OXCBSLIMQWCMHP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- ICYSBMXTQPKXEE-UHFFFAOYSA-N 3-(methoxymethyl)-1-[[2-[(2-methylpropan-2-yl)oxycarbonyl]-1,3-dihydroisoindol-5-yl]methyl]pyrazole-4-carboxylic acid Chemical compound CC(C)(C)OC(N1CC2=CC(CN3N=C(COC)C(C(O)=O)=C3)=CC=C2C1)=O ICYSBMXTQPKXEE-UHFFFAOYSA-N 0.000 description 2
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- IFMHSDZUDAPKHB-UHFFFAOYSA-N 5,6,7,8-tetrahydro-1,6-naphthyridin-2-ylmethanol Chemical compound C1NCCC2=NC(CO)=CC=C21 IFMHSDZUDAPKHB-UHFFFAOYSA-N 0.000 description 2
- IRWSFBDNSXHTLT-UHFFFAOYSA-N 5-(difluoromethyl)-1h-1,2,4-triazole Chemical compound FC(F)C1=NC=NN1 IRWSFBDNSXHTLT-UHFFFAOYSA-N 0.000 description 2
- LMZYCEMOUPTJRS-UHFFFAOYSA-N 5-bromo-2,3,3-trimethylisoindol-1-one Chemical compound C1=C(Br)C=C2C(C)(C)N(C)C(=O)C2=C1 LMZYCEMOUPTJRS-UHFFFAOYSA-N 0.000 description 2
- FUQASOCMZJWFKM-UHFFFAOYSA-N 6-(hydroxymethyl)-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound OCC1=CC=C2C(=O)N(C)CCC2=C1 FUQASOCMZJWFKM-UHFFFAOYSA-N 0.000 description 2
- AUBCNXWUINQWCX-UHFFFAOYSA-N 6-bromo-5-fluoro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=C1C=CC(Br)=C2F AUBCNXWUINQWCX-UHFFFAOYSA-N 0.000 description 2
- WKXOECKPJPOIBK-UHFFFAOYSA-N 7-bromo-1-methyl-3,4-dihydroisoquinoline Chemical compound C1=C(Br)C=C2C(C)=NCCC2=C1 WKXOECKPJPOIBK-UHFFFAOYSA-N 0.000 description 2
- ZMKJGCPZYHYIKK-UHFFFAOYSA-N 7-bromo-6-fluoro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=C1C=C(F)C(Br)=C2 ZMKJGCPZYHYIKK-UHFFFAOYSA-N 0.000 description 2
- ABZAYLFRWGIRDU-UHFFFAOYSA-N 7-bromo-6-fluoroisoquinoline Chemical compound C1=NC=C2C=C(Br)C(F)=CC2=C1 ABZAYLFRWGIRDU-UHFFFAOYSA-N 0.000 description 2
- MVNGHXOUJOLZIK-UHFFFAOYSA-N 7-bromo-8-fluoro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=C1C=CC(Br)=C2F MVNGHXOUJOLZIK-UHFFFAOYSA-N 0.000 description 2
- GNMLQBNEROBNLK-UHFFFAOYSA-N 7-bromospiro[2,3-dihydro-1h-isoquinoline-4,1'-cyclopropane] Chemical compound C=1C(Br)=CC=C2C=1CNCC21CC1 GNMLQBNEROBNLK-UHFFFAOYSA-N 0.000 description 2
- UQNMISYKKAQDDT-UHFFFAOYSA-N 7-o-tert-butyl 2-o-ethyl 6,8-dihydro-5h-imidazo[1,2-a]pyrazine-2,7-dicarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC2=NC(C(=O)OCC)=CN21 UQNMISYKKAQDDT-UHFFFAOYSA-N 0.000 description 2
- WZRPCODOMYHSND-UHFFFAOYSA-N 9-bromo-10b-methyl-5,6-dihydro-[1,3]oxazolo[2,3-a]isoquinoline-2,3-dione Chemical compound BrC1=CC=C2CCN3C(C2=C1)(OC(C3=O)=O)C WZRPCODOMYHSND-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- CBYJUDWEORMISM-UHFFFAOYSA-N BrC1=CC=C2C(=C1)C(C)(C)N(CC2)CC1=CC=CC=C1 Chemical compound BrC1=CC=C2C(=C1)C(C)(C)N(CC2)CC1=CC=CC=C1 CBYJUDWEORMISM-UHFFFAOYSA-N 0.000 description 2
- NEDZFKMOHOOUHZ-UHFFFAOYSA-N BrC=1C(=C(C=CC=1)CCNC(C(F)(F)F)=O)F Chemical compound BrC=1C(=C(C=CC=1)CCNC(C(F)(F)F)=O)F NEDZFKMOHOOUHZ-UHFFFAOYSA-N 0.000 description 2
- ZLOOEFOOXBHALA-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)CC1=C(C(=CC=C1N1N=C(N=C1)C)OC)F Chemical compound C(C)(C)(C)OC(=O)N(C(OC(C)(C)C)=O)CC1=C(C(=CC=C1N1N=C(N=C1)C)OC)F ZLOOEFOOXBHALA-UHFFFAOYSA-N 0.000 description 2
- LHOVZVOZVIECNJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)N1CC2=CC=C(C(=C2CC1)Cl)O Chemical compound C(C)(C)(C)OC(=O)N1CC2=CC=C(C(=C2CC1)Cl)O LHOVZVOZVIECNJ-UHFFFAOYSA-N 0.000 description 2
- UAIIPUKNUYHGAV-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1=CC=C(C(=C1C(=O)OC)F)OC Chemical compound C(C)(C)(C)OC(=O)NC1=CC=C(C(=C1C(=O)OC)F)OC UAIIPUKNUYHGAV-UHFFFAOYSA-N 0.000 description 2
- XMYRGSMFOQGPFZ-UHFFFAOYSA-N C(C)(C)(OC(=O)C=1N(N=C(C=1)C(=O)OC(C)(C)C)C1(CC1)C#N)C Chemical compound C(C)(C)(OC(=O)C=1N(N=C(C=1)C(=O)OC(C)(C)C)C1(CC1)C#N)C XMYRGSMFOQGPFZ-UHFFFAOYSA-N 0.000 description 2
- AKPQEODJHUEDEI-UHFFFAOYSA-N C(C)(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(CCl)C=C2)C Chemical compound C(C)(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(CCl)C=C2)C AKPQEODJHUEDEI-UHFFFAOYSA-N 0.000 description 2
- QUOSTOQXRLXSHP-UHFFFAOYSA-N C(C)(C)(OC(=O)N1CC2=C(CC1)C(Cl)=C(C(=O)O)C=C2)C Chemical compound C(C)(C)(OC(=O)N1CC2=C(CC1)C(Cl)=C(C(=O)O)C=C2)C QUOSTOQXRLXSHP-UHFFFAOYSA-N 0.000 description 2
- MJBHQCHRXBSXOI-UHFFFAOYSA-N C(C)(OC(=O)N1CC(C2=C(C=CC(=C2)CO)C1)(F)F)(C)C Chemical compound C(C)(OC(=O)N1CC(C2=C(C=CC(=C2)CO)C1)(F)F)(C)C MJBHQCHRXBSXOI-UHFFFAOYSA-N 0.000 description 2
- AMYMVXVRZJAJBU-UHFFFAOYSA-N C1(=C(C=CC(=C1CN)N1C=CN=N1)OC)F Chemical compound C1(=C(C=CC(=C1CN)N1C=CN=N1)OC)F AMYMVXVRZJAJBU-UHFFFAOYSA-N 0.000 description 2
- YOMGBBZNVWSHIR-UHFFFAOYSA-N C1(=C(C=CC(=C1CN1C(=O)C2=CC=CC=C2C1=O)N1C=CN=N1)OC)F Chemical compound C1(=C(C=CC(=C1CN1C(=O)C2=CC=CC=C2C1=O)N1C=CN=N1)OC)F YOMGBBZNVWSHIR-UHFFFAOYSA-N 0.000 description 2
- CGZVEGCQTBBFEH-UHFFFAOYSA-N C1(=C(C=CC(=C1CO)N1C=NC(=N1)C(F)F)Cl)F Chemical compound C1(=C(C=CC(=C1CO)N1C=NC(=N1)C(F)F)Cl)F CGZVEGCQTBBFEH-UHFFFAOYSA-N 0.000 description 2
- MWFSZNMAIKNMCX-UHFFFAOYSA-N C1(=C(C=CC(=C1CO)N1N=C(N=C1C)C)OC)F Chemical compound C1(=C(C=CC(=C1CO)N1N=C(N=C1C)C)OC)F MWFSZNMAIKNMCX-UHFFFAOYSA-N 0.000 description 2
- SQFZZKUTKSWTAU-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CBr)N1C=C(N=N1)C(F)F)F Chemical compound C1(=C(OC)C=CC(=C1CBr)N1C=C(N=N1)C(F)F)F SQFZZKUTKSWTAU-UHFFFAOYSA-N 0.000 description 2
- XYDXTCQFRNWYBK-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CBr)N1C=CN=N1)F Chemical compound C1(=C(OC)C=CC(=C1CBr)N1C=CN=N1)F XYDXTCQFRNWYBK-UHFFFAOYSA-N 0.000 description 2
- FFMYWGQYYQOAMK-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CN)N1C(=NC(C)=N1)C)F Chemical compound C1(=C(OC)C=CC(=C1CN)N1C(=NC(C)=N1)C)F FFMYWGQYYQOAMK-UHFFFAOYSA-N 0.000 description 2
- UTJRTKGWDROPPJ-UHFFFAOYSA-N C1(F)=C(C(=O)O)C(N2C=NC(C(F)F)=N2)=CC=C1Cl Chemical compound C1(F)=C(C(=O)O)C(N2C=NC(C(F)F)=N2)=CC=C1Cl UTJRTKGWDROPPJ-UHFFFAOYSA-N 0.000 description 2
- ZXDDSBINRDUPGR-UHFFFAOYSA-N C1(F)=C(C(=O)OCC)C(N2C=C(N=N2)C=O)=CC=C1OC Chemical compound C1(F)=C(C(=O)OCC)C(N2C=C(N=N2)C=O)=CC=C1OC ZXDDSBINRDUPGR-UHFFFAOYSA-N 0.000 description 2
- NZENEXIZBHRESS-UHFFFAOYSA-N C1(F)=C(CBr)C(N2C=NC(C)=N2)=CC=C1OC Chemical compound C1(F)=C(CBr)C(N2C=NC(C)=N2)=CC=C1OC NZENEXIZBHRESS-UHFFFAOYSA-N 0.000 description 2
- VLBDPMCAAPNXPX-UHFFFAOYSA-N C1(F)=C(CCl)C(N2C=NC(C(F)F)=N2)=CC=C1Cl Chemical compound C1(F)=C(CCl)C(N2C=NC(C(F)F)=N2)=CC=C1Cl VLBDPMCAAPNXPX-UHFFFAOYSA-N 0.000 description 2
- CBLXEWDSXJENKY-UHFFFAOYSA-N C1(F)=C(CN)C(N2C=NC(=N2)C(F)F)=CC=C1Cl Chemical compound C1(F)=C(CN)C(N2C=NC(=N2)C(F)F)=CC=C1Cl CBLXEWDSXJENKY-UHFFFAOYSA-N 0.000 description 2
- ZTXQHDAFUQKQLK-UHFFFAOYSA-N C1(F)=C(CN2C(=O)C3=CC=CC=C3C2=O)C(N2C=NC(C(F)F)=N2)=CC=C1Cl Chemical compound C1(F)=C(CN2C(=O)C3=CC=CC=C3C2=O)C(N2C=NC(C(F)F)=N2)=CC=C1Cl ZTXQHDAFUQKQLK-UHFFFAOYSA-N 0.000 description 2
- GXLWHHLIBACTLH-UHFFFAOYSA-N C1(F)=C(CO)C(N2C=CN=N2)=CC=C1OC Chemical compound C1(F)=C(CO)C(N2C=CN=N2)=CC=C1OC GXLWHHLIBACTLH-UHFFFAOYSA-N 0.000 description 2
- KYNIRBRCYKEJJV-UHFFFAOYSA-N C12(CN(CC3=C1C=CC(=C3)CO)C(=O)OC(C)(C)C)CC2 Chemical compound C12(CN(CC3=C1C=CC(=C3)CO)C(=O)OC(C)(C)C)CC2 KYNIRBRCYKEJJV-UHFFFAOYSA-N 0.000 description 2
- UUPYTDPJHYDERC-UHFFFAOYSA-N C12=C(C(=CC=C2CN(CC1)C(=O)C(F)(F)F)Br)F Chemical compound C12=C(C(=CC=C2CN(CC1)C(=O)C(F)(F)F)Br)F UUPYTDPJHYDERC-UHFFFAOYSA-N 0.000 description 2
- VBYNDKFUHYGDMV-UHFFFAOYSA-N C12=C(C=CC(=C2)CN2N=C(COC)C(=C2)C(=O)NCC2=C(C(=CC=C2N2C=C(N=N2)C)OC)F)CNC1 Chemical compound C12=C(C=CC(=C2)CN2N=C(COC)C(=C2)C(=O)NCC2=C(C(=CC=C2N2C=C(N=N2)C)OC)F)CNC1 VBYNDKFUHYGDMV-UHFFFAOYSA-N 0.000 description 2
- ZDADTYBFQWQETF-UHFFFAOYSA-N C1CC(O)N(C1=O)CCC1=CC=C(C=C1)Br Chemical compound C1CC(O)N(C1=O)CCC1=CC=C(C=C1)Br ZDADTYBFQWQETF-UHFFFAOYSA-N 0.000 description 2
- MQOOTWPKXUIMSC-UHFFFAOYSA-N C1N(C(C2=CC(CO)=CC=C2C1)(C)C)C(=O)OC(C)(C)C Chemical compound C1N(C(C2=CC(CO)=CC=C2C1)(C)C)C(=O)OC(C)(C)C MQOOTWPKXUIMSC-UHFFFAOYSA-N 0.000 description 2
- NYTBTABANZJEJJ-UHFFFAOYSA-N C1N(CC2=CC(CO)=CC=C2C1(C)C)C(=O)OC(C)(C)C Chemical compound C1N(CC2=CC(CO)=CC=C2C1(C)C)C(=O)OC(C)(C)C NYTBTABANZJEJJ-UHFFFAOYSA-N 0.000 description 2
- PRMHPZWEZNJSHA-UHFFFAOYSA-N C1N2C(C3=C(C=CC(=C3)Br)C1)CCC2=O Chemical compound C1N2C(C3=C(C=CC(=C3)Br)C1)CCC2=O PRMHPZWEZNJSHA-UHFFFAOYSA-N 0.000 description 2
- FRUNEFKWNIINKM-UHFFFAOYSA-N C1NC(C2=C(C=CC(=C2)C(=O)OC)C1)(C)C Chemical compound C1NC(C2=C(C=CC(=C2)C(=O)OC)C1)(C)C FRUNEFKWNIINKM-UHFFFAOYSA-N 0.000 description 2
- WSAZQZIHXLRCDI-UHFFFAOYSA-N CC(C)(OC(=O)C1=NN2C(C(=O)NCC32CC3)=C1)C Chemical compound CC(C)(OC(=O)C1=NN2C(C(=O)NCC32CC3)=C1)C WSAZQZIHXLRCDI-UHFFFAOYSA-N 0.000 description 2
- RMNNAJWUOPEPAX-UHFFFAOYSA-N CC(C)(OC(=O)C=1C=C2C(=O)N(CC3(N2N=1)CC3)C)C Chemical compound CC(C)(OC(=O)C=1C=C2C(=O)N(CC3(N2N=1)CC3)C)C RMNNAJWUOPEPAX-UHFFFAOYSA-N 0.000 description 2
- VJFCTQXISNDWGL-UHFFFAOYSA-N CC(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(C=O)C=C2)C Chemical compound CC(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(C=O)C=C2)C VJFCTQXISNDWGL-UHFFFAOYSA-N 0.000 description 2
- DXFPYTBJCLCZHZ-UHFFFAOYSA-N CC(C1=C(C(=C(C=C1)N2C=NC(=N2)C(F)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C)C=C4)F)(F)F Chemical compound CC(C1=C(C(=C(C=C1)N2C=NC(=N2)C(F)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCN(C5)C)C=C4)F)(F)F DXFPYTBJCLCZHZ-UHFFFAOYSA-N 0.000 description 2
- DOFCTZXOYDJJMX-UHFFFAOYSA-N CC1(CC2=C(C=C1)C3CCC2N3C(=O)OC(C)(C)C)C(=O)O Chemical compound CC1(CC2=C(C=C1)C3CCC2N3C(=O)OC(C)(C)C)C(=O)O DOFCTZXOYDJJMX-UHFFFAOYSA-N 0.000 description 2
- VTEMVTIQMLZMBZ-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCNC5(C)C)C=C4 Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CCNC5(C)C)C=C4 VTEMVTIQMLZMBZ-UHFFFAOYSA-N 0.000 description 2
- JRKMKSDJOHLXLG-UHFFFAOYSA-N CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CNC5)C=C4.Cl Chemical compound CC1=CN(N=N1)C2=C(C(=C(C=C2)OC)F)CNC(=O)C3=CN(N=C3COC)CC4=CC5=C(CNC5)C=C4.Cl JRKMKSDJOHLXLG-UHFFFAOYSA-N 0.000 description 2
- AWAPALLFVACSCW-HJWRWDBZSA-N CN(\C=C(/C(=O)OCC)\C(=O)C1(CC1)OC)C Chemical compound CN(\C=C(/C(=O)OCC)\C(=O)C1(CC1)OC)C AWAPALLFVACSCW-HJWRWDBZSA-N 0.000 description 2
- HHWLXZXOJCDTSH-UHFFFAOYSA-N CN1CCC2=CC=C(CO)C=C2C1=O Chemical compound CN1CCC2=CC=C(CO)C=C2C1=O HHWLXZXOJCDTSH-UHFFFAOYSA-N 0.000 description 2
- ANZAAADWLHZZOF-UHFFFAOYSA-N COC(=O)C1=CN(N=N1)CC2=CC3=C(CNC3)C=C2.Cl Chemical compound COC(=O)C1=CN(N=N1)CC2=CC3=C(CNC3)C=C2.Cl ANZAAADWLHZZOF-UHFFFAOYSA-N 0.000 description 2
- PSULNVQTALRWEX-UHFFFAOYSA-N COC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C)COC Chemical compound COC(=O)C=1C(=NN(C=1)CC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C)COC PSULNVQTALRWEX-UHFFFAOYSA-N 0.000 description 2
- KNURHMOZMDAHPM-UHFFFAOYSA-N COC(=O)C=1C(=NN(C=1)CC=1C=C2CN(CC2=CC=1)C(=O)OC(C)(C)C)COC Chemical compound COC(=O)C=1C(=NN(C=1)CC=1C=C2CN(CC2=CC=1)C(=O)OC(C)(C)C)COC KNURHMOZMDAHPM-UHFFFAOYSA-N 0.000 description 2
- JYAKZXWKKLRKFT-UHFFFAOYSA-N COC(=O)C=1C=C(C=NC=1)CC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C Chemical compound COC(=O)C=1C=C(C=NC=1)CC1=CC=C2CCN(CC2=C1)C(=O)OC(C)(C)C JYAKZXWKKLRKFT-UHFFFAOYSA-N 0.000 description 2
- VRRUBFXJBGFVIL-UHFFFAOYSA-N COC(=O)C=1N=NN(C=1)CC=1C=C2CN(CC2=CC=1)C(=O)OC(C)(C)C Chemical compound COC(=O)C=1N=NN(C=1)CC=1C=C2CN(CC2=CC=1)C(=O)OC(C)(C)C VRRUBFXJBGFVIL-UHFFFAOYSA-N 0.000 description 2
- AUCDPPJAWANIOI-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)(F)F)CC4=CC5=C(CN(CC5)C6CC6)C=C4 Chemical compound COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)(F)F)CC4=CC5=C(CN(CC5)C6CC6)C=C4 AUCDPPJAWANIOI-UHFFFAOYSA-N 0.000 description 2
- ATXPYJVKXXHUIR-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)F)CC4=CC5=C(CN(CC5)C6CC6)C=C4 Chemical compound COCC1=NN(C=C1C(=O)NCC2=C(C=CC(=C2F)OC)N3C=NC(=N3)C(F)F)CC4=CC5=C(CN(CC5)C6CC6)C=C4 ATXPYJVKXXHUIR-UHFFFAOYSA-N 0.000 description 2
- XCJVQLFHJXRQIL-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)OC)CC1=CC=C2CCNCC2=C1 Chemical compound COCC1=NN(C=C1C(=O)OC)CC1=CC=C2CCNCC2=C1 XCJVQLFHJXRQIL-UHFFFAOYSA-N 0.000 description 2
- QQCSZWGULVAHSF-UHFFFAOYSA-N COCC1=NN(C=C1C(=O)OC)S(=O)(=O)C Chemical compound COCC1=NN(C=C1C(=O)OC)S(=O)(=O)C QQCSZWGULVAHSF-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- VXNYTMLJRJXTOC-UHFFFAOYSA-N ClC1=C2CCN(CC2=CC=C1C(=O)OC)C(=O)OC(C)(C)C Chemical compound ClC1=C2CCN(CC2=CC=C1C(=O)OC)C(=O)OC(C)(C)C VXNYTMLJRJXTOC-UHFFFAOYSA-N 0.000 description 2
- GJYSEYQFHUDNDR-UHFFFAOYSA-N ClC1=C2CCN(CC2=CC=C1CO)C(=O)OC(C)(C)C Chemical compound ClC1=C2CCN(CC2=CC=C1CO)C(=O)OC(C)(C)C GJYSEYQFHUDNDR-UHFFFAOYSA-N 0.000 description 2
- PEUJYNPMNYTADF-UHFFFAOYSA-N ClC=1C(=C(C(=O)O)C(=CC=1)I)F Chemical compound ClC=1C(=C(C(=O)O)C(=CC=1)I)F PEUJYNPMNYTADF-UHFFFAOYSA-N 0.000 description 2
- UDVGKDDMTPUPFY-UHFFFAOYSA-N ClCC1=C2CCN(CC2=CC(=C1)F)C(=O)OC(C)(C)C Chemical compound ClCC1=C2CCN(CC2=CC(=C1)F)C(=O)OC(C)(C)C UDVGKDDMTPUPFY-UHFFFAOYSA-N 0.000 description 2
- RSUYLDOJUNDXRR-UHFFFAOYSA-N ClCC1=CC=C2C(CN(CC2=C1)C(=O)OC(C)(C)C)(F)F Chemical compound ClCC1=CC=C2C(CN(CC2=C1)C(=O)OC(C)(C)C)(F)F RSUYLDOJUNDXRR-UHFFFAOYSA-N 0.000 description 2
- AZPGAVHNSAOLCD-UHFFFAOYSA-N ClCC1=CC=C2CCN(CC2=C1F)C(=O)OC(C)(C)C Chemical compound ClCC1=CC=C2CCN(CC2=C1F)C(=O)OC(C)(C)C AZPGAVHNSAOLCD-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- UVLZSVAPDKZAPW-UHFFFAOYSA-N FC1=C(C(=CC=C1OC)N1N=NN=C1)CN Chemical compound FC1=C(C(=CC=C1OC)N1N=NN=C1)CN UVLZSVAPDKZAPW-UHFFFAOYSA-N 0.000 description 2
- HYAXCCSMOVIHTI-UHFFFAOYSA-N FC1=C(C(=CC=C1OC)N1N=NN=C1)CO Chemical compound FC1=C(C(=CC=C1OC)N1N=NN=C1)CO HYAXCCSMOVIHTI-UHFFFAOYSA-N 0.000 description 2
- UWAUMCXCSSZGDP-UHFFFAOYSA-N FC1=C(CN)C(N2C=C(C)N=N2)=CC=C1OC Chemical compound FC1=C(CN)C(N2C=C(C)N=N2)=CC=C1OC UWAUMCXCSSZGDP-UHFFFAOYSA-N 0.000 description 2
- MQHCZGLCPJCMTC-UHFFFAOYSA-N FC1=C(CN)C(N2C=NC(C)=N2)=CC=C1OC Chemical compound FC1=C(CN)C(N2C=NC(C)=N2)=CC=C1OC MQHCZGLCPJCMTC-UHFFFAOYSA-N 0.000 description 2
- NXRXJWMJGNWTLW-UHFFFAOYSA-N FC1=C(CO)C(N2C=C(N=N2)C(F)F)=CC=C1OC Chemical compound FC1=C(CO)C(N2C=C(N=N2)C(F)F)=CC=C1OC NXRXJWMJGNWTLW-UHFFFAOYSA-N 0.000 description 2
- GTCOTQVZYPHCRY-UHFFFAOYSA-N FC1=C2CCN(CC2=CC=C1C=O)C(=O)OC(C)(C)C Chemical compound FC1=C2CCN(CC2=CC=C1C=O)C(=O)OC(C)(C)C GTCOTQVZYPHCRY-UHFFFAOYSA-N 0.000 description 2
- UGVBBGOINFYXQY-UHFFFAOYSA-N FC1=CC(=C2CCN(CC2=C1)C(=O)OC(C)(C)C)CO Chemical compound FC1=CC(=C2CCN(CC2=C1)C(=O)OC(C)(C)C)CO UGVBBGOINFYXQY-UHFFFAOYSA-N 0.000 description 2
- FKMBFVPHGFGCMX-UHFFFAOYSA-N FC=1C(=CC=C2CCN(CC=12)C(=O)OC(C)(C)C)CO Chemical compound FC=1C(=CC=C2CCN(CC=12)C(=O)OC(C)(C)C)CO FKMBFVPHGFGCMX-UHFFFAOYSA-N 0.000 description 2
- ZPGDNKZUQRBDMZ-UHFFFAOYSA-N FC=1C=C2CCN(CC2=CC=1CO)C(=O)OC(C)(C)C Chemical compound FC=1C=C2CCN(CC2=CC=1CO)C(=O)OC(C)(C)C ZPGDNKZUQRBDMZ-UHFFFAOYSA-N 0.000 description 2
- 101100453988 Homo sapiens KLK1 gene Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
- 102000001399 Kallikrein Human genes 0.000 description 2
- 108060005987 Kallikrein Proteins 0.000 description 2
- 108010077861 Kininogens Proteins 0.000 description 2
- 102000010631 Kininogens Human genes 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- ORFPGMMIEXAEMX-UHFFFAOYSA-N N(=[N+]=[N-])CC1=C(C=CC(=C1F)OC)N1N=NN=C1 Chemical compound N(=[N+]=[N-])CC1=C(C=CC(=C1F)OC)N1N=NN=C1 ORFPGMMIEXAEMX-UHFFFAOYSA-N 0.000 description 2
- BACPGPONZVUOCR-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(7-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=C(CCN(C)C4)C4=CC(F)=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 BACPGPONZVUOCR-UHFFFAOYSA-N 0.000 description 2
- PRVCWMQVRUYLAP-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(7-methyl-6,8-dihydro-5H-imidazo[1,2-a]pyrazin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CN(CCN(C)C4)C4=N3)N=C2C(F)(F)F)=O)=C2F)=CC=C2OC)N=N1 PRVCWMQVRUYLAP-UHFFFAOYSA-N 0.000 description 2
- VJCKJBKNJCONRY-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC(C=C3)=CC4=C3OCCNC4)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 VJCKJBKNJCONRY-UHFFFAOYSA-N 0.000 description 2
- NEPYZWIRSHWGBL-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2,3,3-trimethyl-1H-isoindol-5-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1(C)N(C)CC2=CC=C(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)C=C12 NEPYZWIRSHWGBL-UHFFFAOYSA-N 0.000 description 2
- AUWJOBLWVJFWGH-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(4-methyl-3,5-dihydro-2H-1,4-benzoxazepin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC(C=C3)=CC4=C3OCCN(C)C4)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 AUWJOBLWVJFWGH-UHFFFAOYSA-N 0.000 description 2
- JDQVVSMTQXUMGC-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridin-2-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=NC(CCN(C)C4)=C4S3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 JDQVVSMTQXUMGC-UHFFFAOYSA-N 0.000 description 2
- YOMQFNIHKVQDST-UHFFFAOYSA-N N-[[6-(3-cyclopropylpyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CN1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C5CC5)C=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 YOMQFNIHKVQDST-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- RANLABUMXFRNEU-UHFFFAOYSA-N N1(CCC2=C(C1)C=C(CC1=CC(C(=O)O)=CN=C1)C=C2)C(=O)OC(C)(C)C Chemical compound N1(CCC2=C(C1)C=C(CC1=CC(C(=O)O)=CN=C1)C=C2)C(=O)OC(C)(C)C RANLABUMXFRNEU-UHFFFAOYSA-N 0.000 description 2
- WCGCRUNZKBSRNP-UHFFFAOYSA-N N1=C(C(=CN1CC1=CC2=C(C=C1)CCN(C2)C)C(=O)OC)COC Chemical compound N1=C(C(=CN1CC1=CC2=C(C=C1)CCN(C2)C)C(=O)OC)COC WCGCRUNZKBSRNP-UHFFFAOYSA-N 0.000 description 2
- JKONZVPLFMLUQL-UHFFFAOYSA-N N1=C(N=CC2=C1CN(CC2)C(=O)OC(C)(C)C)C(=O)OC Chemical compound N1=C(N=CC2=C1CN(CC2)C(=O)OC(C)(C)C)C(=O)OC JKONZVPLFMLUQL-UHFFFAOYSA-N 0.000 description 2
- OPPTYXUIJHZBEK-UHFFFAOYSA-N O(C)C1=C(F)C(C(=O)OC)=C(N2C=NC(C)=N2)C=C1 Chemical compound O(C)C1=C(F)C(C(=O)OC)=C(N2C=NC(C)=N2)C=C1 OPPTYXUIJHZBEK-UHFFFAOYSA-N 0.000 description 2
- WLNQJGHFMKEHTG-UHFFFAOYSA-N O(C)C1=C(F)C(CN)=C(N2C=C(N=N2)C(F)F)C=C1 Chemical compound O(C)C1=C(F)C(CN)=C(N2C=C(N=N2)C(F)F)C=C1 WLNQJGHFMKEHTG-UHFFFAOYSA-N 0.000 description 2
- LJIFERLCSUAZPC-UHFFFAOYSA-N O(C)C1=C(F)C(CNC(=O)C=2C=CN(C(=O)C=2)CC2=CC=3CN(CCC=3C=C2)C)=C(N2C=C(N=N2)C)C=C1 Chemical compound O(C)C1=C(F)C(CNC(=O)C=2C=CN(C(=O)C=2)CC2=CC=3CN(CCC=3C=C2)C)=C(N2C=C(N=N2)C)C=C1 LJIFERLCSUAZPC-UHFFFAOYSA-N 0.000 description 2
- QPZAWEXTCWFCKW-UHFFFAOYSA-N O(C)C1=C(F)C(CO)=C(N2C=C(C)N=N2)C=C1 Chemical compound O(C)C1=C(F)C(CO)=C(N2C=C(C)N=N2)C=C1 QPZAWEXTCWFCKW-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 101150097162 SERPING1 gene Proteins 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- KOJFGQVXLRSOMT-UHFFFAOYSA-N [2-fluoro-3-methoxy-6-(4-trimethylsilyltriazol-1-yl)phenyl]methanol Chemical compound COC(C(F)=C1CO)=CC=C1N1N=NC([Si](C)(C)C)=C1 KOJFGQVXLRSOMT-UHFFFAOYSA-N 0.000 description 2
- KEWAXBKXDBAJSJ-UHFFFAOYSA-M [Li+].CC(C)N1CC2=C(C1)C=C(C=C2)CN3C=C(N=N3)C(=O)[O-] Chemical compound [Li+].CC(C)N1CC2=C(C1)C=C(C=C2)CN3C=C(N=N3)C(=O)[O-] KEWAXBKXDBAJSJ-UHFFFAOYSA-M 0.000 description 2
- KGLSWHXJVHVIFU-UHFFFAOYSA-M [Li+].CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)[O-] Chemical compound [Li+].CN1CCC2=C(C1)C=C(C=C2)CN3C=C(C(=N3)COC)C(=O)[O-] KGLSWHXJVHVIFU-UHFFFAOYSA-M 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 229960001174 ecallantide Drugs 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000030407 hereditary angioedema with normal C1Inh Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- CMUYAPPMAUVUBN-UHFFFAOYSA-N methanesulfonate;1h-pyrazol-1-ium Chemical compound CS([O-])(=O)=O.[NH2+]1C=CC=N1 CMUYAPPMAUVUBN-UHFFFAOYSA-N 0.000 description 2
- YMQATLCBIXVTKE-UHFFFAOYSA-N methyl 3,4-bis(trimethylsilyl)benzoate Chemical compound COC(=O)C1=CC=C([Si](C)(C)C)C([Si](C)(C)C)=C1 YMQATLCBIXVTKE-UHFFFAOYSA-N 0.000 description 2
- BDSUCQIRHDWHIH-UHFFFAOYSA-N methyl 4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridine-3-carboxylate Chemical compound COC(=O)c1cnc2CN(C)CCc2c1Cl BDSUCQIRHDWHIH-UHFFFAOYSA-N 0.000 description 2
- HDKYHCGUBVWJHC-UHFFFAOYSA-N methyl 5-(methoxymethyl)-1h-pyrazole-4-carboxylate Chemical compound COCC1=NNC=C1C(=O)OC HDKYHCGUBVWJHC-UHFFFAOYSA-N 0.000 description 2
- FXPJQYIMPTWBKL-UHFFFAOYSA-N methyl 7-methyl-4-oxo-1,5,6,8-tetrahydro-1,7-naphthyridine-3-carboxylate Chemical compound COC(=O)c1c[nH]c2CN(C)CCc2c1=O FXPJQYIMPTWBKL-UHFFFAOYSA-N 0.000 description 2
- ZKXDPSKJJGYMAI-UHFFFAOYSA-N n-[(3-bromo-4-fluorophenyl)methyl]-2,2-dimethoxyethanamine Chemical compound COC(OC)CNCC1=CC=C(F)C(Br)=C1 ZKXDPSKJJGYMAI-UHFFFAOYSA-N 0.000 description 2
- KACRABUOHKIHAB-UHFFFAOYSA-N n-[[1-(4-bromophenyl)cyclopropyl]methyl]-2,2,2-trifluoroacetamide Chemical compound C=1C=C(Br)C=CC=1C1(CNC(=O)C(F)(F)F)CC1 KACRABUOHKIHAB-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
- 231100000822 oral exposure Toxicity 0.000 description 2
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 2
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 2
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000004291 retinal vascular dysfunctions Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MUYQARBHPGKKSN-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-5-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCn2nc(CO)cc2C1 MUYQARBHPGKKSN-UHFFFAOYSA-N 0.000 description 2
- FJOGBVBHIARLMM-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-6,8-dihydro-5h-1,7-naphthyridine-7-carboxylate Chemical compound C1=C(CO)N=C2CN(C(=O)OC(C)(C)C)CCC2=C1 FJOGBVBHIARLMM-UHFFFAOYSA-N 0.000 description 2
- XJUYVCKMKUYQFQ-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-6,8-dihydro-5h-[1,2,4]triazolo[1,5-a]pyrazine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2N=C(CO)N=C21 XJUYVCKMKUYQFQ-UHFFFAOYSA-N 0.000 description 2
- DBEVOASWYWQEFC-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)-6,8-dihydro-5h-imidazo[1,2-a]pyrazine-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2C=C(CO)N=C21 DBEVOASWYWQEFC-UHFFFAOYSA-N 0.000 description 2
- WNDVOXDCPPWAEK-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-6,8-dihydro-5H-1,7-naphthyridine-7-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCC=2C=C(C=NC=2C1)CO WNDVOXDCPPWAEK-UHFFFAOYSA-N 0.000 description 2
- VXLDWHNYZHQCFE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)-11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-triene-11-carboxylate Chemical compound C12=CC(CO)=CC=C2C2N(C(=O)OC(C)(C)C)C1CC2 VXLDWHNYZHQCFE-UHFFFAOYSA-N 0.000 description 2
- QKVLBSKGFSSNSF-UHFFFAOYSA-N tert-butyl 5-(azidomethyl)-1,3-dihydroisoindole-2-carboxylate Chemical compound N(=[N+]=[N-])CC=1C=C2CN(CC2=CC=1)C(=O)OC(C)(C)C QKVLBSKGFSSNSF-UHFFFAOYSA-N 0.000 description 2
- AELZVPRONRWNRQ-UHFFFAOYSA-N tert-butyl 5-(hydroxymethyl)-1,3-dihydroisoindole-2-carboxylate Chemical compound C1=C(CO)C=C2CN(C(=O)OC(C)(C)C)CC2=C1 AELZVPRONRWNRQ-UHFFFAOYSA-N 0.000 description 2
- MPDFXDAJVWVELX-UHFFFAOYSA-N tert-butyl 5-[[4-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methylcarbamoyl]-3-(methoxymethyl)pyrazol-1-yl]methyl]-1,3-dihydroisoindole-2-carboxylate Chemical compound CC(C)(C)OC(N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=NC(C)=C4)=CC=C4OC)=C4F)=O)=C3)=CC=C2C1)=O MPDFXDAJVWVELX-UHFFFAOYSA-N 0.000 description 2
- SRPQMCZDXOFUBX-UHFFFAOYSA-N tert-butyl 5-chloro-6-(trifluoromethylsulfonyloxy)-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC2=CC=C(C(=C2CC1)Cl)OS(=O)(=O)C(F)(F)F SRPQMCZDXOFUBX-UHFFFAOYSA-N 0.000 description 2
- VVTNAXCVGQIIOV-UHFFFAOYSA-N tert-butyl 6-(hydroxymethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound OCC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=C1 VVTNAXCVGQIIOV-UHFFFAOYSA-N 0.000 description 2
- IUWKKLSQJWFZOT-UHFFFAOYSA-N tert-butyl 6-bromo-5-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CC2=CC=C(C(=C2CC1)F)Br IUWKKLSQJWFZOT-UHFFFAOYSA-N 0.000 description 2
- BZMPZBLLRXCSRN-UHFFFAOYSA-N tert-butyl 7-(hydroxymethyl)-1,2,4,5-tetrahydro-3-benzazepine-3-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC2=CC=C(CO)C=C21 BZMPZBLLRXCSRN-UHFFFAOYSA-N 0.000 description 2
- YJTMKANCKBDVKQ-UHFFFAOYSA-N tert-butyl 7-bromo-6-fluoro-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound FC1=C(Br)C=C2CN(C(=O)OC(C)(C)C)CCC2=C1 YJTMKANCKBDVKQ-UHFFFAOYSA-N 0.000 description 2
- XANXQHKNWZAELQ-UHFFFAOYSA-N tert-butyl 8-fluoro-6-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2=CC(CO)=CC(F)=C2C1 XANXQHKNWZAELQ-UHFFFAOYSA-N 0.000 description 2
- HDBRWOFLNNNWRD-UHFFFAOYSA-N tert-butyl N-[3-fluoro-2-(hydroxymethyl)-4-methoxyphenyl]carbamate Chemical compound C(C)(C)(C)OC(NC1=C(C(=C(C=C1)OC)F)CO)=O HDBRWOFLNNNWRD-UHFFFAOYSA-N 0.000 description 2
- NEYQFDOIXGTRIW-UHFFFAOYSA-N tert-butyl-[[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC(C(N1N=C(C)N=C1)=CC=C1OC)=C1F NEYQFDOIXGTRIW-UHFFFAOYSA-N 0.000 description 2
- PTBBDKSERFJMAZ-UHFFFAOYSA-N tert-butyl-[[6-(3,5-dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC(C(F)=C(C=C1)OC)=C1N1N=C(C)N=C1C PTBBDKSERFJMAZ-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- JWCVYQRPINPYQJ-UHFFFAOYSA-N thiepane Chemical compound C1CCCSCC1 JWCVYQRPINPYQJ-UHFFFAOYSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 108010036927 trypsin-like serine protease Proteins 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ATJHLRRHTHOZAF-UHFFFAOYSA-N (1-aminoethylideneamino) 4-methylbenzenesulfonate Chemical compound CC(N)=NOS(=O)(=O)C1=CC=C(C)C=C1 ATJHLRRHTHOZAF-UHFFFAOYSA-N 0.000 description 1
- XTPONJSHIMSJHQ-UHFFFAOYSA-N (1-aminopropylideneamino) 4-methylbenzenesulfonate Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)ON=C(CC)N XTPONJSHIMSJHQ-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YUFCAFFIWRXZQH-UHFFFAOYSA-N (4-methoxycarbonyl-2-trimethylsilylphenyl)-phenyliodanium Chemical compound COC(=O)C1=CC(=C(C=C1)[I+]C1=CC=CC=C1)[Si](C)(C)C YUFCAFFIWRXZQH-UHFFFAOYSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- CSVFWMMPUJDVKH-UHFFFAOYSA-N 1,1-dichloropropan-2-one Chemical compound CC(=O)C(Cl)Cl CSVFWMMPUJDVKH-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical class OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 1
- QCGMEWVZBGQOFN-UHFFFAOYSA-N 1,3-oxazole-5-carboxylic acid Chemical class OC(=O)C1=CN=CO1 QCGMEWVZBGQOFN-UHFFFAOYSA-N 0.000 description 1
- 150000000094 1,4-dioxanes Chemical class 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- VEMQTQYELCZZHA-UHFFFAOYSA-N 1-[(2-pyrrolidin-1-ylpyrimidin-5-yl)methyl]pyrazole-4-carboxamide Chemical compound N1(CCCC1)C1=NC=C(C=N1)CN1N=CC(=C1)C(=O)N VEMQTQYELCZZHA-UHFFFAOYSA-N 0.000 description 1
- APTDRDYSJZQPPI-UHFFFAOYSA-N 1-bromo-4-(2-bromoethyl)benzene Chemical compound BrCCC1=CC=C(Br)C=C1 APTDRDYSJZQPPI-UHFFFAOYSA-N 0.000 description 1
- VNMRRTIDEYNZOV-UHFFFAOYSA-N 1-chloro-2-fluoro-4-iodobenzene Chemical compound FC1=CC(I)=CC=C1Cl VNMRRTIDEYNZOV-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical class OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 description 1
- NUGZBVBZIDWZAD-UHFFFAOYSA-N 1h-pyrazole-4-carbonitrile Chemical compound N#CC=1C=NNC=1 NUGZBVBZIDWZAD-UHFFFAOYSA-N 0.000 description 1
- YMJLEPMVGQBLHL-UHFFFAOYSA-N 1h-pyrazole-5-carbonitrile Chemical compound N#CC1=CC=NN1 YMJLEPMVGQBLHL-UHFFFAOYSA-N 0.000 description 1
- QKWWDTYDYOFRJL-UHFFFAOYSA-N 2,2-dimethoxyethanamine Chemical compound COC(CN)OC QKWWDTYDYOFRJL-UHFFFAOYSA-N 0.000 description 1
- SGPPUPHZQOXDLW-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethanol;hydrochloride Chemical compound Cl.O1CCNCC2=CC(CO)=CC=C21 SGPPUPHZQOXDLW-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical class OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- UJIFQRRRDGPAAG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)ethanamine Chemical compound NCCC1=CC=CC(Br)=C1F UJIFQRRRDGPAAG-UHFFFAOYSA-N 0.000 description 1
- UHOIFEOHBGCPHE-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonyl]-3,4-dihydro-1h-isoquinoline-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=C1 UHOIFEOHBGCPHE-UHFFFAOYSA-N 0.000 description 1
- XJMLPDPXMJKTCH-UHFFFAOYSA-N 2-chloro-4-iodo-1-methoxybenzene Chemical compound COC1=CC=C(I)C=C1Cl XJMLPDPXMJKTCH-UHFFFAOYSA-N 0.000 description 1
- LQCQGKYUMOOPKX-UHFFFAOYSA-N 2-fluoro-6-iodo-3-methoxybenzoic acid Chemical compound COC1=CC=C(I)C(C(O)=O)=C1F LQCQGKYUMOOPKX-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- CMEHMBCDTLQNGB-UHFFFAOYSA-N 4-(1H-pyrazol-5-yl)-1,3-thiazol-2-amine Chemical class S1C(N)=NC(C2=NNC=C2)=C1 CMEHMBCDTLQNGB-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical class OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical class CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- WGZYVHFXLPDNDL-UHFFFAOYSA-N 4-benzoyl-2-phenylpyrazole-3-carbonitrile Chemical compound C=1C=CC=CC=1C(=O)C(=C1C#N)C=NN1C1=CC=CC=C1 WGZYVHFXLPDNDL-UHFFFAOYSA-N 0.000 description 1
- HBEUFGFORMZNFR-UHFFFAOYSA-N 5-(2-phenylphenyl)-1h-pyrazole Chemical group N1C=CC(C=2C(=CC=CC=2)C=2C=CC=CC=2)=N1 HBEUFGFORMZNFR-UHFFFAOYSA-N 0.000 description 1
- KZAQTVQJVOALDK-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-1,2,4-triazole Chemical compound FC(F)(F)C=1N=CNN=1 KZAQTVQJVOALDK-UHFFFAOYSA-N 0.000 description 1
- PYXNITNKYBLBMW-UHFFFAOYSA-N 5-(trifluoromethyl)-1h-pyrazole Chemical compound FC(F)(F)C1=CC=NN1 PYXNITNKYBLBMW-UHFFFAOYSA-N 0.000 description 1
- YXDIKUGVBMNKKQ-UHFFFAOYSA-N 5-O-tert-butyl 2-O-methyl 6,7-dihydro-4H-pyrazolo[1,5-a]pyrazine-2,5-dicarboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCN2N=C(C(=O)OC)C=C21 YXDIKUGVBMNKKQ-UHFFFAOYSA-N 0.000 description 1
- WJNKJYJCWXMBNV-UHFFFAOYSA-N 5-bromo-2,3-dihydroisoindol-1-one Chemical compound BrC1=CC=C2C(=O)NCC2=C1 WJNKJYJCWXMBNV-UHFFFAOYSA-N 0.000 description 1
- GIPMPXNXKQOBTO-UHFFFAOYSA-N 5-chloro-1,2,3,4-tetrahydroisoquinolin-6-ol;hydrobromide Chemical compound Br.C1NCCC2=C(Cl)C(O)=CC=C21 GIPMPXNXKQOBTO-UHFFFAOYSA-N 0.000 description 1
- TXWDVWSJMDFNQY-UHFFFAOYSA-N 5-cyclopropyl-1h-pyrazole Chemical compound C1CC1C1=CC=NN1 TXWDVWSJMDFNQY-UHFFFAOYSA-N 0.000 description 1
- VDLHUQOLSIRYKF-UHFFFAOYSA-N 6-bromo-2-fluoro-3-methoxybenzoic acid Chemical compound COC1=CC=C(Br)C(C(O)=O)=C1F VDLHUQOLSIRYKF-UHFFFAOYSA-N 0.000 description 1
- LHXQWWFCWFMCHO-UHFFFAOYSA-N 6-bromo-3,4-dihydro-1h-isochromene Chemical compound C1OCCC2=CC(Br)=CC=C21 LHXQWWFCWFMCHO-UHFFFAOYSA-N 0.000 description 1
- IRJJBSBDMDDFSO-UHFFFAOYSA-N 6-o-tert-butyl 3-o-methyl 7,8-dihydro-5h-1,6-naphthyridine-3,6-dicarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CC2=CC(C(=O)OC)=CN=C21 IRJJBSBDMDDFSO-UHFFFAOYSA-N 0.000 description 1
- BPFFTXBYFQNXNI-UHFFFAOYSA-N 7-bromo-2-methyl-3,4-dihydroisoquinolin-1-one Chemical compound C1=C(Br)C=C2C(=O)N(C)CCC2=C1 BPFFTXBYFQNXNI-UHFFFAOYSA-N 0.000 description 1
- 230000035495 ADMET Effects 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- LBIUHKQWHNECMJ-UHFFFAOYSA-N BrC1=C2CCNCC2=CC(=C1)F Chemical compound BrC1=C2CCNCC2=CC(=C1)F LBIUHKQWHNECMJ-UHFFFAOYSA-N 0.000 description 1
- 229940122155 Bradykinin receptor antagonist Drugs 0.000 description 1
- VLCUGGBUNWVYLL-UHFFFAOYSA-N C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CN)F)OC Chemical compound C(#N)C1=NN(C=C1)C1=CC=C(C(=C1CN)F)OC VLCUGGBUNWVYLL-UHFFFAOYSA-N 0.000 description 1
- VSQRWXIZBRNZJJ-UHFFFAOYSA-N C(#N)C=1C=NN(C=1)C1=CC=C(C(=C1CN)F)OC Chemical compound C(#N)C=1C=NN(C=1)C1=CC=C(C(=C1CN)F)OC VSQRWXIZBRNZJJ-UHFFFAOYSA-N 0.000 description 1
- RFVRBUFKMQANJF-UHFFFAOYSA-N C(C)(C)(OC(=O)C=1N(N=C(C=1)C(=O)OC(C)(C)C)CC#N)C Chemical compound C(C)(C)(OC(=O)C=1N(N=C(C=1)C(=O)OC(C)(C)C)CC#N)C RFVRBUFKMQANJF-UHFFFAOYSA-N 0.000 description 1
- FGTPWSRAKOILGE-UHFFFAOYSA-N C(C)(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(Br)C=C2)C Chemical compound C(C)(C)(OC(=O)N1CC2=C(C(C1)(F)F)C=C(Br)C=C2)C FGTPWSRAKOILGE-UHFFFAOYSA-N 0.000 description 1
- CNYRSKPTOHYQAB-UHFFFAOYSA-N C1(=C(F)C(CN)=C(N2C=NC(C(F)(F)F)=N2)C=C1)OC Chemical compound C1(=C(F)C(CN)=C(N2C=NC(C(F)(F)F)=N2)C=C1)OC CNYRSKPTOHYQAB-UHFFFAOYSA-N 0.000 description 1
- IFJJSYGXYKTQRA-UHFFFAOYSA-N C1(=C(OC)C=CC(=C1CN)N1C=NC(C(F)F)=N1)F Chemical compound C1(=C(OC)C=CC(=C1CN)N1C=NC(C(F)F)=N1)F IFJJSYGXYKTQRA-UHFFFAOYSA-N 0.000 description 1
- ZOCJOLFRXLPEJM-UHFFFAOYSA-N C1(=O)N(CC2(N3C1=CC(=N3)CO)CC2)C Chemical compound C1(=O)N(CC2(N3C1=CC(=N3)CO)CC2)C ZOCJOLFRXLPEJM-UHFFFAOYSA-N 0.000 description 1
- QZSWKOSQYXSCII-UHFFFAOYSA-N C1(CC1)C1=NN(C=C1)C1=CC=C(C(=C1CN)F)OC Chemical compound C1(CC1)C1=NN(C=C1)C1=CC=C(C(=C1CN)F)OC QZSWKOSQYXSCII-UHFFFAOYSA-N 0.000 description 1
- AEQOVADVUQINQQ-UHFFFAOYSA-N C1(F)=C(CN)C(N2C(=NC=N2)C)=CC=C1OC Chemical compound C1(F)=C(CN)C(N2C(=NC=N2)C)=CC=C1OC AEQOVADVUQINQQ-UHFFFAOYSA-N 0.000 description 1
- YICHQBQWQMFCDX-UHFFFAOYSA-N C12=C(C(=CN=C2CN(CC1)C)CO)Cl Chemical compound C12=C(C(=CN=C2CN(CC1)C)CO)Cl YICHQBQWQMFCDX-UHFFFAOYSA-N 0.000 description 1
- RBSZUOVYUUHXKV-UHFFFAOYSA-N C1=2CNC(=O)C(C1=CC(Br)=CC=2)(F)F Chemical compound C1=2CNC(=O)C(C1=CC(Br)=CC=2)(F)F RBSZUOVYUUHXKV-UHFFFAOYSA-N 0.000 description 1
- MQGCOGLWYHZSTO-UHFFFAOYSA-N C1C2=C(C=CC(=C2)Br)C(C(=O)N1)(F)F Chemical compound C1C2=C(C=CC(=C2)Br)C(C(=O)N1)(F)F MQGCOGLWYHZSTO-UHFFFAOYSA-N 0.000 description 1
- XEGNQBGXYNSORH-UHFFFAOYSA-N CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(C=CN=C4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=CC=C(C=CN=C4)C4=C3)N=C2COC)=O)=C2F)=CC=C2OC)N=N1 XEGNQBGXYNSORH-UHFFFAOYSA-N 0.000 description 1
- ZGVMJRLZELEIAJ-UHFFFAOYSA-N CN1CC2=CC(=CC=C2CC1)CN1C=NC(=C1)C(=O)N Chemical compound CN1CC2=CC(=CC=C2CC1)CN1C=NC(=C1)C(=O)N ZGVMJRLZELEIAJ-UHFFFAOYSA-N 0.000 description 1
- JMSRCAITOOOJKY-UHFFFAOYSA-N COC1(CC1)C(CC(=O)OCC)=O Chemical compound COC1(CC1)C(CC(=O)OCC)=O JMSRCAITOOOJKY-UHFFFAOYSA-N 0.000 description 1
- NZIWYDOFTCWTBC-UHFFFAOYSA-N COC1(CC1)C1=NNC=C1C(=O)OCC Chemical compound COC1(CC1)C1=NNC=C1C(=O)OCC NZIWYDOFTCWTBC-UHFFFAOYSA-N 0.000 description 1
- WOVVTKFZIQGDDZ-UHFFFAOYSA-N COC1=C(C(=C(C=C1)N2C=NC(=N2)C(F)F)CN)Cl Chemical compound COC1=C(C(=C(C=C1)N2C=NC(=N2)C(F)F)CN)Cl WOVVTKFZIQGDDZ-UHFFFAOYSA-N 0.000 description 1
- WTZBXVFJJLJAMU-UHFFFAOYSA-N COCC1=NN(CC2=CC=C3N=CC=CC3=C2)C=C1C(NCC(C(N1N=NN=C1)=CC=C1OC)=C1F)=O Chemical compound COCC1=NN(CC2=CC=C3N=CC=CC3=C2)C=C1C(NCC(C(N1N=NN=C1)=CC=C1OC)=C1F)=O WTZBXVFJJLJAMU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- SKRNDLVLBPTCDE-UHFFFAOYSA-N ClC1=C2CCN(CC2=CC=C1CCl)C(=O)OC(C)(C)C Chemical compound ClC1=C2CCN(CC2=CC=C1CCl)C(=O)OC(C)(C)C SKRNDLVLBPTCDE-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- FRPYRCYPESVDKI-UHFFFAOYSA-N FC1=C(C(=CC=C1OC)N1N=C(C=C1)C(F)(F)F)CN Chemical compound FC1=C(C(=CC=C1OC)N1N=C(C=C1)C(F)(F)F)CN FRPYRCYPESVDKI-UHFFFAOYSA-N 0.000 description 1
- AGUMUKWUEWEMJD-UHFFFAOYSA-N FC1=C(CN)C(N2C=NC(CC)=N2)=CC=C1OC Chemical compound FC1=C(CN)C(N2C=NC(CC)=N2)=CC=C1OC AGUMUKWUEWEMJD-UHFFFAOYSA-N 0.000 description 1
- QPUXTIIDKPUHIE-UHFFFAOYSA-N FC1=C(CNC(=O)C2=CC(CC3=CC=4CN(CCC=4C=C3)C(=O)OC(C)(C)C)=CN=C2)C(N2C=C(C)N=N2)=CC=C1OC Chemical compound FC1=C(CNC(=O)C2=CC(CC3=CC=4CN(CCC=4C=C3)C(=O)OC(C)(C)C)=CN=C2)C(N2C=C(C)N=N2)=CC=C1OC QPUXTIIDKPUHIE-UHFFFAOYSA-N 0.000 description 1
- FQVSTVMTLMJQNU-UHFFFAOYSA-N FC1=C2CCN(CC2=CC=C1CO)C(=O)OC(C)(C)C Chemical compound FC1=C2CCN(CC2=CC=C1CO)C(=O)OC(C)(C)C FQVSTVMTLMJQNU-UHFFFAOYSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- OKLBOBJCIDTQCO-UHFFFAOYSA-N Fc1c(Br)ccc2ccncc12 Chemical compound Fc1c(Br)ccc2ccncc12 OKLBOBJCIDTQCO-UHFFFAOYSA-N 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000975003 Homo sapiens Kallistatin Proteins 0.000 description 1
- 101001077723 Homo sapiens Serine protease inhibitor Kazal-type 6 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 229940122920 Kallikrein inhibitor Drugs 0.000 description 1
- 101710176219 Kallikrein-1 Proteins 0.000 description 1
- 102100023012 Kallistatin Human genes 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 description 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- BPSSGZQFKPCOLD-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methyl]-1-[(7-methyl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound CC1=CN(C(C(CNC(C2=CN(CC3=NC(CN(C)CC4)=C4C=N3)N=C2C(F)(F)F)=O)=C2F)=CC=C2OC)N=N1 BPSSGZQFKPCOLD-UHFFFAOYSA-N 0.000 description 1
- XFHQXUOGKMUMLE-UHFFFAOYSA-N N-[[2-fluoro-3-methoxy-6-(triazol-1-yl)phenyl]methyl]-3-(methoxymethyl)-1-[(2-pyrrolidin-1-ylpyrimidin-5-yl)methyl]pyrazole-4-carboxamide Chemical compound FC1=C(C(=CC=C1OC)N1N=NC=C1)CNC(=O)C=1C(=NN(C=1)CC=1C=NC(=NC=1)N1CCCC1)COC XFHQXUOGKMUMLE-UHFFFAOYSA-N 0.000 description 1
- QJBJSLCWGCZZJY-UHFFFAOYSA-N N-[[6-(3,5-dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl]-3-(methoxymethyl)-1-[(2-propan-2-yl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide Chemical compound CC(C)N1CC2=CC(CN3N=C(COC)C(C(NCC(C(N4N=C(C)N=C4C)=CC=C4OC)=C4F)=O)=C3)=CC=C2CC1 QJBJSLCWGCZZJY-UHFFFAOYSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- NJQXDLRESLRGDI-UHFFFAOYSA-N N1=C(C(=CN1CC1=CN=C(N=C1)N1CCCC1)C(=O)NCC1=C(C(=CC=C1N1C=C(C(F)F)N=N1)OC)F)COC Chemical compound N1=C(C(=CN1CC1=CN=C(N=C1)N1CCCC1)C(=O)NCC1=C(C(=CC=C1N1C=C(C(F)F)N=N1)OC)F)COC NJQXDLRESLRGDI-UHFFFAOYSA-N 0.000 description 1
- DVKRUFCAACRVHI-UHFFFAOYSA-N N1=C(C(=CN1CC1=CN=C(N=C1)N1CCCC1)C(=O)NCC1=C(C(=CC=C1N1C=C(C)N=N1)OC)F)COC Chemical compound N1=C(C(=CN1CC1=CN=C(N=C1)N1CCCC1)C(=O)NCC1=C(C(=CC=C1N1C=C(C)N=N1)OC)F)COC DVKRUFCAACRVHI-UHFFFAOYSA-N 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- WHTOLGNIUGTVNP-UHFFFAOYSA-N OCC1=CC=C2C(=C1)C(C)(C)N(C2)C Chemical compound OCC1=CC=C2C(=C1)C(C)(C)N(C2)C WHTOLGNIUGTVNP-UHFFFAOYSA-N 0.000 description 1
- VXQLLCQWDZQNBR-UHFFFAOYSA-N OCC1=CC=C2C(=C1)C1CCCN1CC2 Chemical compound OCC1=CC=C2C(=C1)C1CCCN1CC2 VXQLLCQWDZQNBR-UHFFFAOYSA-N 0.000 description 1
- 229910020667 PBr3 Inorganic materials 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SOZRMVNRGDOZBY-UHFFFAOYSA-N [1-(4-bromophenyl)cyclopropyl]methanamine Chemical compound C=1C=C(Br)C=CC=1C1(CN)CC1 SOZRMVNRGDOZBY-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- ZDWYFWIBTZJGOR-UHFFFAOYSA-N bis(trimethylsilyl)acetylene Chemical compound C[Si](C)(C)C#C[Si](C)(C)C ZDWYFWIBTZJGOR-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- SWABYVXORFBBAT-UHFFFAOYSA-N ethyl imidazo[1,2-a]pyrazine-2-carboxylate Chemical compound C1=CN=CC2=NC(C(=O)OCC)=CN21 SWABYVXORFBBAT-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- XUURNHOXRBVNSP-UHFFFAOYSA-N methyl 3-(methoxymethyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-ylmethyl)pyrazole-4-carboxylate hydrochloride Chemical compound COCC1=NN(CC2=CC=C(CCNC3)C3=C2)C=C1C(OC)=O.Cl XUURNHOXRBVNSP-UHFFFAOYSA-N 0.000 description 1
- WCGCRUNZKBSRNP-FIBGUPNXSA-N methyl 3-(methoxymethyl)-1-[[2-(trideuteriomethyl)-3,4-dihydro-1H-isoquinolin-7-yl]methyl]pyrazole-4-carboxylate Chemical compound [2H]C([2H])([2H])N1CC2=CC(CN3N=C(COC)C(C(OC)=O)=C3)=CC=C2CC1 WCGCRUNZKBSRNP-FIBGUPNXSA-N 0.000 description 1
- PPGHZOSVKYIRSX-UHFFFAOYSA-N methyl 4-oxo-5,6,7,8-tetrahydro-1h-1,7-naphthyridine-3-carboxylate Chemical compound C1NCCC2=C1NC=C(C(=O)OC)C2=O PPGHZOSVKYIRSX-UHFFFAOYSA-N 0.000 description 1
- DWKTWECZWNVIMB-UHFFFAOYSA-N methyl 5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxylate dihydrochloride Chemical compound Cl.Cl.COC(=O)c1ccc2CCNCc2n1 DWKTWECZWNVIMB-UHFFFAOYSA-N 0.000 description 1
- OLTXJCOSFDVONN-UHFFFAOYSA-N methyl 5-(4,4,5-trimethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate Chemical compound CC1OB(C2=CN=CC(C(OC)=O)=C2)OC1(C)C OLTXJCOSFDVONN-UHFFFAOYSA-N 0.000 description 1
- CAGDCRQKKDKFDS-UHFFFAOYSA-N methyl 6-amino-2-fluoro-3-methoxybenzoate Chemical compound COC(=O)C1=C(N)C=CC(OC)=C1F CAGDCRQKKDKFDS-UHFFFAOYSA-N 0.000 description 1
- TWOBQNWSLXGOBW-UHFFFAOYSA-N methyl 6-bromo-2-fluoro-3-methoxybenzoate Chemical compound COC(=O)C1=C(Br)C=CC(OC)=C1F TWOBQNWSLXGOBW-UHFFFAOYSA-N 0.000 description 1
- HHWWWZQYHPFCBY-UHFFFAOYSA-N methyl 6-oxopyran-3-carboxylate Chemical compound COC(=O)C=1C=CC(=O)OC=1 HHWWWZQYHPFCBY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- IMAKHNTVDGLIRY-UHFFFAOYSA-N methyl prop-2-ynoate Chemical compound COC(=O)C#C IMAKHNTVDGLIRY-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- YMWAWNGTJDKAQE-UHFFFAOYSA-N n-[(3-bromo-4-fluorophenyl)methyl]-n-(2,2-dimethoxyethyl)-4-methylbenzenesulfonamide Chemical compound C=1C=C(C)C=CC=1S(=O)(=O)N(CC(OC)OC)CC1=CC=C(F)C(Br)=C1 YMWAWNGTJDKAQE-UHFFFAOYSA-N 0.000 description 1
- KPVUOSUNLUOQNR-UHFFFAOYSA-N n-[2-(4-bromophenyl)ethyl]acetamide Chemical compound CC(=O)NCCC1=CC=C(Br)C=C1 KPVUOSUNLUOQNR-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 231100000623 nanotoxicology Toxicity 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- VWBWQOUWDOULQN-UHFFFAOYSA-N nmp n-methylpyrrolidone Chemical compound CN1CCCC1=O.CN1CCCC1=O VWBWQOUWDOULQN-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004268 retinal thickening Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- XZPVPNZTYPUODG-UHFFFAOYSA-M sodium;chloride;dihydrate Chemical compound O.O.[Na+].[Cl-] XZPVPNZTYPUODG-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- PFHQVXNDEAIXOZ-UHFFFAOYSA-N tert-butyl 2-(chloromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound N1=C(CCl)N=C2CN(C(=O)OC(C)(C)C)CCC2=C1 PFHQVXNDEAIXOZ-UHFFFAOYSA-N 0.000 description 1
- KIYPBPWOWVKRDG-UHFFFAOYSA-N tert-butyl 2-chloro-6,8-dihydro-5h-pyrido[3,4-d]pyrimidine-7-carboxylate Chemical compound N1=C(Cl)N=C2CN(C(=O)OC(C)(C)C)CCC2=C1 KIYPBPWOWVKRDG-UHFFFAOYSA-N 0.000 description 1
- QNBIHKDUIHTQIZ-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)-7,8-dihydro-5h-1,6-naphthyridine-6-carboxylate Chemical compound C1=C(CO)C=C2CN(C(=O)OC(C)(C)C)CCC2=N1 QNBIHKDUIHTQIZ-UHFFFAOYSA-N 0.000 description 1
- SOYJDCSJRAJNIQ-UHFFFAOYSA-N tert-butyl 5-bromo-7-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCc2c(Br)cc(F)cc2C1 SOYJDCSJRAJNIQ-UHFFFAOYSA-N 0.000 description 1
- IZYPQVWVZKITBP-UHFFFAOYSA-N tert-butyl 6-(bromomethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound BrCC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=C1 IZYPQVWVZKITBP-UHFFFAOYSA-N 0.000 description 1
- CIBOPYLOTAXPDB-UHFFFAOYSA-N tert-butyl 7-(hydroxymethyl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C1=C(CO)C=C2CN(C(=O)OC(C)(C)C)CCC2=C1 CIBOPYLOTAXPDB-UHFFFAOYSA-N 0.000 description 1
- OMFJEKPDQUZCBC-UHFFFAOYSA-N tert-butyl 7-(hydroxymethyl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCOC2=CC=C(CO)C=C21 OMFJEKPDQUZCBC-UHFFFAOYSA-N 0.000 description 1
- DSWACVCHKKRBHK-UHFFFAOYSA-N tert-butyl 7-bromo-4,4-dimethyl-1,3-dihydroisoquinoline-2-carboxylate Chemical compound BrC1=CC=C2C(C)(C)CN(C(=O)OC(C)(C)C)CC2=C1 DSWACVCHKKRBHK-UHFFFAOYSA-N 0.000 description 1
- XCAQIUOFDMREBA-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=O)OC(C)(C)C XCAQIUOFDMREBA-UHFFFAOYSA-N 0.000 description 1
- IZPYBIJFRFWRPR-UHFFFAOYSA-N tert-butyl pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC=C1 IZPYBIJFRFWRPR-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
- VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- This invention relates to enzyme inhibitors that are inhibitors of plasma kallikrein, and to the pharmaceutical compositions, and uses of, such inhibitors.
- heterocyclic derivatives of the present invention are inhibitors of plasma kallikrein and have a number of therapeutic applications, particularly in the treatment of bradykinin-mediated angioedema hereditary angioedema and bradykinin-mediated angioedema non-hereditary (BK-AEnH).
- Plasma kallikrein is a trypsin-like serine protease that can liberate kinins from kininogens (see K. D. Bhoola et al., “Kallikrein-Kinin Cascade”, Encyclopedia of Respiratory Medicine, p 483-493; J. W. Bryant et al., “Human plasma kallikrein-kinin system: physiological and biochemical parameters” Cardiovascular and haematological agents in medicinal chemistry, 7, p 234-250, 2009; K. D. Bhoola et al., Pharmacological Rev., 1992, 44, 1; and D. J.
- Plasma prekallikrein is encoded by a single gene and can be synthesized in the liver, as well as other tissues. It is secreted by hepatocytes as an inactive plasma prekallikrein that circulates in plasma as a heterodimer complex bound to high molecular weight kininogen (HK) which is activated to give the active plasma kallikrein.
- HK high molecular weight kininogen
- This contact activation system can be activated by negatively charged surfaces that activate Factor XII (FXII) to Factor XIIa (FXIIa), by certain proteases e.g. plasmin (Hofman et al Clin Rev Allergy Immunol 2016), which may not require negative surfaces, or by misfolded proteins (Maas et al J Clinical Invest 2008).
- FXIIa mediates conversion of plasma prekallikrein to plasma kallikrein and the subsequent cleavage of high molecular weight kininogen (HK) to generate bradykinin, a potent inflammatory hormone.
- kinins are potent mediators of inflammation that act through G protein-coupled receptors and antagonists of kinins (such as bradykinin receptor antagonists) have previously been investigated as potential therapeutic agents for the treatment of a number of disorders (F. Marceau and D. Regoli, Nature Rev., Drug Discovery, 2004, 3, 845-852).
- Plasma kallikrein is thought to play a role in a number of inflammatory disorders.
- the major inhibitor of plasma kallikrein is the serpin C1 esterase inhibitor.
- Patients who present with a genetic deficiency in C1 esterase inhibitor suffer from hereditary angioedema (HAE) which results in intermittent swelling of face, hands, throat, gastro-intestinal tract and genitals.
- HAE hereditary angioedema
- Blisters formed during acute episodes contain high levels of plasma kallikrein which cleaves high molecular weight kininogen (HK) liberating bradykinin leading to increased vascular permeability.
- HK high molecular weight kininogen
- HAE normal C1 inhibitor HAE
- HAE type 1 is caused by mutations in the SERPING1 gene that lead to reduced levels of C1 inhibitor in the blood.
- HAE type 2 is caused by mutations in the SERPING1 gene that lead to dysfunction of the C1 inhibitor in the blood.
- the cause of normal C1-Inh HAE is less well defined and the underlying genetic dysfunction/fault/mutation can sometimes remain unknown. What is known is that the cause of normal C1-Inh HAE is not related to reduced levels or dysfunction of the C1 inhibitor (in contrast to HAE types 1 and 2).
- Normal C1-Inh HAE can be diagnosed by reviewing the family history and noting that angioedema has been inherited from a previous generation (and thus it is hereditary angioedema). Normal C1-Inh HAE can also be diagnosed by determining that there is a dysfunction/fault/mutation in a gene other than those related to C1 inhibitor. For example, it has been reported that dysfunction/fault/mutation with plasminogen can cause normal C1-Inh HAE (see e.g. Veronez et al., Front Med (Lausanne). 2019 Feb. 21; 6:28. doi: 10.3389/fmed.2019.00028; or Recke et al., Clin Transl Allergy. 2019 Feb. 14; 9:9.
- angioedemas are not necessarily inherited. Indeed, another class of angioedema is bradykinin-mediated angioedema non-hereditary (BK-AEnH), which is not caused by an inherited genetic dysfunction/fault/mutation. Often the underlying cause of BK-AEnH is unknown and/or undefined. However, the signs and symptoms of BK-AEnH are similar to those of HAE, which without being bound by theory, is thought to be on account of the shared bradykinin-mediated pathway between HAE and BK-AEnH.
- BK-AEnH bradykinin-mediated angioedema non-hereditary
- BK-AEnH is characterised by recurrent acute attacks where fluids accumulate outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues such as in the hands, feet, limbs, face, intestinal tract, airway or genitals.
- BK-AEnH include: non-hereditary angioedema with normal C1 Inhibitor (AE-nC1 Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
- AE-nC1 Inh non-hereditary angioedema with normal C1 Inhibitor
- ACE angiotensin converting enzyme
- tPA-induced angioedema tissue plasminogen activator-induced angioedema
- Environmental factors that can induce AE-nC1 Inh include air pollution (Kedarisetty et al, Otolaryngol Head Neck Surg. 2019 Apr. 30:194599819846446. doi: 10.1177/0194599819846446) and silver nanoparticles such as those used as antibacterial components in healthcare, biomedical and consumer products (Long et al., Nanotoxicology. 2016; 10(4):501-11. doi: 10.3109/17435390.2015.1088589).
- tPA-induced angioedema is discussed in various publications as being a potentially life-threatening complication following thrombolytic therapy in acute stroke victims (see e.g. Sim ⁇ o et al., Blood. 2017 Apr. 20; 129(16):2280-2290. doi: 10.1182/blood-2016-09-740670; Fröhlich et al., Stroke. 2019 Jun. 11:STROKEAHA119025260. doi: 10.1161/STROKEAHA.119.025260; Rathbun, Oxf Med Case Reports. 2019 Jan. 24; 2019(1):omy112. doi: 10.1093/omcr/omy112; Lekoubou et al., Neurol Res. 2014 July; 36(7):687-94. doi: 10.1179/1743132813Y.0000000302; Hill et al., Neurology. 2003 May 13; 60(9):1525-7).
- Hermanrud et al. (BMJ Case Rep. 2017 Jan. 10; 2017. pii: bcr2016217802) reports recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV and also discusses acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE).
- Kim et al. (Basic Clin Pharmacol Toxicol. 2019 January; 124(1):115-122. doi: 10.1111/bcpt.13097) reports angiotensin II receptor blocker (ARB)-related angioedema.
- Reichman et al. (Pharmacoepidemiol Drug Saf. 2017 October; 26(10):1190-1196.
- the plasma kallikrein-kinin system is abnormally abundant in patients with advanced diabetic macular edema. It has been recently published that plasma kallikrein contributes to retinal vascular dysfunctions in diabetic rats (A. Clermont et al. “Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats” Diabetes, 2011, 60, p 1590-98). Furthermore, administration of the plasma kallikrein inhibitor ASP-440 ameliorated both retinal vascular permeability and retinal blood flow abnormalities in diabetic rats. Therefore a plasma kallikrein inhibitor should have utility as a treatment to reduce retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
- ASP-634 An Oral Drug Candidate for Diabetic Macular Edema
- ARVO 2012 May 6th-May 9, 2012, Fort Lauderdale, Fla., Presentation 2240 ASP-440
- absorption may be improved by creating a prodrug such as ASP-634.
- prodrugs can suffer from several drawbacks, for example, poor chemical stability and potential toxicity from the inert carrier or from unexpected metabolites.
- indole amides are claimed as compounds that might overcome problems associated with drugs possessing poor or inadequate ADME-tox and physicochemical properties although no inhibition against plasma kallikrein is presented or claimed (Griffioen et al, “Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases”, WO2010142801).
- Plasma kallikrein inhibitors known in the art are generally small molecules, some of which include highly polar and ionisable functional groups, such as guanidines or amidines. Recently, plasma kallikrein inhibitors that do not feature guanidine or amidine functionalities have been reported. For example Brandl et al. (“N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein” WO2012/017020), Evans et al. (“Benzylamine derivatives as inhibitors of plasma kallikrein” WO2013/005045), Allan et al.
- FIG. 1 is a diagram showing key interactions of Example 1 with human plasma kallikrein.
- FIG. 2 is a diagram showing key interactions of Example 1 with human plasma kallikrein.
- FIG. 3 is a diagram showing key interactions of Example 1 with human plasma kallikrein.
- FIG. 4 is a diagram showing key interactions of Example 160 with human plasma kallikrein.
- FIG. 5 is a diagram showing key interactions of Example 160 with human plasma kallikrein.
- FIG. 6 is a diagram showing key interactions of Example 160 with human plasma kallikrein.
- FIG. 7 is a diagram showing key interactions of Example 36 with human plasma kallikrein.
- FIG. 8 is a diagram showing key interactions of Example 36 with human plasma kallikrein.
- FIG. 9 is a diagram showing key interactions of Example 36 with human plasma kallikrein.
- FIG. 10 is a diagram showing key interactions of Example 11 with human plasma kallikrein.
- FIG. 11 is a diagram showing key interactions of Example 11 with human plasma kallikrein.
- FIG. 12 is a diagram showing key interactions of Example 11 with human plasma kallikrein.
- FIG. 13 is a diagram showing key interactions of Example 126 with human plasma kallikrein.
- FIG. 14 is a diagram showing key interactions of Example 126 with human plasma kallikrein.
- FIG. 15 is a diagram showing key interactions of Example 126 with human plasma kallikrein.
- FIG. 16 is a diagram showing key interactions of RC4 with human plasma kallikrein.
- FIG. 17 is a diagram showing key interactions of RC4 with human plasma kallikrein.
- FIG. 18 is a diagram showing key interactions of RC4 with human plasma kallikrein.
- FIG. 19 is a diagram showing an overlay of the interactions of RC4 with Example 1 with plasma kallikrein.
- FIG. 20 is a diagram showing an overlay of the interactions of RC4 with Example 1 with plasma kallikrein.
- the present invention relates to a series of heterocyclic derivatives that are inhibitors of plasma kallikrein. These compounds demonstrate good selectivity for plasma kallikrein and are potentially useful in the treatment of bradykinin-mediated angioedemas such as impaired visual acuity, diabetic retinopathy, macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post-operative surgery.
- the invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions.
- the present invention provides compounds of formula (I):
- the compounds of formula (I) have been carefully developed to be particularly suitable for oral delivery (e.g. possessing an excellent pharmacokinetic profile, in particular bioavailability). As shown by the examples, the inventors have demonstrated that compounds of formula (I) have surprisingly excellent solubility. More surprisingly, compounds of formula (I) exhibit these advantageous effects whilst being highly selective inhibitors of plasma kallikrein, including making key binding interactions.
- the present invention also provides a prodrug of a compound of formula (I) as herein defined, or a pharmaceutically acceptable salt and/or solvate thereof.
- the present invention also provides an N-oxide of a compound of formula (I) as herein defined, or a prodrug or pharmaceutically acceptable salt and/or solvate thereof.
- pharmaceutically acceptable salts and/or solvates thereof means “pharmaceutically acceptable salts thereof”, “pharmaceutically acceptable solvates thereof”, and “pharmaceutically acceptable solvates of salts thereof”.
- A′ is phenyl and A′′ is piperidine.
- A′′ is piperidine.
- A′ is imidazole and A′′ is piperazine.
- A′ can be pyrazole” allows the pyrazole to be “optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF 3 , halo, CN, and CF 3 ”, which is permitted by the above definition of heteroaryl.
- A′1 is directly bonded to A′2.
- alkylene has two free valencies i.e. it is bivalent, meaning that it is capable of being bonded to twice.
- alkylene will be —CH 2 CH 2 CH 2 —.
- heteroalkylene is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C 2 -C 5 ), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O.
- —CH 2 O— is a “heteroalkylene” having 2 carbon atoms wherein one of the 2 carbon atoms has been replaced with O.
- bradykinin-mediated angioedema means hereditary angioedema, and any non-hereditary bradykinin-mediated angioedema.
- bradykinin-mediated angioedema encompasses hereditary angioedema and acute bradykinin-mediated angioedema of unknown origin.
- hereditary angioedema means any bradykinin-mediated angioedema caused by an inherited genetic dysfunction, fault, or mutation.
- HAE includes at least HAE type 1, HAE type 2, and normal C1 inhibitor HAE (normal C1-Inh HAE).
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF 3 ;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF 3 ; or
- R5, R6, R7 and R16 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF 3 .
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14.
- W, X, Y and Z can form a 5-membered heteroaryl selected from furan, oxazole, isoxazole, 1,2,3-oxadiazole, and furazan.
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14.
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF 3 ;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 .
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl. More specifically, W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl selected from pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole. Preferably, W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is pyrazole, in particular when X and Y are N, and W and Z are C. Specifically, the compounds of formula (I) can be selected from:
- R5 is as defined above, and in particular, small alkyl. More specifically, R5 can be selected from methyl and —CH 2 OMe.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is imidazole.
- the compounds of formula (I) can be:
- R6 is as defined above, and in particular, small alkyl. More specifically, R6 can be selected from methyl and —CH 2 OMe.
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14. More specifically, R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 .
- At least one of R5, R6, or R7 can be present and not H (i.e. selected from alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF 3 , aryl, heteroaryl a , N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14). Additionally, or alternatively, R7 can be H.
- At least one of R5, R6, or R7 can be selected from H, alkyl, cycloalkyl, and CF 3 .
- at least two of R5, R6, or R7 can be independently selected from H, alkyl, cycloalkyl, and CF 3 .
- R5, R6, or R7 can be independently selected from H, alkyl, cycloalkyl, and CF 3 .
- R5 can be alkyl.
- the compounds of formula (I) can be:
- R5 can be H.
- R5 can be CF 3 .
- R5 can be cycloalkyl.
- R6 can be alkyl.
- R6 can be H.
- R6 can be CF 3 .
- R6 can be cycloalkyl.
- R7 can be alkyl.
- R7 can be H.
- R7 can be CF 3 .
- R7 can be cycloalkyl.
- R7 is preferably H.
- R16 (when present) can be selected from H, alkyl, cycloalkyl, and CF 3 .
- R5, R6, R7, and/or R16 is alkyl
- R5, R6, R7 and/or R16 is alkyl substituted by at least alkoxy, in particular, —CH 2 OMe.
- R5 or R6 can be —CHF 2 .
- R5 can be —CHF 2 .
- R6 can be —CHF 2 .
- R5, R6, R7, and/or R16 is cycloalkyl
- R5, R6, R7, and/or R16 is cyclopropane, optionally substituted with alkoxy, in particular, —OMe.
- the compounds of formula (I) can be:
- R5 is alkyl substituted by at least alkoxy, in particular, —CH 2 OMe.
- R6 is alkyl substituted by at least alkoxy, in particular, —CH 2 OMe is also preferred. More specifically, one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy, in particular, —CH 2 OMe. For example, it is preferred when R5 is alkyl substituted by alkoxy, in particular, CH 2 OMe and R6 is absent. It is also preferred when R5 is absent and R6 is alkyl substituted by alkoxy, in particular, CH 2 OMe.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (ii) one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy, and (iii) R7 is H.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y are N, and W and Z are C,
- R5 is alkyl substituted with alkoxy, in particular —CH 2 OMe,
- R6 is absent;
- R7 is H.
- B′ can be phenyl.
- B′ can be pyridyl.
- R9 and R10 can be independently H, alkyl, halo, or alkoxy. More specifically, R9 and R10 can be independently halo or alkoxy. For example, one of R9 or R10 can be halo, in particular F. Alternatively, one of R9 or R10 can be alkoxy, specifically, —OMe, or -Ocyclopropyl, in particular —OMe. Preferably, R9 is halo (in particular F) and R10 is alkoxy (in particular —OMe).
- B′ is phenyl
- R9 is halo (in particular F)
- R10 is alkoxy (in particular —OMe). More specifically, the preferred B′ group is
- B′′ is pyrrole, pyrazole, triazole, or tetrazole.
- B′′ can be pyrazole or triazole.
- B′′ can be 1, 2, 3-triazole.
- B′′ can be 1, 2, 4-triazole.
- B′′ can be bonded to B′ through any of the ring atoms on B′′.
- B′′ is bonded to B′ through a nitrogen atom on B′′
- B′′ can be pyrrole.
- B′′ can be pyrrole, n can be 1, and R11 can be selected from alkyl, cycloalkyl, CN, and CF 3 .
- B′′ is pyrrole, n is 1, and R11 is selected from small alkyl, cyclopropyl, CN, and CF 3
- B′′ can be pyrazole.
- B′′ can be pyrazole, n can be 1, and R11 can be selected from alkyl, cycloalkyl, CN, and CF 3 .
- B′′ is pyrazole, n is 1, and R11 is selected from small alkyl, cyclopropyl, CN, and CF 3 .
- B′′ can be selected from:
- B′′ can be 1, 2, 3-triazole.
- B′′ can be 1, 2, 3-triazole, n can be 1, and R11 can be alkyl. More specifically, B′′ can be 1, 2, 3-triazole, n can be 1, and R11 can be selected from CN and small alkyl.
- B′′ is 1, 2, 3-triazole, n is 1, and R11 is selected from CN, methyl, ethyl, and CHF 2 .
- B′′ can be:
- R11 is as defined above.
- B′′ can be 1, 2, 4-triazole.
- B′′ can be 1, 2, 4-triazole, n can be 1 or 2, and each R11 can be independently alkyl, cycloalkyl, CF 3 . More specifically, B′′ can be 1, 2, 4-triazole, n can be 1, and R11 can be alkyl, cycloalkyl, CF 3 . Additionally, when B′′ is 1, 2, 4-triazole and n is 1, R11 can be selected from CN, CF 3 , and small alkyl, and in particular, CN, methyl, ethyl, CHF 2 , CF 3 . When B′′ is 1, 2, 4-triazole and n is 2, both R11 groups are preferably methyl. Specifically, B′′ can be:
- R11 is as defined above.
- B′′ can be 1, 2, 4-triazole, n can be 1, and R11 can be CF 3 .
- B′′ can be 1, 2, 5-triazole.
- B′′ can be 1, 2, 5-triazole, n can be 1, and R11 can be alkyl.
- B′′ is 1, 2, 5-triazole, n is 1, and R11 is selected from methyl and CHF 2 .
- Preferred B′′ groups include:
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl. More specifically, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole
- one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy
- (ix) R7 is H
- (x) B′ is phenyl
- R9 is halo
- (xii) R10 is alkoxy
- (xiii) B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole when X and Y are N, and W and Z are C, R5 can be —CH 2 OMe, R6 can be absent, R7 can be H, and R11 can be methyl.
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,4-triazole.
- n can be 1
- R11 can be CF 3
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole
- one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy
- (ix) R7 is H
- (x) B′ is phenyl
- R9 is halo
- (xii) R10 is alkoxy
- (xiii) B′′ is 1,2,4-triazole.
- n can be 1, and (ix) R11 can be CF 3 .
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole when X and Y are N, and W and Z are C
- R5 can be —CH 2 OMe
- R6 can be absent
- R7 can be H
- R11 can be methyl.
- A′1 can be C.
- A′1 can be N.
- A′2 can be C.
- A′2 can be N.
- A′ can be phenyl
- A′ can be heteroaryl.
- A′ can be heteroaryl selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine.
- A′ can be a 5-membered heteroaryl, preferably selected from pyrrole or imidazole.
- A′ can be a 6-membered heteroaryl, preferably pyridine.
- A′′ can be a non-aromatic carbon-containing monocyclic ring containing 5 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O.
- A′′ can be selected from pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, 3-dioxolane, thiazolidine, and isoxazolidine.
- A′′ is a non-aromatic carbon-containing monocyclic ring containing 5 ring members
- A′′ is preferably pyrrolidine.
- A′′ can be a non-aromatic carbon-containing monocyclic ring containing 6 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O.
- A′′ can be selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane.
- A′′ is preferably piperidine.
- A′′ can be a non-aromatic carbon-containing monocyclic ring containing 7 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O.
- A′′ can be selected from azepane, oxepane, oxazepane (in particular, a 1,4-oxazapane), thiepane, and diazepane.
- A′′ is preferably azepane.
- a carbon ring atom on A′′ can be substituted with an alkylene such that the carbon ring atom on A′′ together with the alkylene forms a cycloalkyl that is spiro to ring A′′.
- the spiro ring formed can be cyclopropane.
- the spiro ring formed can be cyclobutane.
- the spiro ring formed can be cyclopentane.
- the spiro ring formed is cyclohexane.
- a preferred spiro ring is cyclopropane.
- a carbon ring atom on A′′ can be substituted with a heteroalkylene such that the carbon ring atom on A′′ together with the heteroalkylene forms a heterocycloalkyl a that is spiro to ring A′′.
- the spiro ring formed can be 3-membered, e.g. selected from aziridine, oxirane, and thiirane.
- the spiro ring formed can be 4-membered, e.g. selected from azetidine, oxetane, and thietane.
- the spiro ring formed can be 5-membered, e.g.
- the spiro ring formed can be 6-membered, e.g. selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane.
- Two ring atoms on A′′ can be linked by an alkylene to form a non-aromatic ring containing 5, 6, or 7 ring members. More specifically, two ring atoms on A′′ can be linked by an alkylene to form a non-aromatic ring containing 5 ring members, e.g. cyclopentane. Alternatively, the two ring atoms on A′′ can be linked by an alkylene to form a non-aromatic ring containing 6 ring members, e.g. cyclohexane. Alternatively, the two ring atoms on A′′ can be linked by an alkylene to form a non-aromatic ring containing 7 ring members, e.g. cycloheptane.
- Two ring atoms on A′′ can be linked by a heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members. More specifically, the two ring atoms on A′′ can be linked by a heteroalkylene to form a non-aromatic ring containing 5 ring members, e.g. selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine.
- 5 ring members e.g. selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole,
- the two ring atoms on A′′ can be linked by a heteroalkylene to form a non-aromatic ring containing 6 ring members e.g. selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane.
- the two ring atoms on A′′ can be linked by a heteroalkylene to form a non-aromatic ring containing 7 ring members, e.g. selected from azepane, oxepane, oxazepane (in particular, a 1,4-oxazapane), thiepane, and diazepane.
- Preferred A groups include:
- More preferred A groups include:
- a groups include:
- A′ is phenyl
- A′′ is piperidine
- A′ can be phenyl
- A′′ can be piperidine substituted with methyl
- A′ is phenyl
- A′′ is piperidine
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl. More specifically, A′′ can be piperidine substituted with methyl, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- A′ is phenyl
- A′′ is piperidine
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl
- W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole
- one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy
- R7 is H.
- n can be 1, and (xiii) R11 can be alkyl.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C
- R5 can be —CH 2 OMe
- R6 can be absent
- R7 can be H
- R11 can be methyl
- A′′ can be piperidine substituted with methyl.
- A′ is phenyl
- A′′ is piperidine
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,4-triazole.
- n can be 1
- R11 can be CF 3
- W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole
- one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy
- R7 is H.
- n can be 1, and (xiii) R11 can be alkyl.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C
- R5 can be —CH 2 OMe
- R6 can be absent
- R7 can be H
- R11 can be CF 3
- A′′ can be piperidine substituted with methyl.
- A′ is phenyl
- A′′ is pyrrolidine
- A′ can be phenyl
- A′′ can be pyrrolidine substituted with methyl
- A′ is phenyl
- A′′ is pyrrolidine
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1
- R11 can be alkyl. More specifically, A′′ can be piperidine substituted with methyl, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- A′ is phenyl
- A′′ is pyrrolidine
- B′ is phenyl
- R9 is halo
- R10 is alkoxy
- B′′ is 1,2,3-triazole.
- n can be 1,
- R11 can be alkyl
- W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole
- one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy
- R7 is H.
- n can be 1, and (xiii) R11 can be alkyl.
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C
- R5 can be —CH 2 OMe
- R6 can be absent
- R7 can be H
- R11 can be methyl
- A′′ can be pyrrolidine substituted with methyl.
- R8 is independently selected from H, alkyl, cycloalkyl, or heterocycloalkyl b .
- R8 is heterocycloalkyl b , it is preferably a non-aromatic carbon-containing monocyclic ring containing 4 ring members, in particular, oxetane. More specifically, R8 can be independently selected from H, alkyl, or cycloalkyl.
- R8 is alkyl, it is preferably methyl.
- R8 is cycloalkyl, it is preferably cyclopropyl.
- A′ is phenyl and A′′ is piperidine
- specific A groups can be selected from:
- R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- A′ is pyridine, and R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- R13 and R14 can be independently selected from H, alkyl b , aryl b and heteroaryl b . More specifically, R13 and R14 can be in independently selected from H and small alkyl.
- R13 and R14 can together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N12, S, SO, SO 2 , and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkyl b , alkoxy, OH, halo and CF 3 .
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A′′):
- the invention also provides a compound of formula (I), as set out below, which may be combined with the above disclosure:
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A′′):
- the invention also provides a compound of formula (I), as set out below, which may be combined with the above disclosure:
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A′′):
- the invention also provides a compound of formula (I), as set our below, which may be combined with the above disclosure:
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A′′):
- the invention also provides a compound of formula (I), as set our below, which may be combined with the above disclosure:
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A′′):
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the present invention also encompasses, but is not limited to, the below compounds:
- the compounds of the present invention are potent and selective inhibitors of plasma kallikrein. They are therefore useful in the treatment of disease conditions for which over-activity of plasma kallikrein is a causative factor.
- the present invention provides a compound of formula (I) for use in medicine.
- the present invention also provides for the use of a compound of formula (I) in the manufacture of a medicament for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
- the present invention also provides a compound of formula (I) for use in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
- the present invention also provides a method of treatment of a disease or condition in which plasma kallikrein activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I).
- the disease or condition in which plasma kallikrein activity is implicated is a bradykinin-mediated angioedema.
- the bradykinin-mediated angioedema can be non-hereditary.
- the non-hereditary bradykinin-mediated angioedema can be selected from non-hereditary angioedema with normal C1 Inhibitor (AE-nC1 Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE or ace) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
- AE-nC1 Inh normal C1 Inhibitor
- the bradykinin-mediated angioedema can be hereditary angioedema (HAE), which is angioedema caused by an inherited dysfunction/fault/mutation.
- HAE hereditary angioedema
- Types of HAE that can be treated with compounds according to the invention include HAE type 1, HAE type 2, and normal C1 inhibitor HAE (normal C1 Inh HAE).
- the disease or condition in which plasma kallikrein activity is implicated is selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery. More specifically, the disease or condition in which plasma kallikrein activity is implicated can be retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
- Suitable combination therapies include a compound of formula (I) combined with one or more agents selected from agents that inhibit platelet-derived growth factor (PDGF), endothelial growth factor (VEGF), integrin alpha5beta1, steroids, other agents that inhibit plasma kallikrein and other inhibitors of inflammation.
- PDGF platelet-derived growth factor
- VEGF endothelial growth factor
- integrin alpha5beta1 steroids
- specific examples of therapeutic agents that may be combined with the compounds of the present invention include those disclosed in EP2281885A and by S. Patel in Retina, 2009 June; 29(6 Suppl):S45-8.
- the compounds of the present invention and said combination agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
- the compounds of the present invention can be administered in combination with laser treatment of the retina.
- the combination of laser therapy with intravitreal injection of an inhibitor of VEGF for the treatment of diabetic macular edema is known (Elman M, Aiello L, Beck R, et al. “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema” Ophthalmology. 27 Apr. 2010).
- alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C 1 -C 10 ) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C 3 -C 10 ); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C 1 -C 6 )alkoxy, OH, —NR13R14, —COOR13, —CONR13R14, CN, CF 3 , halo.
- alkyl b is a linear saturated hydrocarbon having up to 10 carbon atoms (C 1 -C 10 ) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C 3 -C 10 ); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C 1 -C 6 )alkoxy, OH, CN, CF 3 , and halo.
- alkyl or alkyl b groups include, but are not limited, to C 1 -methyl, C 2 -ethyl, C 3 -propyl and C 4 -n-butyl, C 3 -iso-propyl, C 4 -sec-butyl, C 4 -iso-butyl, C 4 -tert-butyl and C 5 -neo-pentyl), optionally substituted as noted above.
- alkyl or “alkyl b ” can be a linear saturated hydrocarbon having up to 6 carbon atoms (C 1 -C 6 ) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C 3 -C 6 ), optionally substituted as noted above. Even more specifically, “alkyl” or “alkyl b ” can be a linear saturated hydrocarbon having up to 4 carbon atoms (C 1 -C 4 ) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C 3 -C 4 ), optionally substituted as noted above, which is herein called “small alkyl” or “small alkyl b ”, respectively. Preferably, “alkyl” or “alkyl b ” can be defined as a “small alkyl” or “small alkyl b ”.
- alkylene is a bivalent linear saturated hydrocarbon having 1 to 5 carbon atoms (C 1 -C 5 ); alkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C 1 -C 6 )alkoxy, OH, CN, CF 3 , halo. More specifically, alkylene can be a bivalent linear saturated hydrocarbon having 2 to 4 carbon atoms (C 2 -C 4 ), more specifically having 2 to 3 carbon atoms (C 2 -C 3 ), optionally substituted as noted above.
- Aryl and aryl b are as defined above. Typically, aryl or aryl b will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl or aryl b groups include phenyl and naphthyl (each optionally substituted as stated above). Preferably aryl is selected from phenyl, substituted phenyl (wherein said substituents are selected from those stated above) and naphthyl.
- heteroalkylene is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C 2 -C 5 ), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O; heteroalkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl (C 1 -C 6 )alkoxy, OH, CN, CF 3 , halo.
- heteroalkylene can be a valent linear saturated hydrocarbon having 2 to 4 carbon atoms (C 2 -C 4 ), wherein at least one of the 2 to 4 carbon atoms is replaced with NR8, S, or O, or having 2 to 3 carbon atoms (C 2 -C 3 ), wherein at least one of the 2 to 3 carbon atoms is replaced with NR8, S, or O, each optionally substituted as noted above.
- cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C 3 -C 6 ); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl (C 1 -C 6 )alkoxy, OH, CN, CF 3 , halo.
- suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl), optionally substituted as noted above.
- cycloalkyl can be a monocyclic saturated hydrocarbon ring of between 3 and 5 carbon atoms, more specifically, between 3 and 4 carbon atoms), optionally substituted as noted above.
- alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C 1 -C 6 ) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C 3 -C 6 ); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF 3 , and fluoro.
- alkoxy groups include, but are not limited to, C 1 -methoxy, C 2 -ethoxy, C 3 -n-propoxy and C 4 -n-butoxy for linear alkoxy, and C 3 -iso-propoxy, and C 4 -sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, alkoxy can be linear groups of between 1 and 4 carbon atoms (C 1 -C 4 ), more specifically, between 1 and 3 carbon atoms (C 1 -C 3 ). More specifically, alkoxy can be branched groups of between 3 and 4 carbon atoms (C 3 -C 4 ), optionally substituted as noted above.
- Halo can be selected from Cl, F, Br and I. More specifically, halo can be selected from Cl and F.
- heteroaryl is a 5- or 6-membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF 3 , halo, CN, and CF 3 .
- heteroaryl can be selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine, optionally substituted as noted above.
- Heteroaryl a and heteroaryl b are as defined above. Typically, heteroaryl a or heteroaryl b will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable heteroaryl a or heteroaryl b groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl and isoquinolinyl (optionally substituted as stated above).
- heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N, NR8, S, SO, SO2, and O. More specifically, “heterocycloalkyl” can be a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N, NR8, and O, optionally substituted as noted above. More specifically, “heterocycloalkyl” can be a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N or NR8.
- heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from NR8, S, SO, SO 2 , and O; heterocycloalkyl a may be optionally substituted with 1 or 2 substituents independently selected from alkyl (C 1 -C 6 )alkoxy, OH, CN, CF 3 , halo.
- heterocycloalkyl can be a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from NR8, and O; heterocycloalkyl a may be optionally substituted with 1 or 2 substituents independently selected from alkyl (C 1 -C 6 )alkoxy, OH, CN, CF 3 , halo.
- O-linked such as in “O-linked hydrocarbon residue”, means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
- N-linked such as in “N-linked pyrrolidinyl”, means that the heterocycloalkyl group is joined to the remainder of the molecule via a ring nitrogen atom.
- “Pharmaceutically acceptable salt” means a physiologically or toxicologically tolerable salt and includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts.
- pharmaceutically acceptable base addition salts that can be formed include sodium, potassium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, N-methyl-glucamine, diethanolamine or amino acids (e.g.
- a compound of the invention contains a basic group, such as an amino group
- pharmaceutically acceptable acid addition salts that can be formed include hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tosylates, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, camphorates, xinafoates, p-acetamidobenzoates, dihydroxybenzoates, hydroxynaphthoates, succinates, ascorbates, oleates, bisulfates and the like.
- Hemisalts of acids and bases can also be formed, for example, hemisulfate and hemicalcium salts.
- Prodrug refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in ‘The Practice of Medicinal Chemistry, 2 nd Ed. pp 561-585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379.
- the compounds of the invention can exist in both unsolvated and solvated forms.
- solvate is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- solvent molecules for example, ethanol.
- hydrate is employed when the solvent is water.
- the compounds of the invention include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds wherein hydrogen is replaced by deuterium or tritium, or wherein carbon is replaced by 13 C or 14 C are within the scope of the present invention.
- Such compounds are useful, for example, as analytical tools or probes in biological assays.
- references herein to “treatment” include references to curative, palliative and prophylactic treatment.
- the compounds of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
- excipient is used herein to describe any ingredient other than the compound(s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations.
- the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
- compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
- the compounds of the invention may be administered in a form suitable for injection into the ocular region of a patient, in particular, in a form suitable for intra-vitreal injection. It is envisaged that formulations suitable for such use will take the form of sterile solutions of a compound of the invention in a suitable aqueous vehicle. The compositions may be administered to the patient under the supervision of the attending physician.
- the compounds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
- Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, mannitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- excipients such as sugars (including but not restricted to glucose, mannitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
- degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- the compounds of the invention can be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solids and liquids (including multiple phases or dispersed systems).
- Exemplary formulations suitable for oral administration include tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Liquid (including multiple phases and dispersed systems) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
- the total daily dose of the compounds of the invention is typically in the range 0.1 mg and 10,000 mg, or between 1 mg and 5000 mg, or between 10 mg and 1000 mg depending, of course, on the mode of administration. If administered by intra-vitreal injection a lower dose of between 0.0001 mg (0.1 ⁇ g) and 0.2 mg (200 ⁇ g) per eye is envisaged, or between 0.0005 mg (0.5 ⁇ g) and 0.05 mg (50 ⁇ g) per eye.
- the total dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
- the compounds of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples provided herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions, processes and order in which the synthetic steps are performed in the following preparative procedures can be used to prepare these compounds.
- the compounds and intermediates of the invention may be isolated in the form of their pharmaceutically acceptable salts, such as those described previously herein above.
- the interconversion between free form and salt form would be readily known to those skilled in the art.
- reactive functional groups e.g. hydroxy, amino, thio or carboxy
- Conventional protecting groups for example those described by T. W. Greene and P. G. M. Wuts in “Protective groups in organic chemistry” John Wiley and Sons, 4 th Edition, 2006, may be used.
- a common amino protecting group suitable for use herein is tert-butoxy carbonyl (Boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane.
- the amino protecting group may be a benzyloxycarbonyl (Z) group which can be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere or 9-fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by solutions of secondary organic amines such as diethylamine or piperidine in an organic solvent.
- Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide.
- Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively a trichloroethyl ester protecting group is removed with zinc in acetic acid.
- a common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr, or by stirring with borane tribromide in an organic solvent such as DCM. Alternatively where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.
- the compounds according to general formula I can be prepared using conventional synthetic methods for example, but not limited to, the route outlined in Schemes 1a and 1b.
- the halide 1 is reacted with a substituted heterocycle 2, for example substituted pyrazole as shown in Scheme 1a or substituted imidazole as shown in Scheme 1b, (Step 1A) typically using for example potassium carbonate or cesium carbonate to give ester 3, requiring separation of regioisomers confirming their identity by NOESY NMR.
- the Boc protecting group is removed (Step 1B) using acidic conditions such as trifluoroacetic acid to give amine 4.
- this intermediate would be isolated in the form of the acid salt, for example the trifluoroacetate.
- Methylation of the amine (Step 1C) may be carried out using standard conditions for such a transformation.
- amine 4 is treated with formaldehyde (37% in water) followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 5.
- a reducing agent such as sodium triacetoxyborohydride
- Alternative alkylations may be carried out by use of the appropriate alkanone, for example amine 4 is treated with the alkenone, for example acetone, in an organic solvent such as DCM followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 5.
- Alternative reducing agents include sodium borohydride and sodium cyanoborohydride.
- the ester is hydrolysed (Step 1D) using standard literature conditions such as NaOH, KOH, or LiOH.
- the acid (or salt) 6 is coupled to amine (or salt) 7 (Step 1E) to give compound 8.
- This coupling is typically carried out using standard coupling conditions such as hydroxybenzotriazole (HOBt) and carbodiimide such as water soluble carbodiimide in the presence of an organic base.
- Other standard coupling methods include the reaction of acids with amines in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) or benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoium hexafluorophosphate (PyBOP) or bromo-trispyrolidino-phosphonium hexafluorophosphate (PyBroP) or 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (HATU), or 1-ethyl-3-(3-dimethylamin
- the amide formation can take place via an acid chloride in the presence of an organic base.
- acid chlorides can be formed by methods well known in the literature, for example reaction of the acid with oxalyl chloride or thionyl chloride.
- carboxylic acid can be activated using 1,1′-carbonyldiimidazole (CDI) and then amine added.
- CDI 1,1′-carbonyldiimidazole
- halide 1 in Scheme 1 above may be prepared from readily available starting materials using methods known in the art, for example as shown in Scheme 2.
- the alcohol 1-OH may be converted to the chloride 1-CI.
- Methods for such transformations are known in the art, for example reaction with methanesulfonyl chloride in the presence of a base such as N,N-diisopropylethylamine (DIPEA) in a solvent such as dichloromethane.
- DIPEA N,N-diisopropylethylamine
- DMAP 4-Dimethylaminopyridine
- Step A can be carried out via in situ sulfonyl transfer (see Jane Panteleev et al., “Alkylation of Nitrogen-Containing Heterocycles via In Situ Sulfonyl Transfer”, Synlett 26(08)), as shown in Scheme 3.
- the pyrazole mesylate 2a is prepared by treating pyrazole 2 with methanesulfanyl chloride (MsCl) with a base such as triethylamine in a solvent such as dichloromethane.
- MsCl methanesulfanyl chloride
- the pyrazole mesylate 2a may then be coupled to the alcohol 1a in the presence of a base such as caesium carbonate in a solvent such as acetonitrile, typically heating to reflux.
- the alcohol 1a is reacted with substituted pyrazole mesylate 2a (Step 4A) in the presence of a base such as caesium carbonate in a solvent such as acetonitrile, typically heating to reflux to give ester 3, requiring separation of regioisomers confirming their identity by NOESY NMR.
- the ester is hydrolysed (Step 4B) using standard literature conditions such as NaOH, KOH, or LiOH.
- the acid (or salt) 9 is coupled to amine 7 (or salt) (Step 4C) to give compound 10. This coupling is typically carried out using standard coupling conditions such as hydroxybenzotriazole (HOBt) and carbodiimide such as water soluble carbodiimide in the presence of an organic base.
- HOBt hydroxybenzotriazole
- carbodiimide such as water soluble carbodiimide in the presence of an organic base.
- HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
- HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate
- PyBOP benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoium hexafluorophosphate
- PyBroP bromo-trispyrolidino-phosphonium hexafluorophosphate
- organic bases such as triethylamine, diisopropylethylamine or N-methylmorpholine.
- the amide formation can take place via an acid chloride in the presence of an organic base.
- acid chlorides can be formed by methods well known in the literature, for example reaction of the acid with oxalyl chloride or thionyl chloride.
- carboxylic acid can be activated using 1,1′-carbonyldiimidazole (CDI) and then amine added.
- CDI 1,1′-carbonyldiimidazole
- the Boc protecting group is removed (Step 4D) using acidic conditions such as trifluoroacetic acid or hydrogen chloride to give amine 11.
- this intermediate would be isolated in the form of the acid salt, for example the trifluoroacetate or the hydrochloride.
- Alkylation of the amine 11 may be carried out using standard conditions for such a transformation, for example reductive alkylation.
- amine 11 is treated with formaldehyde (37% in water) followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 8.
- a reducing agent such as sodium triacetoxyborohydride
- Alternative alkylations may be carried out by use of the appropriate alkanone, for example amine 11 is treated with the alkenone, for example acetone, in an organic solvent such as DCM followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 8.
- Alternative reducing agents include sodium borohydride and sodium cyanoborohydride.
- Flash chromatography was typically carried out over ‘silica’ (silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Merck silica gel 60)), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution.
- pre-prepared cartridges of silica gel were used.
- Reverse phase preparative HPLC purifications were carried out using a Waters 2525 binary gradient pumping system at flow rates of typically 20 mL/min using a Waters 2996 photodiode array detector.
- Chemical names were generated using automated software such as ChemDraw (PerkinElmer) or the Autonom software provided as part of the ISIS Draw package from MDL Information Systems or the Chemaxon software provided as a component of MarvinSketch or as a component of the IDBS E-WorkBook.
- DIPEA (2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl)methanamine hydrochloride (97.8 mg, 0.36 mmol), HATU (136 mg, 0.36 mmol) and 5-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)nicotinic acid (200 mg, 0.33 mmol) in DCM (2 mL) and NMP (2 mL) and stirred for 20 hrs.
- Methyl 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate was prepared from methyl 1-(isoindolin-5-ylmethyl)triazole-4-carboxylate hydrochloride according to General Method B.
- Lithium 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate was prepared from methyl 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate according to procedure L5a.
- Potassium phthalimide (0.868 g, 4.69 mmol) was added to a solution of 1-[2-(chloromethyl)-3-fluoro-4-methoxy-phenyl]-1,2,4-triazole (1.03 g, 4.26 mmol) in DMF (10 mL) and the mixture warmed to 55° C. for 60 min. Water (30 mL) was added to form a thick precipitate which was filtered, washed with water and dried in vacuo in the presence of CaCl 2 to afford the title compound (1.12 g, 74% yield) as a white solid.
- N′-(tosyloxy)-propanimidamide prepared for example according to analogous procedures in European Patent Application no. 97301695.9 (published as EP0795551A1) the title compound was prepared using methods described for the synthesis of (2-fluoro-3-methoxy-6-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)methanamine (R5c).
- 6-Bromo-2-fluoro-3-methoxy-benzoic acid (30.5 g, 123 mmol) was dissolved in MeCN (500 mL).
- Caesium carbonate 47.9 g, 147 mmol was added followed by dropwise addition of iodoethane (15.2 mL, 189 mmol).
- the mixture was stirred at rt for 3 days.
- the mixture was filtered through Celite, washed with MeCN and concentrated in vacuo.
- the residue was separated between Et 2 O (500 mL) and a brine-water mixture (1:2 brine:water, 750 mL).
- the aqueous phase was extracted with Et 2 O (250 mL).
- the combined organics were dried over Na 2 SO 4 and concentrated in vacuo to afford the title compound as an orange oil that solidified on standing (26.8 g, 79% yield).
- 1,4-Dioxane 50 mL was added to the reaction flask containing the intermediate azide which was wrapped in foil to protect the reaction from light exposure.
- Propargyl alcohol 4410 ⁇ L, 7.04 mmol
- CuI 22 mg, 0.12 mmol
- sodium ascorbate 92 mg, 0.47 mmol
- a further charge of CuI 22 mg, 0.12 mmol
- sodium ascorbate 92 mg, 0.47 mmol
- the mixture was partitioned between EtOAc and saturated NH 4 Cl(aq) and the layers separated. The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated. Flash chromatography (EtOAc/Pet. Ether) afforded the title compound as a beige solid (280 mg, 40%).
- 6-tert-Butoxycarbonylamino-2-fluoro-3-methoxy-benzoic acid methyl ester (480 mg, 1.6 mmol) was dissolved in THE (50 mL) and cooled in an ice/water bath. A 2M solution of lithium borohydride in THE (1.6 mL, 3.21 mmol) was added dropwise. After 18 hrs at rt saturated NH 4 Cl(aq) was added slowly and the mixture extracted with EtOAc. The combined organic extracts were washed with water and brine, dried over Na 2 SO 4 and evaporated in vacuo. Flash chromatography (60% EtOAc, 40% Pet. Ether) afforded the title compound as a white solid (426 mg, 98%).
- Lithium hydroxide monohydrate (33 mg, 1.4 mmol) was added to a solution of methyl 3-(methoxymethyl)-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxylate (301 mg, 0.91 mmol) in a 4:1 mixture of 1,4-dioxane:water (5 mL). The reaction was heated to 70° C. and stirred for 3 hrs before cooling to rt overnight. Solvent was removed in vacuo and the residue was azeotroped with toluene in order to afford the title compound (242 mg, 76%) as an off-white solid.
- tert-Butyl 2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate 890 mg, 3.3 mmol
- 1,1′-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex 130 mg, 0.16 mmol
- TEA 1.3 mL, 9.33 mmol
- the resulting solution was purged 3 times with N 2 gas then 3 times with CO gas.
- the mixture was placed under a 4 bar atmosphere of CO, stirred and heated at 90° C. overnight.
- tert-Butyl 5-chloro-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (949 mg, 3.19 mmol) was dissolved in DCM (15 mL) and cooled in an ice/water bath.
- TEA 750 ⁇ L, 538 mmol
- methanesulfonyl chloride 30 ⁇ L, 0.39 mmol
- the mixture was stirred at rt for 18 hrs.
- the mixture was diluted with DCM (30 mL) and washed with saturated NaHCO 3 (aq) (20 mL).
- tert-Butyl 2-(hydroxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate was synthesised starting with 7-(tert-butyl) 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate and using a similar method to that described for tert-butyl 2-(hydroxymethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (L2d).
- Methyl 4-hydroxy-7-methyl-6,8-dihydro-5H-1,7-naphthyridine-3-carboxylate (77 mg, 0.34 mmol) was heated at 80° C. in phosphorus oxychloride (0.5 mL, 5.36 mmol) for 90 min. The mixture was cooled to 0° C., poured into water (3 mL) and stirred for 20 min. The mixture was then basified to pH8 with saturated Na 2 CO 3 (aq) and extracted with EtOAc. The combined organic layers were combined, dried over Na 2 SO 4 and concentrated in vacuo to give the title compound (54 mg, 65%) as a brown oil.
- Methyl isochromane-6-carboxylate was prepared from 6-bromoisochromane using method L1d.
- Isochroman-6-ylmethanol was prepared from methyl isochromane-6-carboxylate using procedure L2d.
- tert-Butyl 2-(hydroxymethyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate was prepared from 5-(tert-butyl) 2-methyl 6,7-dihydropyrazolo[1,5-a]pyrazine-2,5(4H)-dicarboxylate (reported in WO2010024258) using procedure L2d.
- tert-Butyl 5-(chloromethyl)-7-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate was prepared from tert-butyl 7-fluoro-5-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate according to procedure L6e.
- tert-Butyl 6-(chloromethyl)-4,4-difluoro-1,3-dihydroisoquinoline-2-carboxylate was prepared from tert-butyl 4,4-difluoro-6-(hydroxymethyl)-1,3-dihydroisoquinoline-2-carboxylate using procedure L3d.
- tert-butyl 7-(chloromethyl)-4,4-difluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate was prepared from 7-bromo-4,4-difluoro-1,2-dihydroisoquinolin-3-one according to procedures L1f to L4f.
- tert-Butyl 7-bromo-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate was prepared from 7-bromo-8-fluoro-1,2,3,4-tetrahydroisoquinoline according to procedure L1e.
- tert-Butyl 7-(chloromethyl)-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate was prepared from tert-butyl 8-fluoro-7-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate according to procedure L3d.
- NaBH 4 (2.5 g, 66 mmol) was added portion wise to AcOH (300 mL) at rt.
- 7-Bromo-6-fluoro-isoquinoline (7.4 g, 32.7 mmol) was added and the mixture stirred at rt for 60 min.
- Additional NaBH 4 (2.5 g, 66.1 mmol) was added and the mixture stirred for a further 60 min.
- the mixture was quenched into water (300 mL) and TBME (600 mL) added. The layers were separated, and the aqueous layer extracted further with TBME.
- tert-Butyl 6-fluoro-7-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-methyl 6-fluoro-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d.
- Methyl 3-oxo-2,5,6,10b-tetrahydro-1H-pyrrolo[2,1-a]isoquinoline-9-carboxylate was prepared from 9-bromo-2,5,6,10b-tetrahydro-1H-pyrrolo[2,1-a]isoquinolin-3-one according to procedure L1d.
- methyl 6-oxopyran-3-carboxylate (1 g, 6.49 mmol) and trimethyl(2-trimethylsilylethynyl)silane (3320 mg, 19.5 mmol).
- the vessel was sealed and the mixture heated to 200° C. overnight with stirring.
- the mixture was cooled and absorbed directly onto silica and purified by flash chromatography (0-30% EtOAc in hexane) to afford the title compound (1.76 g) as a colourless viscous oil.
- tert-Butyl 6-(hydroxymethyl)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene-9-carboxylate was prepared from 9-(tert-butyl) 6-methyl-1,2,3,4-tetrahydro-1,4-epiminonaphthalene-6,9-dicarboxylate according to procedure L2d.
- Methyl 2,3,3-trimethyl-1-oxo-isoindoline-5-carboxylate was prepared from 5-bromo-2,3,3-trimethyl-isoindolin-1-one according to procedure L1d.
- Paraformaldehyde (220 mg, 7.33 mmol) was added to a solution of N-[[1-(4-bromophenyl) cyclopropyl]methyl]-2,2,2-trifluoro-acetamide (1.34 g, 4.16 mmol) in acetic acid (9 mL). Sulfuric acid (5.2 mL, 97.6 mmol) was added dropwise and the mixture was heated at 50° C. for 5 h and stirred at rt overnight. The mixture was poured into a mixture of EtOAc (50 mL) and water (40 mL).
- tert-Butyl 7′-(hydroxymethyl)-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate was prepared from 2′-(tert-butyl) 7′-methyl 1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′,7′(3′H)-dicarboxylate according to procedure L2d.
- N-[2-(4-bromophenyl)ethyl]acetamide (1.25 g, 5.16 mmol) and DCM (20 mL) and cooled in an ice/water bath.
- Oxalyl chloride solution (2.0 M in DCM, 2.81 mL, 5.62 mmol) was added dropwise and the mixture allowed to warm to rt overnight.
- the mixture was briefly flushed with N 2 before the addition (in one portion) of ferric chloride (1 g, 6.17 mmol). This caused gas evolution and a mild exotherm which was controlled using an ice/water bath for 5 min.
- Methyl 2-benzyl-1,1-dimethyl-3,4-dihydroisoquinoline-7-carboxylate was prepared from 2-benzyl-7-bromo-1,1-dimethyl-3,4-dihydroisoquinoline according to procedure L1d.
- tert-Butyl 7-(hydroxymethyl)-1,1-dimethyl-3,4-dihydroisoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-methyl 1,1-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d.
- tert-Butyl 7-(hydroxymethyl)-4,4-dimethyl-1,3-dihydroisoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-methyl 4,4-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d.
- tert-Butyl 2-(hydroxymethyl)-6,8-dihydro-5H-1,7-naphthyridine-7-carboxylate was prepared from 7-(tert-butyl) 2-methyl 5,8-dihydro-1,7-naphthyridine-2,7(6H)-dicarboxylate according to procedure L2d.
Abstract
The present invention provides compounds of formula (I):compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
Description
- This application is a divisional of U.S. patent application Ser. No. 17/496,905, filed Oct. 8, 2021, which is a continuation of International Patent Application No. PCT/GB2020/050331, filed Feb. 13, 2020, which claims priority to International Patent Application No. PCT/GB2019/052252, filed Aug. 9, 2019, the disclosures of which are incorporated by reference herein.
- This invention relates to enzyme inhibitors that are inhibitors of plasma kallikrein, and to the pharmaceutical compositions, and uses of, such inhibitors.
- The heterocyclic derivatives of the present invention are inhibitors of plasma kallikrein and have a number of therapeutic applications, particularly in the treatment of bradykinin-mediated angioedema hereditary angioedema and bradykinin-mediated angioedema non-hereditary (BK-AEnH).
- Plasma kallikrein is a trypsin-like serine protease that can liberate kinins from kininogens (see K. D. Bhoola et al., “Kallikrein-Kinin Cascade”, Encyclopedia of Respiratory Medicine, p 483-493; J. W. Bryant et al., “Human plasma kallikrein-kinin system: physiological and biochemical parameters” Cardiovascular and haematological agents in medicinal chemistry, 7, p 234-250, 2009; K. D. Bhoola et al., Pharmacological Rev., 1992, 44, 1; and D. J. Campbell, “Towards understanding the kallikrein-kinin system: insights from the measurement of kinin peptides”, Brazilian Journal of Medical and Biological Research 2000, 33, 665-677). It is an essential member of the intrinsic blood coagulation cascade although its role in this cascade does not involve the release of bradykinin or enzymatic cleavage. Plasma prekallikrein is encoded by a single gene and can be synthesized in the liver, as well as other tissues. It is secreted by hepatocytes as an inactive plasma prekallikrein that circulates in plasma as a heterodimer complex bound to high molecular weight kininogen (HK) which is activated to give the active plasma kallikrein. This contact activation system (or contact system) can be activated by negatively charged surfaces that activate Factor XII (FXII) to Factor XIIa (FXIIa), by certain proteases e.g. plasmin (Hofman et al Clin Rev Allergy Immunol 2016), which may not require negative surfaces, or by misfolded proteins (Maas et al J Clinical Invest 2008). FXIIa mediates conversion of plasma prekallikrein to plasma kallikrein and the subsequent cleavage of high molecular weight kininogen (HK) to generate bradykinin, a potent inflammatory hormone. Kinins are potent mediators of inflammation that act through G protein-coupled receptors and antagonists of kinins (such as bradykinin receptor antagonists) have previously been investigated as potential therapeutic agents for the treatment of a number of disorders (F. Marceau and D. Regoli, Nature Rev., Drug Discovery, 2004, 3, 845-852).
- Plasma kallikrein is thought to play a role in a number of inflammatory disorders. The major inhibitor of plasma kallikrein is the serpin C1 esterase inhibitor. Patients who present with a genetic deficiency in C1 esterase inhibitor suffer from hereditary angioedema (HAE) which results in intermittent swelling of face, hands, throat, gastro-intestinal tract and genitals. Blisters formed during acute episodes contain high levels of plasma kallikrein which cleaves high molecular weight kininogen (HK) liberating bradykinin leading to increased vascular permeability. “Hereditary angioedema” can thus be defined as any disorder characterised by recurrent episodes of bradykinin-mediated angioedema (e.g. severe swelling) caused by an inherited dysfunction/fault/mutation. There are currently three known categories of HAE: (i) HAE
type 1, (ii)HAE type 2, and (iii) normal C1 inhibitor HAE (normal C1-Inh HAE). However, the HAE field is developing quickly so it is expected that further types of HAE might be defined in the future. - Without wishing to be bound by theory, it is thought that
HAE type 1 is caused by mutations in the SERPING1 gene that lead to reduced levels of C1 inhibitor in the blood. Without wishing to be bound by theory, it is thought thatHAE type 2 is caused by mutations in the SERPING1 gene that lead to dysfunction of the C1 inhibitor in the blood. Without wishing to be bound by theory, the cause of normal C1-Inh HAE is less well defined and the underlying genetic dysfunction/fault/mutation can sometimes remain unknown. What is known is that the cause of normal C1-Inh HAE is not related to reduced levels or dysfunction of the C1 inhibitor (in contrast toHAE types 1 and 2). Normal C1-Inh HAE can be diagnosed by reviewing the family history and noting that angioedema has been inherited from a previous generation (and thus it is hereditary angioedema). Normal C1-Inh HAE can also be diagnosed by determining that there is a dysfunction/fault/mutation in a gene other than those related to C1 inhibitor. For example, it has been reported that dysfunction/fault/mutation with plasminogen can cause normal C1-Inh HAE (see e.g. Veronez et al., Front Med (Lausanne). 2019 Feb. 21; 6:28. doi: 10.3389/fmed.2019.00028; or Recke et al., Clin Transl Allergy. 2019 Feb. 14; 9:9. doi: 10.1186/s13601-019-0247-x.). It has also been reported that dysfunction/fault/mutation with Factor XII can cause normal C1-Inh HAE (see e.g. Mansi et al. 2014 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine, 2015, 277; 585-593; or Maat et al. J Thromb Haemost. 2019 January; 17(1):183-194. doi: 10.1111/jth.14325). - However, angioedemas are not necessarily inherited. Indeed, another class of angioedema is bradykinin-mediated angioedema non-hereditary (BK-AEnH), which is not caused by an inherited genetic dysfunction/fault/mutation. Often the underlying cause of BK-AEnH is unknown and/or undefined. However, the signs and symptoms of BK-AEnH are similar to those of HAE, which without being bound by theory, is thought to be on account of the shared bradykinin-mediated pathway between HAE and BK-AEnH. Specifically, BK-AEnH is characterised by recurrent acute attacks where fluids accumulate outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues such as in the hands, feet, limbs, face, intestinal tract, airway or genitals.
- Specific types of BK-AEnH include: non-hereditary angioedema with normal C1 Inhibitor (AE-nC1 Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema). However, reasons why these factors and conditions cause angioedema in only a relatively small proportion of individuals are unknown.
- Environmental factors that can induce AE-nC1 Inh include air pollution (Kedarisetty et al, Otolaryngol Head Neck Surg. 2019 Apr. 30:194599819846446. doi: 10.1177/0194599819846446) and silver nanoparticles such as those used as antibacterial components in healthcare, biomedical and consumer products (Long et al., Nanotoxicology. 2016; 10(4):501-11. doi: 10.3109/17435390.2015.1088589).
- Various publications suggest a link between the bradykinin and contact system pathways and BK-AEnHs, and also the potential efficacy of treatments, see e.g.: Bas et al. (N Engl J Med 2015; Leibfried and Kovary. J Pharm Pract 2017); van den Elzen et al. (Clinic Rev Allerg Immunol 2018); Han et al (JCI 2002).
- tPA-induced angioedema is discussed in various publications as being a potentially life-threatening complication following thrombolytic therapy in acute stroke victims (see e.g. Simão et al., Blood. 2017 Apr. 20; 129(16):2280-2290. doi: 10.1182/blood-2016-09-740670; Fröhlich et al., Stroke. 2019 Jun. 11:STROKEAHA119025260. doi: 10.1161/STROKEAHA.119.025260; Rathbun, Oxf Med Case Reports. 2019 Jan. 24; 2019(1):omy112. doi: 10.1093/omcr/omy112; Lekoubou et al., Neurol Res. 2014 July; 36(7):687-94. doi: 10.1179/1743132813Y.0000000302; Hill et al., Neurology. 2003 May 13; 60(9):1525-7).
- Stone et al. (Immunol Allergy Clin North Am. 2017 August; 37(3):483-495.) reports that certain drugs can cause angioedema.
- Scott et al. (Curr Diabetes Rev. 2018; 14(4):327-333. doi: 10.2174/1573399813666170214113856) reports cases of dipeptidyl Peptidase-4 Inhibitor induced angioedema.
- Hermanrud et al., (BMJ Case Rep. 2017 Jan. 10; 2017. pii: bcr2016217802) reports recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV and also discusses acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE). Kim et al. (Basic Clin Pharmacol Toxicol. 2019 January; 124(1):115-122. doi: 10.1111/bcpt.13097) reports angiotensin II receptor blocker (ARB)-related angioedema. Reichman et al., (Pharmacoepidemiol Drug Saf. 2017 October; 26(10):1190-1196. doi: 10.1002/pds.4260) also reports angioedema risk for patients taking ACE inhibitors, ARB inhibitors and beta blockers. Diestro et al. (J Stroke Cerebrovasc Dis. 2019 May; 28(5):e44-e45. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.030) also reports a possible association between certain angioedemas and ARBs.
- Giard et al. (Dermatology. 2012; 225(1):62-9. doi: 10.1159/000340029) reports that bradykinin-mediated angioedema can be precipitated by oestrogen contraception.
- Treatment with a large protein plasma kallikrein inhibitor has been shown to effectively treat HAE by preventing the release of bradykinin which causes increased vascular permeability (A. Lehmann “Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery” Expert Opin. Biol. Ther. 8, p 1187-99).
- The plasma kallikrein-kinin system is abnormally abundant in patients with advanced diabetic macular edema. It has been recently published that plasma kallikrein contributes to retinal vascular dysfunctions in diabetic rats (A. Clermont et al. “Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats” Diabetes, 2011, 60, p 1590-98). Furthermore, administration of the plasma kallikrein inhibitor ASP-440 ameliorated both retinal vascular permeability and retinal blood flow abnormalities in diabetic rats. Therefore a plasma kallikrein inhibitor should have utility as a treatment to reduce retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
- Other complications of diabetes such as cerebral haemorrhage, nephropathy, cardiomyopathy and neuropathy, all of which have associations with plasma kallikrein may also be considered as targets for a plasma kallikrein inhibitor.
- Synthetic and small molecule plasma kallikrein inhibitors have been described previously, for example by Garrett et al. (“Peptide aldehyde . . . ” J. Peptide Res. 52, p 62-71 (1998)), T. Griesbacher et al. (“Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats” British Journal of Pharmacology 137, p 692-700 (2002)), Evans (“Selective dipeptide inhibitors of kallikrein” WO03/076458), Szelke et al. (“Kininogenase inhibitors” WO92/04371), D. M. Evans et al. (Immunopharmacology, 32, p 115-116 (1996)), Szelke et al. (“Kininogen inhibitors” WO95/07921), Antonsson et al. (“New peptides derivatives” WO94/29335), J. Corte et al. (“Six membered heterocycles useful as serine protease inhibitors” WO2005/123680), J. Sturzbecher et al. (Brazilian J. Med. Biol. Res 27, p 1929-34 (1994)), Kettner et al. (U.S. Pat. No. 5,187,157), N. Teno et al. (Chem. Pharm. Bull. 41, p 1079-1090 (1993)), W. B. Young et al. (“Small molecule inhibitors of plasma kallikrein” Bioorg. Med. Chem. Letts. 16, p 2034-2036 (2006)), Okada et al. (“Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship” Chem. Pharm. Bull. 48, p 1964-72 (2000)), Steinmetzer et al. (“Trypsin-like serine protease inhibitors and their preparation and use” WO08/049595), Zhang et al. (“Discovery of highly potent small molecule kallikrein inhibitors”
Medicinal Chemistry 2, p 545-553 (2006)), Sinha et al. (“Inhibitors of plasma kallikrein” WO08/016883), Shigenaga et al. (“Plasma Kallikrein Inhibitors” WO2011/118672), and Kolte et al. (“Biochemical characterization of a novel high-affinity and specific kallikrein inhibitor”, British Journal of Pharmacology (2011), 162(7), 1639-1649). Also, Steinmetzer et al. (“Serine protease inhibitors” WO2012/004678) describes cyclized peptide analogs which are inhibitors of human plasmin and plasma kallikrein. - To date, no small molecule synthetic plasma kallikrein inhibitor has been approved for medical use. The molecules described in the known art suffer from limitations such as poor selectivity over related enzymes such as KLK1, thrombin and other serine proteases, and poor oral availability. The large protein plasma kallikrein inhibitors present risks of anaphylactic reactions, as has been reported for Ecallantide. Thus there remains a need for compounds that selectively inhibit plasma kallikrein, that do not induce anaphylaxis and that are orally available. Furthermore, the vast majority of molecules in the known art feature a highly polar and ionisable guanidine or amidine functionality. It is well known that such functionalities may be limiting to gut permeability and therefore to oral availability. For example, it has been reported by Tamie J. Chilcote and Sukanto Sinha (“ASP-634: An Oral Drug Candidate for Diabetic Macular Edema”, ARVO 2012 May 6th-May 9, 2012, Fort Lauderdale, Fla., Presentation 2240) that ASP-440, a benzamidine, suffers from poor oral availability. It is further reported that absorption may be improved by creating a prodrug such as ASP-634. However, it is well known that prodrugs can suffer from several drawbacks, for example, poor chemical stability and potential toxicity from the inert carrier or from unexpected metabolites. In another report, indole amides are claimed as compounds that might overcome problems associated with drugs possessing poor or inadequate ADME-tox and physicochemical properties although no inhibition against plasma kallikrein is presented or claimed (Griffioen et al, “Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases”, WO2010142801).
- Other plasma kallikrein inhibitors known in the art are generally small molecules, some of which include highly polar and ionisable functional groups, such as guanidines or amidines. Recently, plasma kallikrein inhibitors that do not feature guanidine or amidine functionalities have been reported. For example Brandl et al. (“N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein” WO2012/017020), Evans et al. (“Benzylamine derivatives as inhibitors of plasma kallikrein” WO2013/005045), Allan et al. (“Benzylamine derivatives” WO2014/108679), Davie et al. (“Heterocyclic derivates” WO2014/188211), Davie et al. (“N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors” WO2016/083820) and Davie et al. (“Pyrazole derivatives as plasma kallikrein inhibitors” WO2017/207983).
- However, there remains a need to develop new plasma kallikrein inhibitors that will have utility to treat a wide range of disorders, in particular bradykinin-mediated angioedema such as hereditary angioedema. In particular, there remains a need to develop new plasma kallikrein inhibitors that have high selectivity for plasma kallikrein and possess a good pharmacokinetic profile for oral delivery (e.g. possessing good bioavailability).
-
FIG. 1 is a diagram showing key interactions of Example 1 with human plasma kallikrein. -
FIG. 2 is a diagram showing key interactions of Example 1 with human plasma kallikrein. -
FIG. 3 is a diagram showing key interactions of Example 1 with human plasma kallikrein. -
FIG. 4 is a diagram showing key interactions of Example 160 with human plasma kallikrein. -
FIG. 5 is a diagram showing key interactions of Example 160 with human plasma kallikrein. -
FIG. 6 is a diagram showing key interactions of Example 160 with human plasma kallikrein. -
FIG. 7 is a diagram showing key interactions of Example 36 with human plasma kallikrein. -
FIG. 8 is a diagram showing key interactions of Example 36 with human plasma kallikrein. -
FIG. 9 is a diagram showing key interactions of Example 36 with human plasma kallikrein. -
FIG. 10 is a diagram showing key interactions of Example 11 with human plasma kallikrein. -
FIG. 11 is a diagram showing key interactions of Example 11 with human plasma kallikrein. -
FIG. 12 is a diagram showing key interactions of Example 11 with human plasma kallikrein. -
FIG. 13 is a diagram showing key interactions of Example 126 with human plasma kallikrein. -
FIG. 14 is a diagram showing key interactions of Example 126 with human plasma kallikrein. -
FIG. 15 is a diagram showing key interactions of Example 126 with human plasma kallikrein. -
FIG. 16 is a diagram showing key interactions of RC4 with human plasma kallikrein. -
FIG. 17 is a diagram showing key interactions of RC4 with human plasma kallikrein. -
FIG. 18 is a diagram showing key interactions of RC4 with human plasma kallikrein. -
FIG. 19 is a diagram showing an overlay of the interactions of RC4 with Example 1 with plasma kallikrein. -
FIG. 20 is a diagram showing an overlay of the interactions of RC4 with Example 1 with plasma kallikrein. - The present invention relates to a series of heterocyclic derivatives that are inhibitors of plasma kallikrein. These compounds demonstrate good selectivity for plasma kallikrein and are potentially useful in the treatment of bradykinin-mediated angioedemas such as impaired visual acuity, diabetic retinopathy, macular edema, hereditary angioedema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post-operative surgery. The invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions.
- In a first aspect, the present invention provides compounds of formula (I):
-
- wherein
- W, X, Y and Z are independently selected from C, C(R16)-C, C(R16)=C, C=N, O and N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14;
- R16 is independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14; or
- W, X, Y and Z are independently selected from C, C(R16)-C, C(R16)=C, C═N and N, and one of R5, R6, R7 or R16 is oxo such that the ring containing W, X, Y and Z is 2-pyridone or 4-pyridone; wherein the others of R5, R6, R7 and R16 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
-
-
- B′ is phenyl or pyridyl;
- B″ is pyrrole, pyrazole, triazole, or tetrazole;
- n is 0, 1, or 2;
- R9 and R10 are independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
- Each R11 is independently alkyl, cycloalkyl, alkoxy, halo, OH, —COOR13, —CONR13NR14, CN, and CF3;
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
-
-
- A′1 and A′2 are independently C or N;
- A′ is heteroaryl or phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3, and wherein heteroaryl may be optionally substituted as stated below;
- A″ is heterocycloalkyl;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
- alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C1-C6)alkoxy, OH, —NR13R14, —COOR13, —CONR13R14, CN, CF3, halo;
- alkylb is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb may optionally be substituted with 1 or 2 substituents independently selected from (C1-C6)alkoxy, OH, CN, CF3, halo;
- alkylene is a bivalent linear saturated hydrocarbon having 1 to 5 carbon atoms (C1-C5); alkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C1-C6)alkoxy, OH, CN, CF3, halo;
- aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, heteroaryla, —(CH2)0-3—O-heteroaryla, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryla, —COOR13, —CONR13R14, —(CH2)1-3—NR13R14, OCF3 and CF3;
- arylb is phenyl, biphenyl or naphthyl, which may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, and CF3; heteroalkylene is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C2-C5), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O; heteroalkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C1-C6)alkoxy, OH, CN, CF3, halo;
- cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl (C1-C6)alkoxy, OH, CN, CF3, halo;
- alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro; halo is F, Cl, Br, or I;
- heteroaryl is a 5- or 6-membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
- heteroaryla is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, NR12, S and O; heteroaryla may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, arylb, —(CH2)1-3-arylb, —(CH2)0-3—NR13R14, heteroarylb, —COOR13, —CONR13R14 and CF3;
- heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, NR12, S and O; wherein heteroarylb may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, arylb, —(CH2)1-3-arylb, and CF3;
- heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N, NR8, S, SO, SO2, and O; wherein heterocycloalkyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- heterocycloalkyla is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from NR8, S, SO, SO2, and O; heterocycloalkyla may be optionally substituted with 1 or 2 substituents independently selected from alkyl, (C1-C6)alkoxy, OH, CN, CF3, halo;
- R8 is independently selected from H, alkyl, cycloalkyl, or heterocycloalkylb;
- heterocycloalkylb is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, NR12, S, and O; heterocycloalkylb may be optionally substituted with 1 or 2 substituents independently selected from alkyl, (C1-C6)alkoxy, OH, CN, CF3, halo;
- R12 is independently selected from H, alkylb, or cycloalkyl;
- R13 and R14 are independently selected from H, alkylb, arylb and heteroarylb or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, NR12, S, SO, SO2 and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3;
- and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
-
- The compounds of formula (I) have been carefully developed to be particularly suitable for oral delivery (e.g. possessing an excellent pharmacokinetic profile, in particular bioavailability). As shown by the examples, the inventors have demonstrated that compounds of formula (I) have surprisingly excellent solubility. More surprisingly, compounds of formula (I) exhibit these advantageous effects whilst being highly selective inhibitors of plasma kallikrein, including making key binding interactions.
- The present invention also provides a prodrug of a compound of formula (I) as herein defined, or a pharmaceutically acceptable salt and/or solvate thereof.
- The present invention also provides an N-oxide of a compound of formula (I) as herein defined, or a prodrug or pharmaceutically acceptable salt and/or solvate thereof.
- It will be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms.
- It will be understood that “pharmaceutically acceptable salts and/or solvates thereof” means “pharmaceutically acceptable salts thereof”, “pharmaceutically acceptable solvates thereof”, and “pharmaceutically acceptable solvates of salts thereof”.
- It will be understood that, for the purposes of naming, each of rings A′ and A″ are defined separately. For example, when A is
- A′ is phenyl and A″ is piperidine. For example, when A is
- A′ is imidazole and A″ is piperazine.
- It will be understood that the compounds of the invention comprise several ring systems. When any of these ring systems is defined more specifically herein, the substituents/optional substituents to these groups described above also apply, unless stated otherwise. For example, “A′ can be pyrazole” allows the pyrazole to be “optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3”, which is permitted by the above definition of heteroaryl.
- It will be understood that in Formula (III)
- A′1 is directly bonded to A′2.
- It will be understood that “alkylene” has two free valencies i.e. it is bivalent, meaning that it is capable of being bonded to twice. For example, when two adjacent ring atoms on A″ are linked by an alkylene to form a cyclopentane, the alkylene will be —CH2CH2CH2—.
- It will be understood that when any variable (e.g. R11, etc) occurs more than once, its definition on each occurrence is independent of every other occurrence.
- It will be understood that combinations of substituents and variables are permissible only if such combinations result in stable compounds.
- It will be understood that lines drawn into the ring systems from substituents represent that the indicated bond can be attached to any of the substitutable ring atoms. For example, in Formula (II), R10 and R9 can be attached to any of the substitutable ring atoms on B′, and R11 (if present) can be attached to any of the substitutable ring atoms on B″.
- As noted above, “heteroalkylene” is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C2-C5), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O. For example, —CH2O— is a “heteroalkylene” having 2 carbon atoms wherein one of the 2 carbon atoms has been replaced with O.
- As used herein the term “bradykinin-mediated angioedema” means hereditary angioedema, and any non-hereditary bradykinin-mediated angioedema. For example, “bradykinin-mediated angioedema” encompasses hereditary angioedema and acute bradykinin-mediated angioedema of unknown origin.
- As used herein, the term “hereditary angioedema” means any bradykinin-mediated angioedema caused by an inherited genetic dysfunction, fault, or mutation. As a result, the term “HAE” includes at
least HAE type 1,HAE type 2, and normal C1 inhibitor HAE (normal C1-Inh HAE). - W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N, O and N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3; or
- W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N and N, and one of R5, R6, R7 or R16 can be oxo such that the ring containing W, X, Y and Z is 2-pyridone or 4-pyridone;
- wherein the others of R5, R6, R7 and R16 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3.
- W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N, O and N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14.
- When at least one of W, X, Y and Z is O, W, X, Y, Z can form a 5-membered heteroaryl selected from furan, oxazole, isoxazole, 1,2,3-oxadiazole, and furazan.
- More specifically, W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N and N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, NR13R14, COOR13, CONR13R14, and NR13COR14.
- More specifically, W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N and N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
- R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
- R16 can be independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3.
- W, X, Y and Z can be independently selected from C, C(R16)-C, C(R16)=C, C═N and N, such that the ring containing W, X, Y and Z is a 6-membered heteroaryl. More specifically, W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a 6-membered heteroaryl selected from pyridine, pyridazine, pyrimidine, and pyrazine.
- Preferably, W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl. More specifically, W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl selected from pyrrole, pyrazole, imidazole, 1,2,3-triazole, 1,2,4-triazole. Preferably, W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is pyrazole, in particular when X and Y are N, and W and Z are C. Specifically, the compounds of formula (I) can be selected from:
- wherein R5 is as defined above, and in particular, small alkyl. More specifically, R5 can be selected from methyl and —CH2OMe.
- Alternatively, it is preferred that W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is imidazole. Specifically, the compounds of formula (I) can be:
- wherein R6 is as defined above, and in particular, small alkyl. More specifically, R6 can be selected from methyl and —CH2OMe.
- As noted above, R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14. More specifically, R5, R6, and R7 can be independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3. At least one of R5, R6, or R7 can be present and not H (i.e. selected from alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, and —NR13COR14). Additionally, or alternatively, R7 can be H.
- At least one of R5, R6, or R7 can be selected from H, alkyl, cycloalkyl, and CF3. Alternatively, at least two of R5, R6, or R7 can be independently selected from H, alkyl, cycloalkyl, and CF3. Alternatively, R5, R6, or R7 can be independently selected from H, alkyl, cycloalkyl, and CF3.
- R5 can be alkyl. For example, the compounds of formula (I) can be:
- Alternatively, R5 can be H. Alternatively, R5 can be CF3. Alternatively, R5 can be cycloalkyl.
- R6 can be alkyl. R6 can be H. R6 can be CF3. R6 can be cycloalkyl.
- R7 can be alkyl. R7 can be H. R7 can be CF3. R7 can be cycloalkyl. R7 is preferably H.
- R16 (when present) can be selected from H, alkyl, cycloalkyl, and CF3.
- When any of R5, R6, R7, and/or R16 is alkyl, it is preferable that R5, R6, R7 and/or R16 is alkyl substituted by at least alkoxy, in particular, —CH2OMe.
- Alternatively, at least one of R5 or R6 can be —CHF2. R5 can be —CHF2. R6 can be —CHF2.
- When any of R5, R6, R7, and/or R16 is cycloalkyl, it is preferable that R5, R6, R7, and/or R16 is cyclopropane, optionally substituted with alkoxy, in particular, —OMe. Specifically, the compounds of formula (I) can be:
- Preferably, R5 is alkyl substituted by at least alkoxy, in particular, —CH2OMe. R6 is alkyl substituted by at least alkoxy, in particular, —CH2OMe is also preferred. More specifically, one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy, in particular, —CH2OMe. For example, it is preferred when R5 is alkyl substituted by alkoxy, in particular, CH2OMe and R6 is absent. It is also preferred when R5 is absent and R6 is alkyl substituted by alkoxy, in particular, CH2OMe.
- Preferably: (i) W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (ii) one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy, and (iii) R7 is H. More specifically: (i) W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y are N, and W and Z are C, (ii) R5 is alkyl substituted with alkoxy, in particular —CH2OMe, (iii) R6 is absent; and (iv) R7 is H.
- B′ can be phenyl. B′ can be pyridyl.
- R9 and R10 can be independently H, alkyl, halo, or alkoxy. More specifically, R9 and R10 can be independently halo or alkoxy. For example, one of R9 or R10 can be halo, in particular F. Alternatively, one of R9 or R10 can be alkoxy, specifically, —OMe, or -Ocyclopropyl, in particular —OMe. Preferably, R9 is halo (in particular F) and R10 is alkoxy (in particular —OMe).
- Preferably, B′ is phenyl, R9 is halo (in particular F) and R10 is alkoxy (in particular —OMe). More specifically, the preferred B′ group is
- As noted above, B″ is pyrrole, pyrazole, triazole, or tetrazole. Preferably, B″ can be pyrazole or triazole. When B″ is triazole, B″ can be 1, 2, 3-triazole. Alternatively, when B″ is triazole, B″ can be 1, 2, 4-triazole.
- B″ can be bonded to B′ through any of the ring atoms on B″. Preferably, B″ is bonded to B′ through a nitrogen atom on B″
- B″ can be pyrrole. B″ can be pyrrole, n can be 1, and R11 can be selected from alkyl, cycloalkyl, CN, and CF3. Preferably, B″ is pyrrole, n is 1, and R11 is selected from small alkyl, cyclopropyl, CN, and CF3
- B″ can be pyrazole. B″ can be pyrazole, n can be 1, and R11 can be selected from alkyl, cycloalkyl, CN, and CF3. Preferably, B″ is pyrazole, n is 1, and R11 is selected from small alkyl, cyclopropyl, CN, and CF3. Specifically, B″ can be selected from:
- B″ can be 1, 2, 3-triazole. B″ can be 1, 2, 3-triazole, n can be 1, and R11 can be alkyl. More specifically, B″ can be 1, 2, 3-triazole, n can be 1, and R11 can be selected from CN and small alkyl. Preferably, when B″ is 1, 2, 3-triazole, n is 1, and R11 is selected from CN, methyl, ethyl, and CHF2. Specifically, B″ can be:
- wherein R11 is as defined above.
- B″ can be 1, 2, 4-triazole. B″ can be 1, 2, 4-triazole, n can be 1 or 2, and each R11 can be independently alkyl, cycloalkyl, CF3. More specifically, B″ can be 1, 2, 4-triazole, n can be 1, and R11 can be alkyl, cycloalkyl, CF3. Additionally, when B″ is 1, 2, 4-triazole and n is 1, R11 can be selected from CN, CF3, and small alkyl, and in particular, CN, methyl, ethyl, CHF2, CF3. When B″ is 1, 2, 4-triazole and n is 2, both R11 groups are preferably methyl. Specifically, B″ can be:
- wherein R11 is as defined above.
- B″ can be 1, 2, 4-triazole, n can be 1, and R11 can be CF3.
- B″ can be 1, 2, 5-triazole. B″ can be 1, 2, 5-triazole, n can be 1, and R11 can be alkyl. Preferably, when B″ is 1, 2, 5-triazole, n is 1, and R11 is selected from methyl and CHF2.
- Specific B″ groups include:
- Preferred B″ groups include:
- and in particular
- Preferably: (i) B′ is phenyl, (ii) R9 is halo, (iii) R10 is alkoxy, and (iv) B″ is 1,2,3-triazole. In addition, (v) n can be 1, and (vi) R11 can be alkyl. More specifically, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- Preferably, (i) B′ is phenyl, (ii) R9 is halo, (iii) R10 is alkoxy, and (iv) B″ is 1,2,3-triazole. In addition, (v) n can be 1, (vi) R11 can be alkyl, (vii) W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (viii) one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy, (ix) R7 is H, (x) B′ is phenyl, (xi) R9 is halo, (xii) R10 is alkoxy, and (xiii) B″ is 1,2,3-triazole. In addition, (viii) n can be 1, and (ix) R11 can be alkyl. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole when X and Y are N, and W and Z are C, R5 can be —CH2OMe, R6 can be absent, R7 can be H, and R11 can be methyl.
- Alternatively: (i) B′ is phenyl, (ii) R9 is halo, (iii) R10 is alkoxy, and (iv) B″ is 1,2,4-triazole. In addition, (v) n can be 1, (vi) R11 can be CF3, (vii) W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (viii) one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy, (ix) R7 is H, (x) B′ is phenyl, (xi) R9 is halo, (xii) R10 is alkoxy, and (xiii) B″ is 1,2,4-triazole. In addition, (viii) n can be 1, and (ix) R11 can be CF3. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole when X and Y are N, and W and Z are C, R5 can be —CH2OMe, R6 can be absent, R7 can be H, and R11 can be methyl.
- A′1 can be C. A′1 can be N. A′2 can be C. A′2 can be N.
- A′ can be phenyl.
- Alternatively, A′ can be heteroaryl. When A′ is heteroaryl, A′ can be heteroaryl selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine. A′ can be a 5-membered heteroaryl, preferably selected from pyrrole or imidazole. Alternatively, A′ can be a 6-membered heteroaryl, preferably pyridine.
- A″ can be a non-aromatic carbon-containing monocyclic ring containing 5 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O. For example, A″ can be selected from pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, 3-dioxolane, thiazolidine, and isoxazolidine. When A″ is a non-aromatic carbon-containing monocyclic ring containing 5 ring members, A″ is preferably pyrrolidine.
- Alternatively, A″ can be a non-aromatic carbon-containing monocyclic ring containing 6 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O. For example, A″ can be selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane. When A″ is a non-aromatic carbon-containing monocyclic ring containing 6 ring members, A″ is preferably piperidine.
- Alternatively, A″ can be a non-aromatic carbon-containing monocyclic ring containing 7 ring members, wherein one or two ring members are independently selected from N, NR8, S, and O. For example, A″ can be selected from azepane, oxepane, oxazepane (in particular, a 1,4-oxazapane), thiepane, and diazepane. When A″ is a non-aromatic carbon-containing monocyclic ring containing 7 ring members, A″ is preferably azepane.
- A carbon ring atom on A″ can be substituted with an alkylene such that the carbon ring atom on A″ together with the alkylene forms a cycloalkyl that is spiro to ring A″. More specifically, the spiro ring formed can be cyclopropane. Alternatively, the spiro ring formed can be cyclobutane. Alternatively, the spiro ring formed can be cyclopentane. Alternatively, the spiro ring formed is cyclohexane. When a spiro ring is present on A″, a preferred spiro ring is cyclopropane.
- A carbon ring atom on A″ can be substituted with a heteroalkylene such that the carbon ring atom on A″ together with the heteroalkylene forms a heterocycloalkyla that is spiro to ring A″. More specifically, the spiro ring formed can be 3-membered, e.g. selected from aziridine, oxirane, and thiirane. Alternatively, the spiro ring formed can be 4-membered, e.g. selected from azetidine, oxetane, and thietane. Alternatively, the spiro ring formed can be 5-membered, e.g. selected from pyrrolidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, 3-dioxolane, thiazolidine, and isoxazolidine. Alternatively, the spiro ring formed can be 6-membered, e.g. selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane.
- Two ring atoms on A″ can be linked by an alkylene to form a non-aromatic ring containing 5, 6, or 7 ring members. More specifically, two ring atoms on A″ can be linked by an alkylene to form a non-aromatic ring containing 5 ring members, e.g. cyclopentane. Alternatively, the two ring atoms on A″ can be linked by an alkylene to form a non-aromatic ring containing 6 ring members, e.g. cyclohexane. Alternatively, the two ring atoms on A″ can be linked by an alkylene to form a non-aromatic ring containing 7 ring members, e.g. cycloheptane.
- Two ring atoms on A″ can be linked by a heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members. More specifically, the two ring atoms on A″ can be linked by a heteroalkylene to form a non-aromatic ring containing 5 ring members, e.g. selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine. Alternatively, the two ring atoms on A″ can be linked by a heteroalkylene to form a non-aromatic ring containing 6 ring members e.g. selected from piperidine, piperazine, morpholine, 1,4-dioxane, thiomorpholine, 1,4-oxathiane, and 1,4-dithiane. Alternatively, the two ring atoms on A″ can be linked by a heteroalkylene to form a non-aromatic ring containing 7 ring members, e.g. selected from azepane, oxepane, oxazepane (in particular, a 1,4-oxazapane), thiepane, and diazepane.
- Specific A groups include:
- Preferred A groups include:
- More preferred A groups include:
- Even more preferred A groups include:
- in particular
- Preferably: (i) A′ is phenyl, and (ii) A″ is piperidine. More specifically, (i) A′ can be phenyl, and (ii) A″ can be piperidine substituted with methyl.
- Preferably: (i) A′ is phenyl, (ii) A″ is piperidine, (iii) B′ is phenyl, (iv) R9 is halo, (v) R10 is alkoxy, and (vi) B″ is 1,2,3-triazole. In addition, (vii) n can be 1, and (viii) R11 can be alkyl. More specifically, A″ can be piperidine substituted with methyl, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- Preferably: (i) A′ is phenyl, (ii) A″ is piperidine, (iii) B′ is phenyl, (iv) R9 is halo, (v) R10 is alkoxy, and (vi) B″ is 1,2,3-triazole. In addition, (vii) n can be 1, (viii) R11 can be alkyl, (ix) W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (x) one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy, and (xi) R7 is H. In addition, (xii) n can be 1, and (xiii) R11 can be alkyl. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C, R5 can be —CH2OMe, R6 can be absent, R7 can be H, R11 can be methyl, A″ can be piperidine substituted with methyl.
- Alternatively: (i) A′ is phenyl, (ii) A″ is piperidine, (iii) B′ is phenyl, (iv) R9 is halo, (v) R10 is alkoxy, and (vi) B″ is 1,2,4-triazole. In addition, (vii) n can be 1, (viii) R11 can be CF3, (ix) W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (x) one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy, and (xi) R7 is H. In addition, (xii) n can be 1, and (xiii) R11 can be alkyl. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C, R5 can be —CH2OMe, R6 can be absent, R7 can be H, R11 can be CF3, A″ can be piperidine substituted with methyl.
- Alternatively: (i) A′ is phenyl, and (ii) A″ is pyrrolidine. More specifically, (i) A′ can be phenyl, and (ii) A″ can be pyrrolidine substituted with methyl.
- Alternatively: (i) A′ is phenyl, (ii) A″ is pyrrolidine, (iii) B′ is phenyl, (iv) R9 is halo, (v) R10 is alkoxy, and (vi) B″ is 1,2,3-triazole. In addition, (vii) n can be 1, and (viii) R11 can be alkyl. More specifically, A″ can be piperidine substituted with methyl, R9 can be F, R10 can be —OMe, n can be 1, and R11 can be methyl.
- Alternatively: (i) A′ is phenyl, (ii) A″ is pyrrolidine, (iii) B′ is phenyl, (iv) R9 is halo, (v) R10 is alkoxy, and (vi) B″ is 1,2,3-triazole. In addition, (vii) n can be 1, (viii) R11 can be alkyl, (ix) W, X, Y and Z can be independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, (x) one of R5 or R6 can be absent and one of R5 or R6 can be alkyl substituted by alkoxy, and (xi) R7 is H. In addition, (xii) n can be 1, and (xiii) R11 can be alkyl. More specifically: W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a pyrazole, in particular when X and Y can be N, and W and Z can be C, R5 can be —CH2OMe, R6 can be absent, R7 can be H, R11 can be methyl, A″ can be pyrrolidine substituted with methyl.
- As noted above, R8 is independently selected from H, alkyl, cycloalkyl, or heterocycloalkylb. When R8 is heterocycloalkylb, it is preferably a non-aromatic carbon-containing monocyclic ring containing 4 ring members, in particular, oxetane. More specifically, R8 can be independently selected from H, alkyl, or cycloalkyl. When R8 is alkyl, it is preferably methyl. When R8 is cycloalkyl, it is preferably cyclopropyl.
- When A′ is phenyl and A″ is piperidine, specific A groups can be selected from:
- wherein R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- Specific A groups can also be selected from:
- wherein A′ is pyridine, and R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- Specific A groups also include:
- wherein R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- Specific A groups also include:
- wherein R8 is as defined above, and more specifically small alkyl, and in particular, methyl.
- R13 and R14 can be independently selected from H, alkylb, arylb and heteroarylb. More specifically, R13 and R14 can be in independently selected from H and small alkyl.
- Alternatively, R13 and R14 can together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N12, S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3.
- The invention provides a compound of formula (I), as set out below, which may be combined with the above disclosure:
-
- wherein
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl (preferably pyrazole);
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond: B″
-
-
- B′ is phenyl;
- B″ is pyrrole, pyrazole, 1, 2, 3-triazole, 1, 2, 4-triazole, or 1, 2, 5-triazole;
- n is 0, 1, or 2;
- R9 is halo (preferably F) and R10 is alkoxy (preferably —OMe);
- Each R11 are independently selected from alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
-
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
- A′1 and A′2 are independently C or N;
- A′ is heteroaryl or phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3, and wherein heteroaryl may be optionally substituted as described herein;
- A″ is heterocycloalkyl; wherein A″ may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
- The invention also provides a compound of formula (I), as set out below, which may be combined with the above disclosure:
-
- wherein
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl (preferably pyrazole);
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3 provided that at least one of R5, R6, or R7 is present and is not H (i.e. independently selected from alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3), preferably,
- wherein one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy (in particular, CH2OMe), and R7 is H;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
-
-
- B′ is phenyl;
- B″ is pyrrole, pyrazole, 1, 2, 3-triazole, 1, 2, 4-triazole, or 1, 2, 5-triazole;
- n is 0, 1, or 2;
- R9 is halo (preferably F) and R10 is alkoxy (preferably —OMe);
- R11 are independently selected from alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3;
-
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
- A′1 and A′2 are independently C or N;
- A′ is heteroaryl or phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3, and
- wherein heteroaryl may be optionally substituted described herein;
- A″ is heterocycloalkyl; wherein A″ may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
- The invention also provides a compound of formula (I), as set out below, which may be combined with the above disclosure:
-
- wherein
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl (preferably pyrazole);
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3 provided that at least one of R5, R6, or R7 is present and is not H (preferably, wherein one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy (in particular, CH2OMe), and R7 is H;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
-
-
- B′ is phenyl;
- B″ is 1, 2, 3-triazole;
- n is 1;
- R9 is halo (preferably F) and R10 is alkoxy (preferably —OMe);
- R11 is alkyl (preferably methyl);
-
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
- A′1 and A′2 are independently C or N;
- A′ is heteroaryl or phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3, and wherein heteroaryl may be optionally substituted described herein;
- A″ is heterocycloalkyl selected from pyrrolidine, piperidine, or azepane; wherein A″ may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
- The invention also provides a compound of formula (I), as set our below, which may be combined with the above disclosure:
-
- wherein
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl (preferably pyrazole);
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3 provided that at least one of R5, R6, or R7 is present and is not H (preferably, wherein one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy (in particular, CH2OMe), and R7 is H;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
-
-
- B′ is phenyl;
- B″ is 1, 2, 3-triazole;
- n is 1;
- R9 is halo (preferably F) and R10 is alkoxy (preferably —OMe);
- R11 is alkyl (preferably methyl);
-
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
- A′1 and A′2 are independently C or N;
- A′ is phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
- A″ is heterocycloalkyl selected from pyrrolidine, piperidine, or azepane; wherein A″ may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
- The invention also provides a compound of formula (I), as set our below, which may be combined with the above disclosure:
-
- wherein
- W, X, Y and Z are independently selected from C and N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl (preferably pyrazole);
- R5, R6, and R7 are independently absent or independently selected from H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, and CF3 provided that at least one of R5, R6, or R7 is present and is not H (preferably, wherein one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted by alkoxy (in particular, CH2OMe), and R7 is H;
- B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
-
-
- B′ is phenyl;
- B″ is 1, 2, 4-triazole;
- n is 1;
- R9 is halo (preferably F) and R10 is alkoxy (preferably —OMe);
- R11 is CF3;
-
- A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
-
- A′1 and A′2 are independently C or N;
- A′ is phenyl, wherein phenyl may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
- A″ is heterocycloalkyl selected from pyrrolidine, piperidine, or azepane; wherein A″ may be optionally substituted with 1, 2, or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, oxo and CN;
- optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
- optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated isotopes, and pharmaceutically acceptable salts and/or solvates thereof.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)pyrazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyclopropylpyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-(2,3-dihydro-1H-isoindol-5-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl-5H,6H,8H-imidazo[1,2-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl-5H,6H,8H-pyrido[3,4-d]pyrimidin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- 1-[(4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-6-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′-yl)methyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- 1-[(7-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(5-chloro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(4-methyl-3,5-dihydro-2H-1,4-benzoxazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-({5-methyl-4H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}methyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethyl)pyrazole-4-carboxamide;
- 1-[(5-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-{[7-(2,2-difluoroethyl)-6,8-dihydro-5H-1,7-naphthyridin-3-yl]methyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- 1-{1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinolin-9-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({11-isopropyl-11-azatricyclo[6.2.1.0{circumflex over ( )}{2,7}]undeca-2(7),3,5-trien-4-yl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2,3,3-trimethyl-1H-isoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(1,1-dimethyl-3,4-dihydro-2H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-l)phenyl]methyl}-3-(methoxymethyl)-1-{[6-(propan-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl]methyl}-1H-pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-7-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[3-(1,1-difluoroethyl)-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-2-oxopyridine-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(1-hydroxy-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide.
The present invention also encompasses, but is not limited to, the below compounds: - N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)pyrazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyclopropylpyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-(2,3-dihydro-1H-isoindol-5-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl-5H,6H,8H-imidazo[1,2-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- 1-[(4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-6-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′-yl)methyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- 1-[(7-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(5-chloro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(4-methyl-3,5-dihydro-2H-1,4-benzoxazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-({5-methyl-4H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}methyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethyl)pyrazole-4-carboxamide;
- 1-[(5-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-{[7-(2,2-difluoroethyl)-6,8-dihydro-5H-1,7-naphthyridin-3-yl]methyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- 1-{1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinolin-9-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({11-isopropyl-11-azatricyclo[6.2.1.0{circumflex over ( )}{2,7}]undeca-2(7),3,5-trien-4-yl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2,3,3-trimethyl-1H-isoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(1,1-dimethyl-3,4-dihydro-2H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-l)phenyl]methyl}-3-(methoxymethyl)-1-{[6-(propan-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl]methyl}-1H-pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-7-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[3-(1,1-difluoroethyl)-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-2-oxopyridine-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-l)phenyl]methyl}-3-(methoxymethyl)-1-{[6-(propan-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl]methyl}-1H-pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-7-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)pyrazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-6-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′-yl)methyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(5-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-{[7-(2,2-difluoroethyl)-6,8-dihydro-5H-1,7-naphthyridin-3-yl]methyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- 1-{1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinolin-9-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-l)phenyl]methyl}-3-(methoxymethyl)-1-{[6-(propan-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl]methyl}-1H-pyrazole-4-carboxamide;
- 1-(3,4-dihydro-1H-2-benzopyran-7-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′-yl)methyl)-1H-pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- 1-{1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinolin-9-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
- 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
- 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
- N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide.
- The present invention also encompasses, but is not limited to, the below compounds:
- N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
- N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
- N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide.
- Therapeutic Applications
- As previously mentioned, the compounds of the present invention are potent and selective inhibitors of plasma kallikrein. They are therefore useful in the treatment of disease conditions for which over-activity of plasma kallikrein is a causative factor.
- Accordingly, the present invention provides a compound of formula (I) for use in medicine.
- The present invention also provides for the use of a compound of formula (I) in the manufacture of a medicament for the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
- The present invention also provides a compound of formula (I) for use in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated.
- The present invention also provides a method of treatment of a disease or condition in which plasma kallikrein activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of formula (I).
- In particular, the disease or condition in which plasma kallikrein activity is implicated is a bradykinin-mediated angioedema.
- The bradykinin-mediated angioedema can be non-hereditary. For example, the non-hereditary bradykinin-mediated angioedema can be selected from non-hereditary angioedema with normal C1 Inhibitor (AE-nC1 Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE or ace) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
- Alternatively, and preferably, the bradykinin-mediated angioedema can be hereditary angioedema (HAE), which is angioedema caused by an inherited dysfunction/fault/mutation. Types of HAE that can be treated with compounds according to the invention include
HAE type 1,HAE type 2, and normal C1 inhibitor HAE (normal C1 Inh HAE). - The disease or condition in which plasma kallikrein activity is implicated is selected from impaired visual acuity, diabetic retinopathy, diabetic macular edema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery and bleeding from post operative surgery. More specifically, the disease or condition in which plasma kallikrein activity is implicated can be retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
- Combination Therapy
- The compounds of the present invention may be administered in combination with other therapeutic agents. Suitable combination therapies include a compound of formula (I) combined with one or more agents selected from agents that inhibit platelet-derived growth factor (PDGF), endothelial growth factor (VEGF), integrin alpha5beta1, steroids, other agents that inhibit plasma kallikrein and other inhibitors of inflammation. Specific examples of therapeutic agents that may be combined with the compounds of the present invention include those disclosed in EP2281885A and by S. Patel in Retina, 2009 June; 29(6 Suppl):S45-8.
- When combination therapy is employed, the compounds of the present invention and said combination agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
- The compounds of the present invention can be administered in combination with laser treatment of the retina. The combination of laser therapy with intravitreal injection of an inhibitor of VEGF for the treatment of diabetic macular edema is known (Elman M, Aiello L, Beck R, et al. “Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema” Ophthalmology. 27 Apr. 2010).
- As noted above, the term “alkyl” is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C1-C6)alkoxy, OH, —NR13R14, —COOR13, —CONR13R14, CN, CF3, halo. As noted above, the term “alkylb” is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1 or 2 substituents independently selected from (C1-C6)alkoxy, OH, CN, CF3, and halo. Examples of such alkyl or alkylb groups include, but are not limited, to C1-methyl, C2-ethyl, C3-propyl and C4-n-butyl, C3-iso-propyl, C4-sec-butyl, C4-iso-butyl, C4-tert-butyl and C5-neo-pentyl), optionally substituted as noted above. More specifically, “alkyl” or “alkylb” can be a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6), optionally substituted as noted above. Even more specifically, “alkyl” or “alkylb” can be a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above, which is herein called “small alkyl” or “small alkylb”, respectively. Preferably, “alkyl” or “alkylb” can be defined as a “small alkyl” or “small alkylb”.
- As noted above, the term “alkylene” is a bivalent linear saturated hydrocarbon having 1 to 5 carbon atoms (C1-C5); alkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl, (C1-C6)alkoxy, OH, CN, CF3, halo. More specifically, alkylene can be a bivalent linear saturated hydrocarbon having 2 to 4 carbon atoms (C2-C4), more specifically having 2 to 3 carbon atoms (C2-C3), optionally substituted as noted above.
- Aryl and arylb are as defined above. Typically, aryl or arylb will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl or arylb groups include phenyl and naphthyl (each optionally substituted as stated above). Preferably aryl is selected from phenyl, substituted phenyl (wherein said substituents are selected from those stated above) and naphthyl.
- As noted above, the term “heteroalkylene” is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C2-C5), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O; heteroalkylene may optionally be substituted with 1 or 2 substituents independently selected from alkyl (C1-C6)alkoxy, OH, CN, CF3, halo. More specifically, heteroalkylene can be a valent linear saturated hydrocarbon having 2 to 4 carbon atoms (C2-C4), wherein at least one of the 2 to 4 carbon atoms is replaced with NR8, S, or O, or having 2 to 3 carbon atoms (C2-C3), wherein at least one of the 2 to 3 carbon atoms is replaced with NR8, S, or O, each optionally substituted as noted above.
- As noted above, the term “cycloalkyl” is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl (C1-C6)alkoxy, OH, CN, CF3, halo. Examples of suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl), optionally substituted as noted above. More specifically, cycloalkyl can be a monocyclic saturated hydrocarbon ring of between 3 and 5 carbon atoms, more specifically, between 3 and 4 carbon atoms), optionally substituted as noted above.
- As noted above, the term “alkoxy” is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro. Examples of such alkoxy groups include, but are not limited to, C1-methoxy, C2-ethoxy, C3-n-propoxy and C4-n-butoxy for linear alkoxy, and C3-iso-propoxy, and C4-sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, alkoxy can be linear groups of between 1 and 4 carbon atoms (C1-C4), more specifically, between 1 and 3 carbon atoms (C1-C3). More specifically, alkoxy can be branched groups of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above.
- Halo can be selected from Cl, F, Br and I. More specifically, halo can be selected from Cl and F.
- As noted above, heteroaryl is a 5- or 6-membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3. For example, heteroaryl can be selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine, optionally substituted as noted above.
- Heteroaryla and heteroarylb are as defined above. Typically, heteroaryla or heteroarylbwill be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable heteroaryla or heteroarylb groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl and isoquinolinyl (optionally substituted as stated above).
- As noted above, “heterocycloalkyl” is a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N, NR8, S, SO, SO2, and O. More specifically, “heterocycloalkyl” can be a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N, NR8, and O, optionally substituted as noted above. More specifically, “heterocycloalkyl” can be a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently selected from N or NR8.
- As noted above, “heterocycloalkyl” is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from NR8, S, SO, SO2, and O; heterocycloalkyla may be optionally substituted with 1 or 2 substituents independently selected from alkyl (C1-C6)alkoxy, OH, CN, CF3, halo. More specifically, “heterocycloalkyl” can be a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from NR8, and O; heterocycloalkyla may be optionally substituted with 1 or 2 substituents independently selected from alkyl (C1-C6)alkoxy, OH, CN, CF3, halo.
- The term “O-linked”, such as in “O-linked hydrocarbon residue”, means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
- The term “N-linked”, such as in “N-linked pyrrolidinyl”, means that the heterocycloalkyl group is joined to the remainder of the molecule via a ring nitrogen atom.
- In groups such as —(CH2)1-3-aryl, “-” denotes the point of attachment of the substituent group to the remainder of the molecule.
- “Pharmaceutically acceptable salt” means a physiologically or toxicologically tolerable salt and includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts. For example (i) where a compound of the invention contains one or more acidic groups, for example carboxy groups, pharmaceutically acceptable base addition salts that can be formed include sodium, potassium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, N-methyl-glucamine, diethanolamine or amino acids (e.g. lysine) and the like; (ii) where a compound of the invention contains a basic group, such as an amino group, pharmaceutically acceptable acid addition salts that can be formed include hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tosylates, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, camphorates, xinafoates, p-acetamidobenzoates, dihydroxybenzoates, hydroxynaphthoates, succinates, ascorbates, oleates, bisulfates and the like.
- Hemisalts of acids and bases can also be formed, for example, hemisulfate and hemicalcium salts.
- For a review of suitable salts, see “Handbook of Pharmaceutical Salts: Properties, Selection and Use” by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
- “Prodrug” refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in ‘The Practice of Medicinal Chemistry, 2nd Ed. pp 561-585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379.
- The compounds of the invention can exist in both unsolvated and solvated forms. The term ‘solvate’ is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term ‘hydrate’ is employed when the solvent is water.
- Where compounds of the invention exist in one or more geometrical, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and trans-forms, E- and Z-forms, R-, S- and meso-forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis).
- Unless otherwise stated, the compounds of the invention include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds wherein hydrogen is replaced by deuterium or tritium, or wherein carbon is replaced by 13C or 14C, are within the scope of the present invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
- In the context of the present invention, references herein to “treatment” include references to curative, palliative and prophylactic treatment.
- General Methods
- The compounds of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term ‘excipient’ is used herein to describe any ingredient other than the compound(s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
- Compounds of the invention intended for pharmaceutical use may be administered as a solid or liquid, such as a tablet, capsule or solution. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
- Accordingly, the present invention provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
- For the treatment of conditions such as retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema, the compounds of the invention may be administered in a form suitable for injection into the ocular region of a patient, in particular, in a form suitable for intra-vitreal injection. It is envisaged that formulations suitable for such use will take the form of sterile solutions of a compound of the invention in a suitable aqueous vehicle. The compositions may be administered to the patient under the supervision of the attending physician.
- The compounds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, mannitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
- The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- The compounds of the invention can be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solids and liquids (including multiple phases or dispersed systems). Exemplary formulations suitable for oral administration include tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Liquid (including multiple phases and dispersed systems) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
- The formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
- For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.1 mg and 10,000 mg, or between 1 mg and 5000 mg, or between 10 mg and 1000 mg depending, of course, on the mode of administration. If administered by intra-vitreal injection a lower dose of between 0.0001 mg (0.1 μg) and 0.2 mg (200 μg) per eye is envisaged, or between 0.0005 mg (0.5 μg) and 0.05 mg (50 μg) per eye.
- The total dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
- Synthetic Methods
- The compounds of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples provided herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. The examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions, processes and order in which the synthetic steps are performed in the following preparative procedures can be used to prepare these compounds.
- The compounds and intermediates of the invention may be isolated in the form of their pharmaceutically acceptable salts, such as those described previously herein above. The interconversion between free form and salt form would be readily known to those skilled in the art.
- It may be necessary to protect reactive functional groups (e.g. hydroxy, amino, thio or carboxy) in intermediates used in the preparation of compounds of the invention to avoid their unwanted participation in a reaction leading to the formation of the compounds. Conventional protecting groups, for example those described by T. W. Greene and P. G. M. Wuts in “Protective groups in organic chemistry” John Wiley and Sons, 4th Edition, 2006, may be used. For example, a common amino protecting group suitable for use herein is tert-butoxy carbonyl (Boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane. Alternatively the amino protecting group may be a benzyloxycarbonyl (Z) group which can be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere or 9-fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by solutions of secondary organic amines such as diethylamine or piperidine in an organic solvent. Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide. Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively a trichloroethyl ester protecting group is removed with zinc in acetic acid. A common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr, or by stirring with borane tribromide in an organic solvent such as DCM. Alternatively where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.
- Examples of synthetic methods that may be used to prepare 4-carboxyimidazoles are described in EP 1426364 A1 (“Imidazole-derivatives as factor Xa inhibitors”, p 27-28).
- Examples of synthetic methods that may be used to prepare 4-carboxyoxazoles and 5-carboxyoxazoles are described in WO2018011628 (“Preparation of heterocyclic compounds for inhibiting plasma kallikrein”).
- Examples of synthetic methods that may be used to prepare 4-carboxypyrazoles are described in WO2012009009 (“Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors”); also U.S. Pat. No. 3,515,715 (“Quaternized pyrazolylazo dyes”); also WO2016083820 (“Preparation of N-((het)arylmethyl)heteroaryl-carboxamides compounds as plasma kallikrein inhibitors”); also WO2017103611 (“Preparation of pyrazole derivatives as kinase inhibitors”); also WO2014152738 (“Preparation of pyrazolyl-biphenyl compounds as LXR modulators”)
- The compounds according to general formula I can be prepared using conventional synthetic methods for example, but not limited to, the route outlined in Schemes 1a and 1b.
- In both Schemes 1a and 1b, the
halide 1 is reacted with a substitutedheterocycle 2, for example substituted pyrazole as shown in Scheme 1a or substituted imidazole as shown in Scheme 1b, (Step 1A) typically using for example potassium carbonate or cesium carbonate to give ester 3, requiring separation of regioisomers confirming their identity by NOESY NMR. The Boc protecting group is removed (Step 1B) using acidic conditions such as trifluoroacetic acid to giveamine 4. Typically this intermediate would be isolated in the form of the acid salt, for example the trifluoroacetate. Methylation of the amine (Step 1C) may be carried out using standard conditions for such a transformation. Forexample amine 4 is treated with formaldehyde (37% in water) followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 5. Alternative alkylations may be carried out by use of the appropriate alkanone, forexample amine 4 is treated with the alkenone, for example acetone, in an organic solvent such as DCM followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give compound 5. Alternative reducing agents include sodium borohydride and sodium cyanoborohydride. The ester is hydrolysed (Step 1D) using standard literature conditions such as NaOH, KOH, or LiOH. The acid (or salt) 6 is coupled to amine (or salt) 7 (Step 1E) to givecompound 8. This coupling is typically carried out using standard coupling conditions such as hydroxybenzotriazole (HOBt) and carbodiimide such as water soluble carbodiimide in the presence of an organic base. Other standard coupling methods include the reaction of acids with amines in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) or benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoium hexafluorophosphate (PyBOP) or bromo-trispyrolidino-phosphonium hexafluorophosphate (PyBroP) or 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (HATU), or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in the presence of organic bases such as triethylamine, diisopropylethylamine or N-methylmorpholine. Alternatively, the amide formation can take place via an acid chloride in the presence of an organic base. Such acid chlorides can be formed by methods well known in the literature, for example reaction of the acid with oxalyl chloride or thionyl chloride. Alternatively, the carboxylic acid can be activated using 1,1′-carbonyldiimidazole (CDI) and then amine added. - The
halide 1 inScheme 1 above may be prepared from readily available starting materials using methods known in the art, for example as shown inScheme 2. - In
Scheme 2 the alcohol 1-OH may be converted to the chloride 1-CI. Methods for such transformations are known in the art, for example reaction with methanesulfonyl chloride in the presence of a base such as N,N-diisopropylethylamine (DIPEA) in a solvent such as dichloromethane. 4-Dimethylaminopyridine (DMAP) may be added. - Alternatively, Step A can be carried out via in situ sulfonyl transfer (see Jane Panteleev et al., “Alkylation of Nitrogen-Containing Heterocycles via In Situ Sulfonyl Transfer”, Synlett 26(08)), as shown in Scheme 3.
- The pyrazole mesylate 2a is prepared by treating
pyrazole 2 with methanesulfanyl chloride (MsCl) with a base such as triethylamine in a solvent such as dichloromethane. The pyrazole mesylate 2a may then be coupled to the alcohol 1a in the presence of a base such as caesium carbonate in a solvent such as acetonitrile, typically heating to reflux. - The compounds according to general formula I can thus be prepared using conventional synthetic methods for example, but not limited to, the route outlined in
Scheme 4. - The alcohol 1a is reacted with substituted pyrazole mesylate 2a (Step 4A) in the presence of a base such as caesium carbonate in a solvent such as acetonitrile, typically heating to reflux to give ester 3, requiring separation of regioisomers confirming their identity by NOESY NMR. The ester is hydrolysed (Step 4B) using standard literature conditions such as NaOH, KOH, or LiOH. The acid (or salt) 9 is coupled to amine 7 (or salt) (Step 4C) to give compound 10. This coupling is typically carried out using standard coupling conditions such as hydroxybenzotriazole (HOBt) and carbodiimide such as water soluble carbodiimide in the presence of an organic base. Other standard coupling methods include the reaction of acids with amines in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) or benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphoium hexafluorophosphate (PyBOP) or bromo-trispyrolidino-phosphonium hexafluorophosphate (PyBroP) or 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate(V) (HATU), in the presence of organic bases such as triethylamine, diisopropylethylamine or N-methylmorpholine. Alternatively, the amide formation can take place via an acid chloride in the presence of an organic base. Such acid chlorides can be formed by methods well known in the literature, for example reaction of the acid with oxalyl chloride or thionyl chloride. Alternatively, the carboxylic acid can be activated using 1,1′-carbonyldiimidazole (CDI) and then amine added. The Boc protecting group is removed (Step 4D) using acidic conditions such as trifluoroacetic acid or hydrogen chloride to give amine 11. Typically this intermediate would be isolated in the form of the acid salt, for example the trifluoroacetate or the hydrochloride. Alkylation of the amine 11 (Step 4E) may be carried out using standard conditions for such a transformation, for example reductive alkylation. For example, amine 11 is treated with formaldehyde (37% in water) followed by the addition of a reducing agent such as sodium triacetoxyborohydride to give
compound 8. Alternative alkylations may be carried out by use of the appropriate alkanone, for example amine 11 is treated with the alkenone, for example acetone, in an organic solvent such as DCM followed by the addition of a reducing agent such as sodium triacetoxyborohydride to givecompound 8. Alternative reducing agents include sodium borohydride and sodium cyanoborohydride. - The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:
-
aq Aqueous solution AIBN Azobisisobutyronitrile tBu Tert- Butyl CDI 1,1′-Carbonyldiimidazole DCM Dichloromethane DIPEA N,N-Diisopropylethylamine DMF N,N-Dimethylformamide DMSO Dimethyl sulfoxide eq Equivalent Et2O Diethyl ether Et Ethyl EtOH Ethanol EtOAc Ethyl Acetate HATU 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3- tetramethylisouronium hexafluorophosphate(V) hrs Hours HOBt Hydroxybenzotriazole LCMS Liquid chromatography mass spectrometry Me Methyl MeCN Acetonitrile MsCl Methanesulfonyl chloride MeOH Methanol min Minutes MS Mass spectrum Ms Methanesulfonyl NMR Nuclear magnetic resonance spectrum NMP N-Methyl-2-pyrrolidone Pet. Ether Petroleum ether fraction boiling at 60-80° C. Ph Phenyl iPr Iso-propyl nPr n-Propyl SWFI Sterile water for injection rt room temperature TBDMS tert-Butyldimethylsilyl TBME tert-Butyl methyl ether THF Tetrahydrofuran TEA Triethylamine TFA Trifluoroacetic acid - All reactions were carried out under an atmosphere of nitrogen unless specified otherwise.
- 1H NMR spectra were recorded on a Bruker (500 MHz or 400 MHz) spectrometer and reported as chemical shift (ppm).
- Molecular ions were obtained using LCMS with appropriate conditions selected from
-
- Chromolith Speedrod RP-18e column, 50×4.6 mm, with a linear gradient 10% to 90% 0.1% HCO2H/MeCN into 0.1% HCO2H/H2O over 13 min, flow rate 1.5 mL/min;
- Agilent, X-Select, acidic, 5-95% MeCN/water over 4 min. Data was collected using a Thermofinnigan Surveyor MSQ mass spectrometer with electrospray ionisation in conjunction with a Thermofinnigan Surveyor LC system;
- LCMS (Waters Acquity UPLC, C18, Waters X-Bridge UPLC C18, 1.7 μm, 2.1×30 mm, Basic (0.1% Ammonium Bicarbonate) 3 min method;
- LCMS (Agilent, X-Select, Waters X-Select C18, 2.5 μm, 4.6×30 mm, Acidic 4 min method, 95-5 MeCN/water);
- LCMS (Agilent, Basic, Waters X-Bridge C18, 2.5 μm, 4.6×30 mm,
Basic 4 min method, 5-95 MeCN/water; - Acquity UPLC BEH C18 1.7 μM column, 50×2.1 mm, with a linear gradient 10% to 90% 0.1% HCO2H/MeCN into 0.1% HCO2H/H2O over 3 minutes, flow
rate 1 mL/min. Data was collected using a Waters Acquity UPLC mass spectrometer with quadropole dalton, photodiode array and electrospray ionisation detectors.
- Flash chromatography was typically carried out over ‘silica’ (silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Merck silica gel 60)), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution. Alternatively, pre-prepared cartridges of silica gel were used. Reverse phase preparative HPLC purifications were carried out using a Waters 2525 binary gradient pumping system at flow rates of typically 20 mL/min using a Waters 2996 photodiode array detector.
- All solvents and commercial reagents were used as received.
- Chemical names were generated using automated software such as ChemDraw (PerkinElmer) or the Autonom software provided as part of the ISIS Draw package from MDL Information Systems or the Chemaxon software provided as a component of MarvinSketch or as a component of the IDBS E-WorkBook.
-
- To ethyl 3-(1-methoxycyclopropyl)-3-oxopropanoate (reported in WO2015022073) (2.25 g, 11.4 mmol) was added 1,1-dimethoxy-N,N-dimethyl-methanamine (2.3 mL, 17.3 mmol) and stirred at rt for 72 hrs. The mixture was concentrated in vacuo to afford the title compound (2.95 g, quantitative).
-
- To a solution of ethyl (Z)-3-(dimethylamino)-2-(1-methoxycyclopropane-1-carbonyl)acrylate (2.95 g, 11.4 mmol) in EtOH (20 mL) was added hydrazine hydrate (50-60%, 1.2 mL) and the mixture heated at reflux for 2 hrs. The mixture was concentrated in vacuo and the residue purified by flash chromatography (0-100% EtOAc in isohexanes) to afford the title compound (2.01 g, 80%) as a white solid.
- [M+H]+=211.1
- 1H NMR (DMSO-d6) 0.95 (2H, s), 1.07 (2H, s), 1.26 (3H, t, J=7.1 Hz), 3.07 (3H, s), 4.19 (2H, q, J=7.1 Hz), 7.97 (1H, s), 13.45 (1H, s)
-
- A mixture of methyl 5-(4,4,5-trimethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate (115 mg, 0.46 mmol), tert-butyl 7-(chloromethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate (100 mg, 0.36 mmol), K2CO3 (98 mg, 0.71 mmol), 1,4-dioxane (1.5 mL) and water (0.5 mL) were combined and degassed briefly with N2. Tetrakis(triphenylphosphine) palladium (0) (41 mg, 0.04 mmol) was added and the mixture degassed with N2 again and heated to 90° C. for 60 min. The mixture was cooled and stored in a freezer overnight. The mixture was partitioned between EtOAc (20 mL) and saturated NaHCO3(aq) (15 mL). The aqueous layer was extracted with EtOAc and the combined organic layers washed with brine, dried over MgSO4 and concentrated in vacuo to afford the title compound which was used without further purification.
-
- A solution of lithium hydroxide (12 mg, 0.50 mmol) in water (2 mL) was added to a mixture of tert-butyl 7-[(5-methoxycarbonyl-3-pyridyl)methyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate (190 mg, 0.34 mmol) in THE (2 mL) and MeOH (4 mL) and stirred at 50° C. for 20 hrs. The mixture was concentrated in vacuo and the residue azeotroped with toluene. The residue was treated with 1M HCl(aq) (0.75 mL) and again azeotroped with toluene to afford the title compound (200 mg) that was used without further purification.
-
- DIPEA (215 mg, 1.66 mmol) was added to a solution of (2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl)methanamine hydrochloride (97.8 mg, 0.36 mmol), HATU (136 mg, 0.36 mmol) and 5-((2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)nicotinic acid (200 mg, 0.33 mmol) in DCM (2 mL) and NMP (2 mL) and stirred for 20 hrs. The mixture was diluted with EtOAc (30 mL), washed with water and brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (30 to 100% EtOAc/isohexanes and then 0-30% MeOH/EtOAc) afforded the title compound (120 mg, 62%) as a colourless oil.
- 1H NMR (DMSO-d6) 1.42 (9H, s), 2.25 (3H, s), 2.72 (2H, t, J=6.0 Hz), 3.52 (2H, t, J=5.8 Hz), 3.92 (3H, s), 3.95 (2H, s), 4.35 (2H, d, J=4.8 Hz), 4.45 (2H, s), 7.03-7.11 (3H, m), 7.24-7.35 (2H, m), 7.87 (1H, t, J=2.2 Hz), 8.13 (1H, s), 8.60 (1H, d, J=2.1 Hz), 8.67 (1H, d, J=2.1 Hz), 8.77 (1H, t, J=4.9 Hz).
-
- To a solution of tert-butyl 5-(hydroxymethyl)-2,3-dihydro-1H-isoindole-2-carboxylate (0.5 g, 2.0 mmol) in toluene (8 mL) and 1,4-dioxane (8 mL) was added diphenyl phosphorylazide (0.85 mL, 3.9 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.95 mL, 6.4 mmol) whilst cooling in an ice/water bath. The mixture was allowed to warm to rt and stirred overnight. The mixture was partitioned between EtOAc and water and the aqueous layer extracted with EtOAc. The combined organic layers were dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-40% EtOAc in hexane) afforded the title compound which was used without further purification.
- (M-tBu+H)+=219.1
-
- To a solution of tert-butyl 5-(azidomethyl)isoindoline-2-carboxylate (550 mg, 2.0 mmol) in DCM (6 mL) was added methyl prop-2-ynoate (0.2 mL, 2.3 mmol), water (2 mL), CuSO4·H2O (20 mg) and sodium ascorbate (45 mg). The mixture was stirred overnight, separated and the aqueous phase extracted with DCM. The combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-30% EtOAc in hexane) afforded the title compound (284 mg, 39%). Regiochemistry was confirmed by ROSEY NMR experiment.
- 1H NMR (DMSO-d6) 1.45 (9H, s), 3.83 (3H, s), 4.56 (4H, d, J=11.7 Hz), 5.66 (2H, s), 7.27-7.37 (3H, m), 8.88 (1H, d, J=3.6 Hz)
-
- tert-Butyl 5-[(4-methoxycarbonyltriazol-1-yl)methyl]isoindoline-2-carboxylate (284 mg, 0.79 mmol) was added to a mixture of 4M HCl in dioxane (4 mL) and water (4 mL) and stirred for 36 hrs. The mixture was reduced in vacuo to afford the title compound (233 mg, 99%) and used without further purification.
-
- Methyl 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate was prepared from methyl 1-(isoindolin-5-ylmethyl)triazole-4-carboxylate hydrochloride according to General Method B.
-
- Lithium 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate was prepared from methyl 1-[(2-isopropylisoindolin-5-yl)methyl]triazole-4-carboxylate according to procedure L5a.
-
- To a solution of (6-amino-2-fluoro-3-methoxyphenyl)methanol (300 mg, 1.45 mmol) and DIPEA (560 mg, 4.34 mmol) in EtOH (30 mL) at 0° C. was added α,α-dichloroacetone p-toluenesulfonylhydrazone (555 mg, 1.88 mmol) and the reaction mixture stirred at rt for 18 hrs. The solvent was removed in vacuo and the residue dissolved in EtOAc (100 mL), was washed with water (30 mL), brine (30 mL), dried over Na2SO4) and evaporated in vacuo. Flash chromatography (2% MeOH, 98% CHCl3) afforded a white solid identified as the title compound (340 mg, 99%).
- [M+H]+=238.2
-
- [2-Fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methanol (340 mg, 1.43 mmol) was dissolved in DCM (50 mL). To this solution was added phosphorous tribromide (776 mg, 2.87 mmol). The reaction mixture was stirred at rt for 18 hrs and diluted with CHCl3 (100 mL) the filtrate was washed with saturated NaHCO3(aq), water, brine, dried over Na2SO4 and concentrated in vacuo to give the title compound as white solid (430 mg, 100%).
- [M+H]+=302.8
-
- Potassium phthalimide (291 mg, 1.58 mmol) was added to a solution of 1-[2-(bromomethyl)-3-fluoro-4-methoxyphenyl]-4-methyl-1H-1,2,3-triazole (430 mg, 1.43 mmol) in DMF (20 mL). The mixture was stirred at 50° C. for 18 hrs. The mixture was diluted with EtOAc (50 mL), washed with water, brine and dried over Na2SO4 and concentrated in vacuo. Flash chromatography (2% MeOH, 98% CHCl3) afforded the title compound as an orange solid (225 mg, 64%).
- [M+H]+=367.2
-
- A solution of 2-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-2,3-dihydro-1H-isoindole-1,3-dione (220 mg, 0.60 mmol) and hydrazine hydrate (50-60% solution, 0.35 mL) in EtOH (50 mL) was stirred at 80° C. for 60 min and for a further 18 hrs at rt. The resulting solid was filtered off, washed with EtOH and discarded. The filtrate was reduced in vacuo and the residue triturated with EtOAc, filtered off and discarded. The EtOAc filtrate was reduced in vacuo to give the title compound as a yellow oil (130 mg, 92%).
-
- To a solution of 2-fluoro-6-iodo-3-methoxy-benzoic acid (10.0 g, 33.6 mmol) in THE was added 4-methyl morpholine (3.9 mL, 36 mmol) and isobutyl chloroformate (4.4 mL, 34 mmol) dropwise. After 60 min the reaction was filtered and washed with a minimum amount of THE. The filtrate was cooled in an ice-bath and a solution of sodium borohydride (2.0 g, 59 mmol) in cold water (3 mL) was added portion-wise over 20 min. The resulting solution was stirred at rt for 18 hrs. The reaction was acidified with 1M HCl and extracted with TBME. The organic layer was washed sequentially with 2M NaOH(aq), 1M HCl(aq) and brine and dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-40% EtOAc in Hexanes) afforded the title compound (4.9 g, 49% yield).
-
- A mixture of (2-fluoro-6-iodo-3-methoxy-phenyl)methanol (2.0 g, 7.1 mmol), 1H-1,2,4-triazole (1.0 g, 14 mmol), (1S,2S)—N1,N2-dimethylcyclohexane-1,2-diamine (1.5 g, 11 mmol) and copper(I) iodide (96 mg, 0.50 mmol) was dissolved in DMF (12 mL) then treated with caesium carbonate (3.47 g, 10.7 mmol) and degassed with N2, then heated at 120° C. for 60 min. The mixture was diluted with DCM (50 mL) and concentrated. Flash chromatography (0 to 50% MeCN/DCM) afforded the title compound (1.2 g, 58% yield).
- [M+H]+=223.9
-
- A stirred solution of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanol (909 mg, 4.07 mmol) in DCM (25 mL) was treated with TEA (0.91 mL, 6.5 mmol) and cooled in an ice-bath under N2. Methanesulfonyl chloride (0.45 mL, 5.8 mmol) was added slowly then the ice-bath removed and the mixture allowed to warm to rt and stirred for 2 days. The mixture was diluted with DCM (20 mL) and partitioned over saturated NaHCO3(aq). The aqueous layer was extracted with further DCM. The combined organics were washed with brine (30 mL), dried (Na2SO4) and concentrated in vacuo to afford the title compound as a viscous yellow oil (1.0 g, 96% yield).
- [M+H]+=241.9/243.9
-
- Potassium phthalimide (0.868 g, 4.69 mmol) was added to a solution of 1-[2-(chloromethyl)-3-fluoro-4-methoxy-phenyl]-1,2,4-triazole (1.03 g, 4.26 mmol) in DMF (10 mL) and the mixture warmed to 55° C. for 60 min. Water (30 mL) was added to form a thick precipitate which was filtered, washed with water and dried in vacuo in the presence of CaCl2 to afford the title compound (1.12 g, 74% yield) as a white solid.
- [M+H]+=352.9
-
- Hydrazine hydrate (50-60% solution, 0.24 mL) was added to a suspension of 2-[[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl]isoindoline-1,3-dione (1.12 g, 3.18 mmol) in MeOH (15 mL) and the reaction mixture heated to 70° C. for 3 hrs. Further hydrazine hydrate (50-60% solution, 0.2 mL) was added and the mixture heated at 70° C. for 60 min, then at rt overnight. The mixture was filtered and the filtrate concentrated in vacuo. The residue was taken up in TBME (40 mL) and sonicated. DCM (10 mL) was added and the mixture worked to a suspension with stirring and sonication. This was filtered and the filtrate concentrated in vacuo then dried in vacuo overnight to afford the title compound (563 mg, 72% yield) as a pale yellow solid.
- [M+H]+=223.0
-
- To a stirred solution of methyl 6-amino-2-fluoro-3-methoxy-benzoate (607 mg, 3.05 mmol) and N′-(tosyloxy)-acetimidamide (833 mg, 3.65 mmol) (prepared for example according to procedures in EP0795551) in THE (15 mL) was added triethylorthoformate (1.0 mL, 6.0 mmol) followed by ethanesulfonic acid (249 μL, 3.05 mmol). The mixture was sonicated then heated to 60° C. for 2 hrs. The reaction was cooled and concentrated in vacuo. Saturated Na2CO3(aq) and DCM were added to the residue and the mixture stirred vigorously for 15 min. The organic phase was isolated via hydrophobic frit and concentrated in vacuo. Flash chromatography (0-100% EtOAc in hexanes) afforded the title compound (597 mg, 72%) as a pale orange oil.
-
- To a stirred solution of methyl 2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)benzoate (619 mg, 2.33 mmol) in DCM (20 mL) at −78° C. was added diisobutylaluminium hydride (1M in DCM, 5.1 mL, 5.1 mmol) dropwise over 30 min. The solution was warmed to rt and stirred for 2 hrs. Additional diisobutylaluminium hydride (1M in DCM, 0.7 mL, 0.7 mmol) was added slowly and the reaction stirred for 18 hrs. The reaction was quenched with water (0.6 mL), 15% NaOH(aq) (0.6 mL) and further water (1.2 mL) and the mixture stirred for 30 min. The mixture was filtered through Celite rinsing with DCM. The filtrate was dried using a hydrophobic frit and concentrated in vacuo. Flash chromatography (50-100% EtOAc in hexanes) afforded the title compound as a white solid (390 mg, 68%).
- [M+H]+=237.9
-
- To a stirred solution of [2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methanol) in DCM (5 mL) at 0° C. was added phosphorous tribromide (78 μL, 0.83 mmol). The resulting mixture was warmed to rt and stirred for 2 hrs. NaHCO3(aq) (15 mL) was added and extracted with EtOAc. The combined organics were washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography (50-100% EtOAc in hexanes) afforded the title compound as a white solid (96 mg, 19%).
- [M+H]+=299.8/301.8
-
- To a stirred solution of tert-butyl N-tert-butoxycarbonylcarbamate (77 mg, 0.35 mmol) in MeCN (1 mL) was added potassium tert-butoxide (40 mg, 0.36 mmol) and the mixture stirred for 10 min. A solution of 1-[2-(bromomethyl)-3-fluoro-4-methoxy-phenyl]-3-methyl-1,2,4-triazole (96 mg, 0.32 mmol) in MeCN (3 mL) was added to the mixture and the reaction stirred for 18 hrs. Water was added and the mixture extracted with EtOAc (2×10 mL). The combined organic phase was washed with brine (5 mL), dried using a hydrophobic frit and concentrated in vacuo. Flash chromatography (0-100% EtOAc in hexanes) afforded the title compound as a white solid (100 mg, 70% yield).
- [M+Na]+=458.9
-
- A solution of tert-butyl N-tert-butoxycarbonyl-N-[[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl]carbamate (100 mg, 0.23 mmol), in 4M HCl in dioxane (2 mL, 8 mmol) was stirred at rt for 2 hrs. The reaction was concentrated in vacuo to afford the title compound as the hydrochloride salt as a white solid.
-
- To a stirred solution of [2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methanol (483 mg, 2.04 mmol) in DCM (15 mL) and DMF (1.5 mL) was added imidazole (209 mg, 3.08 mmol) followed by tert-butyldimethylsilyl chloride (326 mg, 2.16 mmol). The mixture was stirred at rt overnight then diluted with DCM (20 ml) and water (15 ml). The organic phase was washed with saturated NH4Cl(aq) and brine, then dried via a hydrophobic frit and concentrated in vacuo. Flash chromatography (0-70% EtOAc in hexane) afforded the title compound (640 mg, 89% yield) as a clear, colourless oil which solidified to a white solid on standing.
- [M+H]+=352.0
-
- To a stirred solution of tert-butyl-[[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]-methoxy]-dimethylsilane (440 mg, 1.25 mmol) in THE (7 mL), whilst cooling in a cold bath at −78° C., was added n-butyl lithium (2.5M in hexane) (851 μL, 2.13 mmol) drop-wise and the reaction stirred for 30 min. Iodomethane (101 μL, 1.63 mmol) was added and the mixture allowed to warm to rt. Stirring was continued for 2 hrs. Saturated NH4Cl(aq) was added and extracted with EtOAc. The organics were washed with brine, dried via hydrophobic frit and concentrated in vacuo. Flash chromatography (30-90% EtOAc in hexane) afforded the title compound (366 mg, 71% yield) as a yellow oil.
- [M+H]+=366.0
-
- To a stirred solution of 1-(2-(((tert-butyldimethylsilyl)oxy)methyl)-3-fluoro-4-methoxyphenyl)-3,5-dimethyl-1H-1,2,4-triazole (484 mg, 1.18 mmol) in THE (6 mL) was added HCl (4M in dioxane) (1.3 mL, 5.2 mmol). The mixture was stirred at rt for 3 days. The mixture was concentrated in vacuo, triturated with TBME and filtered. The solid was washed with TBME and dried in vacuo to afford the title compound (275 mg, 93% yield) as a brown solid.
- [M+H]+=251.9
-
- Starting with (6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl)methanol the title compound was synthesised using the methods described for the preparations of 1-[2-(chloromethyl)-3-fluoro-4-methoxy-phenyl]-1,2,4-triazole (R3b), 2-[[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl]isoindoline-1,3-dione (R4b) and [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=251.2
-
- Starting with [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanol the title compound was synthesised using the methods described for the preparation of (6-(3,5-dimethyl-1H-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl)methanamine (R4d).
- [M+H]+=237.0
-
- Starting with 3-(trifluoromethyl)-1H-1,2,4-triazole the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
-
- Starting with 3-(difluoromethyl)-1H-1,2,4-triazole the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=256.1
-
- Starting with N′-(tosyloxy)-propanimidamide (prepared for example according to analogous procedures in European Patent Application no. 97301695.9 (published as EP0795551A1) the title compound was prepared using methods described for the synthesis of (2-fluoro-3-methoxy-6-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl)methanamine (R5c).
- [M+H]+=251.0
-
- Starting with 3-(trifluoromethyl)-1H-pyrazole the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=289.9
-
- Starting with 3-cyclopropyl-1H-pyrazole the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=262.0
-
- Starting with 1H-pyrazole-3-carbonitrile the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=247.0
-
- Starting with 1H-pyrazole-4-carbonitrile the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
-
- 6-Bromo-2-fluoro-3-methoxy-benzoic acid (30.5 g, 123 mmol) was dissolved in MeCN (500 mL). Caesium carbonate (47.9 g, 147 mmol) was added followed by dropwise addition of iodoethane (15.2 mL, 189 mmol). The mixture was stirred at rt for 3 days. The mixture was filtered through Celite, washed with MeCN and concentrated in vacuo. The residue was separated between Et2O (500 mL) and a brine-water mixture (1:2 brine:water, 750 mL). The aqueous phase was extracted with Et2O (250 mL). The combined organics were dried over Na2SO4 and concentrated in vacuo to afford the title compound as an orange oil that solidified on standing (26.8 g, 79% yield).
-
- Ethyl 6-bromo-2-fluoro-3-methoxy-benzoate (10 g, 36 mmol) was dissolved in dioxane (250 mL). tert-Butyl carbamate (4.65 g, 39.7 mmol), 4,5-(bis(diphenylphospheno)-9,9-dimethylxanthene (2.09 g, 3.6 mmol), palladium (II) acetate (810 mg, 3.61 mmol) and caesium carbonate (23.5 g, 72.1 mmol) were added and the mixture was stirred for 18 hrs at 100° C. The mixture was cooled, diluted with EtOAc (250 mL) and filtered through Celite washing with EtOAc (150 mL). The combined filtrates were concentrated in vacuo. Flash chromatography (10% EtOAc, 90% Pet. Ether) afforded the title compound as a colourless oil that solidified on standing (8.45 g, 75% yield).
-
- To ethyl 6-((tert-butoxycarbonyl)amino)-2-fluoro-3-methoxybenzoate (3.99 g, 12.7 mmol) was added 4M HCl in dioxane (50 mL) and the mixture stirred at rt for 6 hrs. The mixture was concentrated in vacuo to afford the HCl salt of the title compound as a beige solid. The solid was dissolved in MeOH and passed over polymer supported carbonate and reduced in vacuo to afford the free base of the title compound as an orange/brown oil (2.83 g, 89% yield).
-
- To ethyl 6-amino-2-fluoro-3-methoxybenzoate (500 mg, 2.35 mmol) in MeCN (50 mL) was added 3-methylbutyl nitrite (472 μL, 3.52 mmol) whilst cooling in an ice/water bath. Trimethylsilyl azide (467 μL, 3.52 mmol) was added dropwise. After 10 min the ice/water bath was removed and the mixture allowed to warm to rt and stirred for 3 hrs. The mixture was cooled in an ice/water bath and a further charge of 3-methylbutyl nitrite (100 μL, 0.74 mmol) and trimethylsilyl azide (100 μL, 0.75 mmol) added. The mixture was stirred at rt for 60 min. The mixture was concentrated in vacuo and the residue taken up in EtOAc, washed with water and brine, dried over MgSO4 and concentrated in vacuo to afford the intermediate azide.
- 1,4-Dioxane (50 mL) was added to the reaction flask containing the intermediate azide which was wrapped in foil to protect the reaction from light exposure. Propargyl alcohol (410 μL, 7.04 mmol), CuI (22 mg, 0.12 mmol) and sodium ascorbate (92 mg, 0.47 mmol) were added and the reaction heated at 80° C. overnight. A further charge of CuI (22 mg, 0.12 mmol) and sodium ascorbate (92 mg, 0.47 mmol) were added and heating continued at 80° C. for 24 hrs. The mixture was partitioned between EtOAc and saturated NH4Cl(aq) and the layers separated. The organic layer was washed with brine, dried over Na2SO4 and concentrated. Flash chromatography (EtOAc/Pet. Ether) afforded the title compound as a beige solid (280 mg, 40%).
- [M+H]+=318.2
-
- A solution of ethyl 2-fluoro-6-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-3-methoxybenzoate (225 mg, 0.76 mmol) in EtOAc (75 mL) was treated with 2-iodoxybenzoic acid (1.42 g, 2.29 mmol) and stirred at vigorous reflux for 4 hrs. Additional 2-iodoxybenzoic acid (50 mg) was added and heating continued for a further 60 min. The mixture was cooled to rt and filtered through Celite, washing with EtOAc. The filtrates were concentrated in vacuo and flash chromatography (EtOAc/Pet. Ether) afforded the title compound as an off white solid, (223 mg, 100%).
- [2M+H]+=587.1
-
- To ethyl 2-fluoro-6-(4-formyl-1H-1,2,3-triazol-1-yl)-3-methoxybenzoate (238 mg, 0.81 mmol) in DCM (5 mL) was added diethylaminosulfur trifluoride (161 IL, 1.22 mmol) and the mixture stirred at rt for 18 hrs. The mixture was poured into 20 mL of an iced solution of NaHCO3(aq) and extracted with DCM. The organic phases were combined and washed with water and brine and dried over MgSO4 and concentrated in vacuo. Flash chromatography (EtOAc/Pet. Ether) afforded the title compound as a pale yellow oil which solidified on standing (178 mg, 70%).
-
- To a stirred solution of ethyl 6-(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-2-fluoro-3-methoxybenzoate (228 mg, 0.72 mmol) in THE (15 mL) was added LiBH4 (32 mg, 1.4 mmol) while cooling in an ice/water bath. The reaction was allowed to warm to 20° C., diluted with water (75 mL) and extracted with EtOAc. The combined organic phases were dried over MgSO4 and concentrated in vacuo. Flash chromatography (Pet. Ether/EtOAc) afforded the title compound as a white crystalline solid (182 mg, 92%).
- [M+H]+=274.1
-
- Starting with (6-(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-2-fluoro-3-methoxyphenyl)methanol the title compound was prepared using methods described for the synthesis of 1-[2-(bromomethyl)-3-fluoro-4-methoxyphenyl]-4-methyl-1H-1,2,3-triazole (R2a).
- [M+H]+=337.9
-
- Starting with 1-(2-(bromomethyl)-3-fluoro-4-methoxyphenyl)-4-(difluoromethyl)-1H-1,2,3-triazole the title compound was prepared using methods described for the synthesis of 2-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-2,3-dihydro-1H-isoindole-1,3-dione (R3a)
- [M+H]+=403.0
-
- Starting with 2-(6-(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-2-fluoro-3-methoxybenzyl)isoindoline-1,3-dione the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=273.1
-
- 1-Chloro-2-fluoro-4-iodo-benzene (5 g, 20 mmol) was dissolved in THE (40 mL) and cooled in a cold bath at −78° C. Lithium diisopropylamide (21 mmol in THE (10 mL)) was added dropwise to the mixture over 30 min and then the reaction stirred for 60 min. Solid CO2 (35 g) was crushed and added to the mixture. The mixture was stirred and allowed to warm to rt overnight. The reaction was concentrated in vacuo, 1M NaOH(aq) was added and washed with TBME. The aqueous phase was acidified with 6M HCl(aq) to
pH 1 and extracted with EtOAc. The EtOAc extracts were washed with brine, dried over MgSO4 and concentrated in vacuo to afford the title compound as an off-white solid (4.8 g, 82%). -
- 3-Chloro-2-fluoro-6-iodo-benzoic acid (1.8 g, 5.99 mmol) was added to a degassed mixture of (1S,2S)—N1,N2-dimethylcyclohexane-1,2-diamine (682 mg, 4.79 mmol), copper(I) iodide (79.5 mg, 0.417 mmol), 3-(difluoromethyl)-1H-1,2,4-triazole (1.43 g, 12 mmol) and caesium carbonate (2.93 g, 8.99 mmol) in anhydrous DMSO (27 mL) and heated to 40° C. for 18 hrs. Saturated NaHCO3(aq) was added and the mixture washed with TBME. The aqueous layer was acidified to
pH 1 with 6NHCl(aq) to form a precipitate which was filtered, washed with water and dried in vacuo over CaCl2 to afford the title compound (927 mg, 48%) as a beige powder. - [M+H]+=292.1/294.1
-
- To a stirred solution of 3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-benzoic acid (927 mg, 3.18 mmol) in THE (15 mL) at rt was added borane THE complex (11.5 mL, 11.5 mmol) dropwise. The mixture was heated at reflux for 2.5 hrs. MeOH (15 mL) was added cautiously followed by 4M HCl in dioxanes (15 mL). The mixture was stirred at rt for 30 min then concentrated in vacuo. DCM and saturated NaHCO3(aq) were added and the layers separated and the aqueous layer further extracted with DCM. The combined organics were washed with 1M HCl(aq) and brine, dried over Na2SO4 and concentrated in vacuo. The residue solidified and was sonicated three times with a 5:1 mixture of Iso-Hexanes/TBME and the supernatant decanted each time to afford the title compound (481 mg, 54% yield) as an off-white solid
- [M+H]+=278.1/280.1
-
- Starting with [3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methanol the title compound was prepared using methods described for the synthesis of 1-[2-(chloromethyl)-3-fluoro-4-methoxy-phenyl]-1,2,4-triazole (R3b).
- [M+H]+=296.1/298.1
-
- Starting with 1-[4-chloro-2-(chloromethyl)-3-fluoro-phenyl]-3-(difluoromethyl)-1,2,4-triazole the title compound was prepared using methods described for the synthesis of 2-[[2-Fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl]isoindoline-1,3-dione (R4b).
- [M+H]+=407.2/409.2
-
- Starting with 2-[[3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methyl]isoindoline-1,3-dione the title compound was prepared using methods described for the synthesis of [2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methanamine (R5b).
- [M+H]+=273.2
-
- Starting with 2-chloro-4-iodo-1-methoxybenzene the title compound was prepared using methods described for the synthesis of [3-Chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl]methanamine (R6m).
-
- Methyl 6-bromo-2-fluoro-3-methoxybenzoate (2.0 g, 7.6 mmol) was dissolved in dioxan (50 mL). tert-Butyl carbamate (980 mg, 8.4 mmol), 4,5-(bis(diphenylphospheno)-9,9-dimethylxanthene (440 mg, 0.76 mmol), palladium (II) acetate (171 mg, 0.76 mmol) and cesium carbonate (4.95 g, 15.2 mmol) were added and the reaction mixture was stirred at 100° C. for 18 hrs after which time the mixture was diluted with EtOAc (100 mL), filtered through Celite and the residue washed with EtOAc. The combined filtrates were evaporated in vacuo. Flash chromatography (10% EtOAc, 90% Pet. Ether) afforded the title compound as a yellow oil which solidified on standing (2.09 g, 92%).
-
- 6-tert-Butoxycarbonylamino-2-fluoro-3-methoxy-benzoic acid methyl ester (480 mg, 1.6 mmol) was dissolved in THE (50 mL) and cooled in an ice/water bath. A 2M solution of lithium borohydride in THE (1.6 mL, 3.21 mmol) was added dropwise. After 18 hrs at rt saturated NH4Cl(aq) was added slowly and the mixture extracted with EtOAc. The combined organic extracts were washed with water and brine, dried over Na2SO4 and evaporated in vacuo. Flash chromatography (60% EtOAc, 40% Pet. Ether) afforded the title compound as a white solid (426 mg, 98%).
- [MH]+=277.7
-
- (3-Fluoro-2-hydroxymethyl-4-methoxy-phenyl)-carbamic acid tert-butyl ester (426 mg, 1.57 mmol) was dissolved in 4M HCl in dioxan (50 mL). After one hour at rt the solvent was removed in vacuo to give the title compound as a white solid (320 mg, 98%).
-
- (6-Amino-2-fluoro-3-methoxy-phenyl)-methanol (320 mg, 1.54 mmol) was dissolved in acetic acid (20 mL). Trimethyl orthoformate (491 mg, 4.62 mmol) and sodium azide (301 mg, 4.62 mmol) were added. The mixture was stirred at rt for 18 hrs after which time the mixture was poured into water (50 mL) and extracted with EtOAc. This solution was washed with water and brine, dried over Na2SO4 and evaporated in vacuo. Flash chromatography (60% EtOAc, 40% Pet. Ether) afforded the title compound as a yellow oil (160 mg, 46%).
- [MH]+=225.2
-
- (2-Fluoro-3-methoxy-6-tetrazol-1-yl-phenyl)-methanol (160 mg, 0.71 mmol) was dissolved in DCM (50 mL). To this solution was added phosphorous tribromide (386 mg, 1.43 mmol). The mixture was stirred at rt for 18 hrs and diluted with CHCl3 (100 mL), washed with saturated NaHCO3(aq), water and brine, dried over Na2SO4 and evaporated in vacuo to give the title compound as a white solid which was used without further purification (204 mg, 100%).
- [M+H+MeCN]+=330.1
-
- 1-(2-Bromomethyl-3-fluoro-4-methoxy-phenyl)-1H-tetrazole (205 mg, 0.71 mmol) was dissolved in DMF (20 mL). Sodium azide (93 mg, 1.43 mmol) was added. The mixture was stirred at rt for 18 hrs after which time the mixture was diluted with EtOAc (100 mL). This solution was washed with water and brine, dried over Na2SO4 and evaporated in vacuo. Flash chromatography (60% Pet Ether, 40% EtOAc) afforded the title compound a white solid (128 mg, 72%).
- [M+H+MeCN]+=291.2
-
- 1-(2-Azidomethyl-3-fluoro-4-methoxy-phenyl)-1H-tetrazole (128 mg, 0.51 mmol) was dissolved in MeOH (40 mL) This solution was hydrogenated over 10% Pd/C (50 mg) at atmospheric pressure for 2 hrs after which time the catalyst was filtered off through Celite and the residue washed with MeOH (100 mL). The combined filtrates were evaporated in vacuo to give a yellow oil identified as 2-fluoro-3-methoxy-6-tetrazol-1-yl-benzylamine (100 mg, 87%).
-
- A solution of tert-butyl 7-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (935 mg, 3.6 mmol) in DCM (20 mL) was cooled in an ice-bath and treated with TEA (0.8 mL, 5.7 mmol) followed by methanesulfonyl chloride (0.40 mL, 5.1 mmol) dropwise. The ice-bath was removed and the mixture stirred at rt overnight. The mixture was diluted with DCM (30 mL) and washed with saturated NaHCO3(aq). The aqueous layer was extracted with DCM and the combined organics washed with brine (30 mL), dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (0 to 40% EtOAc/Iso-Hexanes) to afford the title compound (630 mg, 62%) as a clear viscous oil.
- m/z=226.0/228.0 (M-tBu+H)+
- Tert-Butyl 7-((4-(methoxycarbonyl)-3-(methoxymethyl)-1H-pyrazol-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (L2a)
- A mixture of potassium carbonate (460 mg, 3.33 mmol) in tert-butyl 7-(chloromethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (625 mg, 2.22 mmol) and methyl-3-(methoxymethyl)-1H-pyrazole-4-carboxylate (378 mg, 2.22 mmol) in MeCN (6 mL) was heated to 50° C. overnight. The reaction mixture was cooled to rt and diluted with water. The mixture was extracted with EtOAc and the organic layers washed with brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (0 to 100% EtOAc/Iso-Hexanes afforded the title compound as the second eluting of the two regioisomers (533 mg, 54%).
- [M+H]+=416.2
-
- TFA (1 mL, 13 mmol) was added to a solution of tert-butyl 7-((4-(methoxycarbonyl)-3-(methoxymethyl)-1H-pyrazol-1-yl)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (513 mg, 1.23 mmol) in DCM (4 mL) and the reaction mixture was stirred at rt for 3 hrs. The reaction was diluted with MeCN (10 mL) and purified directly by SCX (˜8 g), washing with MeOH, eluting with 1% NH3/MeOH to afford the title compound (392 mg, 73% yield) as a clear gum.
- [M+H]+=316.2
-
- A mixture of methyl 3-(methoxymethyl)-1-((1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxylate (392 mg, 1.24 mmol), TEA (0.35 mL, 2.51 mmol) and formaldehyde (37% in water) (0.43 mL, 14.3 mmol) in DCM (7.5 mL) was stirred for 30 min at rt. Sodium triacetoxyborohydride (650 mg, 3.07 mmol) was added portionwise and the mixture was stirred for 4 hrs. The reaction mixture was partitioned between DCM and saturated NaHCO3(aq), stirred and separated. The aqueous was further extracted with DCM. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (0 to 10% MeOH (1% NH3)/DCM) afforded the title compound (305 mg, 72%) as a clear gum.
- [M+H]+=330.2
-
- Lithium hydroxide monohydrate (33 mg, 1.4 mmol) was added to a solution of methyl 3-(methoxymethyl)-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxylate (301 mg, 0.91 mmol) in a 4:1 mixture of 1,4-dioxane:water (5 mL). The reaction was heated to 70° C. and stirred for 3 hrs before cooling to rt overnight. Solvent was removed in vacuo and the residue was azeotroped with toluene in order to afford the title compound (242 mg, 76%) as an off-white solid.
- [M+H]+=316.2
-
- To a stirred solution of methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate (10 g, 59 mmol) in DCM (200 mL) at 0° C. was added TEA (11 mL, 79 mmol) followed by methanesulfonyl chloride (5 mL, 64 mmol). The mixture was stirred for 10 min then allowed to warm to rt and stirred for an additional 30 min. The mixture was diluted with DCM (100 mL) and NH4Cl(aq) (100 ml) was added. The aqueous phase was extracted with DCM and the combined organics dried over MgSO4 and concentrated in vacuo to afford the title compound as a mixture of regioisomers (14 g, 95%).
-
- To a stirred suspension of tert-butyl 5-(hydroxymethyl)-2,3-dihydro-1H-isoindole-2-carboxylate (3.5 g, 13 mmol) and methyl 3-(methoxymethyl)-1-(methylsulfonyl)-1H-pyrazole-4-carboxylate (3.49 g, 13.9 mmol) in MeCN (140 mL) was added caesium carbonate (5.35 g, 16.4 mmol). The mixture was stirred at 90° C. for 2 hrs, cooled to rt and partitioned between EtOAc (400 mL) and brine (500 mL). The organic extracts were dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-100% EtOAc in isohexane) afforded the title compound (3.3 g, 55% yield) as a colourless oil.
- [M+H]+=402.3
-
- To a stirred solution of tert-butyl 5-((4-(methoxycarbonyl)-3-(methoxymethyl)-1H-pyrazol-1-yl)methyl)isoindoline-2-carboxylate (1.6 g, 4.0 mmol) in 1,4-dioxane (30 mL) was added lithium hydroxide (0.048 g, 2.0 mmol) in water (20 mL). The mixture was heated at 70° C. overnight. The mixture was cooled to rt and concentrated in vacuo. The residue was diluted with water (50 mL), acidified with 10 wt % aqueous citric acid, extracted into EtOAc, dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-10% MeOH in DCM) afforded the title compound (622 mg, 32% yield) as a white solid.
- [M+H]+=388.3
-
- To a stirred suspension of 1-((2-(tert-butoxycarbonyl)isoindolin-5-yl)methyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxylic acid (612 mg, 1.58 mmol), [2-fluoro-3-methoxy-6-(4-methyltriazol-1-yl)phenyl]methanamine hydrochloride (609 mg, 2.05 mmol) and HATU (781 mg, 2.05 mmol) in DCM/DMF (12 mL, 10:1) was added TEA (881 uL, 6.32 mmol) and stirred at rt overnight. The mixture was diluted with DCM (150 mL), washed with saturated NaHCO3(aq), water and brine (150 mL). The organics were passed through a phase separator and concentrated in vacuo. Flash chromatography (0-5% MeOH in DCM) afforded the title compound (660 mg, 53% yield) as a colourless oil which solidified on standing.
- [M+H]+=606.4
-
- To a stirred solution of tert-butyl 5-((4-((2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)carbamoyl)-3-(methoxymethyl)-1H-pyrazol-1-yl)methyl)isoindoline-2-carboxylate (602 mg, 0.77 mmol) in MeOH (5 mL) was added 4M HCl in 1,4-dioxanes (0.58 mL, 19 mmol). The mixture was stirred at rt for 2 hrs, concentrated in vacuo and azeotroped with toluene. The resulting residue was triturated with Et2O/isohexane, filtered and dried to afford the title compound (460 mg, 100% yield) as a brown solid.
- [M+H]+=506.3
-
- To a stirred solution of 2-tert-butoxycarbonyl-3,4-dihydro-1H-isoquinoline-6-carboxylic acid (500 mg, 1.8 mmol) in anhydrous THE (5 mL) at rt was added borane THE complex (1M, 4.5 mL, 4.5 mmol) dropwise over 5 min. The resulting solution was stirred for 20 hrs. Water (0.4 mL) was added dropwise followed by 2M Na2CO3(aq) (0.6 mL). The mixture was stirred for 30 min. EtOAc (20 mL) was added. The organics were separated from the aqueous sediment. The organics were washed with 1M HCl(aq) and brine, dried (hydrophobic frit), filtered and concentrated in vacuo. Flash chromatography (EtOAc/Pet. Ether) afforded the title compound as a colourless oil (478 mg, 99.7%).
- [(M-tBu)+H]+=208.1
-
- To a stirred solution of tert-butyl 6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (478 mg, 1.82 mmol) in THE (10 mL) in an ice/water bath was added phosphorus tribromide (247 mg, 0.91 mmol) and the mixture allowed to warm to rt and stirred for 3 hrs. The mixture was quenched with saturated NaHCO3(aq) (10 mL) and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography (0-5% EtOAc/hexane) afforded the title compound (234 mg, 39%) as a colourless oil which solidified on standing.
- [(M-tBu)+H]+=270.0/272.0
-
- tert-Butyl 2-chloro-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (890 mg, 3.3 mmol) and 1,1′-bis(diphenylphosphino)ferrocenedichloro palladium(II) dichloromethane complex (130 mg, 0.16 mmol) were dissolved in DMF (45 mL) and MeOH (45 mL) before the addition of TEA (1.3 mL, 9.33 mmol). The resulting solution was purged 3 times with N2 gas then 3 times with CO gas. The mixture was placed under a 4 bar atmosphere of CO, stirred and heated at 90° C. overnight. The mixture was concentrated in vacuo and the residue was diluted with DCM (50 mL) and NaHCO3(aq) (30 mL). The layers were separated and aqueous layer was extracted with DCM. The organic layers were combined, washed with water and brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (0 to 80% EtOAc/Iso-hexanes) gave the title compound (0.86 g, 88%) as a yellow oil which solidified to an orange solid on standing.
- [(M-tBu)+H]+=238.1
-
- 7-(tert-Butyl) 2-methyl 5,8-dihydropyrido[3,4-d]pyrimidine-2,7(6H)-dicarboxylate (240 mg, 0.82 mmol) was dissolved in THE (10 mL) before being cooled in an ice/water bath. Lithium borohydride (0.5 mL, 2 mmol) was added dropwise and the mixture was stirred in an ice/water bath for 1.5 hrs. MeOH (10 mL) was added and the mixture stirred for 30 min (until gas evolution had stopped). The mixture was concentrated in vacuo and the resulting residue was partitioned between EtOAc and brine. The aqueous phase was further extracted with EtOAc and the combined organic phases were dried over MgSO4, filtered and concentrated in vacuo. Flash chromatography (50-100% EtOAc in Hexane) afforded the title compound (75 mg, 28%).
- [(M-tBu)+2H]+=210.2
-
- tert-Butyl 2-(hydroxymethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (75 mg, 0.28 mmol) was dissolved in DCM (3 mL) before the addition of TEA (60 μL, 0.43 mmol) and methanesulfonyl chloride (30 μL, 0.39 mmol). The mixture was stirred at rt for 18 hrs. Another equivalent of both methanesulfonyl chloride (30 μL, 0.39 mmol) and TEA (60 μL, 0.43 mmol) were added and the mixture stirred for a further 24 hrs. The mixture was diluted with DCM (5 mL) and washed with saturated NaHCO3(aq) (5 mL). The aqueous layer was extracted with further DCM and the combined organics washed with brine, dried over MgSO4, filtered and concentrated in vacuo to give the title compound (80 mg, 80%).
- [M+H]+=284.1
-
- To a suspension of 5-chloro-1,2,3,4-tetrahydroisoquinoline-6-ol hydrobromide (2.98 g, 11.3 mmol) in DCM (30 mL) at rt was added TEA (4.8 mL, 34.4 mmol). To this suspension was added di-tert-butyl dicarbonate (2.7 g, 12.4 mmol) and the mixture stirred at rt overnight. The mixture was diluted with DCM (50 mL) and washed with water (30 mL) and brine (30 mL). The organic phase was dried via hydrophobic frit and concentrated in vacuo. Flash chromatography (0-100% EtOAc in hexane) afforded the title compound (955 mg, 28%) as a pale yellow solid.
- [(M-tBu)+H]+=227.9
-
- To a stirred solution of tert-butyl 5-chloro-6-hydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylate
- (955 mg, 3.37 mmol) and TEA (1.4 mL, 10 mmol) in DCM (40 mL) in an ice/water bath was added 1,1,1-trifluoro-N-phenyl-N(trifluoromethylsulfonyl)methanesulfonamide (1.32 g, 3.69 mmol). The mixture was warmed to rt and stirred overnight. The mixture was concentrated in vacuo and the residue purified by flash chromatography (0-10% EtOAc in hexane) to give the title compound (1.46 g, 84%) as a colourless oil.
- [(M-Boc)+H]+=315.8
-
- A solution of tert-butyl 5-chloro-6-(trifluoromethylsulfonyloxy)-3,4-dihydro-1H-isoquinoline-2-carboxylate (2.65 g, 6.37 mmol), 3-diphenylphosphanylpropyl(diphenyl)phosphane (265 mg, 0.64 mmol), DIPEA (4.5 mL, 25.8 mmol) and palladium (II) acetate (145 mg, 0.65 mmol) in a mixture of DMF (100 mL) and MeOH (50 mL) was degassed with N2 gas and charged with CO gas. The resulting mixture was concentrated in vacuo and the residue suspended in MeOH (50 mL) and filtered through Celite. The filtrate was concentrated in vacuo. Flash chromatography (5-30% EtOAc in hexane) afforded the title compound (1.85 g, 86%) as a colourless oil.
- [(M-tBu)+H]+=269.9
-
- To a stirred solution of 2-(tert-butyl) 6-methyl 5-chloro-3,4-dihydroisoquinoline-2,6(1H)-dicarboxylate (50 mg, 0.15 mmol) in a mixture of THF (1 mL), MeOH (1 mL), water (0.5 mL) was added LiOH (35 mg, 1.5 mmol). The mixture was heated at 50° C. for 60 min. The mixture was cooled to rt and concentrated in vacuo. The residue was suspended in EtOAc (15 mL), partitioned with 1M HCl(aq) (10 mL) and separated. The organic phase was washed with additional 1M HCl and brine, dried over MgSO4 and concentrated in vacuo to afford the title compound (53 mg, quantitative) as a colourless oil.
- [(M-tBu)+H]+=255.9
-
- To a stirred solution of 2-(tert-butoxycarbonyl)-5-chloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid (1 g, 3.2 mmol), in THE (40 mL) at rt was added borane THE complex (1M in THF, 7 mL, 7 mmol). The mixture was stirred at rt for 4 hrs. The mixture was carefully quenched with MeOH (20 mL) portion-wise. The resulting solution was concentrated in vacuo to give a colourless gum. Flash chromatography (0-40% EtOAc/hexane) afforded the title compound (949 mg, 97%) as a colourless glass.
- [(M-tBu)+H]+=241.9
-
- tert-Butyl 5-chloro-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (949 mg, 3.19 mmol) was dissolved in DCM (15 mL) and cooled in an ice/water bath. TEA (750 μL, 538 mmol) was added followed by the dropwise addition of methanesulfonyl chloride (30 μL, 0.39 mmol). The mixture was stirred at rt for 18 hrs. The mixture was diluted with DCM (30 mL) and washed with saturated NaHCO3 (aq) (20 mL). The aqueous layer was extracted with further DCM and the combined organics washed with brine (10 mL), dried via a hydrophobic frit and concentrated in vacuo. Flash chromatography (10-40% EtOAc/hexane) afforded the title compound (874 mg, 86%).
- [(M-tBu)+H]+=259.9
-
- To a stirred solution of ethyl imidazo[1,2-a]pyrazine-2-carboxylate (3.5 g, 18.3 mmol) in EtOH (140 mL) was added di-tert-butyl dicarbonate (4.79 g, 22 mmol) and 5% palladium on carbon (1.95 g, 0.92 mmol). The resulting suspension was placed in a high-pressure hydrogenation vessel, flushed with N2 gas then and H2 gas. The vessel was charged with H2 gas (3 Bar) and stirred overnight at rt. The mixture was filtered through Celite, washed with EtOH and concentrated in vacuo to afford the crude product. Flash chromatography (0-100% EtOAc in isohexane) afforded the title compound (2.09 g, 6.84 mmol, 37%) as a white solid.
- [M+H]+=296.3
-
- tert-Butyl 2-(hydroxymethyl)-5,6-dihydroimidazo[1,2-a]pyrazine-7(8H)-carboxylate was synthesised starting with 7-(tert-butyl) 2-ethyl 5,6-dihydroimidazo[1,2-a]pyrazine-2,7(8H)-dicarboxylate and using a similar method to that described for tert-butyl 2-(hydroxymethyl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidine-7-carboxylate (L2d).
-
- Synthesis of tert-butyl 2-(hydroxymethyl)-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazine-7(8H)-carboxylate (CAS 265643-95-6) is reported in WO2000023449.
-
- To a stirred solution of methyl 4-hydroxy-5,6,7,8-tetrahydro-1,7-naphthyridine-3-carboxylate (reported in WO2012027564) (200 mg, 0.96 mmol) in DCM (11 mL) was added TEA (550 μL, 3.95 mmol) and the mixture stirred for 30 min at rt. Formaldehyde solution (37% aq., 338 μL, 11.3 mmol) was added and the mixture stirred for a further 45 min before the addition of sodium triacetoxyborohydride (441 mg, 2.08 mmol). The resulting solution was stirred for 3 hrs. The mixture was quenched with 2.5 M HCl(aq) (0.3 mL), diluted with MeOH (20 mL) and purified directly by SCX, washing with MeOH (5×2 mL), eluting with 1% NH3/MeOH (5×2 mL) to give the title compound (144 mg, 67%) as an orange solid.
- [M+H]+=223.1
-
- Methyl 4-hydroxy-7-methyl-6,8-dihydro-5H-1,7-naphthyridine-3-carboxylate (77 mg, 0.34 mmol) was heated at 80° C. in phosphorus oxychloride (0.5 mL, 5.36 mmol) for 90 min. The mixture was cooled to 0° C., poured into water (3 mL) and stirred for 20 min. The mixture was then basified to pH8 with saturated Na2CO3(aq) and extracted with EtOAc. The combined organic layers were combined, dried over Na2SO4 and concentrated in vacuo to give the title compound (54 mg, 65%) as a brown oil.
- [M+H]+=241.1
-
- To a stirred solution of methyl 4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridine-3-carboxylate (54 mg, 0.22 mmol) in THE (2 mL) in a cold bath at −78° C. was added diisobutylaluminium hydride (1M in THF, 1.62 mL, 1.62 mmol) drop-wise. The resulting solution was stirred for 3 hrs, warmed to rt and stirred for 18 hrs. The mixture was quenched with water (0.1 mL) and 15% NaOH(aq) (0.1 mL). The mixture was gently warmed to melt the aqueous phase and additional water added. The mixture was stirred for 15 min before addition of MgSO4 and the mixture was stirred for 15 min at rt. The mixture was filtered through Celite washing with MeOH. The filtrate was concentrated in vacuo to afford the title compound (47 mg, 99%) as a yellow gum.
- [M+H]+=213.1
-
- Methyl isochromane-6-carboxylate was prepared from 6-bromoisochromane using method L1d.
- [M+H]+=192.1
-
- Isochroman-6-ylmethanol was prepared from methyl isochromane-6-carboxylate using procedure L2d.
- [M+H]+=164.1
-
- tert-Butyl 2-(hydroxymethyl)-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate was prepared from 5-(tert-butyl) 2-
methyl 6,7-dihydropyrazolo[1,5-a]pyrazine-2,5(4H)-dicarboxylate (reported in WO2010024258) using procedure L2d. - [M+H]+=254.1
- 1H NMR (DMSO-d6) 1.44 (9H, s), 3.78 (2H, t, J=5.5 Hz), 4.02 (2H, dd, J=6.4, 4.5 Hz), 4.35 (2H, d, J=5.9 Hz), 4.56 (2H, s), 4.95 (1H, t, J=5.7 Hz), 6.05 (1H, s).
-
- 7-(Hydroxymethyl)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one was prepared from 7-bromo-2-methyl-3,4-dihydroisoquinolin-1(2H)-one according to procedures L1d and L2d.
- [M+H]+=192.1
-
- To an ice-cooled solution of di-tert-butyl 1-(cyanomethyl)pyrazole-3,5-dicarboxylate (5.02 g, 15 mmol) and 1-bromo-2-chloro-ethane (1.56 mL, 18.7 mmol) in anhydrous DMF (40 mL) was added sodium hydride (1.35 g, 33.8 mmol) portionwise over 60 min. The mixture was warmed to rt and stirred for 18 hrs. The mixture was carefully quenched with saturated NH4Cl(aq) (30 mL) and stirred for 20 min before being poured into a mixture of water (500 mL) and EtOAc (500 mL) and stirred for 5 min. The organic layer was collected and the aqueous extracted with EtOAc (250 mL). The combined organics were washed with brine (200 mL), dried over MgSO4and concentrated in vacuo to a brown oil. Flash chromatography (0 to 25% EtOAc/Iso-Hexanes) afforded the title compound (3.6 g, 65%) as a clear gum which crystallized on standing.
- 1H NMR (DMSO-d6) 1.52 (9H, s), 1.59 (9H, s), 1.87-1.94 (2H, m), 1.99-2.05 (2H, m), 7.17 (1H, s).
-
- A solution of di-tert-butyl 1-(1-cyanocyclopropyl)pyrazole-3,5-dicarboxylate (100 mg, 0.3 mmol) in 1.75M ammonia in MeOH (6 mL, 10.5 mmol) was passed through a Ra-Ni CatCart using the H-Cube hydrogenation apparatus (30×4 mm, 30 bar, 50° C., 1 mL/min, 2 passes). The mixture was then stirred at rt. Solvents were removed in vacuo and flash chromatography (0 to 100% EtOAc/Iso-Hexanes) afforded the title compound (48 mg, 60%) as a white solid.
- [(M-t-Bu+H)+H]+=208.2
- 1H NMR (DMSO-d6) 1.15-1.21 (2H, m), 1.41-1.45 (2H, m), 1.51 (9H, s), 3.62 (2H, d, J=2.8 Hz), 7.04 (1H, s), 8.49 (1H, s)
-
- A solution of tert-butyl 4-oxospiro[5,6-dihydropyrazolo[1,5-a]pyrazine-7,1′-cyclopropane]-2-carboxylate (200 mg, 0.76 mmol) in anhydrous THE (6 mL) was treated with sodium hydride (61 mg, 1.53 mmol) in two portions, forming a white precipitate. The mixture was allowed to stir for 20 min, treated with iodomethane (95 IL, 1.53 mmol), heated to 55° C. for 60 min and stirred at rt for 18 hrs. Solvents were removed in vacuo and the residue partitioned between DCM (15 mL) and saturated NaHCO3(aq) (15 mL). The aqueous layer was extracted with further DCM and the combined organics dried over Na2SO4 and concentrated in vacuo. The residue was sonicated with iso-hexanes (10 mL) and filtered to afford the title compound (167 mg, 78%) as a pale yellow solid.
- [(M-t-Bu+H)+H]+=222.2
- 1H NMR (DMSO-d6) 1.19-1.24 (2H, m), 1.41-1.47 (2H, m), 1.51 (9H, s), 3.01 (3H, s), 3.80 (2H, s), 7.03 (1H, s)
-
- To tert-butyl 5-methyl-4-oxo-spiro[6H-pyrazolo[1,5-a]pyrazine-7,1′-cyclopropane]-2-carboxylate (182 mg, 0.66 mmol) in anhydrous THE (10 mL) cooled in an ice/water bath was added lithium aluminium hydride (25 mg, 0.66 mmol) portion-wise over 15 min. The mixture was stirred with ice bath in place for 2 hrs, carefully quenched with water (25 μL), 2M NaOH(aq) (25 μL) and further water (75 μL). MgSO4 was added to the mixture and stirred for 15 min at rt. The mixture was filtered and concentrated in vacuo to afford the title compound (93 mg, 73%).
- [M+H]+=208.1
-
- Synthesis of tert-butyl 2-(hydroxymethyl)-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate is reported in WO2016014463.
-
- Synthesis of tert-butyl 3-(hydroxymethyl)-5,8-dihydro-1,7-naphthyridine-7(6H)-carboxylate is reported in WO2016014463.
-
- To a stirred suspension of 5-bromo-7-fluoro-1,2,3,4-tetrahydroisoquinoline HCl (500 mg, 1.88 mmol) in DCM (5 mL) at rt was added TEA (0.78 mL, 5.6 mmol). To this suspension was added di-tert-butyl dicarbonate (450 mg, 2.06 mmol) and the mixture stirred at rt for 18 hrs. The mixture was diluted with DCM (50 mL) and washed with water (2×25 mL) and brine (25 mL). The organic phase was dried via a hydrophobic frit and concentrated in vacuo. Flash chromatography (0-50% EtOAc in hexane) afforded the title compound (598 mg, 97%) as a colourless oil which solidified on standing.
- [M+H]+=331.8/333.8
-
- A solution of tert-butyl 7-fluoro-5-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (598 mg, 1.81 mmol) and 1,1′-bis(diphenylphosphino)ferrocenedichloro palladium(ii) dichloromethane complex (72 mg, 0.09 mmol) in anhydrous DMF (20 mL) was treated with triethylsilane (580 μL, 3.63 mmol) and then TEA (730 μL, 5.24 mmol). The vessel was sealed and the resulting solution was purged 3 times with N2, then 3 times with CO. The mixture was placed under a 4 bar atmosphere of CO, stirred and heated at 110° C. for 18 hrs. The mixture was filtered through Celite, washed with DCM and the filtrate concentrated in vacuo. The resulting residue was diluted with DCM (20 mL) and NaHCO3(aq) (20 mL) and the layers were separated. The aqueous layer was extracted with DCM (2×50 mL), the organic layers were combined, washed with water, brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (0 to 80% EtOAc/Isohexanes) afforded the title compound (0.86 g, 88%) as a colourless oil.
- [(M-tBu)+H]+=223.9
-
- To a solution of tert-butyl 7-fluoro-5-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (327 mg, 1.17 mmol) in a mixture of THF (8 mL) and MeOH (8 mL) was added NaBH4 (71 mg, 1.88 mmol) and stirred in an ice/water bath for 60 min. Solvents were removed in vacuo and the residue partitioned between EtOAc (50 mL) and water (50 mL). The aqueous was extracted with further EtOAc and the combined organics washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo to afford the title compound (336 mg, 95%) as a clear gum.
- [(M-tBu)+H]+=225.9
- 1H NMR (DMSO-d6) 1.43 (9H, s), 2.62 (2H, t, J=6.3 Hz), 3.55 (2H, t, J=6.0 Hz), 4.42-4.56 (4H, m), 5.25 (1H, t, J=5.4 Hz), 6.93 (1H, dd, J=9.4, 2.7 Hz), 7.06 (1H, dd, J=10.1, 2.8 Hz).
-
- tert-Butyl 5-(chloromethyl)-7-fluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate was prepared from tert-butyl 7-fluoro-5-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate according to procedure L6e.
- [(M-tBu)+H]+=243.9
-
- To a solution of 6-bromo-4,4-difluoro-1,2-dihydroisoquinolin-3-one (3.91 g, 14.9 mmol) in anhydrous THE (50 mL) was added borane tetrahydrofuran complex (75 mL, 75 mmol) dropwise and the mixture stirred at reflux for 2 hrs, cooled to rt and allowed to stir overnight. 1M HCl(aq) (60 mL, 60 mmol) was added carefully dropwise. On completion of the addition, the mixture was heated to reflux for 2 hrs and cooled to rt. The mixture was concentrated to low volume and water (75 mL) was added. The pH was adjusted to pH 10 with 2N NaOH(aq). The aqueous was extracted with EtOAc (3×100 mL). The combined organics were washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo to afford a clear oil. The oil was dissolved in THE (75 mL) and di-tert-butyl dicarbonate (3.26 g, 14.9 mmol) added. The mixture was stirred at rt for 60 min. Solvents were removed in vacuo and flash chromatography (silica, eluent: 0-40% EtOAc/Iso-Hexanes) afforded the title compound (4.79 g, 85%) as a clear gum.
- [(M-tBu-HF)+H]+=272.1/274.1
- 1H NMR (d6-DMSO) 1.43 (9H, s), 4.06 (2H, t, J=11.6 Hz), 4.62 (2H, s), 7.39 (1H, d, J=8.3 Hz), 7.73 (1H, d, J=8.4 Hz), 7.81 (1H, s).
-
- A stainless steel bomb with glass insert was used. A solution of tert-butyl 6-bromo-4,4-difluoro-1,3-
- dihydroisoquinoline-2-carboxylate (4.29 g, 12.3 mmol) and 1,1′-bis(diphenylphosphino) ferrocenedichloropalladium(II) dichloromethane complex (504 mg, 0.62 mmol) in DMF (150 mL) was treated with TEA (5.15 mL, 36.9 mmol) then triethylsilane (3.95 mL, 24.7 mmol). The vessel was sealed, purged with N2 gas (×3) before purging with CO gas (×2) and finally pressurising to 4 bar with CO gas. The mixture was heated at 110° C. with stirring for 18 hrs then left at rt for 3 days. The pressure was released and the vessel purged with N2 gas (×3) prior to opening. The crude mixture was filtered through Celite, washed with DCM and concentrated in vacuo. Flash chromatography (0-70% EtOAc/Iso-Hexanes) afforded the title compound (3.25 g, 80%) as a pale yellow viscous oil.
- [(M-tBu-HF)+H]+=222.1
- 1H NMR (d6-DMSO) 1.44 (9H, s), 4.12 (2H, t, J=11.7 Hz), 4.77 (2H, s), 7.64 (1H, d, J=8.1 Hz), 8.02 (1H, d, J=8.1 Hz), 8.21 (1H, s), 10.06 (1H, s).
-
- A solution of tert-
butyl 4,4-difluoro-6-formyl-1,3-dihydroisoquinoline-2-carboxylate (3.25 g, 10.9 mmol) in MeOH (130 mL) was cooled in an ice-baths. NaBH4 (0.83 g, 21.9 mmol) was added portion wise over 20 min and the mixture allowed to stir for 60 min. Solvents were removed in vacuo and the residue partitioned between EtOAc (50 mL) and water (50 mL). The aqueous was extracted with further EtOAc and the combined organics washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-60% EtOAc/Iso-Hexanes) afforded the title compound (2.48 g, 68%) as a clear gum. - [(M-tBu-HF)+H]+=224.2
- 1H NMR (d6-DMSO) 1.43 (9H, s), 4.01-4.10 (2H, m), 4.53 (2H, d, J=5.6 Hz), 4.63 (2H, s), 5.31 (1H, t, J=5.7 Hz), 7.32 (1H, d, J=8.0 Hz), 7.43 (1H, d, J=8.0 Hz), 7.60 (1H, s).
-
- tert-Butyl 6-(chloromethyl)-4,4-difluoro-1,3-dihydroisoquinoline-2-carboxylate was prepared from tert-
butyl 4,4-difluoro-6-(hydroxymethyl)-1,3-dihydroisoquinoline-2-carboxylate using procedure L3d. - [(M-tBu-HF)+H]+=242.2
- 1H NMR (d6-DMSO) 1.43 (9H, s), 4.07 (2H, t, J=10.9 Hz), 4.66 (2H, s), 4.83 (2H, s), 7.41 (1H, d, J=8.0 Hz), 7.58 (1H, d, J=8.0 Hz), 7.74 (1H, s).
-
- tert-butyl 7-(chloromethyl)-4,4-difluoro-3,4-dihydroisoquinoline-2(1H)-carboxylate was prepared from 7-bromo-4,4-difluoro-1,2-dihydroisoquinolin-3-one according to procedures L1f to L4f.
- [(M-tBu-HF)+H]+=242.2
- 1H NMR (d6-DMSO) 1.43 (9H, s), 4.02-4.12 (2H, m), 4.66 (2H, s), 4.79 (2H, s), 7.46 (1H, s), 7.49 (1H, d, J=8.0 Hz), 7.68 (1H, d, J=8.0 Hz)
-
- NaBH4 (1 g, 26.4 mmol) was dissolved in AcOH (40 mL) and 7-bromo-8-fluoro-isoquinoline (1.95 g, 8.63 mmol) was added and stirred for 60 min. A further portion of NaBH4 (500 mg, 13.2 mmol) was added and the mixture stirred for an additional 2 hrs. The mixture was passed directly into 2M NaOH(aq) (200 mL) and washed in with TBME (100 mL). The layers were separated and the aqueous extracted further with TBME. The combined organic layers were washed with brine, dried over MgSO4 and concentrated in vacuo to provide the title compound (1.31 g, 63%) as a colourless oil.
- [M+H]+=230.1
-
- tert-Butyl 7-bromo-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate was prepared from 7-bromo-8-fluoro-1,2,3,4-tetrahydroisoquinoline according to procedure L1e.
- [(M-tBu)+H]+=274.1
-
- To a solution of tert-butyl 7-bromo-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate (1.05 g, 3.18 mmol) in THE (10.5 mL) in a cold bath at −78° C. was added n-butyllithium in THE solution (1.8M, 2 mL, 3.6 mmol) and the solution stirred for 60 min. DMF (600 IL, 7.8 mmol) was added and the mixture stirred in a cold bath at −78° C. for 30 min. Acetic acid (200 μL, 3.49 mmol) was added and the mixture allowed to warm to rt and stirred overnight. To the mixture was added 1M HCl(aq) (20 mL) and DCM (20 mL) and the phases separated. The organics were concentrated in vacuo. The residue was dissolved in THE (5 mL), MeOH (5 mL) and water (5 mL) and NaBH4 (132 mg, 3.5 mmol) added. On completion of the reaction DCM (5 mL) and 1M HCl (aq) (5 mL) were added and the mixture passed through a phase separator. The organics were collected and concentrated in vacuo. Flash chromatography (10-90% TBME in iso-hexanes) afforded the title compound (322 mg, 34%) as a colourless oil.
- [(M-tBu-OH)+H]+=208.0
- 1H NMR (DMSO-d6,) 1.43 (9H, s), 2.77 (2H, d, J=5.8 Hz), 3.56 (2H, d, J=5.8 Hz), 4.44-4.55 (4H, m), 5.20 (1H, d, J=5.7 Hz), 7.00 (1H, d, J=7.8 Hz), 7.27 (1H, d, J=7.8 Hz).
-
- tert-Butyl 7-(chloromethyl)-8-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate was prepared from tert-butyl 8-fluoro-7-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate according to procedure L3d.
- [(M-tBu)+H]+=244.1
- 1H NMR (DMSO-d6) 1.44 (9H, s), 2.81 (2H, d, J=5.8 Hz), 3.57 (2H, t, J=5.8 Hz), 4.52 (2H, s), 4.77 (2H, s), 7.04 (1H, d, J=7.8 Hz), 7.35 (1H, t, J=7.8 Hz).
-
- A suspension of 2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethanol hydrochloride (1 g, 4.6 mmol) in DCM (20 mL) was treated with DIPEA (1 mL, 5.73 mmol). To the stirred solution was added di-tert-butyl dicarbonate (1.2 g, 5.50 mmol). The solvent was removed in vacuo and flash chromatography (0-50% TBME in isohexanes) afforded the title compound (1.3 g, 82%) as a colourless oil.
- [M−H]−=278.3
- 1H NMR (CDCl3) 1.41 (9H, s), 3.80 (2H, t, J=4.4 Hz), 3.98-4.06 (2H, m), 4.45 (2H, m), 4.64 (2H, s), 7.04 (1H, d, J=8.0 Hz), 7.20 (2H, s).
-
- Synthesis of tert-butyl 2-(hydroxymethyl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate (CAS 1190971-76-6) is reported in WO2009124746.
-
- To a stirred solution of 2-(3-bromo-2-fluoro-phenyl)ethanamine (6.2 g, 11.7 mmol) in DCM (27 mL) was added TEA (2.7 mL, 19 mmol). The mixture was cooled in an ice/water bath and trifluoroacetic anhydride (3.1 mL, 22 mmol) slowly added. The mixture was warmed to rt and stirred for 90 min. TEA (1 mL, 7.2 mmol) and trifluoroacetic anhydride (1 mL, 7.1 mmol) were added. The mixture was stirred for 2 hrs, diluted with DCM (100 mL) and washed with saturated NaHCO3(aq), NH4Cl(aq) and brine. The organic layer was dried over MgSO4 and concentrated in vacuo. Flash chromatography (EtOAc:Hexane 0-30%) afforded the title compound (2.5 g, 59%) as a white solid.
- [M+H]+=330.8/332.8
-
- Paraformaldehyde (0.252 g, 8.39 mmol) was added to a solution of N-[2-(3-bromo-2-fluoro-phenyl)ethyl]-2,2,2-trifluoro-acetamide (1.5 g, 4.8 mmol) in AcOH (9 mL). Sulfuric acid (6 mL 113 mmol) was added dropwise and the mixture heated at 50° C. for 5 hrs and at rt overnight. The mixture was cooled to rt and partitioned between EtOAc (50 mL) and water (30 mL). The aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (EtOAc:Hexane 0-30%) afforded the title compound (1.43 g, 85%) as a colourless oil that solidified upon standing.
- [M+H]+=325.6/327.7
-
- Water (3 mL) was added to a suspension of Na2CO3 (0.53 g, 5 mmol) and 1-(6-bromo-5-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,2,2-trifluoro-ethanone (1.46 g, 4.16 mmol) in MeOH (6 mL). The mixture was stirred at rt for 3 hrs. The mixture was concentrated in vacuo to remove MeOH and diluted with EtOAc (10 mL) and water (5 mL). The organic layer was separated and the aqueous phase was extracted with EtOAc. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo to give the title compound (0.96 g, 99%) as a yellow oil.
- [M+H]+=229.9/231.9
-
- TEA (646 uL, 4.63 mmol) was added to a suspension of 6-bromo-5-fluoro-1,2,3,4-tetrahydroisoquinoline (0.964 g, 4.15 mmol) and di-tert-butyl dicarbonate (1.81 g, 8.3 mmol) in THE (24 mL). The mixture was stirred at rt overnight. The mixture was diluted with EtOAc (30 mL) and water (20 mL). The organic layer was separated, the aqueous layer was extracted with EtOAc and the organic layers were combined, dried over Na2SO4 and concentrated in vacuo to give a colourless oil. Flash chromatography (0-40% EtOAc in hexane) afforded the title compound (1.17 g, 84%) as a colourless oil.
- [M+H]+=331.8/333.8
-
- A stirred solution of tert-butyl 6-bromo-5-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate (880 mg, 2.67 mmol) in THE (15 mL) was cooled in a cold bath at −78° C. “BuLi in THE solution (1.5 mL, 2.5M, 3.75 mmol) was added dropwise over 15 min and the mixture stirred for 30 min. DMF (0.5 mL, 6.46 mmol) was added. The mixture was slowly warmed to rt and 5% citric acid (aq) solution (1 mL) was added. The mixture was extracted with TBME (100 mL) and the organic layer washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-20 TBME/isohexane) afforded the title compound (230 mg, 29%) as a colourless solid
- 1H NMR (CDCl3) 1.48 (9H, s), 2.86 (2H, t, J=6.0 Hz), 3.69 (2H, t, J=5.9 Hz), 4.63 (2H, s),
- 6.81-7.04 (1H, m), 7.69 (1H, t, J=7.4 Hz), 10.33 (1H, s).
-
- A stirred solution of tert-butyl 5-fluoro-6-formyl-3,4-dihydro-1H-isoquinoline-2-carboxylate (230 mg, 0.82 mmol) in EtOH (10 mL) was treated with NaBH4 (31.2 mg, 0.82 mmol) and stirring continued for 30 min. Brine (20 mL) was added and 5% citric acid (aq) (1 mL). The mixture was extracted with EtOAc and the combined organic layers were dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-50% EtOAc/isohexanes) afforded the title compound (190 mg, 78%) as a colourless oil.
- 1H NMR (CDCl3) 1.51 (9H, s), 2.83 (2H, t, J=6.0 Hz), 3.67 (2H, t, J=5.9 Hz), 4.59 (2H, s), 4.75 (2H, s), 6.93 (1H, t, J=7.9 Hz), 7.25 (1H, t, J=7.6 Hz).
-
- Synthesis of tert-butyl 8-fluoro-6-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate is reported in WO2016014463.
-
- To 3-bromo-4-fluoro-benzaldehyde (5 g, 25 mmol) in toluene (25 mL) was added 2,2-dimethoxyethanamine (3 mL, 28 mmol) and the mixture stirred at rt. On completion of the reaction the mixture was concentrated in vacuo and the residue dissolved in MeOH (25 mL). NaBH4 (1.1 g, 29 mmol) added portion wise. The mixture was stirred at rt for 2 hrs. Water (15 mL) was added and the volatile organics removed in vacuo. The resulting aqueous solution was extracted with EtOAc and the combined organic extracts dried over MgSO4 and concentrated in vacuo to give the title compound (7.2 g, 100%).
-
- Pyridine (2.14 mL, 26.5 mmol) was added to a solution of N-[(3-bromo-4-fluoro-phenyl)methyl]-2,2-dimethoxyethanamine (7.2 g, 24.6 mmol) and p-toluenesulfonyl chloride (5.45 g, 28.6 mmol) in DCM (80 mL). The mixture was stirred at rt for 18 hrs, diluted with DCM (200 mL) and water (100 mL). The organic phase was separated and the aqueous phase extracted with DCM (200 mL). The combined organic phases were washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (50-100% EtOAc in hexane) afforded the tile compound (9 g, 81%) as a colourless oil.
- [(M−2CH3)+H]+=413.8/415.8
- 1H NMR (DMSO-d6) 2.41 (3H, s), 3.12 (6H, s), 3.17 (2H, d, J=5.3 Hz), 4.28 (1H, t, J=5.3 Hz), 4.34 (2H, s), 7.31-7.37 (2H, m), 7.41-7.45 (2H, m), 7.47-7.50 (1H, m), 7.72-7.77 (2H, m).
-
- N-[3-Bromo-4-fluoro-phenyl)methyl]-N-(2,2-dimethoxyethyl)-4-methyl-benzenesulfonamide (9 g, 20 mmol) in DCM (160 mL) was treated with trichloroalumane (10.7 g, 80.2 mmol) and the mixture stirred at rt for 2 days. The mixture was slowly poured into a mixture of 2N NaOH (aq) (200 mL) and ice (200 g), diluted with DCM (300 mL) and the organic phase collected, dried over MgSO4 and concentrated in vacuo. Flash chromatography (0-100% EtOAc in isohexanes) afforded the title compound (3 g, 55%) as an orange solid.
- [M+H]+=225.8/227.8
-
- NaBH4 (2.5 g, 66 mmol) was added portion wise to AcOH (300 mL) at rt. 7-Bromo-6-fluoro-isoquinoline (7.4 g, 32.7 mmol) was added and the mixture stirred at rt for 60 min. Additional NaBH4 (2.5 g, 66.1 mmol) was added and the mixture stirred for a further 60 min. Additional NaBH4 (0.25 g, 6.61 mmol) and the mixture stirred for a further 60 min. The mixture was quenched into water (300 mL) and TBME (600 mL) added. The layers were separated, and the aqueous layer extracted further with TBME. The organic layers were concentrated in vacuo and taken up in EtOAc (200 mL). The combined aqueous phases were basified to pH 10 using NaOH and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated in vacuo to give the title compound (6.4 g, 78%).
- [M+H]+=230.0/232.1
-
- TEA (6.1 mL, 43.8 mmol) was added to a suspension of di-tert-butyl dicarbonate (14 g, 64.1 mmol) and 7-bromo-6-fluoro-1,2,3,4-tetrahydroisoquinoline (6.4 g, 25.6 mmol) in THE (150 mL). The mixture was stirred at rt overnight and diluted with EtOAc (200 mL) and water (100 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (0-20% EtOAc in hexane) afforded the title compound (8.35 g, 83%) as a white solid.
- [(M-tBu)+H]+=273.9/275.9
- 1H NMR (DMSO-d6) 1.42 (9H, s), 2.74 (2H, t, J=6.0 Hz), 3.52 (2H, t, J=5.9 Hz), 4.42-4.49 (2H, m), 7.20 (1H, d, J=9.6 Hz), 7.57 (1H, d, J=7.1 Hz).
-
- 2-(tert-Butyl) 7-methyl 6-fluoro-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate was prepared from tert-butyl 7-bromo-6-fluoro-3,4-dihydro-1H-isoquinoline-2-carboxylate according to procedure L1d.
- [(M-tBu)+H]+=254.0
-
- tert-Butyl 6-fluoro-7-(hydroxymethyl)-3,4-dihydro-(1H)-isoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-methyl 6-fluoro-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d.
- [(M-tBu-OH)+H]+=208.0
-
- To a suspension of methyl 3-(methoxymethyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-ylmethyl)pyrazole-4-carboxylate hydrochloride (600 mg, 1.71 mmol) and K2CO3 (707 mg, 5.12 mmol) in EtOH (6 mL) was added trideuterio(iodo)methane (0.13 mL, 2.13 mmol). The mixture was stirred at rt overnight, concentrated in vacuo and partitioned between DCM (30 mL) and brine (30 mL). The organic layer was passed through a phase separator and concentrated in vacuo. Flash chromatography (0-10% MeOH in DCM) afforded the title compound (130 mg, 21%) as an orange oil.
- [M+H]+=333.3
- 1H NMR (DMSO-d6) 2.55-2.60 (2H, m), 2.75-2.80 (2H, m), 3.23 (3H, s), 3.45 (2H, s), 3.72 (3H, s), 4.50 (2H, s), 5.25 (2H, s), 6.94-6.98 (1H, m), 7.01-7.05 (1H, m), 7.06-7.09 (1H, m), 8.38 (1H, s).
-
- To a solution of pyrrolidine-2,5-dione (2.24 g, 22.6 mmol) in DMF (39.5 mL) was added NaH (1.00 g, 24.9 mmol) portion wise at rt. The mixture was stirred for 60 min and a solution of 1-bromo-4-(2-bromoethyl)benzene (6.59 g, 25 mmol) in DMF (13 mL) was added dropwise. The mixture was heated at 50° C. for 2 hrs and cooled in an ice-bath. EtOAc (100 mL) and brine (60 mL) were added and the mixture was stirred for 30 min and partitioned. The organic layer was washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was slurried in TBME (40 mL) overnight. The mixture was filtered and air-dried to afford the title compound (4.78 g, 74%) as a white solid.
- [M+H]+=281.9/283.9
-
- 1-[2-(4-bromophenyl)ethyl]pyrrolidine-2,5-dione (1 g, 3.54 mmol) was dissolved in EtOH (125 mL) and water (10 mL) and the solution cooled in an ice-bath. NaBH4 (805 mg, 21.3 mmol) was added and the mixture stirred. HCl (aq) (6M) was added dropwise at 10 min intervals so as to keep the pH value at 8-10 (1-2 drops every 10-20 min). After 2.25 hrs the pH value was adjusted to 4 with 6M (aq) HCl and the mixture poured into water (300 mL). This was extracted with DCM and the combined organics dried over MgSO4, filtered and concentrated in vacuo to afford the title compound (972 mg, 87%) as a white solid.
- [M+H]+=284.0/286.0
-
- 1-[2-(4-Bromophenyl)ethyl]-5-hydroxy-pyrrolidin-2-one (1010 mg, 3.54 mmol) was suspended in DCM (6 mL) and cooled in an ice-bath. Trifluoromethanesulfonic acid (0.63 mL, 7.08 mmol) was added and the mixture stirred at rt overnight. The mixture was diluted with DCM (25 mL) and partitioned over saturated NaHCO3(aq) (30 mL). The aqueous layer was extracted with further DCM and the combined organics dried over Na2SO4 and concentrated in vacuo to afford a clear oil. Flash chromatography (40-100% EtOAc/Iso-Hexanes) afforded the title compound (790 mg, 83%) as a clear oil which crystallized on standing.
- [M+H]+=266.1/268.1
- 1H NMR (DMSO-d6) 1.69 (1H, ddt, J=12.2, 10.9, 9.2 Hz), 2.26 (1H, ddd, J=16.4, 9.4, 1.9 Hz), 2.40-2.48 (1H, m), 2.66-2.81 (3H, m), 2.99 (1H, dddd, J=12.6, 10.8, 4.9, 1.3 Hz), 4.02 (1H, ddd, J=12.9, 6.1, 2.7 Hz), 4.75 (1H, t, J=8.1 Hz), 7.15 (1H, d, J=8.2 Hz), 7.38 (1H, dd, J=8.2, 2.1 Hz), 7.43 (1H, d, J=2.1 Hz)
-
- Methyl 3-oxo-2,5,6,10b-tetrahydro-1H-pyrrolo[2,1-a]isoquinoline-9-carboxylate was prepared from 9-bromo-2,5,6,10b-tetrahydro-1H-pyrrolo[2,1-a]isoquinolin-3-one according to procedure L1d.
- 1H NMR (DMSO-d6) 1.70 (1H, ddt, J=12.2, 11.1, 9.3 Hz), 2.27 (1H, ddd, J=16.4, 9.4, 1.9 Hz), 2.42-2.49 (1H, m), 2.73-2.78 (1H, m), 2.78-2.88 (2H, m), 3.04 (1H, dddd, J=12.6, 10.5, 5.0, 1.3 Hz), 3.85 (3H, s), 4.04 (1H, ddd, J=12.8, 6.0, 2.8 Hz), 4.81 (1H, t, J=8.1 Hz), 7.33 (1H, d, J=8.5 Hz), 7.73-7.81 (2H, m)
-
- A solution of methyl 3-oxo-2,5,6,10b-tetrahydro-1H-pyrrolo[2,1-a]isoquinoline-9-carboxylate (200 mg, 0.69 mmol) in THE (4 mL) was cooled in an ice/water bath prior to the addition of a 1M THE solution of LiAlH4 (3.2 mL, 3.2 mmol) dropwise. The mixture was warmed to rt for 1.5 hrs then cooled in an ice/water bath. A mixture of sodium sulfate decahydrate and Celite was added portion wise and the mixture stirred for 10 min. 1 to 2 drops of water were added cautiously followed by THE (10 mL) and further Celite mixture. This was stirred in an ice/water bath for 60 min then filtered washing with copious THE. Concentration in vacuo gave the title compound (167 mg, 98%) as a brown oil.
- [M+H]+=204.1
- 1H NMR (DMSO-d6) 1.53 (1H, dtd, J=11.8, 10.3, 7.5 Hz), 1.72-1.83 (2H, m), 2.29 (1H, tdd, J=11.5, 5.5, 3.3 Hz), 2.37 (1H, q, J=8.6 Hz), 2.46 (1H, dt, J=10.7, 5.3 Hz), 2.66-2.76 (1H, m), 2.87-3.02 (2H, m), 3.08 (1H, ddd, J=11.1, 6.3, 2.9 Hz), 3.25 (1H, dd, J=9.8, 7.0 Hz), 4.43 (2H, d, J=5.7 Hz), 5.07 (1H, t, J=5.7 Hz), 6.98-7.08 (3H, m).
-
- Synthesis of tert-butyl 7-(hydroxymethyl)-1,2,4,5-tetrahydro-3H-benzo[d]azepine-3-carboxylate is reported in WO2017068412.
-
- To a thick walled pressure vessel was added methyl 6-oxopyran-3-carboxylate (1 g, 6.49 mmol) and trimethyl(2-trimethylsilylethynyl)silane (3320 mg, 19.5 mmol). The vessel was sealed and the mixture heated to 200° C. overnight with stirring. The mixture was cooled and absorbed directly onto silica and purified by flash chromatography (0-30% EtOAc in hexane) to afford the title compound (1.76 g) as a colourless viscous oil.
- [M+H]+=281.1
- 1H NMR (DMSO-d6) 0.37 (18H, t, J=1.7 Hz), 3.86 (3H, s), 7.80 (1H, d, J=7.8 Hz), 7.90 (1H, dd, J=7.9, 1.8 Hz), 8.20 (1H, d, J=1.8 Hz).
-
- To phenyl-3-iodanediyl diacetate (2.1 g, 6.52 mmol) dissolved in DCM (30 mL) in an ice/water bath was added trifluoromethanesulfonic acid (1.3 mL, 12.3 mmol) dropwise over 20 min. The mixture was stirred for 30 min and left to warm to rt. The mixture was again cooled in an ice/water bath and a solution of methyl 3,4-bis(trimethylsilyl)benzoate (1.76 g, 6.27 mmol) in DCM (3 mL) added. The mixture was left to warm to rt and stirred overnight. The volatiles were removed, and the residue triturated and sonicated with TBME (10 mL) to give the title compound (1.7 gl, 48%) as a white solid.
- 1H NMR (DMSO-d6) 0.38 (9H, s), 3.93 (3H, s), 7.54 (2H, dd, J=8.4, 7.0 Hz), 7.60-7.66 (1H, m), 7.91 (1H, d, J=7.8 Hz), 7.93-7.98 (2H, m), 8.23 (1H, dd, J=7.7, 1.6 Hz), 9.08 (1H, d, J=1.6 Hz).
-
- (4-Methoxycarbonyl-2-trimethylsilyl-phenyl)-phenyl-iodium; trifluoromethanesulfonate (1.7 g, 3.03 mmol) was dissolved in DCM (30 mL) and cooled in an ice/water bath. A solution of tert-butyl pyrrole-1-carboxylate (1.7 mL, 10.2 mmol) in THE (4 mL) was added dropwise over 10 min, followed by the addition of tetra-n-butylammonium fluoride solution (1M in THF, 4 mL, 4 mmol). The mixture was stirred for a further 20 min. The mixture was partitioned between water (20 mL) and DCM (20 mL). The aqueous layer extracted with further DCM and the combined organic layers dried over MgSO4. Flash chromatography (dry loaded, 0-10% EtOAc in hexane) afforded the title compound (852 mg, 44%) as a mixture of enantiomers.
- 1H NMR (DMSO-d6) 1.31 (9H, s), 3.82 (3H, s), 5.55 (2H, dd, J=11.4, 1.9 Hz), 7.07 (2H, s), 7.46 (1H, d, J=7.5 Hz), 7.66 (1H, dd, J=7.5, 1.5 Hz), 7.83-7.89 (1H, m)
-
- 9-(tert-Butyl) 6-methyl-1,4-dihydro-1,4-epiminonaphthalene-6,9-dicarboxylate (852 mg, 1.34 mmol) was dissolved in EtOH (10 mL) before addition of Pd/C (120 mg, 1.13 mmol). The hydrogenation
- vessel was sealed and placed under a H2 gas atmosphere and pressure of 55 psi. The mixture was stirred overnight at rt, filtered through Celite and the filtrate concentrated in vacuo to afford the title compound (687 mg, 79%).
- [(M-Boc)+H]+=204.1
- 1H NMR (DMSO-d6) 1.15-1.25 (2H, m), 1.33 (9H, s), 2.04 (2H, dd, J=9.7, 3.0 Hz), 3.84 (3H, s), 5.14 (2H, dd, J=12.2, 3.5 Hz), 7.47 (1H, d, J=7.7 Hz), 7.82 (1H, dd, J=7.6, 1.5 Hz), 7.90 (1H, d, J=1.5 Hz)
-
- tert-Butyl 6-(hydroxymethyl)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene-9-carboxylate was prepared from 9-(tert-butyl) 6-methyl-1,2,3,4-tetrahydro-1,4-epiminonaphthalene-6,9-dicarboxylate according to procedure L2d.
- [(M-Boc)+H]+=176.1
-
- A suspension of sodium hydride (128 mg, 3.2 mmol) and tetrabutylammonium iodide (250 mg, 0.68 mmol) in THE (20 mL) was stirred at rt and a fine suspension of 5-bromoisoindolin-1-one (675 mg, 3.18 mmol) in a mixture of THF (20 mL) and DMF (4 mL) was added. The mixture was left at rt for 15 min, iodomethane (0.198 mL, 3.18 mmol) added and stirring continued for 30 min. Sodium hydride (637 mg, 15.9 mmol) was added portion wise and the mixture stirred for 25 min. Iodomethane (1.19 mL, 19.1 mmol) was added dropwise and stirred for 10 min, heated to reflux for 30 min and stirred at rt overnight. The mixture was cooled in an ice-bath and carefully quenched with saturated NH4Cl(aq) (40 mL). The mixture was extracted with EtOAc and the combined organic layers washed with brine, dried over MgSO4 and concentrated in vacuo. The residue was treated with iso-hexanes and decanted (×3) Flash chromatography (0 to 60% EtOAc/Iso-Hexanes) afforded the title compound (224 mg, 27%).
- [M+H]+=254.0/256.0
- 1H NMR (DMSO-d6) 1.43 (6H, s), 2.90 (3H, s), 7.58 (1H, d, J=8.0 Hz), 7.65 (1H, dd, J=8.0, 1.7 Hz), 8.03 (1H, d, J=1.7 Hz)
-
-
Methyl 2,3,3-trimethyl-1-oxo-isoindoline-5-carboxylate was prepared from 5-bromo-2,3,3-trimethyl-isoindolin-1-one according to procedure L1d. - [M+H]+=234.2
- 1H NMR (DMSO-d6) 1.47 (6H, s), 2.95 (3H, s), 3.90 (3H, s), 7.78 (1H, dd, J=7.9, 0.7 Hz), 8.05 (1H, dd, J=7.9, 1.4 Hz), 8.27 (1H, dd, J=1.5, 0.7 Hz).
-
- A solution of
methyl 2,3,3-trimethyl-1-oxo-isoindoline-5-carboxylate (161 mg, 0.69 mmol) in THE (4 mL) was cooled in an ice-bath. A 1M THE solution of LiAlH4 (3.2 mL, 3.2 mmol) was added dropwise. The mixture was warmed to rt for 1.5 hrs and cooled in an ice bath. A mixture of sodium sulfate decahydrate and Celite was added portion wise and the mixture stirred for 10 min. 1 to 2 drops of water were added cautiously and the mixture was diluted with THE (10 mL) and stirred for 60 min. The mixture was filtered, washing with copious THE and concentrated in vacuo. Flash chromatography (1-12% MeOH (1% NH3)/DCM) afforded the title compound (72 mg, 53%) as a pale pink oil. - [M+H]+=192.2
- 1H NMR (DMSO-d6) 1.17 (6H, s), 2.35 (3H, s), 3.79 (2H, s), 4.47 (2H, d, J=5.8 Hz), 5.11 (1H, t, J=5.7 Hz), 7.07-7.16 (3H, m)
-
- To a stirred solution of [1-(4-bromophenyl)cyclopropyl]methanamine (1.07 g, 4.73 mmol) in DCM (8 mL) was added TEA (0.79 mL, 5.68 mmol). The mixture was cooled in an ice/water bath and treated dropwise with trifluoroacetic anhydride (0.80 mL, 5.68 mmol). The mixture was warmed to rt and stirred for 2 hrs then left in at −20° C. for 48 hrs. The mixture was diluted with DCM (20 mL) and washed with saturated NaHCO3(aq), saturated NH4Cl(aq) and brine, dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.35 g, 88%) as a white solid.
- [M+H]+=320.2/322.0
- 1H NMR (DMSO-d6) 0.72-0.82 (2H, m), 0.89-0.98 (2H, m), 3.40 (2H, d, J=5.6 Hz), 7.22 (2H, d, J=8.5 Hz), 7.46 (2H, d, J=8.5 Hz), 9.44 (1H, t, J=5.1 Hz)
-
- Paraformaldehyde (220 mg, 7.33 mmol) was added to a solution of N-[[1-(4-bromophenyl) cyclopropyl]methyl]-2,2,2-trifluoro-acetamide (1.34 g, 4.16 mmol) in acetic acid (9 mL). Sulfuric acid (5.2 mL, 97.6 mmol) was added dropwise and the mixture was heated at 50° C. for 5 h and stirred at rt overnight. The mixture was poured into a mixture of EtOAc (50 mL) and water (40 mL). The aqueous layer was extracted with EtOAc and the combined organics washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography (0 to 30% EtOAc/Iso-Hexanes) afforded the title compound (436 mg, 31%) as a clear oil which crystallized on standing.
- [M+H]+=334.0/336.0
- 1H NMR (DMSO-d6) 0.99-1.09 (4H, m), 3.67 (2H, d, J=12.4 Hz), 4.89 (2H, d, J=13.9 Hz), 6.83 (1H, dd, J=8.5, 2.5 Hz), 7.38 (1H, ddd, J=8.3, 5.8, 2.2 Hz), 7.49-7.60 (1H, m)
-
- A suspension of 1-(7-bromospiro[1,3-dihydroisoquinoline-4,1′-cyclopropane]-2-yl)-2,2,2-trifluoro-ethanone (432 mg, 1.29 mmol) and Na2CO3 (165 mg, 1.56 mmol) in a mixture of MeOH (2 mL) and water (1 mL) was heated at 40° C. for 6 hrs. Heating was discontinued and the mixture left at rt overnight. MeOH was removed in vacuo. The residue was partitioned between EtOAc (10 mL) and water (10 mL). The aqueous layer was extracted with EtOAc and the combined organics washed with brine, dried over MgSO4 and concentrated in vacuo to afford the title compound (271 mg, 87%) as a clear oil which solidified on standing.
- [M+H]+=238.0/240.0
- 1H NMR (DMSO-d6) 0.79-0.83 (2H, m), 0.87-0.92 (2H, m), 2.63 (1H, s), 2.72 (2H, s), 3.91 (2H, s), 6.67 (1H, d, J=8.4 Hz), 7.19 (1H, d, J=2.2 Hz), 7.22 (1H, dd, J=8.4, 2.2 Hz)
-
- tert-Butyl 7′-bromo-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate was prepared from 7′-bromo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline] according to procedure L1e.
- [(M-Boc)+H]+=238.0/240.0
- 1H NMR (DMSO-d6) 0.95 (4H, dd, J=6.6, 2.0 Hz), 1.41 (9H, s), 3.39 (2H, s), 4.61 (2H, s), 6.77 (1H, d, J=8.4 Hz), 7.30 (1H, dd, J=8.4, 2.2 Hz), 7.39 (1H, d, J=2.2 Hz).
-
- 2′-(tert-Butyl) 7′-
methyl 1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′,7′(3′H)-dicarboxylate was prepared from tert-butyl 7′-bromo-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate according to procedure L1d. - [(M-Boc)+H]+=218.2
- 1H NMR (DMSO-d6) 0.96-1.09 (4H, m), 1.41 (9H, s), 3.43 (2H, s), 3.83 (3H, s), 4.68 (2H, s), 6.95 (1H, d, J=8.2 Hz), 7.71 (1H, dd, J=8.2, 1.9 Hz), 7.74 (1H, d, J=1.7 Hz).
-
- tert-Butyl 7′-(hydroxymethyl)-1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′(3′H)-carboxylate was prepared from 2′-(tert-butyl) 7′-
methyl 1′H-spiro[cyclopropane-1,4′-isoquinoline]-2′,7′(3′H)-dicarboxylate according to procedure L2d. - [(M-tBu-OH)+H]+=216.1
- 1H NMR (DMSO-d6) 0.86-0.98 (4H, m), 1.41 (9H, s), 3.39 (2H, s), 4.42 (2H, d, J=5.7 Hz), 4.59 (2H, s), 5.09 (1H, t, J=5.7 Hz), 6.76 (1H, d, J=8.0 Hz), 7.01-7.12 (2H, m)
-
- To a 100 mL flask was added N-[2-(4-bromophenyl)ethyl]acetamide (1.25 g, 5.16 mmol) and DCM (20 mL) and cooled in an ice/water bath. Oxalyl chloride solution (2.0 M in DCM, 2.81 mL, 5.62 mmol) was added dropwise and the mixture allowed to warm to rt overnight. The mixture was briefly flushed with N2 before the addition (in one portion) of ferric chloride (1 g, 6.17 mmol). This caused gas evolution and a mild exotherm which was controlled using an ice/water bath for 5 min. The mixture was warmed to rt and stirred for 4 hrs then water (20 mL) was added with vigorous stirring. After 5 min the layers were separated and the aqueous extracted with DCM. The combined organics were washed with brine, dried over Na2SO4 and concentrated in vacuo to afford the title compound (1.39 g, 86%) as a coloured solid.
- [M+H]+=296.0/298.0
- 1H NMR (DMSO-d6) 1.98 (3H, s), 2.87 (1H, ddd, J=17.0, 5.5, 1.9 Hz), 2.98 (1H, ddd, J=17.6, 10.9, 6.9 Hz), 3.66 (1H, ddd, J=13.6, 11.0, 5.4 Hz), 4.28 (1H, ddd, J=13.6, 6.9, 2.0 Hz), 7.21 (1H, d, J=8.3 Hz), 7.55 (1H, dd, J=8.3, 2.1 Hz), 7.75 (1H, d, J=2.1 Hz)
-
- A suspension of rac-9-bromo-10b-methyl-5,6-dihydrooxazolo[2,3-a]isoquinoline-2,3-dione (1.39 g, 3.76 mmol) in a mixture of EtOH (30 mL) and H2SO4 (1 mL) was heated at 65° C. for 2 days. The mixture was cooled in an ice/water bath before the addition of 30% aqueous NH3 to basic pH (˜8-9). Solvents were removed in vacuo and the residue diluted with water and 2N NaOH(aq) to pH 10-12, extracted with EtOAc and the combined organics dried over MgSO4 and concentrated in vacuo. Flash chromatography (0 to 100% EtOAc/Iso-Hexanes) afforded the title compound (835 mg 78%) as a pale yellow semi-solid.
- [M+H]+=224.0/226.1
- 1H NMR (DMSO-d6) 2.30 (3H, s), 2.57-2.62 (2H, m), 3.52 (2H, ddd, J=9.1, 5.8, 1.7 Hz), 7.22 (1H, d, J=8.0 Hz), 7.58 (1H, dd, J=8.0, 2.1 Hz), 7.70 (1H, d, J=2.1 Hz)
-
- A suspension of 7-bromo-1-methyl-3,4-dihydroisoquinoline (0.835 g, 3.35 mmol) in acetonitrile (20 mL) was treated with bromomethylbenzene (0.57 mL, 4.7 mmol) and the mixture heated at 70° C. for 3 hrs. The mixture was cooled to rt and stirred overnight. The mixture was concentrated in vacuo and the residue purified by flash chromatography (0 to 7% MeOH/DCM) to afford the title compound (722 mg, 54%) as a pale yellow solid.
- [M]+=314.2/316.2
- 1H NMR (DMSO-d6) 3.01 (3H, s), 3.07 (2H, t, J=7.5 Hz), 3.96 (2H, t, J=7.8 Hz), 5.40 (2H, s), 7.40-7.53 (6H, m), 7.98 (1H, dd, J=8.1, 2.0 Hz), 8.35 (1H, d, J=2.0 Hz)
-
- A suspension of 2-benzyl-7-bromo-1-methyl-3,4-dihydroisoquinolin-2-ium bromide (834 mg, 2.11 mmol) in THE (7 mL) was treated dropwise with a 3M solution of methyl magnesium bromide in Et2O (21 mL, 63 mmol). The mixture was heated to reflux for 1.5 hrs and left at rt overnight. The mixture was quenched carefully into saturated NH4Cl(aq) (100 mL) and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (0 to 60% TBME/Iso-Hexanes) afforded the title compound (448 mg, 58%) as a pale yellow oil which crystallized on standing.
- [M+H]+=330.1/332.1
-
- Methyl 2-benzyl-1,1-dimethyl-3,4-dihydroisoquinoline-7-carboxylate was prepared from 2-benzyl-7-bromo-1,1-dimethyl-3,4-dihydroisoquinoline according to procedure L1d.
- [M+H]+=310.3
- 1H NMR (DMSO-d6) 1.47 (6H, s), 2.63 (2H, t, J=5.6 Hz), 2.71 (2H, t, J=5.6 Hz), 3.70 (2H, s), 3.85 (3H, s), 7.18 (1H, d, J=8.0 Hz), 7.23 (1H, t, J=7.3 Hz), 7.32 (2H, t, J=7.6 Hz), 7.35-7.42 (2H, m), 7.69 (1H, dd, J=7.9, 1.7 Hz), 7.94 (1H, d, J=1.7 Hz)
-
- A solution of methyl 2-benzyl-1,1-dimethyl-3,4-dihydroisoquinoline-7-carboxylate (315 mg, 0.94 mmol) in MeOH (30 mL) was treated with 10% palladium on carbon (92 mg, 0.09 mmol), and placed in sealed hydrogenation apparatus. The vessel was purged with N2 gas then placed under H2 gas at 3 bar pressure at rt for 4 hrs. The mixture was filtered through Celite and concentrated in vacuo to afford the title compound (194 mg, 0.86 mmol, 92%).
- [M+H]+=220.2
- 1H NMR (DMSO-d6) 1.36 (6H, s), 2.31 (1H, s), 2.73 (2H, t, J=5.8 Hz), 2.95 (2H, t, J=5.8 Hz), 3.83 (3H, s), 7.18 (1H, d, J=8.0 Hz), 7.65 (1H, dd, J=7.9, 1.8 Hz), 7.81 (1H, d, J=1.8 Hz)
-
- 2-(tert-Butyl) 7-
methyl 1,1-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate was prepared frommethyl 1,1-dimethyl-3,4-dihydro-2H-isoquinoline-7-carboxylate according to procedure L1e. - 1H NMR (DMSO-d6) 1.46 (9H, s), 1.72 (6H, s), 2.80-2.85 (2H, m), 3.53-3.62 (2H, m), 3.85 (3H, s), 7.27 (1H, d, J=7.9 Hz), 7.72 (1H, dd, J=7.9, 1.7 Hz), 7.93 (1H, d, J=1.7 Hz)
-
- tert-Butyl 7-(hydroxymethyl)-1,1-dimethyl-3,4-dihydroisoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-
methyl 1,1-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d. - [(M-tBu-OH)+H]+=218.1
- 1H NMR (DMSO-d6) 1.45 (9H, s), 1.69 (6H, s), 2.71 (2H, t, J=5.4 Hz) 3.50-3.60 (2H, m), 4.46 (2H, d, J=5.7 Hz), 5.11 (1H, t, J=5.8 Hz), 7.00-7.09 (2H, m), 7.30 (1H, d, J=1.6 Hz)
-
- 2-(tert-Butyl) 7-
methyl 4,4-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate was prepared from tert-butyl 7-bromo-4,4-dimethyl-1,3-dihydroisoquinoline-2-carboxylate (reported in WO2000024717) according to procedure L1d. - [(M-tBu)+H]+=264.3
- 1H NMR (DMSO-d6) 1.22 (6H, s), 1.43 (9H, s), 3.39 (2H, s), 3.83 (3H, s), 4.62 (2H, s), 7.54 (1H, d, J=8.2 Hz), 7.73 (1H, d, J=1.8 Hz), 7.77 (1H, dd, J=8.2, 1.9 Hz).
-
- tert-Butyl 7-(hydroxymethyl)-4,4-dimethyl-1,3-dihydroisoquinoline-2-carboxylate was prepared from 2-(tert-butyl) 7-
methyl 4,4-dimethyl-3,4-dihydroisoquinoline-2,7(1H)-dicarboxylate according to procedure L2d. - [(M-tBu)+H]+=236.2
- 1H NMR (DMSO-d6) 1.19 (6H, s), 1.42 (9H, s), 3.35 (2H, s), 4.42 (2H, d, J=5.8 Hz), 4.53 (2H, s), 5.08 (1H, t, J=5.7 Hz), 7.03 (1H, s), 7.09-7.16 (1H, m), 7.28-7.36 (1H, m).
-
- 7-(tert-Butyl) 2-methyl 5,8-dihydro-1,7-naphthyridine-2,7(6H)-dicarboxylate was prepared from
methyl 5,6,7,8-tetrahydro-1,7-naphthyridine-2-carboxylate dihydrochloride according to procedure L1e. - [M+H]+=293.1
-
- tert-Butyl 2-(hydroxymethyl)-6,8-dihydro-5H-1,7-naphthyridine-7-carboxylate was prepared from 7-(tert-butyl) 2-methyl 5,8-dihydro-1,7-naphthyridine-2,7(6H)-dicarboxylate according to procedure L2d.
- [M+H]+=265.1
-
- Synthesis of 6-(tert-butyl) 3-methyl 7,8-dihydro-1,6-naphthyridine-3,6(5H)-dicarboxylate is reported in WO2012027564.
-
- Synthesis of 6-(hydroxymethyl)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one is reported in WO2012122340.
-
- DIPEA (0.2 mL, 1.2 mmol) was added to a mixture of lithium 3-(methoxymethyl)-1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxylate (70 mg, 0.22 mmol), (2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl)methanamine hydrochloride (65 mg, 0.24 mmol) and HATU (95 mg, 0.25 mmol) in DCM (2 mL) and NMP (0.4 mL) and stirred at rt overnight. The mixture was concentrated in vacuo and flash chromatography (0 to 10% MeOH (1% NH3)/DCM) afforded the title compound (87 mg, 74%). Two minor components were identified as Examples 73 and 162.
- Title compound:
- [M+H]+=534.2
- 1H NMR (d6 DMSO) 2.30 (3H, d, J=0.8 Hz), 2.32 (3H, s), 2.56 (2H, t, J=5.9 Hz), 2.78 (2H, t, J=5.9 Hz), 3.17 (3H, s), 3.44 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J=5.2 Hz), 4.44 (2H, s), 5.20 (2H, s), 6.94 (1H, s), 6.97-7.03 (1H, m), 7.08 (1H, d, J=7.9 Hz), 7.25-7.35 (2H, m), 8.02 (1H, t, J=5.0 Hz), 8.12 (1H, s), 8.15 (1H, d, J=1.0 Hz)
- [M+H]+=548.2
- 1H NMR (Chloroform-d) 2.43 (3H, d, J=0.8 Hz), 2.98 (2H, t, J=6.6 Hz), 3.14 (3H, s), 3.37 (3H, d, J=1.8 Hz), 3.55 (2H, t, J=6.7 Hz), 3.93 (3H, s), 4.38 (2H, dd, J=5.7, 1.5 Hz), 4.56 (2H, d, J=3.5 Hz), 5.23 (2H, s), 6.98 (1H, t, J=8.7 Hz), 7.10-7.16 (2H, m), 7.18-7.23 (1H, m), 7.80 (1H, s), 7.93 (1H, d, J=1.0 Hz), 7.97 (1H, d, J=2.0 Hz), 8.34 (1H, t, J=6.0 Hz)
- [M+H]+=550.2
- 1H NMR (Chloroform-d) 2.43 (3H, d, J=0.8 Hz), 2.99 (1H, dd, J=17.4, 6.2 Hz), 3.35 (3H, s), 3.36 (3H, s), 3.46-3.56 (1H, m), 3.61 (1H, dt, J=11.7, 6.1 Hz), 3.64-3.75 (1H, m), 3.93 (3H, s), 4.36-4.41 (2H, m), 4.44-4.57 (2H, m), 4.55 (2H, s), 5.17 (2H, s), 6.90 (1H, s), 6.99 (1H, t, J=8.7 Hz), 7.13 (2H, dd, J=8.8, 1.7 Hz), 7.21 (1H, d, J=7.9 Hz), 7.84 (2H, d, J=13.6 Hz), 8.27-8.34 (1H, m)
-
- To a solution of N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-1-(isoindolin-5-ylmethyl)-3-(methoxymethyl)-1H-pyrazole-4-carboxamide hydrochloride (350 mg, 0.65 mmol) in DCM (21 mL) was added acetone (12 mL, 160 mmol) and TEA (180 uL, 1.29 mmol). After 30 min sodium triacetoxyborohydride (342 mg, 1.61 mmol) was added and stirring continued for 60 min. The mixture was diluted with MeOH (150 mL) and SCX resin (sufficient to capture the product) was added. The resin was collected by filtration and washed with MeOH. The product was then released by eluting with 1% NH3 in MeOH and the methanolic ammonia solution was concentrated in vacuo. Repeated flash chromatography (10% MeOH in EtOAc) then 0-10% (1% NH3 in MeOH) in DCM afforded an oil which was triturated with Et2O and dried to afford the title compound (84 mg, 23% yield) as an off-white solid.
- [M+H]+=548.4
- 1H NMR (d6 DMSO) 1.08 (6H, d, J=6.3 Hz), 2.29 (3H, s), 2.67 (1H), 3.16 (3H, s), 3.82 (4H, s), 3.92 (3H, s), 4.25 (2H, d, J=5.0 Hz), 4.43 (2H, s), 5.24 (2H, s), 7.05-7.13 (2H, m), 7.17-7.22 (1H, m), 7.25-7.33 (2H, m), 8.02 (1H, t, J=5.1 Hz), 8.10-8.16 (2H, m).
-
TABLE 1 Free Example Base [M + number R8 R5 B″ MW H]+ 1 Me CH2OMe 569.6 570.2 2 Me CH2OMe 533.6 534.2 3 Me H 489.5 490.2 4 Me CH2OMe 533.6 534.0 5 Me CH2OMe 533.6 6 Me CH2OMe 547.6 547.9 7 Me CH2OMe 519.6 520.0 8 Me CH2OMe 586.6 586.9 9 Me CH2OMe 558.6 559.0 10 Me CH2OMe 542.6 11 Me CH2OMe 543.6 543.9 12 Me CH2OMe 533.6 533.9 13 Me CH2OMe 587.6 587.9 14 CH2OMe 559.6 560.5 15 Me CH2OMe 569.6 570.5 16 Et CH2OMe 547.6 548.4 17 iPr CH2OMe 561.7 562.5 18 CH2OMe 573.7 574.5 19 CH2OMe 595.6 596.5 20 CH2OMe 613.3 614.4 21 CH2OMe 569.6 570.5 22 iPr CH2OMe 615.6 616.2 23 iPr CH2OMe 597.6 598.2 24 iPr CH2OMe 571.7 572.2 25 Et CH2OMe 601.6 602.4 26 Et CH2OMe 583.6 584.5 27 Et CH2OMe 557.6 558.5 28 iPr CH2OMe 575.7 576.5 29 Me CH2OMe 547.6 548.4 30 iPr CH2OMe 571.6 572.4 31 Me H 543.5 544.3 32 iPr H 571.6 572.4 33 Me CHF2 539.6 540.2 -
TABLE 2 Free Example Base [M + number R8 R5 B″ MW H]+ 34 Me CH2OMe 569.6 570.2 35 CH2OMe 559.6 560.6 36 Me CH2OMe 533.6 534.5 37 iPr CH2OMe 561.7 562.5 38 Et CH2OMe 547.6 548.0 39 CH2OMe 575.7 40 CH2OMe 573.7 574.4 41 Me CH2OMe 569.6 570.3 42 Me CH2OMe 587.6 588.3 43 Me CH2OMe 543.6 544.3 44 iPr CH2OMe 597.6 598.3 45 iPr CH2OMe 615.6 616.3 46 iPr CH2OMe 571.6 572.4 47 CH2OMe 595.6 596.4 48 CH2OMe 613.6 614.4 49 CH2OMe 569.6 570.4 50 Et CH2OMe 583.6 584.4 51 Et CH2OMe 601.6 602.4 52 Et CH2OMe 557.6 558.4 -
TABLE 4 Example Free number ACH2 R5 Base MW [M + H]+ 61 CF3 547.5 548.4 62 CF3 548.5 63 CF3 559.5 560.4 64 CH2OMe 569.0 569.4 65 CH2OMe 533.6 66 CF3 574.5 67 CH2OMe 569.0 68 CH2OMe 520.6 521.4 69 CF3 559.5 70 CH2OMe 523.6 524.5 71 CH2OH 588.6 72 CHF2 540.5 73 CH2OMe 547.6 548.2 74 CH2OH 596.6 75 CH2OMe 560.6 76 549.6 77 549.6 78 563.6 79 563.6 80 563.6 81 563.6 82 CHF2 555.6 556.6 83 561.6 84 CH2OMe 551.6 85 CH2OMe 564.6 86 CHF2 540.5 87 CH2OMe 575.6 88 CH2OMe 576.6 89 CH2OMe 581.6 90 CHF2 587.6 91 CH2OMe 573.6 92 585.6 93 CHF2 571.6 94 CHF2 557.5 95 CH2OMe 565.6 96 577.6 97 CHF2 559.5 98 579.6 99 CHF2 543.5 100 CH2OMe 537.6 101 549.6 102 CH2OMe 534.6 535.2 103 CH2OMe 551.6 552.0 104 CH2OMe 568.0 567.9 105 CH2OMe 569.6 569.9 106 CH2OMe 569.6 570.5 107 CH2OMe 551.6 552.3 108 CH2OMe 549.6 550.7 109 CH2OMe 540.6 541.5 110 CH2OMe 535.6 536.5 111 CH2OMe 565.7 112 CH2OMe 581.7 113 CH2OMe 597.7 114 CH2OMe 551.6 552.2 115 CH2OMe 584.6 585.5 116 CH2OMe 551.6 552.5 117 CH2OMe 562.6 563.4 118 CH2OMe 551.6 552.4 119 CH2OMe 536.6 537.2 120 CH2OMe 559.6 560.4 121 CH2OMe 547.6 548.4 122 CH2OMe 575.7 576.4 123 CH2OMe 573.7 574.2 124 CH2OMe 547.6 548.4 125 CF3 547.5 548.3 126 CH2OMe 559.6 560.4 127 CH2OMe 545.6 546.4 128 CH2OMe 547.6 548.3 129 CH2OMe 561.7 562.5 130 CH2OMe 547.6 548.4 131 CF3 558.5 559.4 132 CH2OMe 562.6 563.5 133 CH2OMe 520.6 521.5 134 CH2OMe 561.7 562.5 135 CH2OMe 547.6 548.3 136 CHF2 529.5 530.5 137 CHF2 540.5 541.4 138 CF3 558.5 559.2 -
TABLE 5 Example Free number ACH2 Y—R6 Base MW [M + H]+ 139 CCH2OH 596.6 140 CCH3 530.6 141 CCH2OMe 560.6 142 CCH3 519.6 143 CCH2OMe 549.6 144 CCH3 521.6 145 CCH2OMe 551.6 146 CCH2OMe 581.6 147 CCH2OMe 547.6 548.2 148 CCH2OMe 533.6 534.2 149 529.6 530.2 150 543.6 544.3 151 CCH3 503.6 504.2 152 N 490.5 491.2 153 N 504.6 505.2 -
-
-
-
-
-
- Reference Compounds RC1, RC2 and RC3 were prepared according to procedures described herein.
- Reference Compound RC4 is described in WO2017207983.
- Reference Compounds RC5, RC6 and RC7 are described below:
-
- (6-Amino-2-fluoro-3-methoxyphenyl)methanol (described in WO2017207983) (350 mg, 2.05 mmol) was stirred in MeCN (15 mL) and cooled in an ice/water bath. 3-Methylbutyl nitrite (412 μL, 3.07 mmol) was added. Trimethylsilyl azide (407 μL, 3.067 mmol) was added dropwise and after 10 min the ice bath was removed and the mixture was warmed to rt. After 60 min further charges of 3-methylbutyl nitrite (69 μL, 0.51 mmol) and trimethylsilyl azide (68 μL, 0.51 mmol) were made and the mixture stirred for 60 min. The mixture was concentrated in vacuo to low volume and 1,4-dioxane (25 mL) was added, the flask was covered in tin foil and ethynyltrimethylsilane (2.5 mL, 18.40 mmol), CuI (58.4 mg, 0.31 mmol) and sodium ascorbate (243 mg, 1.23 mmol) were added and the mixture heated to 80° C. On completion of the reaction the mixture was cooled and partitioned between EtOAc (50 mL) and saturated NH4Cl(aq) (40 mL) and the layers separated. The organic layer was washed with saturated NaHCO3(aq), brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography afforded the title compound (150 mg, 25%) as a yellow solid.
- [M+H]=296.2
- 1H NMR 0.39 (9H, s), 3.64 (1H, t, J=7.1 Hz), 3.96 (3H, s), 4.50 (2H, dd, J=7.3, 2.5 Hz), 7.02 (1H, t, J=8.7 Hz), 7.15 (1H, dd, J=8.8, 1.8 Hz), 7.85 (1H, s)
-
- To a vial was added (2-fluoro-3-methoxy-6-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)phenyl)methanol (55 mg, 0.186 mmol) in THE (5 mL). A 1M solution of tetra-n-butylammonium fluoride in THE (1.9 mL) was added. The mixture was stirred at rt for 18 hrs, diluted with EtOAc (50 mL) and washed with water, brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (10-100% EtOAC in Pet. Ether) afforded the title compound (36 mg, 87%) as a white solid.
- [M+H]+=224.2
- 1H NMR (CDCl3) 3.38 (1H, t, J=7.1 Hz), 3.97 (3H, s), 4.51 (2H, dd, J=7.1, 2.5 Hz), 7.04 (1H, t, J=8.7 Hz), 7.18 (1H, dd, J=8.8, 1.8 Hz), 7.88 (1H, d, J=0.8 Hz), 7.95 (1H, d, J=0.9 Hz)
-
- (2-Fluoro-3-methoxy-6-(1H-1,2,3-triazol-1-yl)phenyl)methanol (117 mg, 0.52 mmol) was dissolved in THE (15 mL) and PBr3 (170 mg, 0.63 mmol) was added and the mixture stirred at rt for 2 hrs. Dilute NaHCO3(aq) was added followed by DCM. The organic layer was separated and washed with water, brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (10-60% EtOAc in Pet. Ether) afforded the title compound (80 mg, 53%) as an off white solid.
- [M+H]+=285.6
-
- To 1-(2-(bromomethyl)-3-fluoro-4-methoxyphenyl)-1H-1,2,3-triazole (258 mg, 0.90 mmol) in DMF (4 mL) was added potassium phthalimide (159 mg, 0.86 mmol) and stirred at rt. After 5 min K2CO3 (237 mg, 1.72 mmol) was added and the mixture heated to 85° C. overnight. The mixture was concentrated in vacuo and azeotroped with toluene. Flash chromatography (0-10% DCM/MeOH) afforded the title compound (205 mg, 68%) as a white solid.
- [M+H]+=353.1
-
- To a solution of 2-(2-fluoro-3-methoxy-6-(1H-1,2,3-triazol-1-yl)benzyl)isoindoline-1,3-dione (205 mg, 0.58 mmol) in MeOH (10 mL) was added hydrazine hydrate (50-60%, 339 IL) and the mixture stirred at 80° C. for 2 hrs. The mixture was cooled to rt and concentrated in vacuo and azeotroped with toluene. Flash chromatography (0-10% MeOH in DCM) afforded the title compound (129 mg, quantitative) as a white solid.
- [M+H]+=223.1
-
- 3-Methoxymethyl-1-(2-pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-1H-pyrazole-4-carboxylic acid (described in WO 2016083816) (134 mg, 0.43 mmol) and (2-fluoro-3-methoxy-6-(1H-1,2,3-triazol-1-yl)phenyl)methanamine (95 mg, 0.43 mmol) were combined and taken up in DCM (10 mL) in an ice/water bath. The mixture was treated with HOBt (69 mg, 0.51 mmol), TEA (296 μL, 2.13 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (114 mg, 0.60 mmol). The mixture was warmed to rt and stirred for 18 hrs. The mixture was diluted with CHCl3 (50 mL) and saturated NaHCO3(aq) (10 mL) was added. The organic layer was separated and washed with water and brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (1-3% MeOH in DCM) afforded the title compound (138 mg, 62%) as a white solid.
- [M+H]+=522.2
- 1H NMR (d6-DMSO) 1.89-1.92 (4H, m), 3.17 (3H, s), 3.43-3.46 (4H, m), 3.92 (3H, s), 4.22 (2H, d, J=4.4 Hz), 4.42 (2H, s), 5.10 (2H, s), 7.29-7.35 (2H, m), 7.92 (1H, d, J=0.8 Hz), 8.04 (1H, t, J=5.0 Hz), 8.09 (1H, s), 8.34 (2H, s), 8.45 (1H, d, J=0.9 Hz)
-
- 3-Methoxymethyl-1-(2-pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-1H-pyrazole-4-carboxylic acid (150 mg, 0.47 mmol) was dissolved in DCM (30 mL). To the solution was added HBTU (215 mg, 0.57 mmol) and DIPEA (122 mg, 0.95 mmol) and stirred at rt. After 20 min, (2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl)methanamine (117 mg, 0.50 mmol) was added and the mixture stirred at rt for 40 hrs. The mixture was diluted with CHCl3 (50 mL), washed with saturated NaHCO3(aq), water, brine, dried over Na2SO4 and concentrated in vacuo. Flash chromatography (5% MeOH, 95% CHCl3) afforded the title compound (143 mg, 56%) as a white solid.
- [M+H]+=536.3
- 1H NMR (d6-DMSO) 1.89-1.92 (4H, m), 2.28 (3H, s), 3.17 (3H, s), 3.45 (4H, t, J=6.6 Hz), 3.92 (3H, s), 4.24 (2H, d, J=4.6 Hz), 4.42 (2H, s), 5.11 (2H, s), 7.25-7.32 (2H, m), 8.00 (1H, t, J=5.0 Hz), 8.09 (1H, s), 8.13 (1H, s), 8.34 (2H, s)
-
- 3-Methoxymethyl-1-(2-pyrrolidin-1-yl-pyrimidin-5-ylmethyl)-1H-pyrazole-4-carboxylic acid (94 mg, 0.30 mmol) and (6-(4-(difluoromethyl)-1H-1,2,3-triazol-1-yl)-2-fluoro-3-methoxyphenyl) methanamine (135 mg, 0.30 mmol) were taken up in DCM (10 mL) while cooling in an ice/water bath. The mixture was treated with HOBt (48 mg, 0.36 mmol), TEA (207 IL, 1.49 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (80 mg, 0.42 mmol). The mixture was warmed to rt and stirred for 18 hrs. The mixture was diluted with CHCl3 (50 mL) and saturated NaHCO3(aq) (10 mL) added. The organic layer was separated and washed with water and brine, dried over MgSO4 and concentrated in vacuo. Flash chromatography (1-3% MeOH in DCM) afforded the title compound (117 mg, 68%) as a white solid.
- [M+H]+=572.2
- 1H NMR (d6-DMSO) 1.89-1.92 (4H, m), 3.17 (3H, s), 3.43-3.46 (4H, m), 3.93 (3H, s), 4.25 (2H, d, J=4.8 Hz), 4.42 (2H, s), 5.10 (2H, s), 7.28 (1H, t, J=54.1 Hz), 7.31-7.38 (2H, m), 8.08 (1H, s), 8.09 (1H, t, J=5.1 Hz), 8.33 (2H, s), 8.89 (1H, t, J=1.4 Hz)
-
TABLE 10 Compound Names Example Number Name 1 N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 2 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 3 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl- 3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide 4 N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 5 N-(2-fluoro-3-methoxy-6-(4-methyl-2H-1,2,3-triazol-2-yl)benzyl)-3-(methoxymethyl)- 1-((2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxamide 6 N-{[6-(3-ethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 7 N-{[2-fluoro-3-methoxy-6-(1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1- [(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide 8 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)pyrazol-1-yl]phenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 9 N-{[6-(3-cyclopropylpyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 10 N-(6-(3-cyano-1H-pyrrol-1-yl)-2-fluoro-3-methoxybenzyl)-3-(methoxymethyl)-1-((2- methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4-carboxamide 11 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)- 1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide 12 N-{[2-fluoro-3-methoxy-6-(5-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 13 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 14 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6- (4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4- carboxamide 15 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 16 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4- methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 17 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2- isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 18 1-((2-cyclobutyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-N-(2-fluoro-3-methoxy-6- (4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(methoxymethyl)-1H-pyrazole-4- carboxamide 19 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({6-[3-(difluoromethyl)- 1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 20 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 21 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4- dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 22 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1- [(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 23 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2- isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 24 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4- dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 25 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 26 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2- ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 27 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4- dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 28 N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2- isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 29 N-{[6-(dimethyl-1,2,4-triazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 30 N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4- dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 31 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1- [(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide 32 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1- [(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide 33 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 34 N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4- carboxamide 35 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6- (4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4- carboxamide 36 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4- carboxamide 37 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2- isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 38 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4- methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 39 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(methoxymethyl)- 1-((2-(oxetan-3-yl)-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl)-1H-pyrazole-4- carboxamide 40 1-[(2-cyclobutyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6- (4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4- carboxamide 41 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4- carboxamide 42 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4- carboxamide 43 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)- 1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide 44 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2- isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 45 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1- [(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 46 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4- dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 47 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({6-[3-(difluoromethyl)- 1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 48 1-[(2-cyclopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6- [3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 49 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-cyclopropyl-3,4- dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 50 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2- ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 51 1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3- (trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4- carboxamide 52 N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4- dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide 53 1-(2,3-dihydro-1H-isoindol-5-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3- triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 54 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4- carboxamide 55 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2- isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 56 1-[(2-ethyl-1,3-dihydroisoindol-5-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl- 1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 57 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4- carboxamide 58 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4- carboxamide 59 N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2- isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 60 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1- [(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 61 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl- 5H,6H,8H-imidazo[1,2-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4- carboxamide 62 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl- 4H,6H,7H-[1,2,4]triazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4- carboxamide 63 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({7-methyl- 5H,6H,8H-pyrido[3,4-d]pyrimidin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4- carboxamide 64 1-[(4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 65 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(1-oxo-3,4-dihydro-2H-isoquinolin-6-yl)methyl]pyrazole-4- carboxamide 66 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl-2- oxo-1,5,7,8-tetrahydro-1,6-naphthyridin-3-yl)methyl]-3-(trifluoromethyl)pyrazole-4- carboxamide 67 1-[(4-chloro-7-methyl-6,8-dihydro-5H-1,7-naphthyridin-2-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 68 1-(3,4-dihydro-1H-2-benzopyran-6-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl- 1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 69 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({6-methyl- 5H,7H,8H-pyrido[4,3-c]pyridazin-3-yl}methyl)-3-(trifluoromethyl)pyrazole-4- carboxamide 70 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 71 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (hydroxymethyl)-1-{[7-methyl-2-(trifluoromethyl)-6,8-dihydro-5H-1,7-naphthyridin- 3-yl]methyl}pyrazole-4-carboxamide 72 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-2- yl)methyl]pyrazole-4-carboxamide 73 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4- carboxamide 74 1-[6-(2,2-difluoroethyl)-5,7-dihydrospiro[1,6-naphthyridine-8,1′-cyclopropane]-3- ylmethyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (hydroxymethyl)pyrazole-4-carboxamide 75 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{6-methyl-5,7-dihydrospiro[1,6-naphthyridine-8,1′- cyclopropane]-3-ylmethyl}pyrazole-4-carboxamide 76 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 77 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)-1-({7-methyl-5H,6H,8H-imidazo[1,2-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 78 1-({1,6-dimethyl-4H,5H,7H-pyrazolo[3,4-c]pyridin-3-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)pyrazole-4-carboxamide 79 1-({2,6-dimethyl-4H,5H,7H-pyrazolo[3,4-c]pyridin-3-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)pyrazole-4-carboxamide 80 1-({2,5-dimethyl-4H,6H,7H-pyrazolo[4,3-c]pyridin-3-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)pyrazole-4-carboxamide 81 1-({1,5-dimethyl-4H,6H,7H-pyrazolo[4,3-c]pyridin-3-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- methoxycyclopropyl)pyrazole-4-carboxamide 82 3-(difluoromethyl)-N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)- 1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin[-2′- yl)methyl)-1H-pyrazole-4-carboxamide 83 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(1- hydroxycyclopropyl)-1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′- pyrazolo[1,5-a]pyrazin]-2′-yl)methyl)-1H-pyrazole-4-carboxamide 84 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-({5,7,7-trimethyl-4H,6H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 85 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(8-hydroxy- 6,8-dimethyl-5,7-dihydro-1,6-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole- 4-carboxamide 86 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-[(6-methyl-7,8-dihydro-5H-1,6-naphthyridin-2- yl)methyl]pyrazole-4-carboxamide 87 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{2-methyl-1,3-dihydrospiro[isoquinoline-4,3′-oxetane]-7- ylmethyl}pyrazole-4-carboxamide 88 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{6-methyl-5,7-dihydrospiro[1,6-naphthyridine-8,3′-oxetane]-3- ylmethyl}pyrazole-4-carboxamide 89 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-{[7-(2- hydroxypropan-2-yl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]methyl}-3- (methoxymethyl)pyrazole-4-carboxamide 90 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-{[7-(2-hydroxypropan-2-yl)-5-methyl-4H,6H,7H-pyrazolo [1,5-a]pyrazin-2-yl]methyl}pyrazole-4-carboxamide 91 1-{[7-(difluoromethyl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]methyl}-N-{[2- fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)pyrazole-4-carboxamide 92 1-{[7-(difluoromethyl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]methyl}-N-{[2- fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- hydroxycyclopropyl)pyrazole-4-carboxamide 93 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-{[(2R,6S)-7-methyl-4-oxa-1,7,12- triazatricyclo[7.3.0.0{circumflex over ( )}{2,6}]dodeca-9,11-dien-11-yl]methyl}pyrazole-4-carboxamide 94 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-[(2R,6S)-4-oxa-1,7,12-triazatricyclo[7.3.0.0{circumflex over ( )}{2,6}]dodeca-9,11- dien-11-ylmethyl]pyrazole-4-carboxamide 95 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{[(2R,6S)-7-methyl-4-oxa-1,7,12- triazatricyclo[7.3.0.0{circumflex over ( )}{2,6}]dodeca-9,11-dien-11-yl]methyl}pyrazole-4-carboxamide 96 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- hydroxycyclopropyl)-1-{[(2R,6S)-7-methyl-4-oxa-1,7,12- triazatricyclo[7.3.0.0{circumflex over ( )}{2,6}]dodeca-9,11-dien-11-yl]methyl}pyrazole-4-carboxamide 97 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-{[7-(hydroxymethyl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin- 2-yl]methyl}pyrazole-4-carboxamide 98 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-{[7- (hydroxymethyl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]methyl}-3-(1- methoxycyclopropyl)pyrazole-4-carboxamide 99 3-(difluoromethyl)-1-({5,7-dimethyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-N- {[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}pyrazole-4- carboxamide 100 1-({5,7-dimethyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 101 1-({5,7-dimethyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(1- hydroxycyclopropyl)pyrazole-4-carboxamide 102 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3- yl)methyl]pyrazole-4-carboxamide 103 1-[(7-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 104 1-[(5-chloro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 105 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-6-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 106 1-[(4,4-difluoro-2-methyl-1,3-dihydroisoquinolin-7-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 107 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 108 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(4-methyl-3,5-dihydro-2H-1,4-benzoxazepin-7- yl)methyl]pyrazole-4-carboxamide 109 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-({5-methyl-4H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2- yl}methyl)pyrazole-4-carboxamide 110 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-(2,3,4,5-tetrahydro-1,4-benzoxazepin-7-ylmethyl)pyrazole-4- carboxamide 111 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(methoxymethyl)- 1-((4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepin-8-yl)methyl)-1H-pyrazole-4- carboxamide 112 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(methoxymethyl)- 1-((4-methyl-1-oxido-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepin-8-yl)methyl)-1H- pyrazole-4-carboxamide 113 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-3-(methoxymethyl)- 1-((4-methyl-1,1-dioxido-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepin-8-yl)methyl)-1H- pyrazole-4-carboxamide 114 1-[(5-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 115 1-{[7-(2,2-difluoroethyl)-6,8-dihydro-5H-1,7-naphthyridin-3-yl]methyl}-N-{[2-fluoro- 3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)pyrazole-4-carboxamide 116 1-[(8-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 117 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7- isopropyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]-3-(methoxymethyl)pyrazole- 4-carboxamide 118 1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 119 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole- 4-carboxamide 120 1-{1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinolin-9-ylmethyl}-N-{[2-fluoro-3- methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole- 4-carboxamide 121 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7- yl)methyl]pyrazole-4-carboxamide 122 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3- isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole- 4-carboxamide 123 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({11- isopropyl-11-azatricyclo[6.2.1.0{circumflex over ( )}{2,7}]undeca-2(7),3,5-trien-4-yl}methyl)-3- (methoxymethyl)pyrazole-4-carboxamide 124 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2,3,3-trimethyl-1H-isoindol-5-yl)methyl]pyrazole-4- carboxamide 125 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl- 4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)-3-(trifluoromethyl)pyrazole-4- carboxamide 126 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′- ylmethyl}pyrazole-4-carboxamide 127 1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro- 3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)pyrazole-4-carboxamide 128 1-[(1,1-dimethyl-3,4-dihydro-2H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6- (4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4- carboxamide 129 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(1,1,2-trimethyl-3,4-dihydroisoquinolin-7-yl)methyl]pyrazole-4- carboxamide 130 1-[(4,4-dimethyl-2,3-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6- (4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4- carboxamide 131 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7- methyl-5,6,7,8-tetrahydro-1,7-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)-1H- pyrazole-4-carboxamide 132 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{[6-(propan-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-3- yl]methyl}-1H-pyrazole-4-carboxamide 133 1-(3,4-dihydro-1H-2-benzopyran-7-ylmethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl- 1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide 134 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2,4,4-trimethyl-1,3-dihydroisoquinolin-7-yl)methyl]pyrazole-4- carboxamide 135 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-1-oxo-3,4-dihydroisoquinolin-6-yl)methyl]pyrazole-4- carboxamide 136 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 137 3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1- yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3- yl)methyl]pyrazole-4-carboxamide 138 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(6-methyl- 7,8-dihydro-5H-1,6-naphthyridin-2-yl)methyl]-3-(trifluoromethyl)pyrazole-4- carboxamide 139 1-[6-(2,2-difluoroethyl)-5,7-dihydrospiro[1,6-naphthyridine-8,1′-cyclopropane]-3- ylmethyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2- (hydroxymethyl)imidazole-4-carboxamide 140 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-{6- methyl-5,7-dihydrospiro[1,6-naphthyridine-8,1′-cyclopropane]-3-ylmethyl}imidazole- 4-carboxamide 141 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2- (methoxymethyl)-1-{6-methyl-5,7-dihydrospiro[1,6-naphthyridine-8,1′- cyclopropane]-3-ylmethyl}imidazole-4-carboxamide 142 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-2-methyl-1-((5′- methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′- yl)methyl)-1H-imidazole-4-carboxamide 143 N-(2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)benzyl)-2-(methoxymethyl)- 1-((5′-methyl-5′,6′-dihydro-4′H-spiro[cyclopropane-1,7′-pyrazolo[1,5-a]pyrazin]-2′- yl)methyl)-1H-imidazole-4-carboxamide 144 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1- ({5,7,7-trimethyl-4H,6H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)imidazole-4-carboxamide 145 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2- (methoxymethyl)-1-({5,7,7-trimethyl-4H,6H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)imidazole-4-carboxamide 146 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-{[7-(2- hydroxypropan-2-yl)-5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl]methyl}-2- (methoxymethyl)imidazole-4-carboxamide 147 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2- isopropyl-1,3-dihydroisoindol-5-yl)methyl]-2-(methoxymethyl)imidazole-4- carboxamide 148 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4- carboxamide 149 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}- 1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide 150 2-cyclopropyl-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}- 1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]imidazole-4-carboxamide 151 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-2-methyl-1-[(2- methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]imidazole-4-carboxamide 152 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl- 3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide 153 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2- isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide 154 N-{[3-cyclopropoxy-2-fluoro-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2- yl}methyl)pyrazole-4-carboxamide 155 N-({3-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluorophenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 156 N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4- carboxamide 157 N-{[3-(1,1-difluoroethyl)-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2- fluorophenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7- yl)methyl]pyrazole-4-carboxamide 158 N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3- (methoxymethyl)-1-[(3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7- yl)methyl]pyrazole-4-carboxamide 159 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl- 3,4-dihydro-1H-isoquinolin-7-yl)methyl]-2-oxopyridine-4-carboxamide 160 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl- 3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide 161 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl- 3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide 162 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(1-hydroxy- 2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4- carboxamide 163 N-{[2-fluoro-3-methoxy-6-(1H-(1,2,3,4-tetrazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl]-1H- pyrazole-4-carboxamide 164 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-5- (methoxymethyl)-2-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl]-1,3- oxazole-4-carboxamide 165 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-4- (methoxymethyl)-2-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl]-1,3- oxazole-5-carboxamide 166 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-2-[(2- methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl]-1,3-oxazole-4-carboxamide 167 N-{[2-fluoro-3-methoxy-6-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]methyl}-2-[(2- methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)methyl]-1,3-oxazole-5-carboxamide RC1 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-(isoquinolin- 7-ylmethyl)-3-(methoxymethyl)pyrazole-4-carboxamide RC2 N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)phenyl]methyl}-3-(methoxymethyl)- 1-[(2-methylquinolin-6-yl)methyl]pyrazole-4-carboxamide RC3 N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)phenyl]methyl}-3-(methoxymethyl)- 1-(quinolin-6-ylmethyl)pyrazole-4-carboxamide RC4 N-{[2-fluoro-3-methoxy-6-(1,2,3,4-tetrazol-1-yl)phenyl]methyl}-3-(methoxymethyl)- 1-{[2-(pyrrolidin-1-yl)pyrimidin-5-yl]methyl}pyrazole-4-carboxamide RC5 N-{[2-fluoro-3-methoxy-6-(1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1- {[2-(pyrrolidin-1-yl)pyrimidin-5-yl]methyl}pyrazole-4-carboxamide RC6 N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3- (methoxymethyl)-1-{[2-(pyrrolidin-1-yl)pyrimidin-5-yl]methyl}pyrazole-4- carboxamide RC7 N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3- (methoxymethyl)-1-{[2-(pyrrolidin-1-yl)pyrimidin-5-yl]methyl}pyrazole-4- carboxamide -
TABLE 11 1H NMR data of examples (solvent d6 DMSO unless otherwise indicated) Example Number Chemical shift 1 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.42 (2H, s), 3.93 (3H, s), 4.26 (2H, d, J = 4.9 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.92 (1H, s), 6.98 (1H, dd, J = 7.8, 1.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.28 (1H, t, J = 54.1 Hz), 7.31-7.39 (2H, m), 8.10 (2H, d, J = 5.9 Hz), 8.89 (1H, t, J = 1.5 Hz) 2 2.30 (3H, d, J = 0.8 Hz), 2.32 (3H, s), 2.56 (2H, t, J = 5.9 Hz), 2.78 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.44 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.2 Hz), 4.44 (2H, s), 5.20 (2H, s), 6.94 (1H, s), 6.97-7.03 (1H, m), 7.08 (1H, d, J = 7.9 Hz), 7.25-7.35 (2H, m), 8.02 (1H, t, J = 5.0 Hz), 8.12 (1H, s), 8.15 (1H, d, J = 1.0 Hz) 3 2.27 (3H, s), 2.31 (3H, s), 2.55 (2H, t, J = 6.0 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.43 (2H, s), 3.91 (3H, s), 4.22 (2H, d, J = 5.0 Hz), 5.22 (2H, s), 6.90-7.10 (3H, m), 7.22-7.33 (2H, m), 7.77 (1H, s), 8.07-8.15 (2H, m), 8.20 (1H, t, J = 5.0 Hz) 4 2.31 (6H, d, J = 3.0 Hz), 2.56 (2H, d, J = 5.9 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.91 (3H, s), 4.32 (2H, d, J = 5.3 Hz), 4.44 (2H, s), 5.20 (2H, s), 6.94 (1H, s), 6.98-7.02 (1H, m), 7.07 (1H, d, J = 7.8 Hz), 7.23-7.31 (2H, m), 8.02 (1H, t, J = 5.2 Hz), 8.12 (1H, s), 8.64 (1H, s) 6 1.20 (3H, t, J = 7.6 Hz), 2.31 (3H, s), 2.56 (2H, t, J = 5.9 Hz), 2.65-2.69 (2H, m), 2.77 (2H, t, J = 6.0 Hz), 3.15 (3H, s), 3.43 (2H, s), 3.91 (3H, s), 4.32 (2H, d, J = 5.2 Hz), 4.44 (2H, s), 5.20 (2H, s), 6.93 (1H, s), 6.99 (1H, d, J = 8.1 Hz), 7.07 (1H, d, J = 7.8 Hz), 7.27 (2H, d, J = 6.1 Hz), 8.00 (1H, t, J = 5.3 Hz), 8.11 (1H, s), 8.64 (1H, s) 7 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.16 (3H, s), 3.42 (2H, s), 3.91 (3H, s), 4.29 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.19 (2H, s), 6.93 (1H, d, J = 1.7 Hz), 6.99 (1H, dd, J = 7.8, 1.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.25-7.33 (2H, m), 8.03 (1H, t, J = 5.2 Hz), 8.11 (1H, s), 8.20 (1H, s), 8.81 (1H, s) 8 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.15 (3H, s), 3.42 (2H, s), 3.91 (3H, s), 4.22-4.33 (2H, m), 4.43 (2H, s), 5.19 (2H, s), 6.92 (1H, d, J = 1.7 Hz), 6.95 (1H, d, J = 2.5 Hz), 6.98 (1H, dd, J = 7.8, 1.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.24-7.36 (2H, m), 8.03 (1H, t, J = 5.1 Hz), 8.10 (1H, s), 8.23-8.29 (1H, m) 9 0.62-0.70 (2H, m), 0.80-0.88 (2H, m), 1.84-1.93 (1H, m), 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.13 (3H, s), 3.42 (2H, s), 3.88 (3H, s), 4.31 (2H, dd, J = 5.0, 1.6 Hz), 4.43 (2H, s), 5.20 (2H, s), 6.18 (1H, d, J = 2.3 Hz), 6.93 (1H, d, J = 1.8 Hz), 6.99 (1H, dd, J = 7.9, 1.8 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.16-7.26 (2H, m), 7.85 (1H, d, J = 2.4 Hz), 7.94 (1H, t, J = 4.9 Hz), 8.14 (1H, s) 11 2.31 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.17 (3H, s), 3.42 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93 (1H, s), 6.99 (1H, d, J = 7.8 Hz), 7.07 (1H, d, J = 7.8 Hz), 7.17 (1H, d, J = 2.5 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.08 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 12 2.23 (3H, s), 2.32 (3H, s), 2.57 (2H, d, J = 5.8 Hz), 2.78 (2H, t, J = 6.0 Hz), 3.18 (3H, s), 3.43 (2H, s), 3.92 (3H, s), 4.14 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.20 (2H, s), 6.93 (1H, s), 6.99 (1H, d, J = 7.8 Hz), 7.08 (1H, d, J = 7.8 Hz), 7.28 (2H, d, J = 6.6 Hz), 7.99 (1H, s), 8.02 (1H, t, J = 5.2 Hz), 8.10 (1H, s) 13 2.31 (3H, s), 2.55 (2H, d, J = 6.0 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.17 (3H, s), 3.42 (2H, s), 3.93 (3H, s), 4.32 (2H, d, J = 5.3 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.91 (1H, s), 6.98 (1H, d, J = 7.8 Hz), 7.07 (1H, d, J = 7.8 Hz), 7.33 (1H, d, J = 8.8 Hz), 7.42 (1H, d, J = 8.8 Hz), 8.09 (1H, s), 8.13 (1H, d, J = 5.4 Hz), 9.12 (1H, s) 14 0.35-0.41 (2H, m), 0.43-0.54 (2H, m), 1.73-1.82 (1H, m), 2.30 (3H, s), 2.73 (2H, t, J = 5.8 Hz), 2.81 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.66 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 5.19 (2H, s), 6.93-7.03 (2H, m), 7.06 (1H, d, J = 7.8 Hz), 7.25-7.34 (2H, m), 8.03 (1H, d, J = 5.0 Hz), 8.12 (1H, s), 8.16 (1H, s) 15 2.31 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.42 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.3 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.90-6.94 (1H, m), 6.96-7.01 (1H, m), 7.01-7.26 (2H, m), 7.27-7.34 (1H, m), 7.34-7.40 (1H, m), 8.04-8.14 (2H, m), 8.98 (1H, s) 16 1.06 (3H, t, J = 7.2 Hz), 2.29 (3H, s), 2.44-2.48 (2H, m), 2.60 (2H, t, J = 5.8 Hz), 2.76 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.48 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 4.8 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.94 (1H, s), 6.97-7.01 (1H, m), 7.06 (1H, d, J = 7.9 Hz), 7.24-7.33 (2H, m), 8.02 (1H, t, J = 5.0 Hz), 8.11 (1H, s), 8.13-8.15 (1H, m) 17 1.03 (6H, d, J = 6.5 Hz), 2.29 (3H, s), 2.61-2.69 (2H, m), 2.70-2.78 (2H, m), 2.79-2.88 (1H, m), 3.17 (3H, s), 3.54-3.62 (2H, m), 3.92 (3H, s), 4.25 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93-6.95 (1H, m), 6.98 (1H, d, J = 7.9 Hz), 7.05 (1H, d, J = 7.8 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.11 (1H, s), 8.13-8.17 (1H, m) 18 1.61-1.70 (2H, m), 1.78-1.89 (2H, m), 1.99-2.09 (2H, m), 2.29 (3H, s), 2.46-2.50 (2H, m), 2.71-2.78 (2H, m), 2.79-2.89 (1H, m), 3.16 (3H, s), 3.34-3.41 (2H, m), 3.92 (3H, s), 4.22-4.28 (2H, m), 4.43 (2H, s), 5.19 (2H, s), 6.94 (1H, s), 6.99 (1H, d, J = 7.9 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.24-7.33 (2H, m), 8.01 (1H, t, J = 5.0 Hz), 8.11 (1H, s), 8.13-8.16 (1H, m) 19 0.34-0.42 (2H, m), 0.42-0.50 (2H, m), 1.72-1.79 (1H, m), 2.72 (2H, t, J = 5.9 Hz), 2.80 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.65 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.92-7.00 (2H, m), 7.04 (1H, d, J = 7.9 Hz), 7.18 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, dd, J = 8.9, 1.3 Hz), 8.05-8.13 (2H, m), 8.98 (1H, s) 20 0.33-0.42 (2H, m), 0.42-0.49 (2H, m), 1.72-1.79 (1H, m), 2.72 (2H, t, J = 5.9 Hz), 2.80 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.65 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.1 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.93 (1H, s), 6.97 (1H, dd, J = 7.8, 1.8 Hz), 7.04 (1H, d, J = 7.8 Hz), 7.32 (1H, t, J = 8.8 Hz), 7.41 (1H, dd, J = 8.8, 1.4 Hz), 8.08 (1H, s), 8.11 (1H, t, J = 5.3 Hz), 9.11 (1H, s) 21 0.34-0.41 (2H, m), 0.42-0.50 (2H, m), 1.72-1.80 (1H, m), 2.73 (2H, t, J = 5.9 Hz), 2.80 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.65 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 4.7 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.96 (1H, s), 6.98 (1H, dd, J = 7.8, 1.8 Hz), 7.05 (1H, d, J = 7.8 Hz), 7.17 (1H, d, J = 2.5 Hz), 7.25-7.35 (2H, m), 8.01 (1H, t, J = 5.2 Hz), 8.08 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 22 1.03 (6H, d, J = 6.5 Hz), 2.62-2.69 (2H, m), 2.70-2.77 (2H, m), 2.79- 2.86 (1H, m), 3.17 (3H, s), 3.30 (1H, s), 3.57 (2H, s), 3.93 (3H, s), 4.32 (2H, d, J = 5.3 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.92 (1H, s), 6.98 (1H, d, J = 7.8 Hz), 7.05 (1H, d, J = 7.8 Hz), 7.33 (1H, t, J = 8.9 Hz), 7.42 (1H, d, J = 8.9 Hz), 8.08 (1H, s), 8.12 (1H, t, J = 5.3 Hz), 9.12 (1H, s) 23 1.04 (6H, d, J = 6.5 Hz), 2.62-2.71 (2H, m), 2.71-2.78 (2H, m), 2.78- 2.90 (1H, m), 3.17 (3H, s), 3.30 (1H, s), 3.58 (2H, s), 3.93 (3H, s), 4.30 (2H, d, J = 5.8 Hz), 4.44 (2H, s), 5.19 (2H, s), 6.94 (1H, s), 6.98 (1H, d, J = 7.9 Hz), 7.02-7.08 (1H, m), 7.19 (1H, d, J = 53.0 Hz), 7.31 (1H, d, J = 8.8 Hz), 7.38 (1H, d, J = 8.8 Hz), 8.08-8.14 (2H, m), 8.99 (1H, s) 24 1.04 (6H, d, J = 6.5 Hz), 2.62-2.69 (2H, m), 2.71-2.77 (2H, m), 2.79- 2.88 (1H, m), 3.18 (3H, s), 3.30 (1H, s), 3.58 (2H, s), 3.92 (2H, s), 4.31 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.19 (2H, s), 6.94 (1H, s), 6.99 (1H, d, J = 7.9 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.18 (1H, d, J = 2.5 Hz), 7.26-7.35 (2H, m), 8.02 (1H, t, J = 5.2 Hz), 8.08 (1H, s), 8.32 (1H, d, J = 2.6 Hz) 25 1.06 (3H, t, J = 7.2 Hz), 2.46 (2H, q, J = 7.1 Hz), 2.60 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.47 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.3 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.92 (1H, s), 6.98 (1H, d, J = 7.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.32 (1H, t, J = 8.7 Hz), 7.41 (1H, dd, J = 8.9, 1.4 Hz), 8.08 (1H, s), 8.11 (1H, t, J = 5.4 Hz), 9.11 (1H, s) 26 1.06 (3H, t, J = 7.1 Hz), 2.46 (2H, q, J = 7.2 Hz), 2.60 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.48 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.93 (1H, s), 6.99 (1H, dd, J = 7.7, 1.9 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.18 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, dd, J = 8.8, 1.3 Hz), 8.05-8.14 (2H, m), 8.98 (1H, s) 27 1.07 (3H, t, J = 7.1 Hz), 2.43-2.49 (2H, m), 2.54-2.68 (2H, m), 2.72-2.81 (2H, m), 3.17 (3H, s), 3.49 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 4.7 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.94 (1H, s), 6.99 (1H, d, J = 7.6 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.17 (1H, d, J = 2.5 Hz), 7.24-7.35 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.08 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 28 0.91-1.14 (6H, m), 2.16 (3H, s), 2.20 (3H, s), 2.54-2.93 (5H, m), 3.17 (3H, s), 3.42-3.71 (2H, m), 3.91 (3H, s), 4.17 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.13-5.26 (2H, m), 6.89-7.11 (3H, m), 7.19-7.28 (2H, m), 7.96- 8.05 (1H, m), 8.10 (1H, s) 29 2.16 (3H, s), 2.20 (3H, s), 2.31 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.42 (2H, s), 3.91 (3H, s), 4.16 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.19 (2H, s), 6.89-6.95 (1H, m), 6.97-7.01 (1H, m), 7.04-7.08 (1H, m), 7.21-7.26 (2H, m), 7.96-8.04 (1H, m), 8.09 (1H, s) 30 1.03 (6H, d, J = 6.5 Hz), 2.60-2.69 (2H, m), 2.69-2.77 (2H, m), 2.82 (1H, hept, J = 6.5 Hz), 3.17 (3H, s), 3.57 (2H, s), 3.91 (3H, s), 4.31 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.94 (1H, s), 6.96-7.02 (1H, m), 7.05 (1H, d, J = 7.8 Hz), 7.24-7.33 (2H, m), 8.01 (1H, t, J = 5.2 Hz), 8.10 (1H, s), 8.29 (1H, s), 8.87 (1H, s) 31 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.41 (2H, s), 3.92 (3H, s), 4.29 (2H, d, J = 4.8 Hz), 5.21 (2H, s), 6.88-6.91 (1H, m), 6.97 (1H, dd, J = 7.8, 1.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.31 (1H, dd, J = 8.8 Hz), 7.37-7.41 (1H, m), 7.71-7.74 (1H, m), 8.06-8.09 (1H, m), 8.29 (1H, t, J = 5.2 Hz), 9.08-9.10 (1H, m) 32 1.03 (6H, d, J = 6.5 Hz), 2.60-2.69 (2H, m), 2.70-2.77 (2H, m), 2.78- 2.87 (1H, m), 3.51-3.60 (2H, m), 3.92 (3H, s), 4.29 (2H, d, J = 5.1 Hz), 5.21 (2H, s), 6.88-6.91 (1H, m), 6.95-6.99 (1H, m), 7.04 (1H, d, J = 7.8 Hz), 7.31 (1H, dd, J = 8.8 Hz), 7.39 (1H, dd, J = 8.8, 1.4 Hz), 7.73 (1H, s), 8.07 (1H, s), 8.29 (1H, t, J = 5.2 Hz), 9.07-9.10 (1H, m) 33 2.27 (3H, s), 2.32 (3H, s), 2.57 (2H, t, J = 5.9 Hz), 2.79 (2H, t, J = 5.9 Hz), 3.45 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 4.7 Hz), 5.30 (2H, s), 6.99 (1H, s), 7.04 (1H, dd, J = 7.7, 1.8 Hz), 7.10-7.14 (1H, m), 7.22-7.37 (3H, m), 8.09 (1H, s), 8.21 (1H, s), 8.35 (1H, t, J = 4.8 Hz) 34 2.33 (3H, s), 2.58 (2H, s), 2.78 (2H, t, J = 5.9 Hz), 3.18 (3H, s), 3.46 (2H, s), 3.94 (3H, s), 4.27 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.19 (2H, s), 7.00 (3H, d, J = 6.8 Hz), 7.17-7.41 (3H, m), 8.11 (2H, s), 8.90 (1H, d, J = 1.8 Hz) 35 0.35-0.39 (2H, m), 0.47 (2H, dt, J = 6.2, 3.0 Hz), 1.77 (1H, tt, J = 6.6, 3.5 Hz), 2.30 (3H, s), 2.73 (2H, t, J = 6.0 Hz), 2.80 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.67 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.96-7.01 (2H, m), 7.01-7.06 (1H, m), 7.26-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.11 (1H, s), 8.15 (1H, s) 36 2.30 (3H, s), 2.32 (3H, s), 2.57 (2H, s), 2.78 (2H, t, J = 6.0 Hz), 3.17 (3H, s), 3.45 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 5.20 (2H, s), 7.01 (3H, d, J = 5.2 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.13 (1H, s), 8.15 (1H, s) 37 1.04 (6H, d, J = 6.5 Hz), 2.30 (3H, s), 2.66 (2H, d, J = 5.6 Hz), 2.74 (2H, t, J = 5.8 Hz), 2.83 (1H, p, J = 6.4 Hz), 3.17 (3H, s), 3.59 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 4.9 Hz), 4.44 (2H, s), 5.19 (2H, s), 6.98 (2H, d, J = 6.4 Hz), 7.03 (1H, d, J = 8.3 Hz), 7.26-7.33 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.12 (1H, s), 8.15 (1H, s) 38 1.07 (3H, t, J = 7.2 Hz), 2.30 (3H, d, J = 0.8 Hz), 2.47 (2H, t, J = 7.2 Hz), 2.61, (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.49 (2H, s), 3.92 (3H, s), 4.23-4.28 (2H, m), 4.44 (2H, s), 5.20 (2H, s), 6.96-7.06 (3H, m), 7.25-7.35 (2H, m), 8.03 (1H, t, J = 5.1 Hz), 8.10-8.17 (2H, m) 40 1.60-1.71 (2H, m), 1.80-1.90 (2H, m), 2.00-2.06 (2H, m), 2.30 (3H, s), 2.46-2.49 (4H, m), 2.74 (2H, t, J = 6.0 Hz), 2.83 (1H, quin, J = 7.8 Hz), 3.17 (3H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.20 (2H, s), 6.98 (2H, d, J = 7.7 Hz), 7.03 (1H, d, J = 7.8 Hz), 7.25-7.35 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.10-8.17 (2H, m) 41 2.30 (3H, s), 2.54 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 6.0 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.95-7.02 (3H, m), 7.13 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, dd, J = 8.8, 1.3 Hz), 8.07-8.13 (2H, m), 8.98 (1H, s) 42 2.30 (3H, s), 2.54 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.93-7.03 (3H, m), 7.32 (1H, t, J = 8.8 Hz), 7.41 (1H, dd, J = 8.9, 1.4 Hz), 8.09 (1H, s), 8.12 (1H, t, J = 5.3 Hz), 9.11 (1H, s) 43 2.30 (3H, s), 2.54 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.95-7.03 (3H, m), 7.17 (1H, d, J = 2.5 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.2 Hz), 8.09 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 44 1.03 (6H, d, J = 6.5 Hz), 2.64 (2H, t, J = 5.7 Hz), 2.73 (2H, t, J = 5.8 Hz), 2.81 (1H, h, J = 6.5 Hz), 3.17 (3H, s), 3.58 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.94-6.99 (2H, m), 6.99-7.04 (1H, m), 7.18 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, dd, J = 8.9, 1.3 Hz), 8.05-8.14 (2H, m), 8.98 (1H, s) 45 1.03 (6H, d, J = 6.5 Hz), 2.60-2.68 (2H, m), 2.68-2.77 (2H, m), 2.77- 2.88 (1H, m), 3.17 (3H, s), 3.59 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.2 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.91-6.99 (2H, m), 6.99-7.05 (1H, m), 7.32 (1H, t, J = 8.8 Hz), 7.41 (1H, dd, J = 8.9, 1.4 Hz), 8.08 (1H, s), 8.12 (1H, t, J = 5.4 Hz), 9.11 (1H, s) 46 1.03 (6H, d, J = 6.5 Hz), 2.58-2.69 (2H, m), 2.69-2.77 (2H, m), 2.77- 2.87 (1H, m), 3.17 (3H, s), 3.59 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93-7.00 (2H, m), 7.00-7.05 (1H, m), 7.17 (1H, d, J = 2.5 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.2 Hz), 8.08 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 47 0.32-0.39 (2H, m), 0.44-0.50 (2H, m), 1.72-1.79 (1H, m), 2.72 (2H, t, J = 5.9 Hz), 2.79 (2H, t, J = 5.8 Hz), 3.16 (3H, s), 3.66 (2H, s), 3.92 (3H, s), 4.29 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.94-7.00 (2H, m), 7.02 (1H, s), 7.13 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, d, J = 9.1 Hz), 8.05-8.14 (2H, m), 8.98 (1H, s) 48 0.43-0.50 (2H, m), 1.71-1.80 (1H, m), 2.72 (2H, t, J = 5.7 Hz), 2.79 (2H, t, J = 5.8 Hz), 3.16 (3H, s), 3.66 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.3 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.92-7.00 (2H, m), 7.03 (1H, d, J = 7.8 Hz), 7.32 (1H, t, J = 8.8 Hz), 7.41 (1H, dd, J = 8.8, 1.4 Hz), 8.07 (1H, s), 8.12 (1H, t, J = 5.3 Hz), 9.11 (1H, s) 49 0.32-0.40 (2H, m), 0.42-0.50 (2H, m), 1.72-1.79 (1H, m), 2.72 (2H, t, J = 6.0 Hz), 2.80 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.66 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.95-7.01 (2H, m), 7.03 (1H, d, J = 8.3 Hz), 7.17 (1H, d, J = 2.5 Hz), 7.24-7.35 (2H, m), 8.01 (1H, t, J = 5.2 Hz), 8.07 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 50 1.07 (3H, t, J = 7.1 Hz), 2.43-2.49 (2H, m), 2.61 (2H, t, J = 5.8 Hz), 2.75 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.49 (2H, s), 3.92 (3H, s), 4.30 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.95-7.00 (2H, m), 7.00-7.04 (1H, m), 7.18 (1H, t, J = 53.0 Hz), 7.31 (1H, t, J = 8.8 Hz), 7.37 (1H, d, J = 8.9 Hz), 8.07-8.13 (2H, m), 8.98 (1H, s) 51 1.07 (3H, t, J = 7.1 Hz), 2.47 (2H, q, J = 7.4 Hz), 2.60 (2H, t, J = 5.9 Hz), 2.75 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.49 (2H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.1 Hz), 4.42 (2H, s), 5.18 (2H, s), 6.92-6.99 (2H, m), 6.99-7.05 (1H, m), 7.32 (1H, t, J = 8.8 Hz), 7.41 (1H, d, J = 8.9 Hz), 8.09 (1H, s), 8.12 (1H, t, J = 5.3 Hz), 9.11 (1H, s) 52 1.07 (3H, t, J = 7.1 Hz), 2.47 (2H, q, J = 7.4 Hz), 2.60 (2H, t, J = 5.9 Hz), 2.75 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.49 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.96-7.00 (2H, m), 7.03 (1H, d, J = 8.4 Hz), 7.17 (1H, d, J = 2.5 Hz), 7.25-7.35 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.09 (1H, s), 8.31 (1H, d, J = 2.5 Hz) 53 2.30 (3H, s), 3.16 (3H, s), 3.92 (3H, s), 4.25 (2H, d, J = 4.9 Hz), 4.42 (2H, s), 4.46 (4H, t, J = 5.6 Hz), 5.31 (2H, s), 7.24-7.33 (4H, m), 7.37 (1H, d, J = 7.9 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.17 (1H, d, J = 1.0 Hz), 8.19 (1H, s), 9.75 (2H, s) 54 2.31 (3H, s), 2.98 (3H, s), 3.17 (3H, s), 3.93 (3H, s), 4.27 (2H, d, J = 5.0 Hz), 4.43 (6H, s), 5.32 (2H, s), 7.24-7.34 (4H, m), 7.39 (1H, d, J = 7.7 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.18 (1H, s), 8.20 (1H, s), 11.19 (1H, s) 55 1.33 (6H, d, J = 6.5, 2.0 Hz), 2.30 (3H, s), 3.16 (3H, s), 3.61-3.65 (1H, m), 3.92 (3H, s), 4.26 (2H, d, J = 4.2 Hz), 4.42 (2H, s), 4.46-4.54 (2H, m), 4.69 (2H, dd, J = 14.7, 6.1 Hz), 5.32 (2H, s), 7.22 (1H, s), 7.25- (3H, m), 7.36 (1H, d, J = 7.8 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.17 (1H, d, J = 0.9 Hz), 8.20 (1H, s), 11.35 (1H, s) 56 1.08 (3H, t, J = 7.2 Hz), 2.29 (3H, s), 2.65 (2H, q, J = 7.2 Hz), 3.16 (3H, s), 3.78 (4H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.24 (2H, s), 7.04-7.13 (2H, m), 7.19 (1H, d, J = 7.6 Hz), 7.24-7.34 (2H, m), 7.99- 8.05 (1H, m), 8.10-8.17 (2H, m) 57 2.44 (3H, s), 3.17 (3H, s), 3.75 (4H, s), 3.92 (3H, s), 4.27-4.33 (2H, m), 4.43 (2H, s), 5.23 (2H, s), 6.99-7.25 (4H, m), 7.28-7.34 (1H, m), 7.34- 7.40 (1H, m), 8.06-8.14 (2H, m), 8.98 (1H, s) 58 2.44 (3H, s), 3.17 (3H, s), 3.75 (4H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.2 Hz), 4.42 (2H, s), 5.23 (2H, s), 7.02-7.11 (2H, m), 7.15-7.21 (1H, m), 7.29-7.36 (1H, m), 7.38-7.44 (1H, m), 8.08-8.15 (2H, m), 9.11 (1H, s) 59 1.32 (6H, d, J = 6.4 Hz), 3.17 (3H, s), 3.66 (1H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.2 Hz), 4.43 (2H, s), 4.52 (2H, s), 4.71 (2H, d, J = 14.9 Hz), 5.32 (2H, s), 7.15 (1H, t, J = 53.0 Hz), 7.23 (1H, s), 7.28 (1H, d, J = 7.9 Hz), 7.32 (1H, t, J = 8.7 Hz), 7.38 (2H, t, J = 8.8 Hz), 8.12 (1H, s), 8.18 (1H, s), 9.00 (1H, s) 60 1.32 (6H, d, J = 6.4 Hz), 3.17 (3H, s), 3.67 (1H, s), 3.94 (3H, s), 4.33 (2H, d, J = 5.2 Hz), 4.42 (2H, s), 4.53 (2H, s), 4.70 (2H, s), 5.32 (2H, s), 7.22 (1H, s), 7.27 (1H, d, J = 7.9 Hz), 7.35 (2H, q, J = 8.8 Hz), 7.43 (1H, d, J = 8.9 Hz), 8.15 (1H, t, J = 5.3 Hz), 8.17 (1H, s), 9.13 (1H, s) 61 2.28 (3H, s), 2.35 (3H, s), 2.69-2.76 (2H, m), 3.46 (2H, s), 3.89-3.97 (5H, m), 4.22 (2H, d, J = 4.7 Hz), 5.18 (2H, s), 7.13 (1H, s), 7.26-7.34 (2H, m), 8.08 (1H, s), 8.23 (1H, s), 8.38 (1H, t, J = 4.8 Hz) 63 2.31 (3H, s), 2.94 (3H, s), 3.10 (2H, t, J = 21.0 Hz), 3.34 (1H, s), 3.71 (1H, s), 3.94 (3H, s), 4.25 (2H, d, J = 4.6 Hz), 4.37 (1H, d, J = 8.0 Hz), 4.49 (1H, d, J = 17.2 Hz), 5.66 (2H, s), 7.25-7.39 (2H, m), 8.14 (1H, s), 8.44 (1H, s), 8.49 (1H, t, J = 4.8 Hz), 8.74 (1H, s), 10.89 (1H, s) 64 2.30 (3H, s), 2.93 (3H, d, J = 4.1 Hz), 3.07-3.13 (2H, m), 3.16 (3H, s), 3.30-3.40 (1H, m), 3.68-3.76 (1H, m), 3.92 (3H, s), 4.26 (2H, d, J = 4.9 Hz), 4.32-4.40 (1H, m), 4.41 (2H, s), 4.46-4.52 (1H, m), 5.47 (2H, s), 7.26- 7.34 (2H, m), 8.07 (1H, t, J = 5.1 Hz), 8.17 (1H, s), 8.23 (1H, s), 8.40 (1H, s), 11.33 (1H, br s) 68 2.30 (3H, d, J = 0.8 Hz), 2.74 (2H, t, J = 5.7 Hz), 3.18 (3H, s,), 3.85 (2H, t, J = 5.7 Hz), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 4.65 (2H, s), 5.22 (2H, s), 7.00-7.05 (3H, m),7.23-7.35 (2H, m), 8.03 (1H, t, J = 5.0 Hz), 8.10-8.18 (2H, m) 70 2.30 (3H, s), 2.34 (3H, s), 2.79 (2H, t, J = 5.6 Hz), 3.18 (3H, s), 3.50 (2H, s), 3.92 (3H, s), 4.02 (2H, t, J = 5.6 Hz), 4.25 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.16 (2H, s), 5.91 (1H, s), 7.21-7.35 (2H, m), 8.02 (1H, t, J = 5.0 Hz), 8.06 (1H, s), 8.14 (1H, d, J = 0.9 Hz) 73 (Chloroform-d) 2.43 (3H, d, J = 0.8 Hz), 2.98 (2H, t, J = 6.6 Hz), 3.14 (3H, s), 3.37 (3H, d, J = 1.8 Hz), 3.55 (2H, t, J = 6.7 Hz), 3.93 (3H, s), 4.38 (2H, dd, J = 5.7, 1.5 Hz), 4.56 (2H, d, J = 3.5 Hz), 5.23 (2H, s), 6.98 (1H, t, J = 8.7 Hz), 7.10-7.16 (2H, m), 7.18-7.23 (1H, m), 7.80 (1H, s), 7.93 (1H, d, J = 1.0 Hz), 7.97 (1H, d, J = 2.0 Hz), 8.34 (1H, t, J = 6.0 Hz) 82 0.87-0.92 (2H, m), 1.27-1.33 (2H, m), 2.26 (3H, s), 2.35 (3H, s), 2.79 (2H, s), 3.64 (2H, s), 3.92 (3H, s), 4.24 (2H, d, J = 4.8 Hz), 5.24 (2H, s), 5.96 (1H, s), 7.12-7.35 (3H, m), 8.08 (1H, s), 8.17 (1H, s), 8.36 (1H, t, J = 4.9 Hz) 102 2.30 (3H, s), 2.42 (2H, s), 3H under DMSO peak, 2.69 (1H, s), 2.83 (2H, s), 3.17 (3H, s), 3.60 (1H, bm), 3.92 (3H, s), 4.26 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.28 (2H, s), 7.27-7.33 (2H, m), 7.44 (1H, s), 8.03 (1H, t, J = 5.0 Hz), 8.17 (2H, d, J = 13.6 Hz), 8.29 (1H, s) 103 2.30 (6H, d, J = 3.8 Hz), 2.57 (2H, t, J = 5.9 Hz), 2.68 (2H, t, J = 6.0 Hz), 3.18 (3H, s), 3.46 (2H, s), 3.92 (3H, s), 4.27 (2H, d, J = 5.0 Hz), 4.46 (2H, s), 5.28 (2H, s), 6.64 (1H, dd, J = 9.7, 2.6 Hz), 6.90 (1H, dd, J = 9.5, 2.6 Hz), 7.26-7.33 (2H, m), 8.07 (2H, d, J = 12.6 Hz), 8.15 (1H, s) 104 2.30 (3H, s), 2.33 (3H, s), 2.62 (2H, t, J = 6.0 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.18 (3H, s), 3.47 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 5.36 (2H, s), 6.94 (1H, d, J = 7.8 Hz), 7.06 (1H, d, J = 7.9 Hz), 7.25- 7.34 (2H, m), 8.05 (1H, t, J = 5.1 Hz), 8.10 (1H, s), 8.15 (1H, s) 105 2.29 (3H, s), 2.39 (3H, s), 3.01 (2H, t, J = 12.2 Hz), 3.16 (3H, s), 3.58 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.33 (2H, s), 7.21- 7.35 (4H, m), 7.52 (1H, s), 8.04 (1H, t, J = 5.1 Hz), 8.14 (1H, s), 8.19 (1H, s) 106 2.29 (3H, s), 2.39 (3H, s), 3.01 (2H, t, J = 12.2 Hz), 3.17 (3H, s), 3.57 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.32 (2H, s), 7.11 (1H, s), 7.22 (1H, d, J = 8.1 Hz), 7.25-7.34 (2H, m), 7.60 (1H, d, J = 8.1 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.15 (1H, s), 8.18 (1H, s) 107 2.30 (3H, s), 2.38 (4H, s), 2.81 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.48 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.28 (2H, s), 6.96 (1H, d, J = 7.9 Hz), 7.05 (1H, t, J = 7.7 Hz), 7.26-7.34 (2H, m), 8.04 (1H, t, J = 5.1 Hz), 8.11 (1H, s), 8.15 (1H, s) 108 (D2O) 2.27 (3H, s), 2.99 (3H, s), 3.23 (3H, s), 3.57-3.69 (1H, m), 3.76 (2H, m), 3.93 (3H, s), 4.07-4.21 (1H, m), 4.38 (2H, d, J = 8.7 Hz), 4.40- 4.53 (5H, m), 5.27 (2H, s), 7.10 (1H, d, J = 8.9 Hz), 7.19 (2H, d, J = 5.3 Hz), 7.25 (2H, dd, J = 4.5, 2.3 Hz), 7.85-7.92 (1H, m), 7.97 (1H, s) 109 2.30 (3H, s), 2.34 (3H, s), 2.65-2.76 (4H, m), 3.18 (3H, s), 3.53 (2H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.45 (2H, s), 5.58 (2H, s), 7.23-7.36 (2H, m), 8.09 (1H, t, J = 5.0 Hz), 8.15 (1H, s), 8.22 (1H, s) 110 2.30 (3H, s), 2.98-3.02 (2H, m), 3.18 (3H, s), 3.75 (2H, s), 3.92 (5H, d, J = 4.8 Hz), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93 (1H, d, J = 8.1 Hz), 7.06 (1H, dd, J = 8.2, 2.2 Hz), 7.10 (1H, d, J = 2.3 Hz), 7.26- 7.34 (2H, m), 8.03 (1H, t, J = 5.1 Hz), 8.14 (1H, s), 8.16 (1H, s) 114 (d6 DMSO at 90° C.) 2.30 (6H, d, J = 12.1 Hz), 2.57 (2H, t, J = 5.9 Hz), 2.73 (2H, t, J = 6.0 Hz), 3.16 (3H, s), 3.45 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 4.9 Hz), 4.42 (2H, s), 5.27 (2H, s), 6.89 (1H, d, J = 7.9 Hz), 7.03 (1H, t, J = 7.7 Hz), 7.22-7.37 (2H, m), 8.04 (1H, t, J = 5.1 Hz), 8.13 (2H, d, J = 17.6 Hz) 115 2.29 (3H, s), 2.77-2.84 (4H, m), 2.94 (2H, td, J = 15.6, 4.3 Hz), 3.16 (3H, s), 3.74 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.27 (2H, s), 6.22 (1H, tt, J = 55.7, 4.3, 4.2 Hz), 7.25-7.33 (2H, m), 7.41- 7.43 (1H, m), 8.02 (1H, t, J = 5.1 Hz), 8.14 (1H, s), 8.16 (1H, s), 8.27- 8.29 (1H, m) 116 2.30 (3H, s), 2.35 (3H, s), 2.56 (2H, t, J = 5.8 Hz), 2.79 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.92 (3H, s), 4.27 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.23 (2H, s), 6.86 (2H, d, J = 11.4 Hz), 7.27-7.34 (2H, m), 8.03 (1H, t, J = 5.1 Hz), 8.15 (2H, s) 117 1.35 (6H, d, J = 6.6 Hz), 2.30 (3H, d, J = 0.9 Hz), 2.99-3.05 (1H, m), 3.16 (3H, s), 3.20-3.30 (2H, m), 3.64-3.69 (2H, m), 3.92 (3H, s), 4.23-4.28 (2H, m), 4.37-4.43 (4H, m), 5.34 (2H, s), 7.24-7.34 (2H, m), 7.59 (1H, d, J = 2.1 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.17 (1H, s), 8.23 (1H, s), 8.43 (1H, d, J = 2.1 Hz), 10.63 (1H, br. s) 118 2.27-2.32 (6H, m), 2.54 (2H, t, J = 6.0 Hz), 2.79 (2H, t, J = 6.0 Hz), 3.16 (3H, s), 3.39 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.25 (2H, s), 6.94-6.99 (2H, m), 7.25-7.33 (2H, m), 8.04 (1H, t, J = 5.0 Hz), 8.09 (1H, s), 8.13-8.15 (1H, m) 119 2.26-2.32 (3H, m), 2.56 (2H, t, J = 5.8 Hz), 2.77 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.43 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93 (1H, s), 6.97-7.01 (1H, m), 7.04-7.10 (1H, m), 7.24- 7.33 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.11 (1H, s), 8.14-8.15 (1H, m) 120 1.44-1.54 (1H, m), 1.71-1.83 (2H, m), 2.22-2.32 (4H, m), 2.33-2.40 (1H, m), 2.42-2.48 (1H, m), 2.67-2.75 (1H, m), 2.86-3.00 (2H, m), 3.04-3.12 (1H, m), 3.16 (3H, s), 3.19-3.28 (1H, m), 3.92 (3H, s), 4.25 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.21 (2H, s), 6.95-7.02 (2H, m), 7.07 (1H, d, J = 7.8 Hz), 7.23-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.11 (1H, s), 8.14 (1H, s) 121 2.23-2.27 (3H, m), 2.29 (3H, s), 2.39-2.47 (4H, m), 2.78-2.84 (4H, m), 3.17 (3H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.20 (2H, s), 6.97 (1H, dd, J = 7.6, 1.9 Hz), 7.00 (1H, d, J = 1.8 Hz), 7.08 (1H, d, J = 7.6 Hz), 7.25-7.33 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.12 (1H, s), 8.15 (1H, d, J = 0.9 Hz) 122 0.93 (6H, s), 2.29 (3H, s), 2.47-2.54 (4H, m), 2.73-2.83 (4H, m), 2.83- 2.92 (1H, m), 3.17 (3H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.1 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93-7.02 (2H, m), 7.08 (1H, d, J = 7.8 Hz), 7.25-7.34 (2H, m), 8.02 (1H, t, J = 5.0 Hz), 8.13 (1H, s), 8.15 (1H, s) 123 1.21 (3H, d, J = 6.5 Hz), 1.25 (3H, dd, J = 6.4, 2.4 Hz), 1.39-1.49 (2H, m), 2.31 (3H, dd, J = 4.8, 0.8 Hz), 2.32-2.44 (2H, m), 3.17 (3H, d, J = 0.9 Hz), 3.27-3.34 (1H, m), 3.93 (3H, s), 4.27 (2H, d, J = 4.0 Hz), 4.43 (2H, d, J = 13.1 Hz), 5.31-5.44 (4H, m), 7.24-7.36 (4H, m), 7.44-7.50 (1H, m), 8.05 (1H, q, J = 5.4 Hz), 8.19 (1H, dd, J = 6.4, 1.0 Hz), 8.23 (1H, d, J = 4.0 Hz), 9.80 (0.5H, d, J = 9.1 Hz), 10.56 (0.5H, d, J = 8.6 Hz) 124 1.37 (3H, s), 1.72 (3H, s), 2.29 (3H, s), 2.83 (3H, d, J = 5.0 Hz), 3.16 (3H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 4.47 (1H, dd, J = 14.3, 8.2 Hz), 4.61 (1H, dd, J = 14.3, 5.5 Hz), 5.31 (2H, s), 7.19 (1H, dd, J = 7.9, 1.5 Hz), 7.25-7.35 (3H, m), 7.38 (1H, d, J = 7.9 Hz), 8.05 (1H, t, J = 5.1 Hz), 8.17 (1H, d, J = 1.0 Hz), 8.21 (1H, s), 11.19 (1H, s) 125 2.28 (3H, s), 2.36 (3H, s), 2.80 (2H, t, J = 5.6 Hz), 3.53 (2H, s), 3.93 (3H, s), 4.04 (2H, t, J = 5.6 Hz), 4.23 (2H, d, J = 4.7 Hz), 5.30 (2H, s), 5.99 (1H, s), 7.26-7.35 (2H, m), 8.09 (1H, s), 8.26 (1H, s), 8.39 (1H, t, J = 4.8 Hz) 126 0.80-0.92 (4H, m), 2.28 (3H, s), 2.29 (3H, s), 2.40 (2H, s), 3.17 (3H, s), 3.53 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.17 (2H, s), 6.67 (1H, d, J = 8.1 Hz), 6.92 (1H, d, J = 1.8 Hz), 6.97 (1H, dd, J = 8.2, 1.9 Hz), 7.24-7.34 (2H, m), 8.02 (1H, t, J = 5.1 Hz), 8.10 (1H, s), 8.14 (1H, s) 127 0.77-0.83 (2H, m), 0.85-0.91 (2H, m), 2.29 (3H, s), 2.75 (2H, s), 3.16 (3H, s), 3.85-3.95 (5H, m), 4.25 (2H, d, J = 5.0 Hz), 4.42 (2H, s), 5.17 (2H, s), 6.69 (1H, d, J = 8.1 Hz), 6.91 (1H, s), 6.98 (1H, d, J = 8.1 Hz), 7.24-7.34 (2H, m), 8.01 (1H, t, J = 5.1 Hz), 8.10 (1H, s), 8.15 (1H, s) 128 1.31 (6H, s), 2.30 (3H, s), 2.62 (3H, t, J = 5.8 Hz), 2.91 (2H, t, J = 5.8 Hz), 3.17 (3H, s), 3.92 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 5.21 (2H, s), 6.89 (1H, dd, J = 7.6, 1.7 Hz), 6.98 (1H, d, J = 7.8 Hz), 7.20 (1H, d, J = 1.7 Hz), 7.23-7.35 (2H, m), 8.03 (1H, t, J = 5.0 Hz), 8.14 (2H, d, J = 13.4 Hz) 129 1.28 (6H, s), 2.29 (3H, s), 2.31 (3H, s), 2.71 (4H, s), 3.16 (3H, s), 3.91 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.44 (2H, s), 5.22 (2H, s), 6.85-6.94 (1H, m), 6.99 (1H, d, J = 7.8 Hz), 7.22-7.34 (3H, m), 8.02 (1H, t, J = 5.1 Hz), 8.13 (1H, s), 8.14 (1H, d, J = 1.0 Hz) 130 1.17 (6H, s), 2.29 (3H, s), 2.67 (2H, s), 3.17 (3H, s), 3.80 (2H, s), 3.92 (3H, s), 4.22-4.29 (2H, m), 4.43 (2H, s), 5.17 (2H, s), 6.84-6.89 (1H, m), 6.99-7.05 (1H, m), 7.24-7.33 (3H, m), 8.02 (1H, t, J = 5.1 Hz), 8.10-8.17 (2H, m), NH not observed. 131 2.26-2.30 (3H, m), 2.36 (3H, s), 2.60 (2H, t, J = 5.9 Hz), 2.81 (2H, t, J = 5.9 Hz), 3.49 (2H, s), 3.93 (3H, s), 4.22-4.26 (2H, m), 5.43 (2H, s), 7.04 (1H, d, J = 7.8 Hz), 7.27-7.35 (2H, m), 7.56 (1H, d, J = 7.9 Hz), 8.10 (1H, d, J = 1.0 Hz), 8.33 (1H, d, J = 1.0 Hz), 8.41 (1H, t, J = 4.8 Hz) 132 1.34 (6H, t, J = 6.8 Hz), 2.30 (3H, s), 3.08-3.15 (1H, m), 3.16 (3H, s), 3.32-3.45 (2H, m), 3.59-3.66 (1H, m), 3.68-3.74 (1H, m), 3.92 (3H, s), 4.26 (2H, d, J = 4.6 Hz), 4.35-4.47 (4H, m), 5.38 (2H, s), 7.24-7.35 (2H, m), 7.61 (1H, s), 8.06 (1H, t, J = 5.1 Hz), 8.19 (1H, s), 8.25 (1H, s), 8.54 (1H, d, J = 2.0 Hz), 10.97 (1H, s) 133 2.30 (s, 3H), 2.74 (t, 2H, J = 5.8 Hz), 3.17 (s, 3H), 3.85 (t, 2H, J = 5.8 Hz), 3.92 (s, 3H), 4.26 (d, 2H, 5.0 Hz), 4.44 (s, 2H), 4.64 (s, 2H), 5.21 (s, 2H), 6.90-6.95 (m, 1H), 7.05 (dd, 1H, J = 7.8, 1.9 Hz), 7.11 (d, 1H, J = 7.8 Hz), 7.25-7.34 (m, 2H), 8.03 (t, 1H, 5.0 Hz), 8.13 (s, 1H), 8.16 (s, 1H) 134 1.20 (6H, s), 2.22-2.35 (8H, m), 3.17 (3H, s), 3.40 (2H, s), 3.92 (3H, s), 4.25 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.18 (2H, s), 6.89 (1H, d, J = 1.9 Hz), 7.02 (1H, dd, J = 8.0, 1.9 Hz), 7.25-7.34 (3H, m), 8.02 (1H, t, J = 5.1 Hz), 8.14 (2H, d, J = 8.5 Hz) 135 2.29 (3H, d, J = 0.8 Hz), 2.93 (2H, t, J = 6.7 Hz), 3.00 (3H, s), 3.17 (3H, s), 3.51 (2H, t, J = 6.7 Hz), 3.92 (3H, s), 4.26 (2H, d, J = 5.1 Hz), 4.44 (2H, s), 5.32 (2H, s), 7.12 (1H, d, J = 1.7 Hz), 7.17 (1H, dd, J = 1.7, 8.0 Hz), 7.25- 7.34 (2H, m), 7.82 (1H, d, J = 7.9 Hz), 8.04 (1H, t, J = 5.1 Hz), 8.15 (1H, d, J = 1.0 Hz), 8.19 (1H, s) 136 2.27 (3H, s), 2.35 (3H, s), 2.80 (2H, t, J = 5.6 Hz), 3.52 (2H, s), 3.92 (3H, s), 4.04 (2H, t, J = 5.6 Hz), 4.24 (2H, d, J = 4.8 Hz), 5.26 (2H, s), 5.97 (1H, s), 7.09-7.39 (3H, m), 8.09 (1H, d, J = 0.9 Hz), 8.22 (1H, s), 8.37 (1H, t, J = 4.9 Hz) 137 2.26 (3H, s), 2.35 (3H, s), 2.59 (2H, t, J = 5.9 Hz), 2.81 (2H, t, J = 5.9 Hz), 3.51 (2H, s), 3.92 (3H, s), 4.24 (2H, d, J = 4.8 Hz), 5.38 (2H, s), 7.11- 7.34 (3H, m), 7.46 (1H, d, J = 2.1 Hz), 8.06-8.10 (1H, m), 8.22-8.26 (1H, m), 8.32 (1H, d, J = 2.2 Hz), 8.35 (1H, t, J = 4.9 Hz) 138 2.29 (3H, s), 2.92 (3H, s), 3.07 (1H, d, J = 17.9 Hz), 3.27 (1H, d, J = 17.8 Hz), 3.44 (1H, d, J = 9.9 Hz), 3.70 (1H, s), 3.93 (3H, s), 4.25 (2H, d, J = 4.9 Hz), 4.32 (1H, dd, J = 15.9, 8.2 Hz), 4.51 (1H, d, J = 15.5 Hz), 5.51 (2H, s), 7.17 (1H, d, J = 8.0 Hz), 7.28-7.35 (2H, m), 7.68 (1H, d, J = 8.0 Hz), 8.13 (1H, s), 8.42 (1H, s), 8.46 (1H, s) 147 1.36 (6H, d, J = 6.5 Hz), 2.34 (3H, s), 3.29 (3H, s), 3.70 (1H, d, J = 6.9 Hz), 3.94 (3H, s), 4.35 (2H, d, J = 5.3 Hz), 4.47 (2H, s), 4.54 (2H, d, J = 14.0 Hz), 4.72 (2H, d, J = 14.5 Hz), 5.28 (2H, s), 7.20-7.35 (4H, m), 7.39 (1H, d, J = 7.8 Hz), 7.62 (1H, s), 7.65 (1H, t, J = 6.0 Hz), 8.11 (1H, s), 11.34 (1H, s) 148 2.33 (6H, d, J = 10.0 Hz), 2.61 (2H, d, J = 6.2 Hz), 2.79 (2H, t, J = 5.8 Hz), 3.24 (3H, s), 3.48 (2H, s), 3.91 (3H, s), 4.28 (2H, d, J = 5.8 Hz), 4.41 (2H, s), 5.14 (2H, s), 6.94 (1H, s), 7.00 (1H, d, J = 7.9 Hz), 7.09 (1H, d, J = 7.9 Hz), 7.29 (2H, d, J = 8.2 Hz), 7.63 (1H, s), 7.86 (1H, t, J = 5.8 Hz), 8.22 (1H, s) 149 0.80 (2H, dt, J = 5.2, 2.9 Hz), 0.86 (2H, dt, J = 8.1, 3.0 Hz), 1.94 (1H, ddd, J = 13.0, 8.3, 4.9 Hz), 2.32 (6H, d, J = 4.2 Hz), 2.57 (2H, t, J = 6.0 Hz), 2.78 (2H, t, J = 5.9 Hz), 3.45 (2H, s), 3.91 (3H, s), 4.30 (2H, d, J = 5.9 Hz), 5.20 (2H, s), 6.91 (1H, s), 6.97 (1H, d, J = 8.1 Hz), 7.09 (1H, d, J = 7.9 Hz), 7.29 (2H, d, J = 7.9 Hz), 7.56 (1H, s), 7.62 (1H, t, J = 6.0 Hz), 8.22 (1H, s) 150 0.96 (4H, d, J = 7.8 Hz), 1.37 (6H, d, J = 6.5 Hz), 2.02 (1H, p, J = 6.7 Hz), 2.34 (3H, s), 3.69 (1H, s), 3.94 (3H, s), 4.33-4.37 (2H, m), 4.54 (2H, d, J = 12.5 Hz), 4.72 (2H, d, J = 14.8 Hz), 5.38 (2H, s), 7.24-7.32 (4H, m), 7.40 (1H, d, J = 7.9 Hz), 7.66 (1H, s), 7.84 (1H, s), 8.11 (1H, s), 11.60 (1H, s) 151 2.23 (3H, s), 2.31 (3H, s), 2.33 (3H, s), 2.56 (2H, t, J = 5.9 Hz), 2.78 (2H, t, J = 5.9 Hz), 3.44 (2H, s), 3.91 (3H, s), 4.27 (2H, d, J = 5.8 Hz), 5.09 (2H, s), 6.86 (1H, s), 6.91-6.95 (1H, m), 7.09 (1H, d, J = 7.8 Hz), 7.29 (2H, d, J = 7.8 Hz), 7.59 (1H, s), 7.78 (1H, t, J = 5.8 Hz), 8.23 (1H, s) 152 2.29 (3H, s), 2.30 (3H, s), 2.55 (2H, t, J = 6.0 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.43 (2H, s), 3.90 (3H, s), 4.32 (2H, d, J = 5.3 Hz), 5.54 (2H, s), 7.01 (1H, s), 7.03-7.12 (2H, m), 7.24-7.33 (2H, m), 8.18 (1H, s), 8.51 (1H, t, J = 5.5 Hz), 8.55 (1H, s) 153 1.33 (6H, dd, J = 6.5, 2.2 Hz), 2.30 (3H, s), 3.60-3.71 (1H, m), 3.91 (3H, s), 4.33 (2H, d, J = 4.8 Hz), 4.51 (2H, dd, J = 14.3, 8.3 Hz), 4.70 (2H, dd, J = 14.5, 6.7 Hz), 5.68 (2H, s), 7.25-7.34 (3H, m), 7.35-7.42 (2H, m), 8.20 (1H, s), 8.53 (1H, t, J = 5.5 Hz), 8.62 (1H, s), 11.44 (1H, s) 155 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.17 (3H, s), 3.42 (2H, s), 4.39 (2H, d, J = 5.3 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.92 (1H, s), 6.98 (1H, dd, J = 7.8, 1.8 Hz), 7.03-7.28 (2H, m), 7.49 (1H, dd, J = 8.7, 1.4 Hz), 7.80 (1H, t, J = 8.2 Hz), 8.08 (1H, s), 8.18 (1H, t, J = 5.3 Hz), 9.10 (1H, s) 156 2.30 (3H, s), 2.55 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.15 (3H, s), 3.42 (2H, s), 3.95 (3H, s), 4.28 (2H, d, J = 5.0 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.93 (1H, s), 6.99 (1H, dd, J = 7.9, 1.8 Hz), 7.06 (1H, d, J = 7.8 Hz), 7.19 (1H, t, J = 53.0 Hz), 7.31 (1H, d, J = 8.9 Hz), 7.54 (1H, d, J = 8.8 Hz), 8.06 (1H, t, J = 5.0 Hz), 8.12 (1H, s), 8.94 (1H, s) 157 2.06 (3H, t, J = 19.2 Hz), 2.30 (3H, s), 2.54 (2H, t, J = 5.9 Hz), 2.76 (2H, t, J = 5.9 Hz), 3.16 (3H, s), 3.41 (2H, s), 4.41-4.45 (4H, m), 5.19 (2H, s), 6.90-6.93 (1H, m), 6.96-7.00 (1H, m), 7.05 (1H, d, J = 7.0 Hz), 7.17 (1H, t, J = 51.9 Hz), 7.55 (1H, d, J = 8.4 Hz), 7.73 (1H, d, J = 8.1 Hz), 8.09 (1H, s), 8.17 (1H, dd, J = 5.3 Hz), 9.14 (1H, s) 158 2.24 (3H, s), 2.38-2.47 (4H, m), 2.77-2.84 (4H, m), 3.17 (3H, s), 3.93 (3H, s), 4.31 (2H, d, J = 5.4 Hz), 4.43 (2H, s), 5.19 (2H, s), 6.95 (1H, dd, J = 7.5, 1.9 Hz), 6.98 (1H, d, J = 1.8 Hz), 7.07 (1H, d, J = 7.6 Hz), 7.32 (1H, dd, J = 8.8 Hz), 7.42 (1H, dd, J = 8.9, 1.4 Hz), 8.09 (1H, s), 8.12 (1H, t, J = 5.3 Hz), 9.11 (1H, d, J = 0.9 Hz) 159 1.11 (2H, s), 2.29 (3H, s), 2.35 (3H, s), 2.62 (2H, t, J = 5.9 Hz), 2.78 (2H, t, J = 6.0 Hz), 3.08 (1H, s), 3.48 (2H, s), 3.93 (3H, s), 4.29 (2H, d, J = 4.8 Hz), 5.02 (2H, s), 6.40 (1H, dd, J = 7.1, 1.9 Hz), 6.59 (1H, s), 6.66 (1H, d, J = 1.9 Hz), 6.96 (1H, s), 6.98-7.11 (2H, m), 7.19-7.35 (2H, m), 7.81 (1H, d, J = 7.1 Hz), 8.12 (1H, s), 8.74 (1H, t, J = 4.8 Hz) 160 2.26 (3H, s), 2.31 (3H, s), 2.56 (2H, t, J = 6.0 Hz), 2.77 (2H, t, J = 6.0 Hz), 3.43 (2H, s), 3.92 (3H, s), 4.28 (2H, d, J = 4.7 Hz), 5.04 (2H, s), 6.41 (1H, d, J = 9.6 Hz), 6.96 (1H, s), 7.00-7.09 (2H, m), 7.23-7.34 (2H, m), 7.74 (1H, dd, J = 9.6, 2.6 Hz), 8.12 (1H, s), 8.28 (1H, d, J = 2.6 Hz), 8.38 (1H, t, J = 4.9 Hz) 161 2.25 (3H, s), 2.30 (3H, s), 2.54 (2H, t, J = 5.9 Hz), 2.75 (2H, t, J = 6.0 Hz), 3.41 (2H, s), 3.92 (5H, s), 4.34 (2H, d, J = 4.7 Hz), 6.91 (1H, s), 6.95- 7.05 (2H, m), 7.23-7.34 (2H, m), 7.85 (1H, t, J = 2.2 Hz), 8.12 (1H, s), 8.57 (1H, d, J = 2.1 Hz), 8.66 (1H, d, J = 2.0 Hz), 8.77 (1H, t, J = 4.9 Hz) 162 (Chloroform-d) 2.43 (3H, d, J = 0.8 Hz), 2.99 (1H, dd, J = 17.4, 6.2 Hz), 3.35 (3H, s), 3.36 (3H, s), 3.46-3.56 (1H, m), 3.61 (1H, dt, J = 11.7, 6.1 Hz), 3.64-3.75 (1H, m), 3.93 (3H, s), 4.36-4.41 (2H, m), 4.44-4.57 (2H, m), 4.55 (2H, s), 5.17 (2H, s), 6.90 (1H, s), 6.99 (1H, t, J = 8.7 Hz), 7.13 (2H, dd, J = 8.8, 1.7 Hz), 7.21 (1H, d, J = 7.9 Hz), 7.84 (2H, d, J = 13.6 Hz), 8.27-8.34 (1H, m) RC1 2.28 (3H, s), 3.17 (3H, s), 3.91 (3H, s), 4.26 (2H, d, J = 5.0 Hz), 4.45 (2H, s), 5.51 (2H, s), 7.23-7.34 (2H, m), 7.60-7.68 (1H, m), 7.81 (1H, d, J = 5.7 Hz), 7.92-8.00 (2H, m), 8.04 (1H, t, J = 5.0 Hz), 8.15 (1H, d, J = 1.0 Hz), 8.24 (1H, s), 8.50 (1H, d, J = 5.7 Hz), 9.30 (1H, s) RC2 2.64 (3H, s), 3.19 (3H, s), 3.93 (3H, s), 4.23 (2H, d, J = 4.8 Hz), 4.44 (2H, s), 5.46 (2H, s), 7.33-7.43 (3H, m), 7.56 (1H, dd, J = 8.7, 1.5 Hz), 7.76 (1H, d, J = 1.2 Hz), 7.88 (1H, d, J = 8.6 Hz), 8.18-8.23 (3H, m), 9.75 (1H, s) RC3 3.19 (3H, s), 3.93 (3H, s), 4.24 (2H, d, J = 5.4 Hz), 4.44 (2H, s), 5.50 (2H, s), 7.29-7.44 (2H, m), 7.53 (1H, dd, J = 8.3, 4.2 Hz), 7.61 (1H, dd, J = 8.7, 2.0 Hz), 7.82 (1H, d, J = 1.9 Hz), 8.00 (1H, d, J = 8.7 Hz), 8.18 (1H, t, J = 5.3 Hz), 8.21 (1H, s), 8.35 (1H, dd, J = 8.4, 1.8 Hz), 8.89 (1H, dd, J = 4.2, 1.7 Hz), 9.74 (1H, s) RC5 1.89-1.92 (4H, m), 3.17 (3H, s), 3.43-3.46 (4H, m), 3.92 (3H, s), 4.22 (2H, d, J = 4.4 Hz), 4.42 (2H, s), 5.10 (2H, s), 7.29-7.35 (2H, m), 7.92 (1H, d, J = 0.8 Hz), 8.04 (1H, t, J = 5.0 Hz), 8.09 (1H, s), 8.34 (2H, s), 8.45 (1H, d, J = 0.9 Hz) RC6 1.89-1.92 (4H, m), 2.28 (3H, s), 3.17 (3H, s), 3.45 (4H, t, J = 6.6 Hz), 3.92 (3H, s), 4.24 (2H, d, J = 4.6 Hz), 4.42 (2H, s), 5.11 (2H, s), 7.25-7.32 (2H, m), 8.00 (1H, t, J = 5.0 Hz), 8.09 (1H, s), 8.13 (1H, s), 8.34 (2H, s) RC7 1.89-1.92 (4H, m), 3.17 (3H, s), 3.43-3.46 (4H, m), 3.93 (3H, s), 4.25 (2H, d, J = 4.8 Hz), 4.42 (2H, s), 5.10 (2H, s), 7.28 (1H, t, J = 54.1 Hz), 7.31-7.38 (2H, m), 8.08 (1H, s), 8.09 (1H, t, J = 5.1 Hz), 8.33 (2H, s), 8.89 (1H, t, J = 1.4 Hz) - Some of the specific examples in Table 11 were isolated in the form of their pharmaceutically acceptable salts, typically HCl salt. Thus, 1H NMR data was collected for some of these specific examples when in the form of a pharmaceutically acceptable salt. Where 1H NMR data has been collected on a HCl salt of one of the specific examples, an extra proton may have been detected. Those skilled in the art would readily be able to identify this extra proton. Those skilled in the art would also readily know how to convert from a salt form to a free base (and vice versa).
- Biological Methods
- The ability of the compounds of formula (I) to inhibit plasma kallikrein may be determined using the following biological assay:
- Determination of the IC50 for Plasma Kallikrein
- Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori et al., Biochem. Pharmacol., 1992, 43, 1209; Sturzebecher et al., Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human plasma kallikrein (Protogen) was incubated at 25° C. with the fluorogenic substrate H-DPro-Phe-Arg-AFC and various concentrations of the test compound. Residual enzyme activity (initial rate of reaction) was determined by measuring the change in optical absorbance at 410 nm and the IC50 value for the test compound was determined.
- Data acquired from this assay are shown in Table 12 using the following scale:
-
Category IC50 (nM) A <10 B 10-30 C 30-100 D 100-1000 - Selected compounds were further screened for inhibitory activity against the related enzyme KLK1. The ability of the compounds of formula (I) to inhibit KLK1 may be determined using the following biological assay:
- Determination of the IC50 for KLK1
- KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori et al., Biochem. Pharmacol., 1992, 43, 1209; Sturzebecher et al., Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human KLK1 (Callbiochem) was incubated at 25° C. with the fluorogenic substrate H-DVal-Leu-Arg-AFC and various concentrations of the test compound. Residual enzyme activity (initial rate of reaction) was determined by measuring the change in optical absorbance at 410 nm and the IC50 value for the test compound was determined.
- Data acquired from this assay are shown in Table 12.
- Selected compounds were further screened for inhibitory activity against the related enzyme FXIa. The ability of the compounds of formula (I) to inhibit FXIa may be determined using the following biological assay:
- Determination of the % Inhibition for FXIa
- FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori et al., Biochem. Pharmacol., 1992, 43, 1209; Sturzebecher et al., Biol. Chem. Hoppe-Seyler, 1992, 373, 1025). Human FXIa (Enzyme Research Laboratories) was incubated at 25° C. with the fluorogenic substrate Z-Gly-Pro-Arg-AFC and 40 μM of the test compound (or alternatively at various concentrations of the test compound in order to determine IC50). Residual enzyme activity (initial rate of reaction) was determined by measuring the change in optical absorbance at 410 nm and the IC50 value for the test compound was determined.
- Data acquired from this assay are shown in Table 12.
-
TABLE 12 Enzyme inhibition data Example IC50 IC50 IC50 Number (human PKal) (human KLK1) nM (human FXIa) nM 1 A >40000 >40000 2 A >40000 >40000 3 A >40000 >40000 4 A >40000 1030 6 A >40000 >40000 7 A >40000 >40000 8 B >40000 >40000 9 C >40000 >40000 11 A >40000 18900 12 A >40000 >40000 13 A >40000 >40000 14 A >40000 28100 15 A >40000 >40000 16 A >40000 >40000 17 A >40000 >40000 18 A >40000 >40000 19 A >40000 >40000 20 B >40000 >40000 21 A >40000 36800 22 A >40000 >40000 23 A >40000 >40000 24 A >40000 23800 25 A >40000 >40000 26 A >40000 >40000 27 A >40000 33900 29 A >40000 >40000 30 A >40000 39600 31 A >40000 34600 32 A >40000 19600 33 A 34 A >40000 >40000 35 C >40000 >40000 36 A >4000 >4000 37 A >40000 >40000 38 A >40000 >40000 40 B >40000 >40000 41 A >40000 >40000 42 A >40000 >40000 43 A >40000 31800 44 A >40000 >40000 45 A >40000 >40000 46 A >40000 >40000 47 C >40000 >40000 48 C >40000 >40000 49 B >40000 >40000 50 A >40000 >40000 51 A >40000 >40000 52 A >40000 >40000 53 C >4000 >4000 54 A >4000 >4000 55 A >40000 >40000 56 A >40000 16300 57 A >40000 28800 58 A >40000 17000 59 A >40000 >40000 60 A >40000 >40000 61 C >40000 >40000 64 C >40000 >40000 68 B >40000 >40000 70 B >40000 >40000 73 C >40000 11300 82 A >40000 18200 102 A >40000 34200 103 C >40000 >40000 104 C >40000 >40000 105 A >40000 30000 106 A >40000 23100 107 A >40000 >40000 108 D >40000 >40000 109 D >40000 >40000 110 D >40000 >40000 114 B >40000 >40000 115 B >4000 >4000 116 A >4000 >4000 117 B >40000 >40000 118 A >40000 9900 119 A 120 A >40000 >40000 121 A >40000 >40000 122 A >40000 >40000 123 C >40000 >40000 124 C >40000 >40000 125 A >40000 >40000 126 A >40000 >40000 127 A >40000 >40000 128 C 129 B 130 B 131 B 132 B 133 D >40000 >40000 134 B >40000 >40000 135 B >40000 16296 136 A >40000 >40000 137 A >40000 21890 138 B >40000 >40000 147 B >40000 >40000 148 B >40000 >40000 149 B >40000 >40000 150 B >40000 >40000 151 B >40000 >40000 152 A >40000 >40000 153 A >40000 >40000 155 D >40000 >40000 156 A >40000 >40000 157 D >40000 >40000 158 A >40000 >40000 159 D >40000 >40000 160 A >40000 >40000 161 A >40000 >40000 RC1 D RC2 A >40000 218 RC3 A >40000 1920 RC4 A >40000 127 RC5 A >40000 970 RC6 A >40000 1840 RC7 A >40000 559 - Selected compounds were further screened for solubility in Fasted State Simulated Intestinal Fluid (FaSSIF). The solubility after 24 hrs in FaSSIF of the compounds of formula (I) may be determined using the following test method:
- Approximately 1 mg of test compound is accurately weighed into a 2 mL vial. Volumes of the FaSSIF solution (pre-heated to 37° C.) were added to a vial to give a nominal concentration of 1 mg/mL (as free base). The FaSSIF solution was prepared on the day of use. The samples were vortexed before being placed in a Titramax 1000 shaker for 24 hrs at 37° C. and approximately 500 rpm. The samples were transferred to eppendorf tubes and centrifuged at 15,000 g (r.c.f.) for 10 min at 37° C. and analysed for concentration of test compound by LCMS.
- Data acquired from this assay are shown in Table 13.
-
TABLE 13 Solubility Example FASSIF Solubility Number 24 hrs, mg/ mL 1 0.93 2 0.71 4 >1 11 0.73 13 0.86 15 >1 22 0.76 23 0.87 24 0.73 25 1.00 26 >1 27 0.96 30 0.92 34 >1 35 0.51 36 0.88 37 >1 38 0.74 40 >1 41 >1 42 0.87 43 0.80 44 >1 45 0.84 46 >1 50 0.72 51 0.77 54 0.82 55 >1 117 0.90 118 0.93 119 0.96 122 0.73 125 0.65 126 0.88 127 0.81 132 0.56 133 0.05 136 0.73 137 0.81 138 >1 147 >1 148 >1 149 0.91 151 0.75 152 1.00 153 0.95 156 >1 160 0.82 161 >1 RC1 0.04 RC2 0.02 RC3 0.02 RC4 0.17 RC5 0.02 RC6 0.10 RC7 0.01 - Pharmacokinetics
- Pharmacokinetic studies of the compounds in Table 14 were performed to assess the pharmacokinetics following a single oral dose in male Sprague-Dawley rats. Two rats were given a single po dose of 5 mL/kg of a nominal 1 mg/mL (5 mg/kg) composition of test compound in 10% DMSO/10% cremophor/80% SWFI vehicle. Following dosing, blood samples were collected over a period of 24 hours. Sample times were 5, 15 and 30 minutes then 1, 2, 4, 6, 8 and 12 hours. Following collection, blood samples were centrifuged and the plasma fraction analysed for concentration of test compound by LCMS. Oral exposure data acquired from these studies are shown below:
-
TABLE 14 Oral exposure data Example Dose po Cmax Number (mg/kg) (ng/mL) 1 6.1 88 2 6.8 134 13 5 88 15 5.1 78 23 4.9 20 24 5.1 24 37 5.0 38 38 6.1 51 46 5.6 34 54 5.0 154 55 5 136 126 6.3 63 127 5.2 9 - X-Ray Crystal Data
- Crystal structures were solved with molecular replacement using the structure of human plasma kallikrein bound to benzamidine (PDB code 2ANW) (Tang, Journal of Biological Chemistry, Vol. 280, no. 49, pp. 41077-41089, Dec. 9, 2005). The residues are numbered using the canonical chymotrypsin numbering system.
FIGS. 1 to 20 were constructed using Maestro (Schrodinger). -
FIGS. 1 to 20 show that compounds of the invention can make a series of key interactions with plasma kallikrein. In particular, compounds of the invention can make a cation Pi interaction between Trp215 and the heteroatom on A″. Moreover, upon binding to plasma kallikrein, compounds of the invention can cause a shift in Trp215 to maximise the favourability of the cation Pi interaction. RC4 does not make this cation Pi interaction with Trp215. Without wishing to be bound by theory, the inventors consider that this cation Pi interaction contributes to the effects of the invention, which are inter alia, providing compounds with high potency and selectivity for inhibiting plasma kallikrein, and high solubility.
Claims (47)
1. A compound of formula (I),
wherein:
W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N, O or N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
R5, R6, and R7 are independently absent or independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14;
R16 is independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14; or
W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N or N, and one of R5, R6, R7 or R16 is oxo such that the ring containing W, X, Y and Z is 2-pyridone or 4-pyridone;
wherein the others of R5, R6, R7 and R16 are independently absent or independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14;
B is of Formula (II) comprising aromatic rings B′ and B″ that are linked by a bond:
B′ is phenyl or pyridyl;
B″ is pyrrole, pyrazole, triazole, or tetrazole;
n is 0, 1, or 2;
R9 and R10 are independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, or CF3;
Each R11 is independently alkyl, cycloalkyl, alkoxy, halo, OH, —COOR13, —CONR13NR14, CN, or CF3;
A is a heterocyclic ring of Formula (III) comprising an aromatic ring (A′) fused to a non-aromatic ring (A″):
A′1 and A′2 are independently C or N;
A′ is heteroaryl or phenyl, wherein phenyl optionally substituted with 1, 2, or 3 substituents that are independently alkyl, alkoxy, OH, OCF3, halo, CN, or CF3, and wherein heteroaryl is optionally substituted as stated below;
A″ is heterocycloalkyl;
optionally wherein a carbon ring atom on A″ is substituted with an alkylene or a heteroalkylene such that the carbon ring atom on A″ together with the alkylene or the heteroalkylene forms a cycloalkyl or heterocycloalkyla that is spiro to ring A″; and/or
optionally wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members;
alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl is optionally substituted with 1 or 2 substituents that are independently (C1-C6)alkoxy, OH, —NR13R14, —COOR13, —CONR13R14, CN, CF3, or halo;
alkylb is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb is optionally substituted with 1 or 2 substituents that are independently (C1-C6)alkoxy, OH, CN, CF3, or halo;
alkylene is a bivalent linear saturated hydrocarbon having 1 to 5 carbon atoms (C1-C5); alkylene is optionally substituted with 1 or 2 substituents that are independently alkyl, (C1-C6)alkoxy, OH, CN, CF3, or halo;
aryl is phenyl, biphenyl or naphthyl; aryl is optionally substituted with 1, 2 or 3 substituents that are independently alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, heteroaryla, —(CH2)0-3—O-heteroaryla, arylb, —O-arylb, —(CH2)1-3-arylb, —(CH2)1-3-heteroaryla, —COOR13, —CONR13R14, —(CH2)0-3—NR13R14, OCF3 or CF3;
arylb is phenyl, biphenyl or naphthyl; arylb is optionally substituted with 1, 2 or 3 substituents that are independently alkylb, alkoxy, OH, halo, CN, or CF3;
heteroalkylene is a bivalent linear saturated hydrocarbon having 2 to 5 carbon atoms (C2-C5), wherein at least one of the 2 to 5 carbon atoms is replaced with NR8, S, or O; heteroalkylene is optionally substituted with 1 or 2 substituents that are independently alkyl (C1-C6)alkoxy, OH, CN, CF3, or halo;
cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl is optionally substituted with 1 or 2 substituents that are independently alkyl, (C1-C6)alkoxy, OH, CN, CF3, or halo;
alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6) or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy is optionally substituted with 1 or 2 substituents that are independently OH, CN, CF3, or fluoro;
halo is F, Cl, Br, or I;
heteroaryl is a 5- or 6-membered carbon-containing aromatic ring containing one, two or three ring members that are N, NR8, S, or O; heteroaryl is optionally substituted with 1, 2 or 3 substituents that are independently alkyl, alkoxy, OH, OCF3, halo, CN, or CF3;
heteroaryla is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members are independently N, NR12, S or O; heteroaryla is optionally substituted with 1, 2 or 3 substituents that are independently alkyl, alkoxy, OH, OCF3, halo, CN, arylb, —(CH2)1-3-arylb, —(CH2)0-3—NR13R14, heteroarylb, —COOR13, —CONR13R14 or CF3;
heteroarylb is a 5, 6, 9 or 10 membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members that are independently N, NR12, S or O; wherein heteroarylb is optionally substituted with 1, 2 or 3 substituents that are independently alkylb, alkoxy, OH, halo, CN, arylb, —(CH2)1-3-arylb, or CF3;
heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 5, 6, or 7 ring members, wherein one or two ring members are independently N, NR8, S, SO, SO2, or O; wherein heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents that are independently alkyl, alkoxy, OH, OCF3, halo, oxo or CN;
heterocycloalkyla is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently NR8, S, SO, SO2, or O; heterocycloalkyla is optionally substituted with 1 or 2 substituents that are independently alkyl (C1-C6)alkoxy, OH, CN, CF3, or halo;
R8 is independently H, alkyl, cycloalkyl, or heterocycloalkylb;
heterocycloalkylb is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently N, NR12, S, or O; heterocycloalkylb is optionally substituted with 1 or 2 substituents that are independently alkyl, (C1-C6)alkoxy, OH, CN, CF3, or halo;
R12 is independently H, alkylb, or cycloalkyl;
R13 and R14 are independently H, alkylb, arylb or heteroarylb or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom that is N, NR12, S, SO, SO2, or O, which is optionally saturated or unsaturated with 1 or 2 double bonds and which is optionally mono- or di-substituted with substituents that are oxo, alkylb, alkoxy, OH, halo or CF3;
or a tautomer, isomer, deuterated isotope, or a pharmaceutically acceptable salt and/or solvate thereof.
2. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or a pharmaceutically acceptable salt and/or solvate thereof,
wherein W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N or N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
R5, R6, and R7 are independently absent, H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14;
R16 is independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14; or
W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N or N, and one of R5, R6, R7 or R16 is oxo such that the ring containing W, X, Y and Z is 2-pyridone or 4-pyridone;
wherein the others of R5, R6, R7 and R16 are independently absent, H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, CF3, aryl, heteroaryla, N-linked pyrrolidinyl, N-linked piperidinyl, N-linked morpholinyl, N-linked piperazinyl, —NR13R14, —COOR13, —CONR13R14, or —NR13COR14.
3. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein W, X, Y and Z is independently C, C(R16)-C, C(R16)=C, C═N or N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl;
R5, R6, and R7 are independently absent, H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, or CF3;
R16 is independently H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, or CF3; or
W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N or N, and one of R5, R6, R7 or R16 is oxo such that the ring containing W, X, Y and Z is 2-pyridone or 4-pyridone;
wherein the others of R5, R6, R7 and R16 are independently absent, H, alkyl, cycloalkyl, alkoxy, halo, OH, CN, or CF3.
4. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or a pharmaceutically acceptable salt and/or solvate thereof,
wherein W, X, Y and Z are independently C, C(R16)-C, C(R16)=C, C═N or N, such that the ring containing W, X, Y and Z is a 5-, or 6-membered heteroaryl.
5. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or a pharmaceutically acceptable salt and/or solvate thereof,
wherein W, X, Y and Z are independently C or N, such that the ring containing W, X, Y and Z is a 5-membered heteroaryl.
6. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein W, X, Y and Z are independently C or N, such that the ring containing W, X, Y and Z is pyrazole.
7. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein at least one of R5, R6, or R7 is present and is not H.
8. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein R7 is H.
9. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein one of R5 or R6 is absent and one of R5 or R6 is alkyl substituted with optionally substituted alkoxy.
10. The compound of formula (I) according to claim 9 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein one of R5 or R6 is absent and one of R5 or R6 is —CH2OMe.
11. The compound of formula (I) according to claim 1 , or a tautomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B′ is optionally substituted phenyl.
12. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein R9 is halo and R10 is alkoxy.
13. The compound of formula (I) according to claim 12 , or a tautomer, isomer, a deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein R9 is F and R10 is —OMe.
14. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B″ pyrrole, pyrazole, or triazole.
15. The compound of formula (I) according to claim 14 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B″ is pyrazole, or triazole.
16. The compound of formula (I) according to claim 15 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B″ is optionally substituted pyrazole.
17. The compound of formula (I) according to claim 15 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B″ is optionally substituted 1, 2, 3-triazole.
18. The compound of formula (I) according to claim 15 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein B″ is optionally substituted 1, 2, 4-triazole.
19. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein n is 1, and R11 is alkyl, cyclopropyl, CN, or CF3.
20. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is optionally substituted phenyl.
21. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is optionally substituted heteroaryl.
22. The compound of formula (I) according to claim 21 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is an optionally substituted 5-membered heteroaryl.
23. The compound of formula (I) according to claim 22 or a tautomer, isomer, deuterated isotope, or a pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is optionally substituted pyrrole or imidazole.
24. The compound of formula (I) according to claim 21 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is a optionally substituted 6-membered heteroaryl.
25. The compound of formula (I) according to claim 24 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A′ is optionally substituted pyridine.
26. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is an optionally substituted non-aromatic carbon-containing monocyclic ring containing 5 ring members, wherein one or two ring members are independently N, NR8, S, or O.
27. The compound of formula (I) according to claim 26 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is optionally substituted pyrrolidine.
28. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is an optionally substituted non-aromatic carbon-containing monocyclic ring containing 6 ring members, wherein one or two ring members are independently N, NR8, S, or O.
29. The compound of formula (I) according to claim 28 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is optionally substituted piperidine.
30. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is an optionally substituted non-aromatic carbon-containing monocyclic ring containing 7 ring members, wherein one or two ring members are independently N, NR8, S, or O.
31. The compound of formula (I) according to claim 30 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein A″ is optionally substituted azepane.
32. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein a carbon ring atom on A″ is substituted with an alkylene such that the carbon ring atom on A″ together with the alkylene forms an optionally substituted cycloalkyl that is spiro to ring A″.
33. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein a carbon ring atom on A″ is substituted with an alkylene such that the carbon ring atom on A″ together with the alkylene forms an optionally substituted cyclopropane that is spiro to ring A″.
34. The compound of formula (I) according to claim 1 , or a tautomer, isomer, deuterated isotope, or pharmaceutically acceptable salt and/or solvate thereof,
wherein two ring atoms on A″ are linked by an alkylene or heteroalkylene to form a non-aromatic ring containing 5, 6, or 7 ring members.
35. The compound of formula (I) according to claim 1 , wherein the isomer is a stereoisomer.
36. The compound of formula (I) of claim 35 , wherein the stereoisomer is an enantiomer, diastereomer, or a racemic or scalemic mixture thereof.
37. A compound that is:
N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(3-methyl-1,2,4-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[6-(4-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({6-[4-(difluoromethyl)-1,2,3-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[6-(3-cyanopyrazol-1-yl)-2-fluoro-3-methoxyphenyl]methyl}-1-[(2-isopropyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-({6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-2-fluoro-3-methoxyphenyl}methyl)-1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
1-[(2-ethyl-3,4-dihydro-1H-isoquinolin-6-yl)methyl]-N-({2-fluoro-3-methoxy-6-[3-(trifluoromethyl)-1,2,4-triazol-1-yl]phenyl}methyl)-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-[(2-methyl-1,3-dihydroisoindol-5-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
1-[(6-fluoro-2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{[2-(2H3)methyl-3,4-dihydro-1H-isoquinolin-7-yl]methyl}pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(3-isopropyl-1,2,4,5-tetrahydro-3-benzazepin-7-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)-1-{2′-methyl-1′,3′-dihydrospiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}pyrazole-4-carboxamide;
1-{2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-isoquinoline]-7′-ylmethyl}-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-3-(methoxymethyl)pyrazole-4-carboxamide;
3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-({5-methyl-4H,6H,7H-pyrazolo[1,5-a]pyrazin-2-yl}methyl)pyrazole-4-carboxamide;
3-(difluoromethyl)-N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(7-methyl-6,8-dihydro-5H-1,7-naphthyridin-3-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-1,2,3-triazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-isopropyl-1,3-dihydroisoindol-5-yl)methyl]-1,2,3-triazole-4-carboxamide;
N-({2-chloro-6-[3-(difluoromethyl)-1,2,4-triazol-1-yl]-3-methoxyphenyl}methyl)-3-(methoxymethyl)-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyrazole-4-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-1-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]-6-oxopyridine-3-carboxamide;
N-{[2-fluoro-3-methoxy-6-(4-methyl-1,2,3-triazol-1-yl)phenyl]methyl}-5-[(2-methyl-3,4-dihydro-1H-isoquinolin-7-yl)methyl]pyridine-3-carboxamide;
or a pharmaceutically acceptable salt and/or solvate thereof.
38. The compound of formula (I) according to claim 1 that is a pharmaceutically acceptable salt thereof.
39. The compound of formula (I) according to claim 1 that is a pharmaceutically acceptable solvate thereof.
40. The compound of formula (I) according to claim 1 that is a pharmaceutically acceptable solvate of a salt thereof.
41. A pharmaceutical composition comprising:
(i) a compound of formula (I) according to claim 1 , a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable solvate of a salt thereof; and
(ii) a pharmaceutically acceptable carrier, diluent or excipient.
42. A method of treatment of a disease or condition in which plasma kallikrein activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of claim 1 .
43. The method of claim 42 , wherein the disease or condition in which plasma kallikrein activity is implicated is a bradykinin-mediated angioedema.
44. The method of claim 43 , wherein the bradykinin-mediated angioedema is hereditary angioedema.
45. The method of claim 43 , wherein the bradykinin-mediated angioedema is non hereditary.
46. The method of claim 43 , wherein the bradykinin-mediated angioedema is hereditary angioedema or an acute non-hereditary bradykinin-mediated angioedema.
47. The method of claim 42 , wherein the disease or condition in which plasma kallikrein activity is implicated is impaired visual acuity, diabetic retinopathy, diabetic macular edema, diabetes, pancreatitis, cerebral haemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, cardiopulmonary bypass surgery or bleeding from post operative surgery.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/126,646 US20230250080A1 (en) | 2019-08-09 | 2023-03-27 | Enzyme inhibitors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2019/052252 WO2021028645A1 (en) | 2019-08-09 | 2019-08-09 | Plasma kallikrein inhibitors |
WOPCT/GB2019/052252 | 2019-08-09 | ||
PCT/GB2020/050331 WO2021028649A1 (en) | 2019-08-09 | 2020-02-13 | Plasma kallikrein inhibitors |
US17/496,905 US11613527B2 (en) | 2019-08-09 | 2021-10-08 | Enzyme inhibitors |
US18/126,646 US20230250080A1 (en) | 2019-08-09 | 2023-03-27 | Enzyme inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/496,905 Division US11613527B2 (en) | 2019-08-09 | 2021-10-08 | Enzyme inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230250080A1 true US20230250080A1 (en) | 2023-08-10 |
Family
ID=67659908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/496,905 Active 2040-03-13 US11613527B2 (en) | 2019-08-09 | 2021-10-08 | Enzyme inhibitors |
US18/126,646 Pending US20230250080A1 (en) | 2019-08-09 | 2023-03-27 | Enzyme inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/496,905 Active 2040-03-13 US11613527B2 (en) | 2019-08-09 | 2021-10-08 | Enzyme inhibitors |
Country Status (15)
Country | Link |
---|---|
US (2) | US11613527B2 (en) |
EP (1) | EP4010333A1 (en) |
JP (1) | JP2022543515A (en) |
KR (1) | KR20220046592A (en) |
CN (1) | CN114206852A (en) |
AR (1) | AR118081A1 (en) |
AU (1) | AU2020328208A1 (en) |
BR (1) | BR112022001025A2 (en) |
CA (1) | CA3147390A1 (en) |
CL (1) | CL2022000214A1 (en) |
CO (1) | CO2022000426A2 (en) |
IL (1) | IL289764A (en) |
MX (1) | MX2022000545A (en) |
TW (1) | TW202115020A (en) |
WO (2) | WO2021028645A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3515715A (en) | 1967-01-23 | 1970-06-02 | Eastman Kodak Co | Quaternized pyrazolylazo dyes |
DE2402182B2 (en) | 1973-01-19 | 1980-03-13 | Matsushita Electric Industrial Co. Ltd., Kadoma, Osaka (Japan) | Battery charger |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (en) | 1993-06-03 | 1993-06-03 | Ab Astra | NEW PEPTIDE DERIVATIVES |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them |
US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
JPH09301965A (en) | 1996-03-15 | 1997-11-25 | Katayama Seiyakushiyo:Kk | Production of 5-amiono-1,2,4-thiadiazole acetic acid derivative |
US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
GB9821977D0 (en) | 1998-10-08 | 1998-12-02 | Smithkline Beecham Plc | Compounds |
EP1121361B1 (en) | 1998-10-16 | 2007-08-29 | Merck Sharp & Dohme Limited | Pyrazolo-triazine derivatives as ligands for gaba receptors |
EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US6682761B2 (en) | 2000-04-20 | 2004-01-27 | Rtp Pharma, Inc. | Water-insoluble drug particle process |
CA2423336C (en) | 2000-09-20 | 2011-03-08 | Rtp Pharma Inc. | Stabilised fibrate microparticles |
AR035216A1 (en) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS |
EP1441734B1 (en) | 2001-10-26 | 2007-02-28 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
CA2483159C (en) | 2002-04-26 | 2010-08-10 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
DE10301300B4 (en) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Use of acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
WO2004069792A2 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid vr1 receptor |
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
DK1784402T3 (en) | 2004-09-03 | 2011-11-14 | Yuhan Corp | Pyrrolo [3,2-c] pyridine derivatives as well as processes for their preparation |
EP1858542A4 (en) | 2005-02-24 | 2009-08-19 | Joslin Diabetes Center Inc | Compositions and methods for treating vascular permeability |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR101142363B1 (en) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | A composition for treating a cancer comprising pyrrolopyridine derivatives |
EP1904452A2 (en) | 2005-07-14 | 2008-04-02 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
DK1854477T3 (en) | 2006-03-16 | 2016-11-28 | Dyax Corp | Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders |
GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
PT2049478E (en) | 2006-07-06 | 2012-07-16 | Glaxo Group Ltd | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DE102006050672A1 (en) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations |
RU2485114C2 (en) | 2006-12-29 | 2013-06-20 | Эбботт Гмбх Унд Ко.Кг | Carboxamide compounds and use thereof as calpain inhibitors |
WO2008091692A2 (en) | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
WO2008109178A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a squaramide moiety |
KR20090125852A (en) | 2007-03-30 | 2009-12-07 | 사노피-아벤티스 | Pyrimidine hydrazide compounds as pgds inhibitors |
WO2008119825A2 (en) | 2007-04-03 | 2008-10-09 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
BRPI0814314A2 (en) | 2007-07-26 | 2015-05-26 | Syngenta Participations Ag | Microbiocides |
AU2008288897A1 (en) | 2007-08-22 | 2009-02-26 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | Methods for treatment of kallikrein-related disorders |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
ATE543811T1 (en) | 2008-03-13 | 2012-02-15 | Bristol Myers Squibb Co | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS |
TW200944530A (en) | 2008-04-09 | 2009-11-01 | Gruenenthal Chemie | Substituted sulfonamide derivatives |
PL2308838T3 (en) | 2008-07-08 | 2016-08-31 | Daiichi Sankyo Co Ltd | Nitrogen-containing aromatic heterocyclyl compound |
US20110230472A1 (en) | 2008-08-29 | 2011-09-22 | Shionogi & Co., Ltd. | Ring-fused azole derivative having pi3k-inhibiting activity |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
SG10201408429UA (en) | 2009-12-18 | 2015-02-27 | Activesite Pharmaceuticals Inc | Prodrugs of inhibitors of plasma kallikrein |
EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
US20130058965A1 (en) | 2009-12-31 | 2013-03-07 | Mannkind Corporation | Injectable formulations for parenteral administration |
JP2011157349A (en) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | Pharmaceutical composition containing nitrogen-containing aromatic heterocyclyl compound |
JP5709902B2 (en) | 2010-01-28 | 2015-04-30 | ザ メディシンズ カンパニー (ライプツィヒ) ゲーエムベーハー | Trypsin-like serine protease inhibitors and their preparation and use |
JP2013121919A (en) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | Plasma kallikrein inhibitor |
ES2483802T3 (en) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
US8471026B2 (en) | 2010-08-26 | 2013-06-25 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
EP2458315B1 (en) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerative heat exchanger with forced rotor seal |
US8761853B2 (en) | 2011-01-20 | 2014-06-24 | Nitto Denko Corporation | Devices and methods for non-invasive optical physiological measurements |
US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
GB201111138D0 (en) | 2011-06-30 | 2011-08-17 | Leman Micro Devices Uk Ltd | Personal health data collection |
GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
EP2760829B1 (en) | 2011-09-27 | 2016-05-18 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
WO2013049096A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
EP2807157A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
WO2013111107A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | Aminopyridine derivatives as plasma kallikrein inhibitors |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
US10136823B2 (en) | 2012-08-28 | 2018-11-27 | Board Of Trustees Of Michigan State University | Methods and apparatus for determining cuff blood pressure |
PH12015501492B1 (en) | 2013-01-08 | 2015-09-28 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
MA38323B1 (en) | 2013-01-08 | 2018-05-31 | Hoffmann La Roche | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
EP4234583A3 (en) | 2013-01-20 | 2024-01-24 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
MX360972B (en) | 2013-02-13 | 2018-11-23 | Leman Micro Devices Sa | Non-invasive blood analysis. |
EP2967073B9 (en) | 2013-03-15 | 2019-04-10 | Bristol-Myers Squibb Company | Lxr modulators |
MX2015012867A (en) | 2013-03-15 | 2016-06-10 | Verseon Corp | Multisubstituted aromatic compounds as serine protease inhibitors. |
EP2999697B1 (en) | 2013-05-23 | 2017-04-19 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
EP3033342A1 (en) | 2013-08-13 | 2016-06-22 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
US10221161B2 (en) | 2013-08-14 | 2019-03-05 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
AU2014373735B2 (en) | 2013-12-30 | 2020-03-12 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
US9611252B2 (en) * | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
HUE060660T2 (en) | 2014-03-07 | 2023-04-28 | Biocryst Pharm Inc | Substituted pyrazoles as human plasma kallikrein inhibitors |
WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
US9695166B2 (en) | 2014-05-05 | 2017-07-04 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
WO2016011209A1 (en) | 2014-07-16 | 2016-01-21 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
ES2784477T3 (en) | 2014-07-22 | 2020-09-28 | Boehringer Ingelheim Int | Heterocyclic carboxylic acids as activators of soluble guanylate cyclase |
DK3182962T3 (en) | 2014-08-22 | 2023-09-18 | Biocryst Pharm Inc | COMPOSITIONS AND USES OF AMIDINE DERIVATIVES |
CN106687445A (en) | 2014-09-17 | 2017-05-17 | 维颂公司 | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
US11412987B2 (en) | 2014-12-16 | 2022-08-16 | Leman Micro Devices Sa | Personal health data collection |
CN107405333A (en) | 2015-02-27 | 2017-11-28 | 维颂公司 | Substituted pyrazole compound as serpin |
EP3317241A4 (en) | 2015-07-01 | 2019-01-23 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
EP3317259A4 (en) * | 2015-07-01 | 2019-06-12 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
IL291017B2 (en) | 2015-10-21 | 2023-11-01 | Otsuka Pharma Co Ltd | Benzolactam compounds as protein kinase inhibitors |
EP3368529B1 (en) | 2015-10-27 | 2022-04-06 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
WO2017072021A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
EP3390395B1 (en) | 2015-12-16 | 2020-09-09 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
GB201602875D0 (en) | 2016-02-18 | 2016-04-06 | Leman Micro Devices Sa | Personal hand-held monitor |
GB201608781D0 (en) | 2016-05-19 | 2016-07-06 | Leman Micro Devices Sa | Non-invasive blood analysis |
GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
ME03794B (en) | 2016-05-31 | 2021-04-20 | Kalvista Pharmaceuticals Ltd | Pyrazole derivatives as plasma kallikrein inhibitors |
GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
GB201713660D0 (en) | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
KR102451023B1 (en) | 2017-10-11 | 2022-10-04 | 삼성전자주식회사 | Apparatus and method for measuring bio-information |
GB201721515D0 (en) | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2019106359A1 (en) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
BR112022001341A2 (en) | 2019-08-21 | 2022-03-22 | Kalvista Pharmaceuticals Ltd | enzyme inhibitors |
CN114269431A (en) | 2019-08-21 | 2022-04-01 | 卡尔维斯塔制药有限公司 | Enzyme inhibitors |
WO2021032935A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
CN114269430A (en) | 2019-08-21 | 2022-04-01 | 卡尔维斯塔制药有限公司 | Enzyme inhibitors |
GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
-
2019
- 2019-08-09 WO PCT/GB2019/052252 patent/WO2021028645A1/en unknown
- 2019-08-09 CN CN201980099093.9A patent/CN114206852A/en active Pending
- 2019-08-09 EP EP19753461.3A patent/EP4010333A1/en not_active Withdrawn
-
2020
- 2020-02-13 AR ARP200100395A patent/AR118081A1/en unknown
- 2020-02-13 KR KR1020227006880A patent/KR20220046592A/en unknown
- 2020-02-13 WO PCT/GB2020/050331 patent/WO2021028649A1/en active Application Filing
- 2020-02-13 MX MX2022000545A patent/MX2022000545A/en unknown
- 2020-02-13 BR BR112022001025A patent/BR112022001025A2/en unknown
- 2020-02-13 AU AU2020328208A patent/AU2020328208A1/en active Pending
- 2020-02-13 CA CA3147390A patent/CA3147390A1/en active Pending
- 2020-02-13 TW TW109104462A patent/TW202115020A/en unknown
- 2020-02-13 JP JP2021560272A patent/JP2022543515A/en not_active Ceased
-
2021
- 2021-10-08 US US17/496,905 patent/US11613527B2/en active Active
-
2022
- 2022-01-11 IL IL289764A patent/IL289764A/en unknown
- 2022-01-19 CO CONC2022/0000426A patent/CO2022000426A2/en unknown
- 2022-01-27 CL CL2022000214A patent/CL2022000214A1/en unknown
-
2023
- 2023-03-27 US US18/126,646 patent/US20230250080A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR118081A1 (en) | 2021-09-15 |
CL2022000214A1 (en) | 2022-10-14 |
WO2021028649A1 (en) | 2021-02-18 |
IL289764A (en) | 2022-03-01 |
MX2022000545A (en) | 2022-02-10 |
KR20220046592A (en) | 2022-04-14 |
CA3147390A1 (en) | 2021-02-18 |
US11613527B2 (en) | 2023-03-28 |
CO2022000426A2 (en) | 2022-01-28 |
US20220048894A1 (en) | 2022-02-17 |
EP4010333A1 (en) | 2022-06-15 |
CN114206852A (en) | 2022-03-18 |
BR112022001025A2 (en) | 2022-06-14 |
AU2020328208A1 (en) | 2022-02-24 |
TW202115020A (en) | 2021-04-16 |
JP2022543515A (en) | 2022-10-13 |
WO2021028645A1 (en) | 2021-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11084809B2 (en) | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors | |
AU2021200140B2 (en) | Pyrazole derivatives as plasma kallikrein inhibitors | |
US11613527B2 (en) | Enzyme inhibitors | |
US9533987B2 (en) | Heterocyclic derivates | |
US10781181B2 (en) | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | |
US9738641B2 (en) | Bicyclic inhibitors | |
US20220298141A1 (en) | Enzyme inhibitors | |
US20220289727A1 (en) | Enzyme inhibitors | |
US20240059691A1 (en) | Enzyme inhibitors | |
KR20230157981A (en) | Factor XIIA inhibitors | |
WO2024084217A1 (en) | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |